0000012208-21-000024.txt : 20210430 0000012208-21-000024.hdr.sgml : 20210430 20210430165655 ACCESSION NUMBER: 0000012208-21-000024 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 72 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210430 DATE AS OF CHANGE: 20210430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-RAD LABORATORIES, INC. CENTRAL INDEX KEY: 0000012208 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 941381833 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-07928 FILM NUMBER: 21879219 BUSINESS ADDRESS: STREET 1: 1000 ALFRED NOBEL DRIVE CITY: HERCULES STATE: CA ZIP: 94547 BUSINESS PHONE: 5107247000 MAIL ADDRESS: STREET 1: 1000 ALFRED NOBEL DRIVE CITY: HERCULES STATE: CA ZIP: 94547 FORMER COMPANY: FORMER CONFORMED NAME: BIO RAD LABORATORIES INC DATE OF NAME CHANGE: 19920703 10-Q 1 bio-20210331.htm 10-Q MARCH 31, 2021 bio-20210331
000001220812/312021Q1false00000122082021-01-012021-03-310000012208us-gaap:CommonClassAMember2021-01-012021-03-310000012208us-gaap:CommonClassBMember2021-01-012021-03-31xbrli:shares0000012208us-gaap:CommonClassAMember2021-04-230000012208us-gaap:CommonClassBMember2021-04-23iso4217:USD00000122082021-03-3100000122082020-12-310000012208us-gaap:CommonClassAMember2021-03-310000012208us-gaap:CommonClassAMember2020-12-310000012208us-gaap:CommonClassBMember2021-03-310000012208us-gaap:CommonClassBMember2020-12-310000012208bio:TreasuryClassAMember2021-03-310000012208bio:TreasuryClassAMember2020-12-3100000122082020-01-012020-03-31iso4217:USDxbrli:shares00000122082019-12-3100000122082020-03-310000012208us-gaap:OtherCurrentAssetsMember2021-03-310000012208us-gaap:OtherCurrentAssetsMember2020-03-310000012208us-gaap:OtherAssetsMember2021-03-310000012208us-gaap:OtherAssetsMember2020-03-310000012208us-gaap:CommonStockMember2020-12-310000012208us-gaap:AdditionalPaidInCapitalMember2020-12-310000012208us-gaap:TreasuryStockMember2020-12-310000012208us-gaap:RetainedEarningsMember2020-12-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000012208us-gaap:CommonStockMember2021-01-012021-03-310000012208us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310000012208us-gaap:TreasuryStockMember2021-01-012021-03-310000012208us-gaap:RetainedEarningsMember2021-01-012021-03-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310000012208us-gaap:CommonStockMember2021-03-310000012208us-gaap:AdditionalPaidInCapitalMember2021-03-310000012208us-gaap:TreasuryStockMember2021-03-310000012208us-gaap:RetainedEarningsMember2021-03-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310000012208us-gaap:CommonStockMember2019-12-310000012208us-gaap:AdditionalPaidInCapitalMember2019-12-310000012208us-gaap:TreasuryStockMember2019-12-310000012208us-gaap:RetainedEarningsMember2019-12-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000012208us-gaap:CommonStockMember2020-01-012020-03-310000012208us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310000012208us-gaap:TreasuryStockMember2020-01-012020-03-310000012208us-gaap:RetainedEarningsMember2020-01-012020-03-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310000012208us-gaap:CommonStockMember2020-03-310000012208us-gaap:AdditionalPaidInCapitalMember2020-03-310000012208us-gaap:TreasuryStockMember2020-03-310000012208us-gaap:RetainedEarningsMember2020-03-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-31xbrli:pure0000012208srt:EuropeMember2021-01-012021-03-310000012208srt:EuropeMember2020-01-012020-03-310000012208srt:AsiaPacificMember2021-01-012021-03-310000012208srt:AsiaPacificMember2020-01-012020-03-310000012208country:US2021-01-012021-03-310000012208country:US2020-01-012020-03-310000012208srt:AmericasMember2021-01-012021-03-310000012208srt:AmericasMember2020-01-012020-03-310000012208us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310000012208us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-03-310000012208us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-03-310000012208us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310000012208us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310000012208us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-03-310000012208us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-03-310000012208us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-03-310000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-03-310000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-03-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMember2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CashEquivalentsMember2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel3Member2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMember2021-03-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMember2021-03-310000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-03-310000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-03-310000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310000012208us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310000012208us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-03-310000012208us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-03-310000012208us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignGovernmentDebtSecuritiesMember2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignGovernmentDebtSecuritiesMember2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2021-03-310000012208us-gaap:ForeignGovernmentDebtMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310000012208us-gaap:ForeignGovernmentDebtMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-03-310000012208us-gaap:ForeignGovernmentDebtMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-03-310000012208us-gaap:ForeignGovernmentDebtMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310000012208us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310000012208us-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-03-310000012208us-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-03-310000012208us-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2021-03-310000012208us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000012208us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310000012208us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310000012208us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000012208us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310000012208us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310000012208us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000012208us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000012208us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310000012208us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310000012208us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2020-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2020-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-12-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMember2020-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CashEquivalentsMember2020-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel3Member2020-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMember2020-12-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310000012208us-gaap:FairValueMeasurementsRecurringMember2020-12-310000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000012208us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000012208us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310000012208us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310000012208us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2020-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignGovernmentDebtSecuritiesMember2020-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignGovernmentDebtSecuritiesMember2020-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2020-12-310000012208us-gaap:ForeignGovernmentDebtMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000012208us-gaap:ForeignGovernmentDebtMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310000012208us-gaap:ForeignGovernmentDebtMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310000012208us-gaap:ForeignGovernmentDebtMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000012208us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000012208us-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310000012208us-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310000012208us-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2020-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2020-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Member2020-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2020-12-310000012208bio:RestrictedInvestmentMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310000012208bio:RestrictedInvestmentMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherInvestmentsMember2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherInvestmentsMember2020-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2020-12-310000012208bio:OrdinaryVotingSharesMember2021-03-310000012208bio:PreferenceSharesMember2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2020-12-310000012208us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310000012208us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000012208bio:DistributorMember2020-10-012020-12-310000012208bio:DistributorMember2021-01-012021-03-310000012208bio:DistributorMember2021-03-310000012208bio:CelseeMember2021-03-310000012208bio:CelseeMember2020-04-010000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2021-03-310000012208us-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:ShortTermInvestmentsMember2021-03-310000012208us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2021-03-310000012208us-gaap:ForeignGovernmentDebtMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:OtherLongTermInvestmentsMember2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherLongTermInvestmentsMember2021-03-310000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2020-12-310000012208us-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2020-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:ShortTermInvestmentsMember2020-12-310000012208us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2020-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2020-12-310000012208us-gaap:ForeignGovernmentDebtMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2020-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:OtherLongTermInvestmentsMember2020-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherLongTermInvestmentsMember2020-12-310000012208us-gaap:USTreasuryAndGovernmentMember2021-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2021-03-310000012208bio:ForwardforeignexchangecontracttosellforeigncurrencyMember2021-03-310000012208bio:ForwardforeignexchangecontracttosellforeigncurrencyMember2021-01-012021-03-310000012208bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember2021-03-310000012208bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember2021-01-012021-03-310000012208bio:LifeScienceMember2021-03-310000012208bio:LifeScienceMember2020-12-310000012208bio:ClinicalDiagnosticsMember2020-12-310000012208bio:ClinicalDiagnosticsMember2021-03-310000012208us-gaap:CustomerRelationshipsMember2021-01-012021-03-310000012208us-gaap:CustomerRelationshipsMember2021-03-310000012208bio:KnowHowMember2021-01-012021-03-310000012208bio:KnowHowMember2021-03-310000012208us-gaap:DevelopedTechnologyRightsMember2021-01-012021-03-310000012208us-gaap:DevelopedTechnologyRightsMember2021-03-310000012208us-gaap:LicensingAgreementsMember2021-01-012021-03-310000012208us-gaap:LicensingAgreementsMember2021-03-310000012208us-gaap:TradeNamesMember2021-01-012021-03-310000012208us-gaap:TradeNamesMember2021-03-310000012208us-gaap:NoncompeteAgreementsMember2021-01-012021-03-310000012208us-gaap:NoncompeteAgreementsMember2021-03-310000012208us-gaap:OtherIntangibleAssetsMember2021-03-310000012208us-gaap:InProcessResearchAndDevelopmentMember2021-03-310000012208us-gaap:CustomerRelationshipsMember2020-01-012020-12-310000012208us-gaap:CustomerRelationshipsMember2020-12-310000012208bio:KnowHowMember2020-01-012020-12-310000012208bio:KnowHowMember2020-12-310000012208us-gaap:DevelopedTechnologyRightsMember2020-01-012020-12-310000012208us-gaap:DevelopedTechnologyRightsMember2020-12-310000012208us-gaap:LicensingAgreementsMember2020-01-012020-12-310000012208us-gaap:LicensingAgreementsMember2020-12-310000012208us-gaap:TradeNamesMember2020-01-012020-12-310000012208us-gaap:TradeNamesMember2020-12-310000012208us-gaap:NoncompeteAgreementsMember2020-01-012020-12-310000012208us-gaap:NoncompeteAgreementsMember2020-12-310000012208us-gaap:OtherIntangibleAssetsMember2020-12-310000012208us-gaap:InProcessResearchAndDevelopmentMember2020-12-310000012208us-gaap:OtherIntangibleAssetsMember2021-01-012021-03-310000012208us-gaap:OtherIntangibleAssetsMember2020-01-012020-12-310000012208bio:FinanceLeaseObligationsMemberbio:FinanceLeasesandOtherDebtMember2021-03-310000012208bio:FinanceLeaseObligationsMemberbio:FinanceLeasesandOtherDebtMember2020-12-310000012208us-gaap:LineOfCreditMember2021-03-310000012208us-gaap:StandbyLettersOfCreditMember2021-03-310000012208us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-310000012208us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-03-310000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-03-310000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-03-310000012208us-gaap:AccumulatedTranslationAdjustmentMember2021-03-310000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-03-310000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-03-310000012208us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-310000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-12-310000012208us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-03-310000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-03-310000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-03-310000012208us-gaap:AccumulatedTranslationAdjustmentMember2020-03-310000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-03-310000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-03-310000012208bio:LifeScienceMember2021-01-012021-03-310000012208bio:ClinicalDiagnosticsMember2021-01-012021-03-310000012208us-gaap:AllOtherSegmentsMember2021-01-012021-03-310000012208bio:LifeScienceMember2020-01-012020-03-310000012208bio:ClinicalDiagnosticsMember2020-01-012020-03-310000012208us-gaap:AllOtherSegmentsMember2020-01-012020-03-310000012208us-gaap:OperatingSegmentsMember2021-01-012021-03-310000012208us-gaap:OperatingSegmentsMember2020-01-012020-03-310000012208us-gaap:MaterialReconcilingItemsMemberus-gaap:ForeignCurrencyGainLossMember2021-01-012021-03-310000012208us-gaap:MaterialReconcilingItemsMemberus-gaap:ForeignCurrencyGainLossMember2020-01-012020-03-310000012208us-gaap:MaterialReconcilingItemsMember2021-01-012021-03-310000012208us-gaap:MaterialReconcilingItemsMember2020-01-012020-03-310000012208us-gaap:MaterialReconcilingItemsMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-01-012021-03-310000012208us-gaap:MaterialReconcilingItemsMemberus-gaap:OtherNonoperatingIncomeExpenseMember2020-01-012020-03-310000012208bio:EuropeanReorganizationMember2021-03-310000012208us-gaap:AccountsPayableAndAccruedLiabilitiesMemberbio:EuropeanReorganizationMember2021-03-310000012208us-gaap:OtherNoncurrentLiabilitiesMemberbio:EuropeanReorganizationMember2021-03-310000012208us-gaap:CostOfSalesMemberbio:EuropeanReorganizationMember2021-01-012021-03-310000012208bio:EuropeanReorganizationMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-03-310000012208us-gaap:ResearchAndDevelopmentExpenseMemberbio:EuropeanReorganizationMember2021-01-012021-03-310000012208bio:LifeScienceMemberbio:EuropeanReorganizationMember2020-12-310000012208bio:ClinicalDiagnosticsMemberbio:EuropeanReorganizationMember2020-12-310000012208bio:EuropeanReorganizationMember2020-12-310000012208bio:LifeScienceMemberbio:EuropeanReorganizationMember2021-01-012021-03-310000012208bio:ClinicalDiagnosticsMemberbio:EuropeanReorganizationMember2021-01-012021-03-310000012208bio:EuropeanReorganizationMember2021-01-012021-03-310000012208bio:LifeScienceMemberbio:EuropeanReorganizationMember2021-03-310000012208bio:ClinicalDiagnosticsMemberbio:EuropeanReorganizationMember2021-03-310000012208srt:MinimumMember2021-01-012021-03-310000012208srt:MaximumMember2021-01-012021-03-310000012208bio:CurrentLiabilityMember2021-03-310000012208bio:CurrentLiabilityMember2020-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period endedMarch 31, 2021
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from______________to __________
Commission file number1-7928
BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Delaware94-1381833
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
1000 Alfred Nobel Drive,Hercules,California94547
(Address of principal executive offices)(Zip Code)
(510)724-7000
(Registrant's telephone number, including area code)
No Change
(Former name, former address and former fiscal year, if changed since last report.)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A Common Stock, Par Value $0.0001 per shareBIONew York Stock Exchange
Class B Common Stock, Par Value $0.0001 per shareBIObNew York Stock Exchange
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes☒No☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232,405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit files).
Yes☒No☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.  (Check one):
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes☐No☒
.
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Common Shares Outstanding at April 23, 2021:Class A - 24,692,554Class B - 5,071,060



BIO-RAD LABORATORIES, INC.

FORM 10-Q MARCH 31, 2021

TABLE OF CONTENTS

2

INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS

Other than statements of historical fact, statements made in this report include forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements with respect to our future financial performance, operating results, plans and objectives that involve risk and uncertainties.  These forward-looking statements may also include statements regarding the impact of the COVID-19 pandemic on Bio-Rad’s results and operations and steps governments, universities, hospitals and private industry, including diagnostic laboratories, are taking or may take as a result of the pandemic. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions.  Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements.  We have based these forward-looking statements on our current expectations and projections about future events.  However, actual results may differ materially from those currently anticipated depending on a variety of risk factors including, but not limited to, the duration, severity and impact of the COVID-19 pandemic, global economic conditions, our ability to develop and market new or improved products, our ability to compete effectively, foreign currency exchange fluctuations, reductions in government funding or capital spending of our customers, international legal and regulatory risks, supply chain issues, product quality and liability issues, our ability to integrate acquired companies, products or technologies into our company successfully, changes in the healthcare industry, natural disasters and other catastrophic events beyond our control, and other risks and uncertainties identified under “Part II, Item 1A, Risk Factors” of this Quarterly Report on Form 10-Q. We caution you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

3

PART I – FINANCIAL INFORMATION

BIO-RAD LABORATORIES, INC.
Condensed Consolidated Balance Sheets
(In thousands, except share data)
March 31, 2021December 31, 2020
ASSETS:(Unaudited)
Cash and cash equivalents$673,470 $662,205 
Short-term investments346,398 328,913 
Restricted investments5,560 5,560 
Accounts receivable, less allowance for doubtful accounts of $18,553 at 2021 and $19,807 at 2020
408,137 419,424 
Inventories:
Raw materials122,605 126,911 
Work in process150,628 151,931 
Finished goods331,923 343,411 
Total inventories605,156 622,253 
Prepaid expenses110,271 90,621 
Other current assets26,325 10,859 
Total current assets2,175,317 2,139,835 
Property, plant and equipment1,420,284 1,452,761 
Less: accumulated depreciation and amortization(937,572)(961,390)
Property, plant and equipment, net482,712 491,371 
Operating lease right-of-use assets196,224 202,136 
Goodwill, net291,916 291,916 
Purchased intangibles, net191,764 199,497 
Other investments10,503,038 9,561,140 
Other assets92,189 86,723 
Total assets$13,933,160 $12,972,618 

















The accompanying notes are an integral part of these condensed consolidated financial statements. 



4

BIO-RAD LABORATORIES, INC.
Condensed Consolidated Balance Sheets
(continued)
(In thousands, except share data)



March 31, 2021December 31, 2020
LIABILITIES AND STOCKHOLDERS’ EQUITY:(Unaudited) 
Accounts payable$138,494 $139,451 
Accrued payroll and employee benefits174,889 222,875 
Current maturities of long-term debt and notes payable1,738 1,798 
Income and other taxes payable89,074 57,335 
Current operating lease liabilities39,235 36,507 
Other current liabilities166,462 173,570 
Total current liabilities609,892 631,536 
Long-term debt, net of current maturities10,901 12,258 
Deferred income taxes2,306,112 2,076,785 
Operating lease liabilities168,326 175,128 
Other long-term liabilities228,870 196,971 
Total liabilities3,324,101 3,092,678 
Stockholders’ equity:  
Class A common stock, shares issued 25,086,359 and 25,072,619 at 2021 and 2020, respectively; shares outstanding 24,692,104 and 24,767,870 at 2021 and 2020, respectively
2 2 
Class B common stock, shares issued and outstanding, 5,071,060 at 2021 and 5,076,186 at 2020
1 1 
Additional paid-in capital445,101 429,376 
Class A treasury stock at cost, 394,255 at 2021 and 304,749 shares at 2020
(149,905)(99,907)
Retained earnings10,245,426 9,268,012 
Accumulated other comprehensive income68,434 282,456 
Total stockholders’ equity10,609,059 9,879,940 
Total liabilities and stockholders’ equity$13,933,160 $12,972,618 


















The accompanying notes are an integral part of these condensed consolidated financial statements. 

5



BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Income
(In thousands, except per share data)
(Unaudited)
 Three Months Ended
 March 31,
 20212020
Net sales$726,796 $571,644 
Cost of goods sold326,169 254,276 
Gross profit400,627 317,368 
Selling, general and administrative expense225,853 193,692 
Research and development expense73,912 49,303 
Income from operations100,862 74,373 
Interest expense398 5,690 
Foreign currency exchange losses, net71 928 
Change in fair market value of equity securities(1,179,403)(827,671)
Other income, net(17,407)(3,273)
Income before income taxes1,297,203 898,699 
Provision for income taxes(319,789)(212,787)
Net income$977,414 $685,912 
Basic earnings per share:  
Net income per basic share$32.77 $22.97 
Weighted average common shares - basic29,823 29,865 
Diluted earnings per share:  
Net income per diluted share$32.38 $22.72 
Weighted average common shares - diluted30,186 30,196 


The accompanying notes are an integral part of these condensed consolidated financial statements. 



6

BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Comprehensive Income
(In thousands)
(Unaudited)
Three Months Ended
March 31,
 20212020
Net income$977,414 $685,912 
Other comprehensive income (loss):
Foreign currency translation adjustments, net of income taxes(214,323)(62,011)
Foreign other post-employment benefits adjustments, net of income taxes1,857 731 
Net unrealized holding loss on available-for-sale (AFS) debt investments, net of income taxes(1,556)(327)
Other comprehensive loss, net of income taxes(214,022)(61,607)
Comprehensive income$763,392 $624,305 



The accompanying notes are an integral part of these condensed consolidated financial statements.

7


BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Cash Flows
(In thousands, unaudited)
 Three Months Ended
 March 31,
 20212020
Cash flows from operating activities:  
Cash received from customers$728,013 $569,001 
Cash paid to suppliers and employees(612,803)(509,683)
Interest paid, net(309)(231)
Income tax payments, net(14,727)(4,528)
Dividend proceeds and miscellaneous receipts, net12,193 3,912 
Proceeds from forward foreign exchange contracts, net1,243 4,337 
Net cash provided by operating activities113,610 62,808 
Cash flows from investing activities:  
Capital expenditures(19,547)(21,591)
Proceeds from dispositions of property, plant and equipment12 38 
Payments for purchases of intangible assets— (100)
Payments for purchases of marketable securities and investments(74,925)(98,151)
Proceeds from sales of marketable securities and investments15,624 39,672 
Proceeds from maturities of marketable securities and investments30,509 67,710 
Net cash used in investing activities(48,327)(12,422)
Cash flows from financing activities:  
Payments on long-term borrowings(1,401)(1,415)
Payments of contingent consideration— (1,265)
Proceeds from issuances of common stock for share-based compensation4,052 4,068 
Payments for purchases of treasury stock(49,998)(100,005)
Net cash used in financing activities(47,347)(98,617)
Effect of foreign exchange rate changes on cash(7,347)(5,977)
Net increase (decrease) in cash, cash equivalents, and restricted cash10,589 (54,208)
Cash, cash equivalents, and restricted cash at beginning of period667,115 662,651 
Cash, cash equivalents, and restricted cash at end of period$677,704 $608,443 

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that agrees to the same amounts shown in the condensed consolidated statements of cash flows (in thousands):
March 31, 2021March 31, 2020
Cash and cash equivalents$673,470 $603,551 
Restricted cash included in Other current assets3,354 3,110 
Restricted cash included in Other assets880 1,782 
Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows$677,704 $608,443 

These restricted cash items are primarily related to performance guarantees and other restricted deposits.

The accompanying notes are an integral part of these condensed consolidated financial statements.

8

BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Changes in Stockholders' Equity
(In thousands)
(Unaudited)

Common StockAdditional Paid-in CapitalTreasury StockRetained EarningsAccumulated Other Comprehensive Income (Loss)Total Stockholders' Equity
Balance at December 31, 2020$3 $429,376 $(99,907)$9,268,012 $282,456 $9,879,940 
Net income— — — 977,414 — 977,414 
Other comprehensive loss, net of tax— — — — (214,022)(214,022)
Issuance of common stock— 4,052 — — — 4,052 
Stock compensation expense— 11,673 — — — 11,673 
Purchase of treasury stock— — (49,998)— — (49,998)
Balance at March 31, 2021$3 $445,101 $(149,905)$10,245,426 $68,434 $10,609,059 



Common StockAdditional Paid-in CapitalTreasury StockRetained EarningsAccumulated Other Comprehensive Income (Loss)Total Stockholders' Equity
Balance at December 31, 2019$3 $410,020 $(38,397)$5,470,779 $(87,348)$5,755,057 
Net income— — — 685,912 — 685,912 
Other comprehensive loss, net of tax— — — — (61,607)(61,607)
Issuance of common stock— 4,068 — — — 4,068 
Stock compensation expense— 9,654 — — — 9,654 
Purchase of treasury stock— — (100,005)— — (100,005)
Balance at March 31, 2020$3 $423,742 $(138,402)$6,156,691 $(148,955)$6,293,079 


The accompanying notes are an integral part of these condensed consolidated financial statements. 

9

BIO-RAD LABORATORIES, INC

Notes to Condensed Consolidated Financial Statements
(Unaudited)

1.BASIS OF PRESENTATION AND USE OF ESTIMATES

Basis of Presentation

In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries.  The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented.  All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year.  The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2020.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.

Use of Estimates

The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.

Revenue Recognition

We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.
10


Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recognized until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to customer specifications, which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control in relation to the equipment has occurred at that point as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon customer acceptance because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service.

At the time revenue is recognized, a provision is recorded for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns.

Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately.

The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.

We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.

Reagent Rental Agreements

Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. For purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the Company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Generally these arrangements do not contain an option for the lessee to purchase the underlying asset.

11

We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606.

Maintenance services, along with the reagents, are allocated to the non-lease elements and are recognized as income. Generally, the terms of the arrangements result in the transfer of control for reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer.

Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments.  Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales-type leases represent in aggregate an immaterial amount of lease income. Our reported lease income is primarily variable in nature and is recognized upon delivery or as the reagents are consumed by the customer.
Revenue allocated to the lease elements of these reagent rental arrangements represented approximately 2% and 3% of total revenue for the three months ended March 31, 2021 and March 31, 2020, respectively, and are included as part of Net sales in our condensed consolidated statements of income.

Contract costs:

As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income.

Disaggregation of Revenue:

The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions):
Three Months Ended
March 31,
20212020
Europe$247.7 $195.7 
Asia168.9 111.4 
United States271.4 229.5 
Other (primarily Canada and Latin America)38.8 35.0 
Total net sales$726.8 $571.6 

The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenue by industry segment sources are presented in our Segment Information footnote (see Note 10).

Deferred revenues primarily represents unrecognized fees billed or collected for extended service arrangements. The deferred revenue balance at March 31, 2021 and December 31, 2020 was $66.2 million and $60.0 million, respectively. The short-term deferred revenue balance at March 31, 2021 and December 31, 2020 was $48.0 million and $42.5 million, respectively.

12

We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income.  

Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the three month period ended March 31, 2021 and 2020 were as follows (in millions):
Three Months Ended
March 31,
20212020
Balance at beginning of period$9.8 $9.0 
Provision for warranty2.7 1.9 
Actual warranty costs(2.6)(2.7)
Balance at end of period$9.9 $8.2 

Allowance for Doubtful Accounts

We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. We review our exposure to accounts receivable and reserve for amounts if collectability is no longer reasonably assured based on an assessment of various factors including historical loss rates and expectations of forward-looking loss estimates.

Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer.

Changes in our allowance for doubtful accounts were as follows (in millions):
Three Months Ended
March 31,
20212020
Balance at beginning of period$19.8 $20.2 
Provision (recovery) for expected credit losses(0.6)(0.8)
Write-offs charged against the allowance(0.6)(0.5)
Balance at end of period$18.6 $18.9 



13



Recent Accounting Pronouncements Adopted

In March 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-04, "Facilitation of the Effects of Reference Rate Reform on Financial Reporting (Topic 848)"  The ASU provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate (e.g., LIBOR) reform if certain criteria are met, for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting.  The ASU is effective as of March 12, 2020 through December 31, 2022.  We will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis.  The ASU is currently not expected to have a material impact on our condensed consolidated financial statements. 
In January 2020, the FASB issued ASU 2020-01, "Clarifying the Interactions between Topic 321 Investments—Equity Securities, Topic 323 Investments—Equity Method and Joint Ventures, and Topic 815 Derivatives and Hedging." ASU 2020-01 clarifies that a company should consider observable transactions that require a company to either apply or discontinue the equity method of accounting under Topic 323 for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. ASU 2020-01 also clarifies that, when determining the accounting for certain forward contracts and purchased options a company should not consider, whether upon settlement or exercise, if the underlying securities would be accounted for under the equity method or fair value option. The ASU is currently not expected to have a material impact on our condensed consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes," which
eliminates certain exceptions within ASC 740, Income Taxes, and clarifies other aspects of the current guidance to
promote consistency among reporting entities. ASU 2019-12 was effective for fiscal years beginning after
December 15, 2020, with any adjustments reflected as of January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the condensed consolidated financial statements.


2.    FAIR VALUE MEASUREMENTS

We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:

•Level 1: Quoted prices in active markets for identical instruments
•Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)
•Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)

14

Financial assets and liabilities carried at fair value and measured on a recurring basis as of March 31, 2021 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Commercial paper$— $29.3 $— $29.3 
U.S. government sponsored agencies— 2.6 — 2.6 
Time deposits8.7 10.0 — 18.7 
Money market funds61.3 — — 61.3 
Total cash equivalents (a)70.0 41.9 — 111.9 
Restricted investments (b)6.8 — — 6.8 
Equity securities (c)10,524.3 — — 10,524.3 
Available-for-sale investments:
Corporate debt securities— 162.2 — 162.2 
U.S. government sponsored agencies— 71.8 — 71.8 
Foreign government obligations— 4.0 — 4.0 
Other foreign obligations— 2.1 — 2.1 
Municipal obligations— 14.1 — 14.1 
Asset-backed securities— 28.1 — 28.1 
Total available-for-sale investments (d)— 282.3 — 282.3 
Forward foreign exchange contracts (e)— 0.6 — 0.6 
Total financial assets carried at fair value$10,601.1 $324.8 $— $10,925.9 
Financial liabilities carried at fair value:   
Forward foreign exchange contracts (f)$— $1.1 $— $1.1 
Contingent consideration (g)— — 0.7 0.7 
Total financial liabilities carried at fair value$— $1.1 $0.7 $1.8 


15

Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2020 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Commercial paper$— $41.7 $— $41.7 
Time deposits17.6 10.0 — 27.6 
Asset-backed securities— 0.9 — 0.9 
U.S. government sponsored agencies— 2.5— 2.5 
Money market funds60.1 — — 60.1 
Total cash equivalents (a)77.7 55.1 — 132.8 
Restricted investments (b)6.7 — — 6.7 
Equity securities (c)9,582.4 — — 9,582.4 
Available-for-sale investments:
Corporate debt securities— 133.2 — 133.2 
U.S. government sponsored agencies— 76.9 — 76.9 
Foreign government obligations— 4.0 — 4.0 
Other foreign obligations— 2.1 — 2.1 
Municipal obligations— 15.2 — 15.2 
Asset-backed securities— 36.2 — 36.2 
Total available-for-sale investments (d)— 267.6 — 267.6 
Forward foreign exchange contracts (e)— 1.0 — 1.0 
Total financial assets carried at fair value$9,666.8 $323.7 $— $9,990.5 
Financial liabilities carried at fair value:
Forward foreign exchange contracts (f)$— $1.0 $— $1.0 
Contingent consideration (g)— — 0.7 0.7 
Total financial liabilities carried at fair value$— $1.0 $0.7 $1.7 

(a)Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.

(b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):
March 31, 2021December 31, 2020
Restricted investments$5.6 $5.6 
Other investments1.2 1.1 
    Total$6.8 $6.7 

(c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):
March 31, 2021December 31, 2020
Short-term investments$64.2 $61.4 
Other investments10,460.1 9,521.0 
        Total$10,524.3 $9,582.4 

16

The change in fair market value on our equity securities for the three months ended March 31, 2021 was a $1,179.4 million gain, which was primarily due to our investment in Sartorius AG and is recorded in our condensed consolidated statements of income.

As of March 31, 2021, we own 12,987,900 ordinary voting shares and 9,588,908 preference shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 37% of the ordinary outstanding voting shares (excluding treasury shares) and 28% of the preference shares of Sartorius as of March 31, 2021.

(d) Available-for-sale investments are included in the following accounts in the condensed consolidated balance sheets (in millions):
 March 31, 2021December 31, 2020
Short-term investments$282.2 $267.5 
Other investments0.1 0.1 
Total$282.3 $267.6 

(e) Forward foreign exchange contracts in an asset position are included in other current assets in the condensed consolidated balance sheets.

(f) Forward foreign exchange contracts in a liability position are included in other current liabilities in the condensed consolidated balance sheets.

(g) Contingent consideration liability is included in the following accounts in the condensed consolidated balance sheets (in millions):
March 31, 2021December 31, 2020
Other current liabilities$0.6 $0.6 
Other long-term liabilities0.1 0.1 
   Total$0.7 $0.7 

During the fourth quarter of 2019, we recognized a contingent consideration liability for earn-out targets related to our acquisition of a foreign distributor. The first earn-out payment of $0.7 million was paid by the acquisition date and the remaining payment is anticipated to be paid in the first half of 2021. The maximum earn-out payment due is $1.4 million. The contingent consideration was accrued at its estimated fair value of $0.6 million as of March 31, 2021 which is unchanged from the fair value at December 31, 2020.

During the second quarter of 2020, we recognized a contingent consideration liability upon our acquisition of Celsee, Inc. which represents the future potential earn-out payments of up to $60.0 million payable in cash upon the achievement of certain net revenues for the period beginning on January 1, 2021 and ending on December 31, 2022. The fair value of the earn-out as of the Acquisition Date was approximately $0.1 million which was determined by using a Black-Scholes-Merton option-pricing valuation model that includes significant assumptions and unobservable inputs such as the projected revenues of Celsee over the earn-out period and the probability of the earn-out threshold being met. The fair value of the contingent consideration is remeasured at each reporting period based on the assumptions and inputs on the date of remeasurement. The achievement of net revenues was not met as of March 31, 2021 and therefore the fair value of the earn-out remained unchanged at approximately $0.1 million as of March 31, 2021.

17


To estimate the fair value of Level 2 debt securities as of March 31, 2021, our primary pricing provider uses Reuters as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Reuters does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source.

Available-for-sale investments consist of the following (in millions):
 March 31, 2021
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Allowances for Credit Losses
Fair
Value
Short-term investments:    
Corporate debt securities$160.3 $1.9 $— $— $162.2 
Municipal obligations14.0 0.1 — — 14.1 
Asset-backed securities27.7 0.3 — — 28.0 
U.S. government sponsored agencies70.6 1.3 (0.1)— 71.8 
Foreign government obligations4.0 — — — 4.0 
  Other foreign obligations2.1 — — — 2.1 
 278.7 3.6 (0.1)— 282.2 
Long-term investments:    
Asset-backed securities0.1 — — — 0.1 
 0.1 — — — 0.1 
Total$278.8 $3.6 $(0.1)$— $282.3 

The following is a summary of the amortized cost and estimated fair value of our debt securities at March 31, 2021 by contractual maturity date (in millions):
Amortized
Cost		Estimated Fair
Value
Mature in less than one year$173.6 $174.1 
Mature in one to five years66.2 67.9 
Mature in more than five years39.0 40.3 
Total$278.8 $282.3 

18

Available-for-sale investments consist of the following (in millions):
 December 31, 2020
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Allowances for Credit LossesEstimated
Fair
Value
Short-term investments:    
Corporate debt securities$130.5 $2.7 $— — $133.2 
Municipal obligations15.0 0.2 — — 15.2 
Asset-backed securities35.8 0.3 — — 36.1 
U.S. government sponsored agencies74.7 2.2 — — 76.9 
Foreign government obligations4.0 — — — 4.0 
  Other foreign obligations2.1 — — — 2.1 
 262.1 5.4 — — 267.5 
Long-term investments:    
Asset-backed securities0.1 — — — 0.1 
 0.1 — — — 0.1 
Total$262.2 $5.4 $— $— $267.6 

The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):
March 31, 2021
Less than 12 monthsGreater than 12 monthsTotal
Description of securities:Fair ValueUnrealized LossesFair ValueUnrealized LossesFair ValueUnrealized Losses
U.S. government sponsored agencies7.4 0.1 — — 7.4 0.1 
Total$7.4 $0.1 $— $— $7.4 $0.1 

The unrealized losses of $0.1 million as of March 31, 2021 are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others.  

There were no significant unrealized losses as of December 31, 2020 in either the less than or greater than 12 month categories.
Our evaluation of credit losses for available-for-sale debt securities included the extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are limited to the amount that the fair value of an instrument is less than its amortized cost basis.

At March 31, 2021, we have concluded that all payments related to our available-for-sale investments are expected to be made in full and on time at par value. The diminution of value in the intervening period is due to market conditions such as illiquidity and interest rate movements and not due to significant, inherent credit concerns surrounding the issuer. As a result, we have no allowances for credit losses on our available-for-sale investments portfolio as of March 31, 2021.

19


Included in other current assets are $1.4 million of interest receivable as of March 31, 2021 and December 31, 2020, primarily associated with securities in our available-for-sale investments portfolio. Associated interest on these securities is typically payable semi-annually. Due to the short-term nature of our interest receivable asset, we have made an accounting policy election not to measure an allowance for credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue greater than one year to be impaired for purposes of write-off. For the three months ended March 31, 2021, we have not written-off any uncollected interest receivable.

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes.  We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date.  The notional principal amounts provide one measure of the transaction volume outstanding as of March 31, 2021 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties.  The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in foreign currency exchange losses, net in the condensed consolidated statements of income.

The following is a summary of our forward foreign exchange contracts (in millions):
 March 31,
 2021
Contracts maturing in April through June 2021 to sell foreign currency: 
Notional value$284.0 
Unrealized loss$0.4 
Contracts maturing in April through June 2021 to purchase foreign currency: 
Notional value$252.3 
Unrealized gain or loss$— 

Included in other investments in the condensed consolidated balance sheets are investments without readily determinable fair value measured at cost with adjustments for observable price changes in price or impairments. The carrying value of these investments was $6.5 million and $0.5 million as of March 31, 2021 and December 31, 2020, respectively.

Also included in other investments in the condensed consolidated balance sheets are our equity method investments, for which our share of the equity method investees earnings is included in other income, net in our condensed consolidated statements of income. The carrying value of these investments was $35.2 million and $38.4 million as of March 31, 2021 and December 31, 2020, respectively.


20

3    GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment were as follows (in millions):
Life
Science		Clinical
Diagnostics		Total
Balances as of March 31, 2021 and December 31, 2020:
Goodwill277.9 349.2 627.1 
Accumulated impairment losses(41.8)(293.4)(335.2)
Goodwill, net$236.1 $55.8 $291.9 

Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions):
March 31, 2021
Weighted-Average Remaining Amortization Period (years)Purchase
Price		Accumulated
Amortization		Net
Carrying
Amount
Customer relationships/lists5.47$112.4 $(85.6)$26.8 
Know how4.50192.7 (172.6)20.1 
Developed product technology13.83217.1 (108.6)108.5 
Licenses7.5165.2 (38.0)27.2 
Tradenames7.716.4 (4.2)2.2 
Covenants not to compete3.664.6 (2.2)2.4 
Other—0.1 (0.1)— 
     Total definite-lived intangible assets598.5 (411.3)187.2 
In-process research and development4.6 — 4.6 
     Total purchased intangible assets $603.1 $(411.3)$191.8 
 December 31, 2020
Weighted-Average Remaining Amortization Period (years)Purchase
Price		Accumulated
Amortization		Net
Carrying
Amount
Customer relationships/lists5.51$116.6 $(87.2)$29.4 
Know how4.75196.6 (175.4)21.2 
Developed product technology14.00218.1 (107.1)111.0 
Licenses7.7365.6 (37.4)28.2 
Tradenames7.826.6 (4.2)2.4 
Covenants not to compete3.874.5 (2.0)2.5 
Other—0.1 (0.1)— 
     Total definite-lived intangible assets608.1 (413.4)194.7 
In-process research and development4.8 — 4.8 
     Total purchased intangible assets $612.9 $(413.4)$199.5 

21


Amortization expense related to purchased intangible assets is as follows (in millions):
Three Months Ended
 March 31,
 20212020
Amortization expense$7.2 $5.9 



4.    SUPPLEMENTAL CASH FLOW INFORMATION

The reconciliation of net income to net cash provided by operating activities is as follows (in millions):
Three Months Ended
March 31, 2021March 31, 2020
Net income$977.4 $685.9 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization32.7 33.6 
Reduction in the carrying amount of right-of-use assets9.8 9.6 
Share-based compensation11.7 9.7 
Gains on dispositions of securities(0.1)(0.4)
Other-than-temporary impairment losses on investment0.8 — 
Changes in fair market value of equity securities(1,179.4)(827.7)
Losses on dispositions of fixed assets0.3 0.1 
Changes in fair value of contingent consideration— (0.1)
Payments for operating lease liabilities(9.9)(9.3)
Decrease in accounts receivable1.3 2.2 
Decrease (increase) in inventories5.8 (13.7)
Increase in other current assets(37.5)(9.5)
Decrease in accounts payable and other current liabilities(44.5)(25.6)
Increase in income taxes payable27.3 20.9 
Increase in deferred income taxes274.8 171.8 
Increase in other long term liabilities43.8 15.7 
Other(0.7)(0.4)
Net cash provided by operating activities$113.6 $62.8 
Non-cash investing activities:
   Purchased property, plant and equipment$4.7 $6.0 
   Purchased marketable securities and investments$— $2.7 







22


5.    LONG-TERM DEBT

The principal components of long-term debt are as follows (in millions):
March 31,
2021		December 31,
2020
Finance leases and other debt$12.6 $14.1 
Less current maturities(1.7)(1.8)
Long-term debt$10.9 $12.3 

Credit Agreement

In April 2019, Bio-Rad entered into a $200.0 million unsecured revolving credit facility ("Credit Agreement"). Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of March 31, 2021; however, $0.2 million was utilized for domestic standby letters of credit that reduced our borrowing availability as of March 31, 2021. The Credit Agreement matures in April 2024. If we had borrowed against our Credit Agreement, the borrowing rate would have been 1.315% at March 31, 2021, which is based on the 3-month LIBOR.

The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens.  We were in compliance with all of these ratios and covenants as of March 31, 2021.



23



6.    ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Accumulated other comprehensive income included in our condensed consolidated balance sheets consists of the following components (in millions):
Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains on available-for-sale investmentsTotal accumulated other comprehensive income (loss)
Balances as of January 1, 2021:$298.6 $(26.0)$9.8 $282.4 
Other comprehensive (loss) income, before reclassifications(214.7)1.7 (1.9)(214.9)
Amounts reclassified from Accumulated other comprehensive income— 0.5 (0.1)0.4 
Income tax effects0.4 (0.3)0.4 0.5 
Other comprehensive (loss) income, net of income taxes(214.3)1.9 (1.6)(214.0)
Balances as of March 31, 2021:$84.3 $(24.1)$8.2 $68.4 
Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains on available-for-sale investmentsTotal accumulated other comprehensive income (loss)
Balances as of January 1, 2020:$(72.4)$(22.2)$7.2 $(87.4)
Other comprehensive (loss) income, before reclassifications(62.9)0.2 — (62.7)
Amounts reclassified from Accumulated other comprehensive income— 0.3 (0.4)(0.1)
Income tax effects0.9 0.2 0.1 1.2 
Other comprehensive (loss) income, net of income taxes(62.0)0.7 (0.3)(61.6)
Balances as of March 31, 2020:$(134.4)$(21.5)$6.9 $(149.0)

All amounts reclassified out of accumulated other comprehensive income were reclassified into other income, net in the condensed consolidated statements of income. The reclassification adjustments are calculated using the specific identification method.





24

7.    EARNINGS PER SHARE

Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect of including such securities would be anti-dilutive.

The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands):
Three Months Ended
March 31,
 20212020
Basic weighted average shares outstanding29,823 29,865 
Effect of potentially dilutive stock options and restricted stock awards
363 331 
Diluted weighted average common shares30,186 30,196 
Anti-dilutive shares23 62 


8.    OTHER INCOME AND EXPENSE, NET

Other (income) expense, net includes the following components (in millions):
Three Months Ended
March 31,
 20212020
Interest and investment income$(18.3)$(2.8)
Net realized gains on investments(0.1)(0.4)
Other-than-temporary impairment loss on investment0.8 — 
Other expense (income) 0.2 (0.1)
Other (income), net$(17.4)$(3.3)


25

9.    INCOME TAXES

Our effective income tax rate was 24.7% and 23.7% for the three months ended March 31, 2021 and 2020, respectively.

The realization of deferred tax assets is dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that certain foreign deferred tax assets will not be realized as of March 31, 2021, and have maintained a valuation allowance on such deferred tax assets.

Our income tax returns are routinely audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues around the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

Our gross unrecognized tax benefits were $57.5 million and $55.8 million as of March 31, 2021 and December 31, 2020, respectively. The increase to our gross unrecognized tax benefits is primarily the result of a $1.7 million net increase in tax positions taken in the current year net of foreign currency translation adjustments.

As of March 31, 2021, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitations for certain jurisdictions, we believe that within the next 12 months it is reasonably possible that our previously unrecognized tax benefits could decrease by up to $16.7 million primarily related to various foreign jurisdictions.

10.    SEGMENT INFORMATION

Information regarding operating segments for the three months ended March 31, 2021 and 2020 is as follows (in millions):
Life
Science		Clinical
Diagnostics		Other
Operations
Segment net sales 2021$366.5 $358.5 $1.8 
 2020$227.2 $340.3 $4.1 
Segment net profit (loss)2021$102.3 $(1.9)$0.1 
 2020$23.7 $43.8 $1.1 

26


Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. Our chief operating decision maker ("CODM") views all operating expenses, interest expense and corporate overhead as directly supporting the strategies of our segments. As a result, starting in 2021 these costs are fully allocated to our reportable segments. Prior to this change, the difference between total segment allocated interest expense, depreciation and amortization, and the corresponding consolidated amounts was attributable to our corporate headquarters.

The historical segment information has been recast to conform to the current allocation methodology of corporate operating and other expenses to the segments.  Interest expense is charged to segments based on the carrying amount of inventory and receivables employed by that segment. The following reconciles total segment profit to consolidated income before income taxes (in millions):

Three Months Ended
March 31,
 20212020
Total segment profit $100.5 $68.6 
Foreign currency exchange losses, net(0.1)(0.9)
Change in fair market value of equity securities1,179.4 827.7 
Other income, net17.4 3.3 
Consolidated income before income taxes$1,297.2 $898.7 


11.    LEGAL PROCEEDINGS

We are a party to various claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.


12.    RESTRUCTURING COSTS

In February 2021, we announced our strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance. The restructuring plan primarily impacts our operations in Europe and includes the elimination of certain positions, the consolidation of certain functions, and the relocation of certain manufacturing operations from Europe to Asia. The restructuring plan will be implemented in phases and is expected to be substantially complete by the end of 2022. The liability of $71.2 million as of March 31, 2021 consisted of $35.2 million recorded in Accrued payroll and employee benefits and $36.0 million recorded in Other long-term liabilities in the condensed consolidated balance sheets. The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense were $23.9 million, $34.7 million and $17.0 million in the condensed consolidated statements of income for the three months ended March 31, 2021, respectively. The amounts are preliminary estimates based on the information currently available to management. It is possible that additional adjustments and future cash payments could occur in relation to the restructuring actions.

27


The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions):

Life ScienceClinical DiagnosticsTotal
Balances as of December 31, 2020:$— $— $— 
Charged to expense - employee termination benefits12.9 62.7 75.6 
Cash payments(0.1)(1.9)(2.0)
Foreign currency translation gains(0.4)(2.0)(2.4)
Balances as of March 31, 2021:$12.4 $58.8 $71.2 


13.    LEASES: FINANCE AND OPERATING WHERE WE ACT AS LESSEE

For operating leases where we act as lessor in reagent rental agreements, see Note 1. We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. For operating leases, we have elected not to separate lease and non-lease components for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 18 years, which includes our determination to exercise renewal options.

We determine if an arrangement is a lease at inception. Right-of-use (ROU) assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Operating lease ROU assets also include any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

The components of lease expense were as follows (in millions):
Three Months Ended
March 31,
20212020
Operating lease cost$11.7 $12.6 
Finance lease cost:
  Amortization of right-of-use assets$0.1 $0.1 
  Interest on lease liabilities0.2 0.2 
        Total finance lease cost$0.3 $0.3 
Sublease income$0.7 $0.7 
The sublease is for a building with a term that ends in 2025, with no options to extend or renew.

Operating lease cost includes original reduction in the carrying amount of ROU assets, the impact of remeasurements, modifications, impairments and abandonments.

28


Our short-term leases are expensed as incurred, reflecting leases with a lease term of one year or less, and are not significant for both the three months ended March 31, 2021 and 2020. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial for both the three months ended March 31, 2021 and 2020.

Supplemental cash flow information related to leases was as follows (in millions):

Three Months Ended
March 31,
20212020
Cash paid for amounts included in the measurement of lease liabilities:
  Operating cash flows from operating leases$11.8 $11.4 
  Operating cash flows from finance leases$0.1 $0.2 
  Financing cash flows from finance leases$0.2 $0.1 
Right-of-use assets obtained in exchange for new lease obligations:
  Operating leases$4.2 $10.8 
  Finance leases$— $— 
Supplemental balance sheet information related to leases was as follows (in millions):
March 31, 2021December 31, 2020
Operating Leases
  Operating lease right-of-use assets$196.2 $202.1 
  Current operating lease liabilities$39.3 $36.5 
  Operating lease liabilities168.3 175.1 
     Total operating lease liabilities$207.6 $211.6 

Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities (in millions):
March 31, 2021December 31, 2020
Finance Leases
  Property, plant and equipment, gross$12.2 $12.2 
  Less: accumulated depreciation and amortization(5.1)(5.0)
      Property, plant and equipment, net$7.1 $7.2 
  Current maturities of long-term debt and notes payable$0.5 $0.5 
  Long-term debt, net of current maturities10.9 11.0 
      Total finance lease liabilities$11.4 $11.5 

29

March 31, 2021December 31, 2020
Weighted Average Remaining Lease Term
  Operating leases - in years88
  Finance leases - in years1616
Weighted Average Discount Rate
  Operating leases3.9 %3.9 %
  Finance leases6.2 %6.2 %

Maturities of lease liabilities were as follows (in millions):
Year Ending December 31,Operating LeasesFinance Leases
2021 (excluding the three months ended March 31, 2021)$35.3 $1.0 
202238.6 1.3 
202332.4 1.2 
202426.4 1.1 
202523.1 1.1 
Thereafter90.6 14.0 
   Total lease payments246.4 19.7 
Less imputed interest(38.8)(8.3)
    Total$207.6 $11.4 

The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles, and other equipment with shorter terms and higher-turn over.


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This discussion should be read in conjunction with the information contained in both our consolidated financial statements for the year ended December 31, 2020 and the condensed consolidated financial statements for the three months ended March 31, 2021.

Overview.  We are a multinational manufacturer and worldwide distributor of our own life science research and clinical diagnostics products. Our business is organized into two reportable segments, Life Science and Clinical Diagnostics, with the mission to provide scientists with specialized tools needed for biological research and health care specialists with products needed for clinical diagnostics.

We sell more than 9,000 products and services to a diverse client base comprised of scientific research, healthcare, education and government customers worldwide. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.

We manufacture and supply our customers with a range of reagents, apparatus and equipment to separate complex chemical and biological materials and to identify, analyze and purify components. Because our customers require standardization for their experiments and test results, much of our revenues are recurring.  


30

We are impacted by the support of many governments for both research and healthcare. The current global economic outlook is still uncertain as the need to control government social spending by many governments limits opportunities for growth. Adding to this uncertainty is the withdrawal of the United Kingdom from the European Union. Approximately 37% of our year-to-date 2021 consolidated net sales are derived from the United States and approximately 63% are derived from international locations, with Europe being our largest international region. The international sales are largely denominated in local currencies such as the Euro, Swiss Franc, Japanese Yen, Chinese Yuan and British Sterling. As a result, our consolidated net sales expressed in dollars benefit when the U.S. dollar weakens and suffer when the dollar strengthens. When the U.S. dollar strengthens, we benefit from lower cost of sales from our own international manufacturing sites as well as non-U.S. suppliers, and from lower international operating expenses. We regularly discuss our changes in revenue and expense categories in terms of both changing foreign exchange rates and in terms of a currency neutral basis, if notable, to explain the impact currency has on our results.

COVID-19

The full impact of the COVID-19 pandemic continues to be inherently uncertain at the time of this report. The COVID-19 pandemic has impacted and, we expect, will continue to disrupt parts of our business operations, impacting our financial conditions and results of operations in a variety of ways. We saw strong demand for products associated with COVID-19 testing and related research. For more discussions relating to the impacts on the COVID-19 pandemic, please see "Item 1A. Risk Factors" to this Form 10-Q.

Restructuring

In February 2021, we announced our strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance. The restructuring plan primarily impacts our operations in Europe and includes the elimination of certain positions, the consolidation of certain functions, and the relocation of certain manufacturing operations from Europe to Asia. The restructuring plan will be implemented in phases and is expected to be substantially complete by the end of 2022. The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense were $23.9 million, $34.7 million and $17.0 million in the condensed consolidated statements of income for the three months ended March 31, 2021, respectively. As of March 31, 2021, we have a restructuring accrual of $71.2 million. The amounts are preliminary estimates based on the information currently available to management.

Results of Operations

The following table shows cost of goods sold, gross profit, components of operating expense, change in fair market value of equity securities, and net income as a percentage of net sales:
Three Months Ended
March 31,
 20212020
Net sales100.0 %100.0 %
Cost of goods sold44.9 44.5 
Gross profit55.1 55.5 
Selling, general and administrative expense31.1 33.9 
Research and development expense10.2 8.6 
Change in fair market value of equity securities162.3 144.8 
Net income134.5 120.0 



31

Critical Accounting Policies and Estimates

An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably likely to occur could materially impact the financial statements.  Management believes that there have been no significant changes during the three months ended March 31, 2021 to the items that we disclosed as our critical accounting policies and estimates in Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.  

Other than the recent accounting pronouncement adoptions as discussed in Note 1 to the condensed consolidated financial statements, there have been no substantial changes in our significant accounting policies during the three months ended March 31, 2021, compared with the significant accounting policies described in our Annual Report on Form 10-K for the year ended December 31, 2020.

Three Months Ended March 31, 2021 Compared to
Three Months Ended March 31, 2020

Results of Operations -- Sales, Margins and Expenses

Percentage sales growth in currency neutral amounts are calculated by translating prior period sales in each local currency using the current period monthly average foreign exchange rates for that currency and comparing that to current period sales.

Net sales (sales) for the first quarter of 2021 were $726.8 million compared to $571.6 million in the first quarter of 2020, an increase of 27.1%.  Excluding the impact of foreign currency, first quarter 2021 sales increased by approximately 23.4% compared to the same period in 2020. Currency neutral sales increased in all regions, led by Asia Pacific and Europe.

The Life Science segment sales for the first quarter of 2021 were $366.5 million, an increase of 61.3% compared to the same period last year.  On a currency neutral basis, sales increased 56.9% compared to the first quarter in 2020. Currency neutral sales were up in nearly all product lines but were primarily driven by growth in our qPCR, Western Blotting, Droplet Digital PCR, and Process Media products. A significant portion of the Life Sciences segment growth came from products used to support COVID-19 research and testing. All regions experienced double digit currency neutral sales growth compared to the first quarter of 2020.

The Clinical Diagnostics segment sales for the first quarter of 2021 were $358.5 million, an increase of 5.4% compared to the same period last year.  On a currency neutral basis, sales increased 2.2% compared to the first quarter in 2020.  The currency neutral sales increase was primarily driven by the recovery in our diabetes monitoring business and the continuing performance of the quality controls business, especially in Asia Pacific.

Consolidated gross margins were 55.1% for the first quarter of 2021 compared to 55.5% for the first quarter of 2020.  Life Science segment gross margins for the first quarter of 2021 increased from the prior year period by approximately 6.0 percentage points. Favorable product mix related to higher sales of Gene Expression and Process Media products and lower production costs drove the margins higher. Clinical Diagnostics segment gross margins for the first quarter of 2021 decreased by approximately 7.7 percentage points from the same period last year. Clinical Diagnostics margins were significantly impacted by $23.9 million in expenses related to the restructuring plan that was announced in February 2021.

Selling, general and administrative expenses (SG&A) increased to $225.9 million or 31.1% of sales for the first quarter of 2021 compared to $193.7 million or 33.9% of sales for the first quarter of 2020.  The increase to SG&A was primarily related to $34.7 million in expenses related to the restructuring plan announced in February 2021.

32

Research and development (R&D) expense increased to $73.9 million or 10.2% of sales in the first quarter of 2021 compared to $49.3 million or 8.6% of sales in the first quarter of 2020.  Life Science segment R&D increased in the first quarter of 2021 compared to the prior year period, primarily from increased headcount from the Celsee acquisition, increased personnel costs, and increased investment in outside services to complete projects in key investment areas. Clinical Diagnostics segment R&D increased in the first quarter of 2021 from the prior year period, primarily due to $17.0 million in expenses related to the restructuring plan announced in February 2021.

Results of Operations – Non-operating

Interest expense for the first quarter of 2021 and 2020 was $0.4 million and $5.7 million, respectively, a decrease of $5.3 million primarily due to the repayment of the $425.0 million principal amount of Senior Notes in December 2020.

Foreign currency exchange gains and losses consist primarily of foreign currency transaction gains and losses on intercompany net receivables and payables and the change in fair value of our forward foreign exchange contracts used to manage our foreign currency exchange risk.  Foreign currency exchange net losses were $0.1 million for the first quarter of 2021 compared to $0.9 million for the first quarter of 2020. Gains and losses are primarily due to the estimating process inherent in the timing of product shipments and intercompany debt payments, market volatility, and the change in the fair value of our foreign exchange contracts.

Change in fair market value of equity securities was a gain of $1.18 billion and $827.7 million for the first quarter of 2021 and 2020, respectively, primarily resulting from the recognition of higher holding gains in the first quarter of 2021 compared to the first quarter of 2020 on our position in Sartorius AG.

Other income, net for the first quarter of 2021 was $17.4 million compared to $3.3 million for the first quarter of 2020. The increase of $14.1 million of income was primarily due to Sartorius AG dividends of $19.0 million that were declared in the first quarter of 2021 compared to no Sartorius AG dividends in the first quarter of 2020, partially offset by $4.7 million of lower investment income compared to the first quarter of 2020.

Our effective income tax rate was 24.7% and 23.7% for the three months ended March 31, 2021 and 2020, respectively. The increase in our effective income tax rate was due to the restructuring initiative announced in February 2021.

Our income tax returns are routinely audited by U.S. federal, state and foreign tax authorities. We are currently
under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations,
and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of
deductions and allocations of income among various tax jurisdictions. We do not believe any currently pending
uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an
adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the
results of operations for that period.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe the
resolution of our uncertain tax positions will have a material adverse effect on our consolidated financial statements,
although an adverse resolution of one or more of these uncertain tax positions in any period may have a material
impact on the results of operations for that period.

As of March 31, 2021, based on the expected outcome of certain examinations or as a result of the expiration of
statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible
that our previously unrecognized tax benefits could decrease by approximately $16.7 million. Substantially all such
amounts will impact our effective income tax rate.

33


Liquidity and Capital Resources

Bio-Rad operates and conducts business globally, primarily through subsidiary companies established in the markets in which we trade.  Goods are manufactured in a small number of locations, and are then shipped to local distribution facilities around the world.  Our product mix is diversified, and certain products compete largely on product efficacy, while others compete on price.  Gross margins are generally sufficient to exceed normal operating costs, and funding for research and development of new products, as well as routine outflows for capital expenditures, interest and taxes.  In addition to the annual positive cash flow from operating activities, additional liquidity is readily available via the sale of short-term investments and access to our $200.0 million unsecured revolving credit facility (Credit Agreement) that we entered into in April 2019, and to a lesser extent international lines of credit.  Borrowings under the Credit Agreement are available on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the 2019 Credit Agreement as of March 31, 2021, however, $0.2 million was utilized for domestic standby letters of credit that reduced our borrowing availability. Management believes that this availability, together with cash flow from operations, will be adequate to meet our current objectives for operations, research and development, capital additions for manufacturing and distribution, plant and equipment, information technology systems and acquisitions of reasonable proportion to our existing total available capital.

Because the Company might be deemed an investment company under the Investment Company Act based on the market value of our position in Sartorius AG, the Company may not be able to access the capital markets or otherwise obtain additional financing until it is determined that the Company is not an investment company. The inability to obtain additional financing may have a negative impact on the Company's ability to make acquisitions or other non-routine investments.

At March 31, 2021, we had available $1.03 billion in cash, cash equivalents and short-term investments, of which approximately 31% was held in our foreign subsidiaries. We believe that our holdings of cash, cash equivalents and short-term investments in the U.S. and in our foreign subsidiaries are sufficient to meet both the current and long-term needs of our global operations. The amount of funds held in the United States can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as acquisitions. As part of our ongoing liquidity assessments, we regularly monitor the mix of domestic and foreign cash flows (both inflows and outflows).

It is generally our intention to repatriate certain foreign earnings to the extent that such repatriations are not restricted by local laws or accounting rules, and there are no substantial incremental costs. 

Demand for our products and services could change more dramatically in the short-term than in previous years due to the impacts of the COVID-19 pandemic, as well as due to funding, reimbursement constraints and support levels from government, universities, hospitals and private industry, including diagnostic laboratories. The need for certain sovereign nations with large annual deficits to curtail spending, international trade disputes and increased regulation, could lead to slower growth of, or even a decline in, our business. Sovereign nations either delaying payment for goods and services or renegotiating their debts could impact our liquidity.


Cash Flows from Operations

Net cash provided by operations was $113.6 million compared to $62.8 million for the three months ended March 31, 2021 and 2020, respectively.  The increase in operating cash flows was primarily due to higher cash received from customers as a result of the growth in sales for product lines used for COVID-19, and higher investment income as we received the Sartorius AG ordinary dividends in the first quarter of 2021 compared to receiving no Sartorius AG dividends in the first quarter of 2020. These increases were partially offset by higher cash paid to suppliers primarily for materials associated with COVID-19 products, cash paid for employee related expenses such as salaries, bonuses and benefits, and to a lesser extent for employee restructuring programs. The increases were also partially offset by higher income taxes paid.
34


Cash Flows from Investing Activities

Our investing activities have consisted primarily of capital expenditures and activity related to the purchases, sales and maturities of marketable securities.

Net cash used in investing activities was $48.3 million and $12.4 million for the for the three months ended March 31, 2021 and 2020, respectively. The increase was primarily attributable to a $38.0 million increase in net cash outflows from maturities, sales and purchases of marketable securities and investments, partially offset by lower capital expenditures.
Cash Flows from Financing Activities

Our financing activities have consisted primarily of cash used for purchases of treasury stock and payments for contingent consideration, and cash proceeds from the issuance of common stock for share-based compensation.

Net cash used in financing activities was $47.3 million and $98.6 million for the three months ended March 31, 2021, and 2020, respectively. This decrease was primarily attributable to a $50.0 million decrease in cash used to purchase treasury stock.

Treasury Shares

During the first quarter of 2021, we repurchased 89,506 shares of Class A common stock for $50.0 million under our Share Repurchase Program compared to the repurchase of 291,941 shares of our Class A common stock for $100.0 million in 2020. No shares were purchased for the remainder of 2020. We designated these repurchased shares as treasury stock. As of March 31, 2021, $223.1 million remained under the Share Repurchase Program.

Recent Accounting Pronouncements Adopted

See Note 1 to the condensed consolidated financial statements for recent accounting pronouncements adopted and to be adopted.


Item 3. Quantitative and Qualitative Disclosures about Market Risk

During the three months ended March 31, 2021, there have been no material changes from the disclosures about market risk provided in our Annual Report on Form 10-K for the year ended December 31, 2020.


Item 4. Controls and Procedures

Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its
35

judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Subject to the limitations noted above, our management, with the participation of our CEO and CFO, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, the CEO and CFO have concluded that, as of such date, our disclosure controls and procedures were effective to meet the objective for which they were designed and operate at the reasonable assurance level.

Changes to Internal Control Over Financial Reporting

We identified no changes in internal control over financial reporting that occurred during our quarter ended March 31, 2021 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.



PART II – OTHER INFORMATION

Item 1. Legal Proceedings

See Note 11, “Legal Proceedings” in the Notes to the condensed consolidated financial statements of Part I, Item 1 of this Quarterly Report on Form 10-Q.



Item 1A. Risk Factors

In evaluating our business and whether to invest in any of our securities, you should carefully read the following risk factors in addition to the other information contained in this report. We believe that any of the following risks could have a material effect on our business, results of operations or financial condition, our industry or the trading price of our common stock. We operate in a continually changing business environment, and new risks and uncertainties emerge from time to time. We cannot predict these new risks and uncertainties, nor can we assess the extent to which any such new risks and uncertainties or the extent to which the risks and uncertainties set forth below may adversely affect our business, results of operations, financial condition, our industry or the trading price of our common stock. Please carefully consider the following discussion of significant factors, events and uncertainties that make an investment in our securities risky and provide important information for the understanding of the “forward-looking” statements discussed this report. In addition to the effects of the COVID-19 pandemic and resulting global disruptions on our business and operations discussed in this report, additional or unforeseen effects from the COVID-19 pandemic and the global economic climate may give rise to or amplify many of these risks discussed below.

Business, Economic, Legal and Industry Risks

Pandemics or disease outbreaks, such as the COVID-19 pandemic, have affected and could materially adversely affect our business, operations, financial condition, and results of operations.

Although we expect that vaccinations for COVID-19 will continue to improve conditions, the COVID-19 pandemic is having and is expected to continue to have an adverse effect on the United States and global economies, as well as on aspects of our operations and those of third parties on whom we rely. The COVID-19 pandemic has impacted and, we expect, will continue to impact parts of our business, operations, financial condition and results of operations in a variety of ways.
36


Although demand has increased for certain of our products being used in fighting the COVID-19 pandemic, we are experiencing some decreases in product demand in certain of our other businesses. Many of our customers continue to have reduced or modified operations to various extents, resulting in labs, universities and other customers' facilities being opened at reduced capacity, hospital visits have declined as people delay elective surgeries and avoid non-essential trips to the hospital, and routine diagnostic testing has slowed. Although certain locations have experienced an improvement in conditions related to the pandemic, we expect that parts of our business will continue to suffer negative impacts from the pandemic even as conditions improve in some locations. An improvement in the COVID-19 pandemic conditions may result in a decrease in demand for our products being used in fighting the COVID-19 pandemic and have a negative impact on our financial results.

On the supply side, we continue to experience some challenges with the supply of raw materials and components used in the production of our products, with some suppliers operating at reduced or modified capacity and otherwise unable to meet our increased demand for raw materials and inputs to manufacture our products being used in fighting the COVID-19 pandemic. In addition, we continue to experience some transportation challenges in moving goods across regions, including reduced freight availability as many airlines have significantly scaled back flight operations and increased freight surcharges due to reduced freight capacity. Countries have closed their borders and imposed travel restrictions and may continue to impose measures that restrict the movement of our goods. While we have not experienced significant raw material cost increases as a result of the COVID-19 pandemic, we may experience such cost increases in the future. The invocation by the U.S. federal government of the Defense Production Act of 1950 with respect to our manufacturing operations, or the enforcement of comparable laws by other governmental entities, could disrupt our manufacturing and distribution operations.

With respect to our personnel, as a critical health care supplier, we continue to keep essential production, distribution and service teams onsite working in manufacturing and supply chain facilities throughout the world. Although we are adhering to government mandated and Environmental, Health and Safety protocols, an outbreak of COVID-19 at one or more of our facilities could nonetheless cause shutdowns of facilities and a reduction in our workforce, which could dramatically affect our ability to operate our business and our financial results.

The duration of the COVID-19 pandemic is unknown, even with the distribution of a vaccine, and it is difficult to predict the full extent of potential impacts the pandemic will have in the future on our business, operations, and financial results, or on our customers, suppliers, logistics providers, or on the global economy as a whole.

Our international operations expose us to additional costs and legal and regulatory risks, which could have a material adverse effect on our business, results of operations and financial condition.

We have significant international operations. We have direct distribution channels in over 36 countries outside the United States, and during the three months ended March 31, 2021 our foreign entities generated 63% of our net sales. Compliance with complex foreign and U.S. laws and regulations that apply to our international operations increases our cost of doing business. These numerous and sometimes conflicting laws and regulations include, among others, data privacy requirements, labor relations laws, tax laws, anti-competition regulations, import and trade restrictions, tariffs, duties, quotas and other trade barriers, export requirements, U.S. laws such as the Foreign Corrupt Practices Act ("FCPA") and other U.S. federal laws and regulations established by the office of Foreign Asset Control, foreign laws such as the UK Bribery Act 2010 or other foreign laws which prohibit corrupt payments to governmental officials or certain payments or remunerations to customers. In addition, changes in laws or regulations potentially could be disruptive to our operations and business relationships in the affected regions. For example, the United Kingdom's withdrawal from the European Union (commonly referred to as “Brexit”) is causing some disruption to the free movement of goods, services and people between the United Kingdom and the European Union and could result in increased regulatory, legal, labor and tax complexities.

37


Given the high level of complexity of the foreign and U.S. laws and regulations that apply to our international operations, there is a risk that we may inadvertently breach some provisions, for example, through fraudulent or negligent behavior of individual employees, our failure to comply with certain formal documentation requirements, or otherwise. Our success depends, in part, on our ability to anticipate these risks and manage these challenges through policies, procedures and internal controls. However, we have a dispersed international sales organization, and we use distributors and agents in many of our international operations. This structure makes it more difficult for us to ensure that our international selling operations comply with laws and regulations, and our global policies and procedures.

Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Violations of laws and regulations also could result in prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, or our business, results of operations and financial condition. As previously disclosed, we entered into a non-prosecution agreement (NPA) with the U.S. Department of Justice (DOJ) and the Securities and Exchange Commission (SEC) and consented to the entry of an Order by the SEC (SEC Order), effective November 3, 2014, which actions resolved both the DOJ and the SEC investigations into our violations of the FCPA. Any future violations of the FCPA could result in more punitive actions by the SEC and DOJ and/or could harm our reputation with customers, either of which could materially adversely affect our business, results of operations and financial condition. See also our risk factors regarding the COVID-19 pandemic above and regarding government regulations and global economic conditions below.

The industries and market segments in which we operate are highly competitive, and we may not be able to compete effectively.

The life science and clinical diagnostics markets are each highly competitive. Some of our competitors have greater financial resources than we do, making them better equipped to license technologies and intellectual property from third parties or to fund research and development, manufacturing and marketing efforts. Moreover, competitive and regulatory conditions in many markets in which we operate restrict our ability to fully recover, through price increases, higher costs of acquired goods and services resulting from inflation and other drivers of cost increases. Many public tenders have become more competitive due to governments lengthening the commitments of their public tenders to multiple years, which reduce the number of tenders in which we can participate annually. Because the value of these multiple-year tenders is so high, our competitors have been more aggressive with their pricing. Our failure to compete effectively and/or pricing pressures resulting from competition could adversely affect our business, results of operations and financial condition.

We may not be able to grow our business because of our failure to develop new or improved products.

Our future growth depends in part on our ability to continue to improve our product offerings and develop and introduce new product lines and extensions that integrate technological advances. In particular, we may not be able to keep up with changes in the clinical diagnostics industry, such as the trend toward molecular diagnostics or point-of-care tests. If we are unable to integrate technological advances into our product offerings or to design, develop, manufacture and market new product lines and extensions successfully and in a timely manner, our business, results of operations and financial condition will be adversely affected. The COVID-19 pandemic may delay our ability to develop and introduce new products. We have experienced product launch delays in the past and may do so in the future. We cannot assure you that our product and process development efforts will be successful or that new products we introduce will achieve market acceptance. Failure to launch successful new products or improvements to existing products may cause our products to become obsolete, which could harm our business, results of operations and financial condition.

38


Breaches of our information systems could have a material adverse effect on our business and results of operations.

We have experienced and expect to continue to experience attempts by computer programmers and hackers to attack and penetrate our layered security controls, like the December 2019 Cyberattack that was previously discussed in Item 7 of our Annual Report for the period ended December 31, 2019. Through our sales and eCommerce channels, we collect and store confidential information that customers provide to, among other things, purchase products or services, enroll in promotional programs and register on our web site. We also acquire and retain information about suppliers and employees in the normal course of business. Such information on our systems includes personally identifiable information and, in limited instances, protected health information. We also create and maintain proprietary information that is critical to our business, such as our product designs and manufacturing processes. Despite recent initiatives to improve our technology systems, such as our enterprise resource planning implementation and the centralization of our global information technology organization, we could experience a significant data security breach. Increased use of remote work arrangements and rapidly evolving work scenarios in response to the COVID-19 pandemic expose us to additional risk of cyberattack and disruption. Because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and often are not recognized until launched against a target, we may not be able to anticipate all of these techniques or to implement adequate preventive measures. Computer hackers have attempted to penetrate and will likely continue to attempt to penetrate our and our vendors’ information systems and, if successful, could misappropriate confidential customer, supplier, employee or other business information, such as our intellectual property. Third parties could also gain control of our systems and use them for criminal purposes while appearing to be us. As a result, we could lose existing customers, have difficulty attracting new customers, be exposed to claims from customers, financial institutions, payment card associations, employees and other persons, have regulatory sanctions or penalties imposed, incur additional expenses or lose revenues as a result of a data privacy breach, or suffer other adverse consequences. Our operations and ability to process sales orders, particularly through our eCommerce channels, could also be disrupted, as they were in the December 2019 Cyberattack. Any significant breakdown, intrusion, interruption, corruption, or destruction of our systems, as well as any data breaches, could have a material adverse effect on our business and results of operations. See also our risk factors regarding our information technology systems and our enterprise resource planning system (ERP) implementation below.

If our information technology systems are disrupted, or if we fail to successfully implement, manage and integrate our information technology and reporting systems, our business, results of operations and financial condition could be harmed.

Our information technology (IT) systems are an integral part of our business, and a serious disruption of our IT systems could have a material adverse effect on our business, results of operations and financial condition. We depend on our IT systems to process orders, manage inventory and collect accounts receivable. Our IT systems also allow us to efficiently purchase products from our suppliers and ship products to our customers on a timely basis, maintain cost-effective operations and provide customer service. We may experience disruption of our IT systems due to redundancy issues with our network servers. We cannot assure you that our contingency plans will allow us to operate at our current level of efficiency.

Our ability to implement our business plan in a rapidly evolving market requires effective planning, reporting and analytical processes. We expect that we will need to continue to improve and further integrate our IT systems, reporting systems and operating procedures by training and educating our employees with respect to these improvements and integrations on an ongoing basis in order to effectively run our business. We may suffer interruptions in service, loss of data or reduced functionality when we upgrade or change systems. If we fail to successfully manage and integrate our IT systems, reporting systems and operating procedures, it could adversely affect our business, results of operations and financial condition. See also our risk factors regarding our data security above and ERP implementation and events beyond our control below.

39


We are subject to foreign currency exchange fluctuations, which could have a material adverse effect on our results of operations and financial condition.

As stated above, a significant portion of our operations and sales are outside of the United States. When we make purchases and sales in currencies other than the U.S. dollars, we are exposed to fluctuations in foreign currencies relative to the U.S. dollar that may adversely affect our results of operations and financial condition. Our international sales are largely denominated in local currencies. As a result, the strengthening of the U.S. dollar negatively impacts our consolidated net sales expressed in U.S. dollars. Conversely, when the U.S. dollar weakens, our expenses at our international sites increase. In addition, the volatility of other currencies may negatively impact our operations outside of the United States and increase our costs to hedge against currency fluctuations. We cannot assure you that future shifts in currency exchange rates will not have a material adverse effect on our results of operations and financial condition.

Changes in the market value of our position in Sartorius AG materially impact our financial results and might cause us to be deemed an investment company.
Changes in the market value of our position in Sartorius AG will continue to materially impact our consolidated statements of income and other financial statements. A decline in the market value of our position in Sartorius AG will result in significant losses due to write-downs in the value of the equity securities. An increase in the market value of our position in Sartorius AG will result in a significant and favorable impact to net income independent of the actual operating performance of our business. As a result of the market value of our position in Sartorius AG, we might be deemed to be an “investment company” under Section 3(a)(1)(C) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), even though we are primarily engaged in a business other than that of investing, reinvesting, owning, holding or trading in securities. Because the Company might be deemed an investment company under the Investment Company Act based on the market value of our position in Sartorius AG alone, the Company has limited access to the capital markets and may not be able to obtain additional financing until it is determined that the Company is not an investment company. The Company does not believe it is an investment company and intends to continue to conduct our operations so that we will not be deemed an investment company. If the Company were deemed to be an investment company such determination could have a material adverse effect on our business.

Our share price may change significantly based upon changes in the market valuation of Sartorius AG, and such change are unrelated to the actual performance of our business. Non-operating income for a period may be significantly impacted by the timing of dividends paid by Sartorius AG, particularly in comparison to prior year periods.

We may incur losses in future periods due to write-downs in the value of financial instruments.
We have positions in a variety of financial instruments including asset backed securities and other similar instruments. Financial markets are volatile, particularly in light of the COVID-19 pandemic, and the markets for these securities can be illiquid. The value of these securities will continue to be impacted by external market factors including default rates, changes in the value of the underlying property, such as residential or commercial real estate, rating agency actions, the prices at which observable market transactions occur and the financial strength of various entities, such as financial guarantors who provide insurance for the securities. Should we need to convert these positions to cash, we may not be able to sell these instruments without significant losses due to current debtor financial conditions or other market considerations.

We also have positions in equity securities, including our position in Sartorius AG. Financial markets are volatile and the markets for these equity securities can be illiquid as well. A decline in the market value of our investments in equity securities that we own could result in significant losses due to write-downs in the value of the equity securities. In addition, if we need to convert these positions to cash, we may not be able to sell these equity securities without significant losses.

40

We may experience difficulties implementing our new global enterprise resource planning system.

We are engaged in a multi-year implementation of a new global enterprise resource planning system (ERP). The ERP is designed to efficiently maintain our books and records and provide information important to the operation of our business to our management team. The ERP will continue to require significant investment of human and financial resources. In implementing the ERP, we may experience significant delays, increased costs and other difficulties, as we already have with some of our earlier deployments. Any significant disruption or deficiency in the design and implementation of the ERP could adversely affect our ability to process orders, ship product, send invoices and track payments, fulfill contractual obligations or otherwise operate our business. We expect to implement the remaining smaller phases of the ERP platform over the next few years. In addition, our efforts to centralize various business processes and functions within our organization in connection with our ERP implementation may continue to disrupt our operations and negatively impact our business, results of operations and financial condition.

Recent and planned changes to our organizational structure could negatively impact our business.

We made significant changes to our organizational structure over the past few years. We have continued to reorganize aspects of our European operations since 2016, including the reorganization announced in February 2021. At the beginning of 2020, we restructured the Clinical Diagnostics segment based on functional groups rather than product line divisions. These changes may have unintended consequences, such as distraction of our management and employees, business disruption, some disruption of supply, attrition of our workforce, inability to attract or retain key employees, and reduced employee morale or productivity.

Risks relating to intellectual property rights may negatively impact our business.

We rely on a combination of copyright, trade secret, patent and trademark laws and third-party nondisclosure agreements to protect our intellectual property rights and products. However, we cannot assure you that our intellectual property rights will not be challenged, invalidated, circumvented or rendered unenforceable, or that meaningful protection or adequate remedies will be available to us. For instance, unauthorized third parties have attempted to copy our intellectual property, reverse engineer or obtain and use information that we regard as proprietary, or have developed equivalent technologies independently, and may do so in the future. Additionally, third parties have asserted patent, copyright and other intellectual property rights to technologies that are important to us and may do so in the future. If we are unable to license or otherwise access protected technology used in our products, or if we lose our rights under any existing licenses, we could be prohibited from manufacturing and marketing such products. From time to time, we also must enforce our patents or other intellectual property rights or defend ourselves against claimed infringement of the rights of others through litigation. As a result, we could incur substantial costs, be forced to redesign our products, or be required to pay damages or royalties to an infringed party. Any of the foregoing matters could adversely impact our business, results of operations and financial condition.

Global economic and geopolitical conditions could adversely affect our operations.

In recent years, we have been faced with very challenging global economic conditions. The COVID-19 pandemic, as discussed above, is currently causing disruptions to global economic conditions. It is unknown how long such disruptions will continue and whether such disruptions will become more severe. A deterioration in the global economic environment may, and is currently, resulting generally in some decrease in demand for certain of our products not being used in fighting the COVID-19 pandemic, increased competition, downward pressure on the prices for our products and longer sales cycles. A weakening of macroeconomic conditions may, and currently is, also adversely affecting our suppliers, which could result in interruptions in supply in the future. Additionally, the United States and other countries, such as China and India, recently have imposed tariffs on certain goods. While tariffs imposed by other countries on U.S. goods have not yet had a significant impact on our business, further escalation of tariffs or other trade barriers could adversely impact our profitability and/or our competitiveness. See also our risk factors regarding the COVID-19 pandemic and our international operations above and regarding government regulations below.

41

Reductions in government funding and the capital spending programs of our customers could have a material adverse effect on our business, results of operations or financial condition.

Our customers include universities, clinical diagnostics laboratories, government agencies, hospitals and pharmaceutical, biotechnology and chemical companies. The capital spending programs of these institutions and companies have a significant effect on the demand for our products. Such programs are based on a wide variety of factors, including the resources available to make such purchases, the availability of funding from grants by governments or government agencies, the spending priorities for various types of equipment and the policies regarding capital expenditures during industry downturns or recessionary periods. If government funding to our customers were to decrease, or if our customers were to decrease or reallocate their budgets in a manner adverse to us, our business, results of operations or financial condition could be materially and adversely affected.

Changes in the healthcare industry could have an adverse effect on our business, results of operations and financial condition.

There have been, and will continue to be, significant changes in the healthcare industry in an effort to reduce costs. These changes include:

•The trend towards managed care, together with healthcare reform of the delivery system in the United States and efforts to reform in Europe, has resulted in increased pressure on healthcare providers and other participants in the healthcare industry to reduce selling prices. Consolidation among healthcare providers and consolidation among other participants in the healthcare industry has resulted in fewer, more powerful groups, whose purchasing power gives them cost containment leverage. In particular, there has been a consolidation of laboratories and a consolidation of blood transfusion centers. These industry trends and competitive forces place constraints on the levels of overall pricing, and thus could have a material adverse effect on our gross margins for products we sell in clinical diagnostic markets.

•Third party payors, such as Medicare and Medicaid in the United States, have reduced their reimbursements for certain medical products and services. Our Clinical Diagnostics business is impacted by the level of reimbursement available for clinical tests from third party payors. In the United States payment for many diagnostic tests furnished to Medicare fee-for-service beneficiaries is made based on the Medicare Clinical Laboratory Fee Schedule (CLFS), a fee schedule established and adjusted from time to time by the Centers for Medicare and Medicaid Services (CMS). Some commercial payors are guided by the CLFS in establishing their reimbursement rates. Laboratories and clinicians may decide not to order or perform certain clinical diagnostic tests if third party payments are inadequate, and we cannot predict whether third party payors will offer adequate reimbursement for tests utilizing our products to make them commercially attractive. Legislation, such as the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (PPACA) and the Middle Class Tax Relief and Job Creation Act of 2012, has reduced the payments for clinical laboratory services paid under the CLFS. In addition, the Protecting Access to Medicare Act of 2014 (PAMA) has made significant changes to the way Medicare will pay for clinical laboratory services, which has further reduced reimbursement rates.

To the extent that the healthcare industry seeks to address the need to contain costs stemming from reform measures such as those contained in the PPACA and the PAMA, or in future legislation, by limiting the number of clinical tests being performed or the amount of reimbursement available for such tests, our business, results of operations and financial condition could be adversely affected. If these changes in the healthcare markets in the United States and Europe continue, we could be forced to alter our approach in selling, marketing, distributing and servicing our products.

42


We are subject to substantial government regulation, and any changes in regulation or violations of regulations by us could adversely affect our business, prospects, results of operations or financial condition.

Some of our products (primarily our Clinical Diagnostic products), production processes and marketing are subject to U.S. federal, state and local, and foreign regulation, including by the FDA in the United States and its foreign counterparts. The FDA regulates our Clinical Diagnostic products as medical devices, and we are subject to significant regulatory clearances or approvals to market our Clinical Diagnostic products and other requirements including, for example, recordkeeping and reporting requirements, such as the FDA’s medical device reporting regulations and reporting of corrections and removals. The FDA has broad regulatory and enforcement powers. If the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety of enforcement actions ranging from public warning letters, fines, injunctions, consent decrees and civil penalties to suspension or delayed issuance of approvals, seizure or recall of our products, total or partial shutdown of production, withdrawal of approvals or clearances already granted, and criminal prosecution.

The FDA can also require us to repair, replace or refund the cost of devices that we manufactured or distributed. In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval or clearance of our products or impact our ability to modify our currently approved or cleared products on a timely basis. Changes in the FDA’s review of certain clinical diagnostic products referred to as laboratory developed tests, which are tests developed by a single laboratory for use only in that laboratory, could affect some of our customers who use our Life Science instruments for laboratory developed tests. In the past, the FDA has chosen to not enforce applicable regulations and has not reviewed such tests for approval. However, the FDA has issued draft guidance that it may begin enforcing its medical device requirements, including premarket submission requirements, to such tests. Any delay in, or failure to receive or maintain, clearance or approval for our products could prevent us from generating revenue from these products and adversely affect our business operations and financial results. Additionally, the FDA and other regulatory authorities have broad enforcement powers. Regulatory enforcement or inquiries, or other increased scrutiny on us, could affect the perceived safety and efficacy of our products and dissuade our customers from using our products.

Many foreign governments have similar rules and regulations regarding the importation, registration, labeling, sale and use of our products. Such agencies may also impose new requirements that may require us to modify or re-register products already on the market or otherwise impact our ability to market our products in those countries. For example, in April 2017 the European Parliament voted to enact final regulations that include broad changes regarding in vitro diagnostic devices and medical devices, which will require us to modify or re-register some products and will result in additional costs. In addition, Russia has enacted more stringent medical product registration and labeling regulations, China has enacted stricter labeling requirements, and we expect other countries, such as Brazil and India, to impose more regulations that impact our product registrations. Brexit is resulting in additional regulatory requirements associated with goods sold in the United Kingdom and will likely result in additional complexities and possible delays with respect to goods, raw materials and personnel moving between the United Kingdom and the European Union. In addition, new government administrations may interpret existing regulations or practices differently. For example, the Mexican health regulatory agency COFEPRIS in 2019 cited Bio-Rad’s Mexican subsidiary for operating practices that had been endorsed by a prior administration, which has impacted our ability to conduct our Clinical Diagnostics business in Mexico. Due to these evolving and diverse requirements, we face uncertain product approval timelines, additional time and effort to comply, as well as the potential for reduced sales and/or fines for noncompliance. Increasing protectionism in such countries also impedes our ability to compete with local companies. For example, we may not be able to participate in certain public tenders in Russia because of increasing measures to restrict access to such tenders for companies without local manufacturing capabilities. Certain tenders in China and India also are including local manufacturing preferences or requirements. Such regulations could adversely affect our business, results of operations and financial condition. See also our risk factors regarding our international operations and regarding global economic and geopolitical conditions above.

43


We are also subject to government regulation of the use and handling of a number of materials and controlled substances. The U.S. Drug Enforcement Administration establishes registration, security, recordkeeping, reporting, storage, distribution and other requirements for controlled substances pursuant to the Controlled Substances Act of 1970. Failure to comply with present or future laws and regulations could result in substantial liability to us, suspension or cessation of our operations, restrictions on our ability to expand at our present locations or require us to make significant capital expenditures or incur other significant expenses.

We cannot assure you that we will be able to integrate acquired companies, products or technologies into our company successfully, or we may not be able to realize the anticipated benefits from the acquisitions.

As part of our overall business strategy, we pursue acquisitions of and investments in complementary companies, products and technologies. The benefits of any acquisition may prove to be less than anticipated and may not outweigh the costs reported in our financial statements. Completing any potential future acquisitions could cause significant diversion of our management’s time and resources. If we acquire new companies, products or technologies, we may be required to assume contingent liabilities or record impairment charges for goodwill and other intangible assets over time. Goodwill and non-amortizable intangible assets are subject to impairment testing, and potential periodic goodwill impairment charges, amortization expenses related to certain intangible assets, and other write-offs could harm our operating results. Impairment tests are highly sensitive to changes in assumptions and minor changes to assumptions could result in impairment losses. If the results forecast in our impairment tests are not achieved, or business trends vary from the assumptions used in forecasts, or external factors change detrimentally, future impairment losses may occur, as they have occurred in the past. We cannot assure you that we will successfully overcome these risks or any other problems we encounter in connection with any acquisitions, and any such acquisitions could adversely affect our business, results of operations and financial condition.

Product quality and liability issues could harm our reputation and negatively impact our business, results of operations and financial condition.

We must adequately address quality issues associated with our products, including defects in our engineering, design and manufacturing processes, as well as defects in third-party components included in our products. Our instruments, reagents and consumables are complex, and identifying the root cause of quality issues, especially those affecting reagents or third-party components, is difficult. We may incur significant costs and expend substantial time in researching and remediating such issues. Quality issues could also delay our launching or manufacturing of new products. In addition, quality issues, unapproved uses of our products, or inadequate disclosure of risks related to our products, could result in product recalls or product liability or other claims being brought against us. These issues could harm our reputation, impair our relationship with existing customers and harm our ability to attract new customers, which could negatively impact our business, results of operations and financial condition.

Lack of key personnel could hurt our business.

Our products are very technical in nature, and we operate in a complex and competitive business environment. In general, only highly qualified and well-trained scientists have the necessary skills to develop, market and sell our products, and many of our manufacturing positions require very specialized knowledge and skills. In addition, the global nature of our business also requires that we have sophisticated and experienced staff to comply with increasingly complex international laws and regulations. We face intense competition for these professionals from our competitors, customers, marketing partners and other companies throughout our industry. In particular, the job market in Northern California, where many of our employees are located, is very competitive. If we do not offer competitive compensation and benefits, we may fail to retain or attract a sufficient number of qualified personnel, which could impair our ability to properly run our business.

44


A reduction or interruption in the supply of components and raw materials could adversely affect our manufacturing operations and related product sales.

The manufacture of many of our products requires the timely delivery of sufficient amounts of quality components and materials. We manufacture our products in numerous manufacturing facilities around the world. We acquire our components and materials from many suppliers in various countries. We work closely with our suppliers to ensure the continuity of supply, but we cannot guarantee these efforts will always be successful. Further, while we seek to diversify our sources of components and materials, in certain instances we acquire components and materials from a sole supplier. In addition, due to the regulatory environment in which we operate, we may be unable to quickly establish additional or replacement sources for some components or materials. If our supply is reduced or interrupted or of poor quality, and we are unable to develop alternative sources for such supply, our ability to manufacture our products in a timely or cost-effective manner could be adversely affected, which would adversely affect our ability to sell our products. See also our risk factor regarding the COVID-19 pandemic above.

We may have higher than anticipated tax liabilities.

We are subject to income taxes in the United States and many foreign jurisdictions. We report our results of operations based on our determination of the amount of taxes owed in various tax jurisdictions in which we operate. The determination of our worldwide provision for income taxes and other tax liabilities requires estimation, judgment and calculations where the ultimate tax determination may not be certain. Our determination of our tax liabilities is subject to review or examination by tax authorities in various tax jurisdictions. Tax authorities have disagreed with our judgment in the past and may disagree with positions we take in the future resulting in assessments of additional taxes. Any adverse outcome of such review or examination could have a negative impact on our operating results and financial condition.

Economic and political pressures to increase tax revenues in various jurisdictions may make resolving tax disputes more difficult. For example, in recent years, the tax authorities in Europe have disagreed with our tax positions related to hybrid debt, research and development credits, transfer pricing and indirect taxes, among others. We regularly assess the likelihood of the outcome resulting from these examinations to determine the adequacy of our provision for income taxes. Although we believe our tax estimates are reasonable, the final determination of tax audits and any related litigation could be materially different from our historical income tax provisions and accruals.

Changes in tax laws or rates, changes in the interpretation of tax laws or changes in the jurisdictional mix of our earnings could adversely affect our financial position and results of operations.

On December 22, 2017, the U.S. enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”) which made a number of substantial changes to how the United States imposes income tax on multinational corporations. The U.S Treasury, Internal Revenue Service and other standard setting bodies continue to issue guidance and interpretation relating to the Tax Act. As future guidance is issued, we may make adjustments to amounts previously reported that could materially impact our financial statements.

On March 31, 2021, the current U.S. presidential administration proposed the “American Jobs Plan” to create domestic jobs, rebuild national infrastructure and increase American competitiveness. To fund its cost, the administration also proposed the “Made in America Tax Plan”. If enacted, our effective tax rate and cash tax liability will increase and could materially impact our financial statements.

The tax effect of our position in Sartorius AG and the jurisdictional mix of our earnings could continue to materially affect our financial results and cash flow. In addition, the adoption of some or all of the recommendations set forth in the Organization for Economic Co-operation and Development’s project on “Base Erosion and Profit Shifting” (BEPS) by tax authorities in the countries in which we operate, could negatively impact our effective tax rate. These recommendations focus on payments from affiliates in high tax jurisdictions to affiliates in lower tax jurisdictions and the activities that give rise to a taxable presence in a particular country.

45

Environmental, health and safety regulations and enforcement proceedings may negatively impact our business, results of operations and financial condition.

Our operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as transportation of goods, emissions to air and discharges to water, as well as handling and disposal practices for solid, hazardous and medical wastes. In addition to environmental laws that regulate our operations, we are also subject to environmental laws and regulations that create liability and clean-up responsibility for spills, disposals or other releases of hazardous substances into the environment as a result of our operations or otherwise impacting real property that we own or operate. The environmental laws and regulations also subject us to claims by third parties for damages resulting from any spills, disposals or releases resulting from our operations or at any of our properties. We must also comply with various health and safety regulations in the United States and abroad in connection with our operations.

We may in the future incur capital and operating costs to comply with currently existing laws and regulations, and possible new statutory enactments, and these expenditures may be significant. We have incurred, and may in the future incur, fines related to environmental matters and/or liability for costs or damages related to spills or other releases of hazardous substances into the environment at sites where we have operated, or at off-site locations where we have sent hazardous substances for disposal. We cannot assure you, however, that such matters or any future obligations to comply with environmental or health and safety laws and regulations will not adversely affect our business, results of operations or financial condition.

Our debt may restrict our future operations.

As of March 31, 2021, we have a revolving credit facility that provides for up to $200.0 million in borrowing capacity, $0.2 million of which has been utilized for domestic standby letters of credit. Our existing credit facility and agreements we may enter in the future, contain or may contain covenants imposing restrictions on our business. These restrictions may affect our ability to operate our business and may limit our ability to take advantage of potential business opportunities as they arise. Existing covenants place restrictions on our ability to, among other things: incur additional debt; acquire other businesses or assets through merger or purchase; create liens; make investments; enter into transactions with affiliates; sell assets; in the case of some of our subsidiaries, guarantee debt; and declare or pay dividends, redeem stock or make other distributions to stockholders. Our existing credit facility also requires that we comply with certain financial ratios, including a maximum consolidated leverage ratio test and a minimum consolidated interest coverage ratio test. Our ability to comply with these covenants may be affected by events beyond our control, including prevailing economic, financial and industry conditions. The breach of any of these restrictions could result in a default. An event of default under our debt agreements would permit some of our lenders to declare all amounts borrowed from them to be due and payable, together with accrued and unpaid interest.

As noted above, because the Company might be deemed an investment company under the Investment Company Act based on the market value of our position in Sartorius AG, the Company may not be able to access the capital markets or otherwise obtain additional financing until it is determined that the Company is not an investment company. The inability to obtain additional financing may have a negative impact on the Company’s existing business, our ability to grow our business, and our ability to make acquisitions.

46


We are subject to healthcare laws and regulations and could face substantial penalties if we are unable to fully comply with such laws.

We are subject to healthcare regulation and enforcement by both the U.S. federal government and the U.S. states and foreign governments in which we conduct our business. These healthcare laws and regulations include, for example:

•the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from soliciting, receiving, offering or providing remuneration, directly or indirectly, in return for or to induce either the referral of an individual for, or the purchase order or recommendation of, any item or services for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs;

•U.S. federal false claims laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent. In addition, the U.S. federal government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes;

•the U.S. Physician Payment Sunshine Act, which requires certain manufacturers of drugs, biologics, devices and medical supplies to record any transfers of value to U.S. physicians and U.S. teaching hospitals;

•the Health Insurance Portability and Accountability Act ("HIPAA"), as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; and

•state or foreign law equivalents of each of the U.S. federal laws above, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers.

These laws will continue to impose administrative, cost and compliance burdens on us. The shifting compliance environment and the need to build and maintain robust systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may violate one or more of these requirements. In addition, any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business, results of operations and financial condition.

47


Risks Related to Being a Public Company

Our failure to establish and maintain effective internal control over financial reporting could result in material misstatements in our financial statements, our failure to meet our reporting obligations and cause investors to lose confidence in our reported financial information, which in turn could cause the trading price of our common stock to decline.

Maintaining effective disclosure controls and procedures and internal controls over financial reporting are necessary for us to produce reliable financial statements. Material weaknesses in our internal control over financial reporting have adversely affected us in the past and could affect us in the future, and the results of our periodic management evaluations and annual auditor attestation reports regarding the effectiveness of our internal control over financial reporting required by Section 404 of the Sarbanes-Oxley Act of 2002. Any failure to maintain or implement new or improved internal controls, or any difficulties that we may encounter in their maintenance or implementation, could result in additional material weaknesses, result in material misstatements in our consolidated financial statements and cause us to fail to meet our reporting obligations. This could cause us to lose public confidence and could cause the trading price of our common stock to decline.

General Business Risks

Natural disasters, terrorist attacks, acts of war or other events beyond our control may cause damage or disruption to us and our employees, facilities, information systems, security systems, vendors and customers, which could significantly impact our business, results of operations and financial condition.

We have significant manufacturing and distribution facilities, including in the western United States, France, Switzerland, Germany and Singapore. In particular, the western United States has experienced a number of earthquakes, wildfires, floods, landslides and other natural disasters in recent years. These occurrences could damage or destroy our facilities which may result in interruptions to our business and losses that exceed our insurance coverage. In addition, electricity outages, strikes or other labor unrest at any of our sites or surrounding areas could cause disruption to our business. Acts of terrorism, bioterrorism, violence or war, or public health issues such as the outbreak of a contagious disease like COVID-19 could also affect the markets in which we operate, our business operations and strategic plans. Political unrest may affect our sales in certain regions, such as in Southeast Asia, the Middle East and Eastern Europe. Any of these events could adversely affect our business, results of operations and financial condition.

Risks Related to Our Common Stock
A significant majority of our voting stock is held by the Schwartz family, which could lead to conflicts of interest.

We have two classes of voting stock: Class A Common Stock and Class B Common Stock. With a few exceptions, holders of Class A and Class B Common Stock vote as a single class. When voting as a single class, each share of Class A Common Stock is entitled to one-tenth of a vote, while each share of Class B Common Stock has one vote. In the election or removal of directors, the classes vote separately and the holders of Class A Common Stock are entitled to elect 25% of the Board of Directors, with holders of Class B Common Stock electing the remaining directors. As a result of the Schwartz family's ownership of our Class A and Class B Common Stock, they are able to elect a majority of our directors, effect fundamental changes in our direction and control matters affecting us, including the determination of business opportunities that may be suitable for our company. The Schwartz family may exercise its control over us according to interests that are different from other investors’ or debtors’ interests. In particular, this concentration of ownership and voting power may have the effect of delaying or preventing a change in control of our company.

48


The forum selection provision in our bylaws could increase costs to bring a claim, discourage claims or limit the ability of the Company’s stockholders to bring a claim in a judicial forum viewed by the stockholders as more favorable for disputes with the Company or the Company’s directors, officers or other employees.

Our bylaws provide that unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state court located within the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company’s stockholders, (iii) any action arising pursuant to any provision of the General Corporation Law of the State of Delaware, the Certificate of Incorporation or the Bylaws (in each case, as may be amended from time to time) or (iv) any action asserting a claim against the Company or any of its directors, officers or other employees governed by the internal affairs doctrine of the State of Delaware. This choice of forum provision may increase costs to bring a claim, discourage claims or limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Company or the Company’s directors, officers or other employees, which may discourage such lawsuits against the Company or the Company’s directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in the Company’s bylaws to be inapplicable or unenforceable in an action, the Company may incur additional costs associated with resolving such action in other jurisdictions.

Application of the choice of forum provision may be limited in some instances by applicable law. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the choice of forum provision will not apply to actions arising under the Exchange Act or the rules and regulations thereunder. Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder, subject to a limited exception for certain “covered class actions.” There is uncertainty, particularly in light of current litigation, as to whether a court would enforce the choice of forum provision with respect to claims under the Securities Act. Our stockholders will not be deemed, by operation of the Company’s choice of forum provision, to have waived claims arising under the federal securities laws and the rules and regulations thereunder.


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

In November 2017, the Board of Directors authorized a new share repurchase program, granting Bio-Rad authority to repurchase, on a discretionary basis, up to $250.0 million of outstanding shares of our common stock (“Share Repurchase Program”). In July 2020, the Board of Directors authorized increasing the Share Repurchase Program to allow us to repurchase up to an additional $200.0 million of stock. As of March 31, 2021, $223.1 million remained under the Share Repurchase Program.
Repurchases under the Share Repurchase Program may be made at management's discretion from time to time on the open market or through privately negotiated transactions. The authorization has no expiration.

The following table contains information on the shares of our common stock that we purchased or otherwise acquired during the three months ended March 31, 2021.

49

PeriodTotal Number of Shares PurchasedAverage Price Paid per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or ProgramsMaximum Number (or Approximate Dollar Value) of Shares that May yet be Purchased Under the Plans or Programs (in millions)
January 1 to January 31, 2021—$— —$273.1 
February 1 to February 28, 2021—$— —$273.1 
March 1 to March 31, 202189,506 Class A$558.60 89,506 Class A$223.1 

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.


Item 5. Other Information

Submission of Matters to a Vote of Security Holders.

Bio-Rad Laboratories, Inc. (the “Company”) held its Annual Meeting of Stockholders on April 27, 2021. The matters voted upon at the meeting and the results of those votes are set forth below.

1. Each of the nominated directors was elected and received the affirmative vote of a majority of the votes cast in the respective class of Common Stock, as follows:

Class of Common Stock to ElectVotes ForVotes AgainstVotes AbstainingBroker Non-Votes
Melinda LitherlandClass A17,503,731 1,730,341 37,580 2,003,086 
Arnold A. PinkstonClass A16,097,255 3,136,398 37,999 2,003,086 
Jeffrey L. EdwardsClass B4,908,297 374 26 77,156 
Gregory K. HinckleyClass B4,908,297 374 26 77,156 
Alice N. SchwartzClass B4,905,030 3,641 26 77,156 
Norman SchwartzClass B4,905,647 3,024 26 77,156 

2. The proposal to ratify the selection of KPMG LLP as the Company’s independent auditors for the fiscal year ending December 31, 2021 was ratified and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows:

Votes ForVotes AgainstVotes AbstainingBroker Non-Votes
7,095,58913,9643,773—
50


Item 6. Exhibits

(a)  Exhibits

The following documents are filed as part of this report:

Exhibit
No.		 
31.1
  
31.2
  
32.1
  
32.2
  
101.INSThe instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
101.LABInline XBRL Taxonomy Extension Labels Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
104.1The cover page Interactive Data File is formatted in Inline XBRL and is contained in Exhibits 101

51


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereto duly authorized.
BIO-RAD LABORATORIES, INC.
(Registrant)
    
Date:April 30, 2021 /s/ Norman Schwartz
   Norman Schwartz, Chairman of the Board,
   President and Chief Executive Officer
    
Date:April 30, 2021 /s/ Ilan Daskal
   Ilan Daskal, Executive Vice President,
   Chief Financial Officer
52
 EX-31.1 2 ex31133121.htm EX-31.1 CEO SECTION 302 CERTIFICATION 3.31.21 Document

Exhibit 31.1

Certification of Chief Executive Officer Required By
Exchange Act Rules 13a-14(a) and 15d-14(a)

I, Norman Schwartz, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Bio-Rad Laboratories, Inc.

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:April 30, 2021 /s/ Norman Schwartz
   Norman Schwartz, Chairman of the Board,
   President and Chief Executive Officer


 EX-31.2 3 ex31233121.htm EX-31.2 CFO SECTION 302 CERTIFICATION 3.31.21 Document

Exhibit 31.2

Certification of Chief Financial Officer Required By
Exchange Act Rules 13a-14(a) and 15d-14(a)

I, Ilan Daskal, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Bio-Rad Laboratories, Inc.

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:April 30, 2021 /s/ Ilan Daskal
   Ilan Daskal
   Executive Vice President,
   Chief Financial Officer

 EX-32.1 4 ex32133121.htm EX-32.1 CEO SECTION 906 CERTIFICATION 3.31.21 Document

Exhibit 32.1




Certification of Periodic Report


I, Norman Schwartz, Chief Executive Officer of Bio-Rad Laboratories, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:


(1)the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date:April 30, 2021 /s/ Norman Schwartz
   Norman Schwartz, Chairman of the Board,
   President and Chief Executive Officer


The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

 EX-32.2 5 ex32233121.htm EX-32.2 CFO SECTION 906 CERTIFICATION 3.31.21 Document

Exhibit 32.2




Certification of Periodic Report


I, Ilan Daskal, Chief Financial Officer of Bio-Rad Laboratories, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:


(1)the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:April 30, 2021 /s/ Ilan Daskal
   Ilan Daskal
   Executive Vice President,
   Chief Financial Officer


The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.


 EX-101.SCH 6 bio-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets Parenthetical link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity Statement link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - 1. Basis of Presentation and Use of Estimates link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - 1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Policies) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - 1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables) link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - 1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - 1. Basis of Presentation and Use of Estimates Capitalized Cloud Computing Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - 1. Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details) link:presentationLink link:calculationLink link:definitionLink 2108102 - Disclosure - 2. Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - 2. Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - 2. Fair Value Measurements Fair Value Level Table (Details) link:presentationLink link:calculationLink link:definitionLink 2411406 - Disclosure - 2. Fair Value Measurements 3. Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 2412407 - Disclosure - 2. Foreign Exchange Forward Contracts (Details) link:presentationLink link:calculationLink link:definitionLink 2413408 - Disclosure - 2. Available-for-Sale Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2414409 - Disclosure - 2. Amortized Cost and Fair Value of Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2415410 - Disclosure - 2. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) link:presentationLink link:calculationLink link:definitionLink 2416411 - Disclosure - 2. Fair Value Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2117103 - Disclosure - 3. Intangible Assets, Goodwill and Other link:presentationLink link:calculationLink link:definitionLink 2318303 - Disclosure - 3. Intangible Assets, Goodwill and Other (Tables) link:presentationLink link:calculationLink link:definitionLink 2419412 - Disclosure - 3. Intangible Assets, Goodwill and Other (Details) link:presentationLink link:calculationLink link:definitionLink 2420413 - Disclosure - 3. Intangible Assets, Goodwill and Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2121104 - Disclosure - 4. Statement of Cash Flows, Supplemental Disclosures link:presentationLink link:calculationLink link:definitionLink 2322304 - Disclosure - 4. Supplemental Cash Flow Information Cash Flow, Supplemental Disclosure - (Tables) link:presentationLink link:calculationLink link:definitionLink 2423414 - Disclosure - 4. Supplemental Cash Flow Information - (Details) link:presentationLink link:calculationLink link:definitionLink 2124105 - Disclosure - 5. Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 2325305 - Disclosure - 5. Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2426415 - Disclosure - 5. Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2127106 - Disclosure - 6. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Notes) link:presentationLink link:calculationLink link:definitionLink 2328306 - Disclosure - 6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2429416 - Disclosure - 6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2130107 - Disclosure - 7. Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2331307 - Disclosure - 7. Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2432417 - Disclosure - 7. Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2133108 - Disclosure - 8. Other Income and Expenses link:presentationLink link:calculationLink link:definitionLink 2334308 - Disclosure - 8. Other Income and Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 2435418 - Disclosure - 8. Other Income and Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2136109 - Disclosure - 9. Income Taxes link:presentationLink link:calculationLink link:definitionLink 2437419 - Disclosure - 9. Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2138110 - Disclosure - 10. Segment Information Segment Reporting link:presentationLink link:calculationLink link:definitionLink 2339309 - Disclosure - 10. Segment Information Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 2440420 - Disclosure - Segment Reporting (Details) link:presentationLink link:calculationLink link:definitionLink 2441421 - Disclosure - 10. Segment Information Segment Profit Reconciliations (Details) link:presentationLink link:calculationLink link:definitionLink 2442422 - Disclosure - 10. Segment Information Segment Asset Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2143111 - Disclosure - 11. Legal Proceedings link:presentationLink link:calculationLink link:definitionLink 2444423 - Disclosure - 11. Legal Proceedings 12. Contingent Liability (Details) link:presentationLink link:calculationLink link:definitionLink 2145112 - Disclosure - 12. Restructuring Costs (Notes) link:presentationLink link:calculationLink link:definitionLink 2346310 - Disclosure - 12. Restructuring Costs (Tables) link:presentationLink link:calculationLink link:definitionLink 2447424 - Disclosure - 12. Restructuring Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2148113 - Disclosure - 13. Leases (Notes) link:presentationLink link:calculationLink link:definitionLink 2349311 - Disclosure - 13. Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2450425 - Disclosure - 13. Leases (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 bio-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 bio-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 bio-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Line of Credit, Current Line of Credit, Current Restricted Investments, at Fair Value Restricted Investments, at Fair Value Document Type Document Type Other Nonoperating Income (Expense) Other (income) expense, net Other Nonoperating Income (Expense) Other Nonoperating Income (Expense) Schedule of Product Warranty Liability [Table Text Block] Schedule of Product Warranty Liability [Table Text Block] Contingent consideration milestone payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Treasury Stock [Member] Treasury Stock [Member] Segments [Axis] Segments [Axis] Segments [Axis] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] In Process Research and Development [Member] In Process Research and Development [Member] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Other Current Assets Other Current Assets [Member] Mature in one to five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Licensing Agreements [Member] Licensing Agreements [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] LIABILITIES AND STOCKHOLDERS' EQUITY: Liabilities and Equity [Abstract] Line of Credit [Member] Line of Credit [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Finance Lease, Right-of-Use Asset, Amortization Finance Lease, Right-of-Use Asset, Amortization Increase in other long term liabilities Increase (Decrease) in Other Noncurrent Liabilities Deferred income taxes Deferred Income Tax Liabilities, Net Security Exchange Name Security Exchange Name Sales milestone percentage of annual invoices low [Member] Sales milestone percentage of annual invoices low [Member] Sales milestone percentage of annual invoices low [Member] Purchased intangibles, net Intangible Assets, Net (Excluding Goodwill) Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Sales milestone percentage of annual invoices [Member] Sales milestone percentage of annual invoices [Member] Sales milestone percentage of annual invoices [Member] Finance Lease, Right-Of-Use Asset, before Accumulated Amortization Finance Lease, Right-of-Use Asset, before Accumulated Amortization Deferred Revenue, Current Deferred Revenue, Current Segment profit (loss) Operating Income (Loss) Payments for credit agreement renewal fees Payments of Debt Issuance Costs Total current liabilities Liabilities, Current Reclassification Out Of Accumulated Other Comprehensive Income [Member] Reclassification out of Accumulated Other Comprehensive Income [Member] Proceeds from Reissuance of Treasury Stock Proceeds from Sale of Treasury Stock Other Investments Other Investments Finance Lease, Liability, Payment, Due Finance Lease, Liability, Payment, Due Payments for purchases of treasury stock Payments for Repurchase of Common Stock ASSETS: Assets [Abstract] Lessee, Operating Lease, Liability, Payments, Due after Year Five Lessee, Operating Lease, Liability, to be Paid, after Year Five Income and other taxes payable Taxes Payable, Current Entity Address, Country Entity Address, State or Province Operating Lease, Payments Operating Lease, Payments Accounts payable Accounts Payable, Current Sublease Income Sublease Income Stockholders' Equity Note Disclosure [Text Block] Comprehensive Income (Loss) Note [Text Block] Allowance for Loan and Lease Losses, Write-offs Allowance for Loan and Lease Losses, Write-offs Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Retained earnings Retained earnings Retained Earnings (Accumulated Deficit) Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Noncash or Part Noncash Acquisition, Fixed Assets Acquired Noncash or Part Noncash Acquisition, Fixed Assets Acquired Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Year One Common Class B [Member] Common Class B [Member] Common Class B [Member] Finance Lease, Liability, to be Paid, Year One Finance Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, Payments, Due Year Four Lessee, Operating Lease, Liability, to be Paid, Year Four Schedule of financial assets and liabilities carried at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Legal Proceedings. Legal Matters and Contingencies [Text Block] Organization, Consolidation and Presentation of Financial Statements [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Deferred Revenue Deferred Revenue US Government Sponsored Agencies [Member] US Treasury and Government [Member] Other long-term liabilities Other Liabilities, Noncurrent (Payments for) recovery of purchases of intangible assets Payments for (Proceeds from) Other Investing Activities Finance Lease, Principal Payments Finance Lease, Principal Payments Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Loss on Foreign Currency Derivative Instruments not Designated as Hedging Instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments APIC, Share-based Payment Arrangement, Increase for Cost Recognition APIC, Share-based Payment Arrangement, Increase for Cost Recognition Segment Reconciling Items [Member] Segment Reconciling Items [Member] Total inventories Inventory, Net Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Net sales Revenue from Contract with Customer, Excluding Assessed Tax Measurement Frequency [Domain] Measurement Frequency [Domain] Finance Leases and Other Debt [Member] Finance Leases and Other Debt [Member] Finance Leases and Other Debt [Member] Life Science [Member] Life Science [Member] Life Sciences [Member] Treasury Stock Reissued at Lower than Repurchase Price Treasury Stock Reissued at Lower than Repurchase Price Loss Contingency, Information about Litigation Matters [Abstract] Loss Contingency, Information about Litigation Matters [Abstract] Business Acquisition [Axis] Business Acquisition [Axis] Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Other Long-term Debt, Current Other Long-term Debt, Current Geographical [Domain] Geographical [Domain] Mature in more than five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block] Statement [Line Items] Statement [Line Items] Increase in deferred income taxes Increase (Decrease) in Deferred Income Taxes Forecast [Member] Forecast [Member] Class of Stock [Domain] Class of Stock [Domain] Business Combination, Contingent Consideration, Liability, Noncurrent Business Combination, Contingent Consideration, Liability, Noncurrent Statement [Table] Statement [Table] Standard Product Warranty, Policy [Policy Text Block] Standard Product Warranty, Policy [Policy Text Block] Type of Restructuring [Domain] Type of Restructuring [Domain] Statistical Measurement [Axis] Statistical Measurement [Axis] Distributor [Member] Distributor [Member] Distributor [Member] Reduction in the carrying amount of right-of-use assets Operating Lease, Right-of-Use Asset, Amortization Expense Foreign Currency Gain (Loss) [Member] Foreign Currency Gain (Loss) [Member] Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares Schedule of Weighted Average Number of Shares [Table Text Block] Entity Small Business Entity Small Business Restricted investments Restricted Investments, Current Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Prepaid expenses Prepaid Expense, Current Proceeds from Issuance of Common Stock Proceeds from Issuance of Common Stock Selling, General and Administrative Expenses [Member] Selling, General and Administrative Expenses [Member] Amendment Flag Amendment Flag Document and Entity Information (Parenthetical) [Abstract] Document and Entity Information (Parenthetical) [Abstract] Document and Entity Information (Parenthetical) [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Contingent Consideration Type [Domain] Contingent Consideration by Type [Domain] Contingent Consideration Type [Domain] Investment ownership percentage Investment ownership percentage Investment ownership percentage Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Outstanding borrowings Long-term Line of Credit Payments for Acquisitions, net of cash received Payments for Previous Acquisition Other Investments [Member] Other Investments [Member] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Decrease in accounts payable and other current liabilities Increase (Decrease) in Accounts Payable and Other Operating Liabilities Entity Central Index Key Entity Central Index Key Restructuring and Related Activities Disclosure [Text Block] Restructuring and Related Activities Disclosure [Text Block] Fair Value by Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Derivative Instrument [Axis] Derivative Instrument [Axis] Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Acquired Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Estimated fair value of financial instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Other Noncurrent Liabilities [Member] Other Noncurrent Liabilities [Member] Amortization [Abstract] Amortization [Abstract] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer Cash Flow, Supplemental Disclosures [Text Block] Cash Flow, Supplemental Disclosures [Text Block] Standby Letters of Credit [Member] Standby Letters of Credit [Member] Geographical [Axis] Geographical [Axis] Segments [Domain] Segments [Domain] Segments [Domain] Amortized Cost Total Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Fair Value of Investments with Gross Unrealized Losses in loss position 12 months or more Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Effect of Exchange Rate on Cash and Cash Equivalents Effect of Exchange Rate on Cash and Cash Equivalents Income Statement Location [Axis] Income Statement Location [Axis] Accounts receivable allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Income Statement Location [Domain] Income Statement Location [Domain] (Gain) Loss on Sale of Securities, Net Debt and Equity Securities, Gain (Loss) Lessee, Operating Lease, Liability, Payments, Due Year Two Lessee, Operating Lease, Liability, to be Paid, Year Two Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Selling, general and administrative expense Selling, General and Administrative Expense Celsee Celsee [Member] Celsee Derivative, Notional Amount Derivative, Notional Amount Amortization expense Amortization of Intangible Assets Lease, Cost [Table Text Block] Lease, Cost [Table Text Block] Long-term Debt and Lease Obligation, Including Current Maturities Long-term Debt and Lease Obligation, Including Current Maturities Lessee, Operating Lease, Liability, Payments, Due Year Three Lessee, Operating Lease, Liability, to be Paid, Year Three Segment Reporting Disclosure [Text Block] Segment Reporting Disclosure [Text Block] Cash and Cash Equivalents, Fair Value Disclosure Cash and Cash Equivalents, Fair Value Disclosure Senior Notes 4.875% due 2020 [Member] Senior Notes 4.875% due 2020 [Member] Senior Notes 4.875% [Member] Finance Lease, Interest Payment on Liability Finance Lease, Interest Payment on Liability Assets Assets Assets Statement, Scenario [Axis] Statement, Scenario [Axis] Scenario [Axis] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Foreign Government Obligations [Member] Debt Security, Government, Non-US [Member] Title of 12(b) Security Title of 12(b) Security Noncash or Part Noncash Acquisition, Investments Acquired Noncash or Part Noncash Acquisition, Investments Acquired Net Carrying Amount Finite-Lived Intangible Assets, Net Net unrealized holding gains (losses) on available-for-sale investments net of tax expense OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Cost of Sales [Member] Cost of Sales [Member] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification Out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Interest expense Interest Expense Short-term Investments [Member] Short-term Investments [Member] Other Intangible Assets [Member] Other Intangible Assets [Member] Total liabilities Liabilities Investment Type [Axis] Investment Type [Axis] Other Long-term Debt Other Long-term Debt Supplemental Cash Flow Elements [Abstract] Supplemental Cash Flow Elements [Abstract] Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Other Segments [Member] Other Segments [Member] Debt Securities, Available-for-sale, Unrealized Loss Position Debt Securities, Available-for-sale, Unrealized Loss Position Other Comprehensive Income Location [Domain] Other Comprehensive Income Location [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Decrease (increase) in inventories Increase (Decrease) in Inventories Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Analytical Flow Cytometer Platform [Member] Analytical Flow Cytometer Platform [Member] Analytical Flow Cytometer Platform Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Debt Instrument [Axis] Debt Instrument [Axis] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Schedule of other income (expense), net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Other assets Other Assets Operating Segments [Member] Operating Segments [Member] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Treasury Stock, Value, Acquired, Cost Method Treasury Stock, Value, Acquired, Cost Method Finance Lease, Interest Expense Finance Lease, Interest Expense Accounts Payable and Accrued Liabilities [Member] Accounts Payable and Accrued Liabilities [Member] Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure Foreign Currency Contract, Asset, Fair Value Disclosure Equity Method Investments Equity Method Investments Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) Schedule of Goodwill [Table] Schedule of Goodwill [Table] Revenue Allocation Percent To Lease Elements Revenue Allocation Percent To Lease Elements Revenue Allocation Percent To Lease Elements Research and Development Expense Research and Development Expense Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to purchase foreign currency [Member] Cash Equivalents [Member] Cash Equivalents [Member] Leases of Lessee Disclosure [Text Block] Leases of Lessee Disclosure [Text Block] Effect of potentially dilutive stock options and restricted stock awards Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Revenue from External Customers by Geographic Areas [Table Text Block] Revenue from External Customers by Geographic Areas [Table Text Block] Restructuring Plan [Domain] Restructuring Plan [Domain] Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value Sales milestone minimum amount [Member] Sales milestone minimum amount [Member] Sales milestone minimum amount [Member] Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of Segment Reporting Information, by Segment [Table Text Block] Estimate of Fair Value, Fair Value Disclosure [Member] Estimate of Fair Value Measurement [Member] Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure Foreign Currency Contracts, Liability, Fair Value Disclosure Income Statement [Abstract] Income Statement [Abstract] AOCI Attributable to Parent [Member] AOCI Attributable to Parent [Member] Gain on sale of land Gain (Loss) on Disposition of Assets Summary of amortized cost and estimated fair value of debt securities by contractual maturity date Investments Classified by Contractual Maturity Date [Table Text Block] Operating lease liabilities Operating Lease, Liability, Noncurrent Legal Proceedings [Abstract] Legal Proceedings [Abstract] -- None. No documentation exists for this element. -- Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Forward foreign exchange contract to sell foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Income Tax Authority [Domain] Income Tax Authority [Domain] Goodwill Goodwill, Gross Finance Lease, Liability, Payments, Due Year Three Finance Lease, Liability, to be Paid, Year Three Payments of operating lease liabilities Increase (Decrease) in Deferred Liabilities Net realized (gain) loss on investments Realized Investment Gains (Losses) Scenario [Domain] Scenario [Domain] Asia Pacific [Member] Asia Pacific [Member] Capital expenditures Payments to Acquire Property, Plant, and Equipment City Area Code City Area Code Consolidation Items [Domain] Consolidation Items [Domain] Investment proceeds and miscellaneous receipts, net Proceeds from Other Operating Activities Income Tax Authority [Axis] Income Tax Authority [Axis] Document Period End Date Document Period End Date Long-term Debt Long-term Debt [Text Block] Price Change Debt Security Price Change Debt Security Price Change Debt Security Business Combination, Contingent Consideration, Liability Business Combination, Contingent Consideration, Liability Goodwill and Intangible Assets Disclosure Goodwill and Intangible Assets Disclosure [Text Block] Debt Securities, Available-for-sale, Allowance for Credit Loss Debt Securities, Available-for-sale, Allowance for Credit Loss Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss Income before income taxes Income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Restructuring Costs [Abstract] Restructuring Costs [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification Out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Accumulated impairment loss Goodwill, Impaired, Accumulated Impairment Loss Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block] Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block] Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block] Other Comprehensive Income (Loss), before Reclassifications, before Tax Other Comprehensive Income (Loss), before Reclassifications, before Tax Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Share-based Compensation Share-based Payment Arrangement, Noncash Expense Equity Securities Equity Securities, FV-NI Tax payments from net share settlement Payment, Tax Withholding, Share-based Payment Arrangement Unsecured Debt Unsecured Debt Restructuring and Related Costs [Table Text Block] Restructuring and Related Costs [Table Text Block] Goodwill, Acquired During Period Goodwill, Acquired During Period Debt Securities, Available-for-sale [Table Text Block] Debt Securities, Available-for-sale [Table Text Block] Restructuring Reserve, Accrual Adjustment Restructuring Reserve, Accrual Adjustment Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Clinical Diagnostics [Member] Clinical Diagnostics [Member] Clinical Diagnostics [Member] Restricted investment [Member] Restricted investment [Member] Restricted investment Unrealized Gain on Securities Equity Securities, FV-NI, Unrealized Gain Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Long-term debt Long-term Debt Goodwill [Line Items] Goodwill [Line Items] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Debt and Lease Obligation Debt and Lease Obligation Debt Securities [Member] Debt Securities [Member] Other Income and Other Expense Disclosure Other Income and Other Expense Disclosure [Text Block] Increase in other current assets Increase (Decrease) in Other Current Assets Customer Relationships [Member] Customer Relationships [Member] Cost of goods sold Cost of Goods and Services Sold Debt Securities, Available-for-sale Estimated Fair Value Debt Securities, Available-for-sale Segment Reporting, Asset Reconciling Item [Line Items] Segment Reporting, Asset Reconciling Item [Line Items] Equity Components [Axis] Equity Components [Axis] Actual warranty costs Standard and Extended Product Warranty Accrual, Decrease for Payments Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Net payments on line-of-credit arrangements and notes payable Proceeds from (Repayments of) Lines of Credit Minimum [Member] Minimum [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Accounts Receivable, Allowance for Credit Loss [Table Text Block] Accounts Receivable, Allowance for Credit Loss [Table Text Block] Equity Method Investment, Other than Temporary Impairment Equity Method Investment, Other than Temporary Impairment Property, plant and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Current operating lease liabilities Operating Lease, Liability, Current Warranty accrual, beginning of period Warranty accrual, end of period Standard and Extended Product Warranty Accrual Europe [Member] Europe [Member] Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Asset-backed Securities [Member] Asset-backed Securities [Member] Gain on divestiture of a division Gain (Loss) on Disposition of Other Assets Entity Interactive Data Current Entity Interactive Data Current UNITED STATES UNITED STATES Fair Value Measurements Fair Value Disclosures [Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Finite-Lived Intangible Assets, Remaining Amortization Period Finite-Lived Intangible Assets, Remaining Amortization Period Proceeds from maturities of marketable securities and investments Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Restructuring Reserve, Foreign Currency Translation (Gain) Loss Restructuring Reserve, Foreign Currency Translation Gain (Loss) Entity Registrant Name Entity Registrant Name Derivative [Table] Derivative [Table] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Discount Rate, Percent Increase (Decrease) in Other Operating Liabilities Increase (Decrease) in Other Operating Liabilities Schedule of identifiable purchased intangible assets with definite lives Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Proceeds from dispositions of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Intangible Assets, Gross (Excluding Goodwill) Intangible Assets, Gross (Excluding Goodwill) Changes in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Mature in less than one year Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Finance Lease, Liability, Undiscounted Excess Amount Finance Lease, Liability, Undiscounted Excess Amount Provision for warranty Standard and Extended Product Warranty Accrual, Increase for Warranties Issued Debt Instrument, Interest Rate, Effective Percentage Debt Instrument, Interest Rate, Effective Percentage Research and Development Expense [Member] Research and Development Expense [Member] Consolidation Items [Axis] Consolidation Items [Axis] Schedule of available-for-sale investments Available-for-sale Securities [Table Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Finished goods Inventory, Finished Goods, Gross Lessee, Operating Lease, Liability, Payments, Due Lessee, Operating Lease, Liability, to be Paid Other Comprehensive Income Location [Axis] Other Comprehensive Income Location [Axis] Restructuring Reserve Restructuring Reserve Ordinary voting shares [Member] Ordinary voting shares [Member] Ordinary voting shares Restricted Cash, Noncurrent Restricted Cash, Noncurrent Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restructuring Type [Axis] Restructuring Type [Axis] Payments for Restructuring Payments for Restructuring Goodwill, net Goodwill Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Mature in less than one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Document Transition Report Document Transition Report Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Increase in income taxes payable Increase (Decrease) in Income Taxes Payable Face amount of debt sold Debt Instrument, Face Amount Mature in more than five years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Other current assets Other Assets, Current Document Quarterly Report Document Quarterly Report Changes to goodwill by segment Schedule of Goodwill [Table Text Block] Assets, Fair Value Disclosure Assets, Fair Value Disclosure Derivative Contract [Domain] Derivative Contract [Domain] Weighted average common shares - diluted Diluted weighted average common shares Weighted Average Number of Shares Outstanding, Diluted Fair Value Measurements, Recurring and Nonrecurring Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Net income per share basic attributable to Bio-Rad Earnings Per Share, Basic Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Tolerable variance Level 2 debt security pricing Tolerable variance Level 2 debt security pricing Tolerable variance Level 2 debt security pricing Entity File Number Entity File Number Debt Disclosure [Abstract] Debt Disclosure [Abstract] Other Current Liabilities [Member] Other Current Liabilities [Member] Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Accounts Receivable, Allowance for Credit Loss, Recovery Accounts Receivable, Allowance for Credit Loss, Recovery Restructuring Plan [Axis] Restructuring Plan [Axis] Unsecured Debt [Member] Unsecured Debt [Member] Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Payments on long-term borrowings Repayments of Long-term Debt Accumulated Net Unrealized Investment Gain (Loss) [Member] AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Depreciation and amortization Other Depreciation and Amortization Unrecognized Tax Benefits Unrecognized Tax Benefits Balance Sheet Location [Axis] Balance Sheet Location [Axis] Common stock Common Stock, Value, Issued Other investments Long-term Investments Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Commercial Paper [Member] Commercial Paper [Member] Restricted Cash, Current Restricted Cash, Current Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Entity Current Reporting Status Entity Current Reporting Status Finance Lease, Liability, Payments, Due Year Four Finance Lease, Liability, to be Paid, Year Four Interest and investment income Investment Income, Interest and Dividend Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Inventories: Inventory, Net [Abstract] Finance Lease Obligations [Member] Finance Lease Obligations [Member] Finance Lease Obligations [Member] Treasury Class A [Member] Treasury Class-A [Member] Treasury Class A [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Common Stock, Shares, Issued Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Investment Owned, Balance, Shares Investment Owned, Balance, Shares Operating Lease, Liability Operating Lease, Liability Long-term debt, net of current maturities Long-term Debt, Excluding Current Maturities Segment Reporting [Abstract] Segment Reporting [Abstract] Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Decrease in accounts receivable Increase (Decrease) in Accounts Receivable Debt Instrument [Line Items] Debt Instrument [Line Items] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Total stockholders' equity Total Stockholders' Equity Total Stockholders' Equity Stockholders' Equity Attributable to Parent Preference shares [Member] Preference shares [Member] Preference shares Proceeds from forward foreign exchange contracts, net Payments for (proceeds from) derivative instruments, operating activities Payments for (proceeds from) derivative instruments, operating activities Total liabilities and stockholders' equity Liabilities and Equity Accumulated other comprehensive loss Beginning balance, Accumulated other comprehensive income Ending balance, Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Income Taxes Income Tax Disclosure [Text Block] Raw materials Inventory, Raw Materials, Gross Entity Address, City or Town Entity Address, City or Town Payments for Operating Lease Liabilities Increase (Decrease) in Operating Liabilities Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Accrued payroll and employee benefits Employee-related Liabilities, Current Reconciliation of Assets from Segment to Consolidated [Table] Reconciliation of Assets from Segment to Consolidated [Table] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Operating Lease, Cost Operating Lease, Cost Time Deposits [Member] Bank Time Deposits [Member] Other Assets Other Assets [Member] Financial Instrument [Axis] Financial Instrument [Axis] Anti-dilutive shares Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Finance Lease, Weighted Average Remaining Lease Term Finance Lease, Weighted Average Remaining Lease Term Finance Lease Cost Finance Lease Cost Finance Lease Cost Loss on Disposition of Property Plant Equipment Gain (Loss) on Disposition of Property Plant Equipment Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Changes in fair market value of equity securities Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Equity Component [Domain] Equity Component [Domain] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Foreign Government Debt [Member] Foreign Government Debt [Member] Line of Credit Facility, Interest Rate at Period End Line of Credit Facility, Interest Rate at Period End Gross profit Gross Profit Entity Tax Identification Number Entity Tax Identification Number Revenue from Contract with Customer [Policy Text Block] Revenue from Contract with Customer [Policy Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Marketable Securities, Unrealized (Gain) Loss Marketable Securities, Unrealized Gain (Loss) Marketable Securities, Unrealized Gain (Loss) Net income attributable to Bio-Rad Net Income (Loss) Attributable to Parent Net Income Attributable to Parent Net Income (Loss) Attributable to Parent Finance Lease, Liability, Noncurrent Finance Lease, Liability, Noncurrent Business Acquisition, Contingent Consideration, Potential Percentage Payout Business Acquisition, Contingent Consideration, Potential Percentage Payout business acquisition contingent consideration percentage payout Lessee Supplemental Balance Sheet Information [Table Text Block] Lessee Supplemental Balance Sheet Information [Table Text Block] Lessee Supplemental Balance Sheet Information [Table Text Block] Other current liabilities Other Liabilities, Current Finance Lease, Right-Of-Use Asset, after Accumulated Amortization Finance Lease, Right-Of-Use Asset, after Accumulated Amortization Finance Lease, Right-Of-Use Asset, after Accumulated Amortization Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Total other comprehensive income (loss) net of tax Other Comprehensive Income (Loss), Net of Tax Trade Names [Member] Trade Names [Member] Work in process Inventory, Work in Process, Gross Mature in one to five years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Earnings Per Share [Abstract] Earnings Per Share [Abstract] Restructuring Charges Restructuring Charges Finance Lease, Liability Finance Lease, Liability Property, plant, and equipment Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Finance Lease, Right-Of-Use Asset, Accumulated Amortization Finance Lease, Right-of-Use Asset, Accumulated Amortization Other Nonoperating (Income) Other Nonoperating Income Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss Accumulated Defined Benefit Plans Adjustment [Member] Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Gain on Disposition of a division Gain (Loss) on Disposition of Business Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Developed Technology Rights [Member] Developed Technology Rights [Member] Document Fiscal Period Focus Document Fiscal Period Focus Know How [Member] Know How [Member] Know how [Member] Less: accumulated depreciation and amortization Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization 14. Leases [Abstract] 13. Leases [Abstract] 13. Leases [Abstract] Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Finance Lease, Liability, Payments, Due after Year Five Finance Lease, Liability, to be Paid, after Year Five Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Current liability Current liability [Member] Current liability Debt Instrument, Redemption Price, Percentage Debt Instrument, Redemption Price, Percentage Other Long-term Investments [Member] Other Long-term Investments [Member] Entity Filer Category Entity Filer Category Common Stock [Member] Common Stock [Member] Accumulated Translation Adjustment [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Reclassification Out of Accumulated Other Comprehensive Income [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Finance Lease, Weighted Average Discount Rate, Percent Finance Lease, Weighted Average Discount Rate, Percent Fair Value of Investments with Gross Unrealized Losses in loss position less than 12 months Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value Lease Contractual Term [Axis] Lease Contractual Term [Axis] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] US Treasury Securities US Treasury Securities [Member] Other Comprehensive Income (Loss), Tax Other Comprehensive Income (Loss), Tax Purchase Price Finite-Lived Intangible Assets, Gross Other Nonoperating Income (Expense) [Member] Other Nonoperating Income (Expense) [Member] Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Finite-Lived Intangible Assets, Net [Abstract] Finite-Lived Intangible Assets, Net [Abstract] Money Market Funds [Member] Money Market Funds [Member] Municipal Obligations (Member) Municipal obligations [Member] Municipal Bonds [Member] Common Class A [Member] Common Class A [Member] Common Class A [Member] Diluted earnings per share: Earnings Per Share, Diluted [Abstract] Interest Receivable, Current Interest Receivable, Current Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Nonoperating Income (Expense) Nonoperating (Income( Expense Nonoperating Income (Expense) Weighted average common shares - basic Basic weighted average shares outstanding Weighted Average Number of Shares Outstanding, Basic Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Treasury Stock, Shares Treasury Stock, Shares Restructuring Reserve, Current Restructuring Reserve, Current Other than temporary impairment losses on investments Other than Temporary Impairment Losses, Investments Current maturities of long-term debt and notes payable Notes and Loans Payable, Current Carrying (Reported) Amount, Fair Value Disclosure [Member] Reported Value Measurement [Member] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Interest paid, net Interest Paid, Excluding Capitalized Interest, Operating Activities Equity Securities without Readily Determinable Fair Value, Amount Equity Securities without Readily Determinable Fair Value, Amount Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Organization, Consolidation and Presentation of Financial Statements Disclosure Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Finance Lease, Liability, Payments, Remainder of Fiscal Year Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Additional paid-in capital Additional paid-in-capital Additional Paid in Capital Total long-term debt, excluding capital leases and current maturities Long-term Debt, Fair Value Payments to Fund Long-term Loans to Related Parties Payments to Fund Long-term Loans to Related Parties Foreign exchange (gains) losses, net Foreign Currency Transaction Gain (Loss), before Tax Class of Stock [Axis] Class of Stock [Axis] Discussion of current derivative risk management Schedule of Derivative Instruments [Table Text Block] (Provision) benefit for income taxes Income Tax Expense (Benefit) Income tax payments, net Income Taxes Paid, Net Beginning Cash, Cash Equivalents, and Restricted Cash Ending Cash, Cash Equivalents, and Restricted Cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Revenue from external customers [Table] Accounting Standards Update and Change in Accounting Principle [Table] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Liabilities, Fair Value Disclosure Financial and Nonfinancial Liabilities, Fair Value Disclosure Net income per share diluted attributable to Bio-Rad Earnings Per Share, Diluted Finance Lease, Liability, Current Finance Lease, Liability, Current European Reorganization European Reorganization [Member] European Reorganization Proceeds from Sale of Debt Securities, Available-for-sale Proceeds from Sale of Debt Securities, Available-for-sale Local Phone Number Local Phone Number Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Americas [Member] Americas [Member] Finite-lived Intangible Assets Amortization Expense [Table Text Block] Finite-lived Intangible Assets Amortization Expense [Table Text Block] Reconciliation of Assets from Segment to Consolidated [Table Text Block] Reconciliation of Assets from Segment to Consolidated [Table Text Block] Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Long-term Debt Instruments [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Noncompete Agreements [Member] Noncompete Agreements [Member] Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-lived Intangible Assets (Excluding Goodwill) Indefinite-lived Intangible Assets (Excluding Goodwill) Cash paid to suppliers and employees Payments to Suppliers and Employees Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Line of credit maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Lessee Operating And Finance Leases Remaining Lease Term Lessee Operating And Finance Leases Remaining Lease Term Lessee Operating And Finance Leases Remaining Lease Term Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Lease Contractual Term [Domain] Lease Contractual Term [Domain] Maximum [Member] Maximum [Member] Retained Earnings [Member] Retained Earnings [Member] Measurement Basis [Axis] Measurement Basis [Axis] Payments of contingent consideration Payment for Contingent Consideration Liability, Financing Activities Effective tax rate Effective Income Tax Rate Reconciliation, Percent Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Payments for purchases of marketable securities and investments Payments to Acquire Investments Accounts Receivable, Allowance for Credit Loss Accounts Receivable, Allowance for Credit Loss Other Nonoperating Expense Other Nonoperating Expense Investments [Domain] Investments [Domain] Cash received from customers Proceeds from Customers Corporate Debt Securities [Member] Corporate Debt Securities [Member] Trading Symbol Trading Symbol Goodwill, Other Increase (Decrease) Goodwill, Other Increase (Decrease) Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Treasury stock Treasury Stock, Value Lessee Supplemental Cash Flow Information [Table Text Block] Lessee Supplemental Cash Flow Information [Table Text Block] Lessee Supplemental Cash Flow Information [Table Text Block] Earnings Per Share Earnings Per Share [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Entity Shell Company Entity Shell Company Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Fair Value, Recurring [Member] Fair Value, Recurring [Member] Finance Lease, Liability, Payments, Due Year Two Finance Lease, Liability, to be Paid, Year Two Summary of fair value of gross unrealized losses for investments with unrealized losses Schedule of Unrealized Loss on Investments [Table Text Block] New Accounting Pronouncements, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Basic earnings per share: Earnings Per Share, Basic [Abstract] Short-term investments Short-term Investments EX-101.PRE 10 bio-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 bio-20210331_htm.xml IDEA: XBRL DOCUMENT 0000012208 2021-01-01 2021-03-31 0000012208 us-gaap:CommonClassAMember 2021-01-01 2021-03-31 0000012208 us-gaap:CommonClassBMember 2021-01-01 2021-03-31 0000012208 us-gaap:CommonClassAMember 2021-04-23 0000012208 us-gaap:CommonClassBMember 2021-04-23 0000012208 2021-03-31 0000012208 2020-12-31 0000012208 us-gaap:CommonClassAMember 2021-03-31 0000012208 us-gaap:CommonClassAMember 2020-12-31 0000012208 us-gaap:CommonClassBMember 2021-03-31 0000012208 us-gaap:CommonClassBMember 2020-12-31 0000012208 bio:TreasuryClassAMember 2021-03-31 0000012208 bio:TreasuryClassAMember 2020-12-31 0000012208 2020-01-01 2020-03-31 0000012208 2019-12-31 0000012208 2020-03-31 0000012208 us-gaap:OtherCurrentAssetsMember 2021-03-31 0000012208 us-gaap:OtherCurrentAssetsMember 2020-03-31 0000012208 us-gaap:OtherAssetsMember 2021-03-31 0000012208 us-gaap:OtherAssetsMember 2020-03-31 0000012208 us-gaap:CommonStockMember 2020-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000012208 us-gaap:TreasuryStockMember 2020-12-31 0000012208 us-gaap:RetainedEarningsMember 2020-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000012208 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000012208 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0000012208 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000012208 us-gaap:CommonStockMember 2021-03-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000012208 us-gaap:TreasuryStockMember 2021-03-31 0000012208 us-gaap:RetainedEarningsMember 2021-03-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000012208 us-gaap:CommonStockMember 2019-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000012208 us-gaap:TreasuryStockMember 2019-12-31 0000012208 us-gaap:RetainedEarningsMember 2019-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000012208 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000012208 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0000012208 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000012208 us-gaap:CommonStockMember 2020-03-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000012208 us-gaap:TreasuryStockMember 2020-03-31 0000012208 us-gaap:RetainedEarningsMember 2020-03-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000012208 srt:EuropeMember 2021-01-01 2021-03-31 0000012208 srt:EuropeMember 2020-01-01 2020-03-31 0000012208 srt:AsiaPacificMember 2021-01-01 2021-03-31 0000012208 srt:AsiaPacificMember 2020-01-01 2020-03-31 0000012208 country:US 2021-01-01 2021-03-31 0000012208 country:US 2020-01-01 2020-03-31 0000012208 srt:AmericasMember 2021-01-01 2021-03-31 0000012208 srt:AmericasMember 2020-01-01 2020-03-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-03-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-03-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-03-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-03-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2021-03-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2021-03-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2021-03-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2021-03-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2021-03-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2021-03-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2021-03-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2021-03-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtMember 2021-03-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtMember 2021-03-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtMember 2021-03-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtMember 2021-03-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2021-03-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2021-03-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2021-03-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2021-03-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2021-03-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2021-03-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2021-03-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2021-03-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2020-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2020-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2020-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2020-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtMember 2020-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtMember 2020-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtMember 2020-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtMember 2020-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2020-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2020-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2020-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2020-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-12-31 0000012208 bio:RestrictedInvestmentMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 bio:RestrictedInvestmentMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 bio:OrdinaryVotingSharesMember 2021-03-31 0000012208 bio:PreferenceSharesMember 2021-03-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 bio:DistributorMember 2020-10-01 2020-12-31 0000012208 bio:DistributorMember 2021-01-01 2021-03-31 0000012208 bio:DistributorMember 2021-03-31 0000012208 bio:CelseeMember 2021-03-31 0000012208 bio:CelseeMember 2020-04-01 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-03-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2021-03-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2021-03-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2021-03-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2021-03-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtMember 2021-03-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2021-03-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2020-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2020-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtMember 2020-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember 2021-03-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2021-03-31 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2021-03-31 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2021-01-01 2021-03-31 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2021-03-31 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2021-01-01 2021-03-31 0000012208 bio:LifeScienceMember 2021-03-31 0000012208 bio:LifeScienceMember 2020-12-31 0000012208 bio:ClinicalDiagnosticsMember 2020-12-31 0000012208 bio:ClinicalDiagnosticsMember 2021-03-31 0000012208 us-gaap:CustomerRelationshipsMember 2021-01-01 2021-03-31 0000012208 us-gaap:CustomerRelationshipsMember 2021-03-31 0000012208 bio:KnowHowMember 2021-01-01 2021-03-31 0000012208 bio:KnowHowMember 2021-03-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2021-01-01 2021-03-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2021-03-31 0000012208 us-gaap:LicensingAgreementsMember 2021-01-01 2021-03-31 0000012208 us-gaap:LicensingAgreementsMember 2021-03-31 0000012208 us-gaap:TradeNamesMember 2021-01-01 2021-03-31 0000012208 us-gaap:TradeNamesMember 2021-03-31 0000012208 us-gaap:NoncompeteAgreementsMember 2021-01-01 2021-03-31 0000012208 us-gaap:NoncompeteAgreementsMember 2021-03-31 0000012208 us-gaap:OtherIntangibleAssetsMember 2021-03-31 0000012208 us-gaap:InProcessResearchAndDevelopmentMember 2021-03-31 0000012208 us-gaap:CustomerRelationshipsMember 2020-01-01 2020-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2020-12-31 0000012208 bio:KnowHowMember 2020-01-01 2020-12-31 0000012208 bio:KnowHowMember 2020-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2020-01-01 2020-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2020-12-31 0000012208 us-gaap:LicensingAgreementsMember 2020-01-01 2020-12-31 0000012208 us-gaap:LicensingAgreementsMember 2020-12-31 0000012208 us-gaap:TradeNamesMember 2020-01-01 2020-12-31 0000012208 us-gaap:TradeNamesMember 2020-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2020-01-01 2020-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2020-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember 2020-12-31 0000012208 us-gaap:InProcessResearchAndDevelopmentMember 2020-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember 2021-01-01 2021-03-31 0000012208 us-gaap:OtherIntangibleAssetsMember 2020-01-01 2020-12-31 0000012208 bio:FinanceLeasesandOtherDebtMember bio:FinanceLeaseObligationsMember 2021-03-31 0000012208 bio:FinanceLeasesandOtherDebtMember bio:FinanceLeaseObligationsMember 2020-12-31 0000012208 us-gaap:LineOfCreditMember 2021-03-31 0000012208 us-gaap:StandbyLettersOfCreditMember 2021-03-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-03-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-03-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-01-01 2021-03-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2021-03-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-03-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-03-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-03-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-03-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-03-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-03-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-03-31 0000012208 bio:LifeScienceMember 2021-01-01 2021-03-31 0000012208 bio:ClinicalDiagnosticsMember 2021-01-01 2021-03-31 0000012208 us-gaap:AllOtherSegmentsMember 2021-01-01 2021-03-31 0000012208 bio:LifeScienceMember 2020-01-01 2020-03-31 0000012208 bio:ClinicalDiagnosticsMember 2020-01-01 2020-03-31 0000012208 us-gaap:AllOtherSegmentsMember 2020-01-01 2020-03-31 0000012208 us-gaap:OperatingSegmentsMember 2021-01-01 2021-03-31 0000012208 us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2021-01-01 2021-03-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2020-01-01 2020-03-31 0000012208 us-gaap:MaterialReconcilingItemsMember 2021-01-01 2021-03-31 0000012208 us-gaap:MaterialReconcilingItemsMember 2020-01-01 2020-03-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2021-01-01 2021-03-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-03-31 0000012208 bio:EuropeanReorganizationMember 2021-03-31 0000012208 us-gaap:AccountsPayableAndAccruedLiabilitiesMember bio:EuropeanReorganizationMember 2021-03-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember bio:EuropeanReorganizationMember 2021-03-31 0000012208 us-gaap:CostOfSalesMember bio:EuropeanReorganizationMember 2021-01-01 2021-03-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:EuropeanReorganizationMember 2021-01-01 2021-03-31 0000012208 us-gaap:ResearchAndDevelopmentExpenseMember bio:EuropeanReorganizationMember 2021-01-01 2021-03-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2020-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2020-12-31 0000012208 bio:EuropeanReorganizationMember 2020-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2021-01-01 2021-03-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2021-01-01 2021-03-31 0000012208 bio:EuropeanReorganizationMember 2021-01-01 2021-03-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2021-03-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2021-03-31 0000012208 srt:MinimumMember 2021-01-01 2021-03-31 0000012208 srt:MaximumMember 2021-01-01 2021-03-31 0000012208 bio:CurrentLiabilityMember 2021-03-31 0000012208 bio:CurrentLiabilityMember 2020-12-31 shares iso4217:USD iso4217:USD shares pure 0000012208 --12-31 2021 Q1 false 10-Q true 2021-03-31 false 1-7928 BIO-RAD LABORATORIES, INC. DE 94-1381833 1000 Alfred Nobel Drive, Hercules, CA 94547 (510) 724-7000 Class A Common Stock, Par Value $0.0001 per share BIO NYSE Class B Common Stock, Par Value $0.0001 per share BIOb NYSE Yes Yes Large Accelerated Filer false false false false 24692554 5071060 673470000 662205000 346398000 328913000 5560000 5560000 18553000 19807000 408137000 419424000 122605000 126911000 150628000 151931000 331923000 343411000 605156000 622253000 110271000 90621000 26325000 10859000 2175317000 2139835000 1420284000 1452761000 937572000 961390000 482712000 491371000 196224000 202136000 291916000 291916000 191764000 199497000 10503038000 9561140000 92189000 86723000 13933160000 12972618000 138494000 139451000 174889000 222875000 1738000 1798000 89074000 57335000 39235000 36507000 166462000 173570000 609892000 631536000 10901000 12258000 2306112000 2076785000 168326000 175128000 228870000 196971000 3324101000 3092678000 25086359 25072619 24692104 24767870 2000 2000 5071060 5071060 5076186 5076186 1000 1000 445101000 429376000 394255 304749 149905000 99907000 10245426000 9268012000 68434000 282456000 10609059000 9879940000 13933160000 12972618000 726796000 571644000 326169000 254276000 400627000 317368000 225853000 193692000 73912000 49303000 100862000 74373000 398000 5690000 -71000 -928000 1179403000 827671000 17407000 3273000 1297203000 898699000 319789000 212787000 977414000 685912000 32.77 22.97 29823000 29865000 32.38 22.72 30186000 30196000 977414000 685912000 -214323000 -62011000 -1857000 -731000 -1556000 -327000 -214022000 -61607000 763392000 624305000 728013000 569001000 612803000 509683000 309000 231000 14727000 4528000 12193000 3912000 -1243000 -4337000 113610000 62808000 19547000 21591000 12000 38000 0 100000 74925000 98151000 15624000 39672000 30509000 67710000 -48327000 -12422000 1401000 1415000 0 1265000 4052000 4068000 49998000 100005000 -47347000 -98617000 -7347000 -5977000 10589000 -54208000 667115000 662651000 677704000 608443000 673470000 603551000 3354000 3110000 880000 1782000 677704000 608443000 3000 429376000 -99907000 9268012000 282456000 9879940000 0 0 0 977414000 0 977414000 0 0 0 0 -214022000 -214022000 0 4052000 0 0 0 4052000 0 11673000 0 0 0 11673000 0 0 49998000 0 0 49998000 3000 445101000 -149905000 10245426000 68434000 10609059000 3000 410020000 -38397000 5470779000 -87348000 5755057000 0 0 0 685912000 0 685912000 0 0 0 0 -61607000 -61607000 0 4068000 0 0 0 4068000 0 9654000 0 0 0 9654000 0 0 100005000 0 0 100005000 3000 423742000 -138402000 6156691000 -148955000 6293079000 BASIS OF PRESENTATION AND USE OF ESTIMATES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries.  The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented.  All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year.  The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recognized until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to customer specifications, which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control in relation to the equipment has occurred at that point as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon customer acceptance because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At the time revenue is recognized, a provision is recorded for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Reagent Rental Agreements </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. For purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the Company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Generally these arrangements do not contain an option for the lessee to purchase the underlying asset. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Maintenance services, along with the reagents, are allocated to the non-lease elements and are recognized as income. Generally, the terms of the arrangements result in the transfer of control for reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments.  Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales-type leases represent in aggregate an immaterial amount of lease income. Our reported lease income is primarily variable in nature and is recognized upon delivery or as the reagents are consumed by the customer.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Revenue allocated to the lease elements of these reagent rental arrangements represented approximately 2% and 3% of total revenue for the three months ended March 31, 2021 and March 31, 2020, respectively, and are included as part of Net sales in our condensed consolidated statements of income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Contract costs:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:64.912%"><tr><td style="width:1.0%"/><td style="width:48.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.134%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.731%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">247.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">195.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">168.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">111.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">271.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">229.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other (primarily Canada and Latin America)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">38.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">35.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total net sales</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">726.8 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">571.6 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenue by industry segment sources are presented in our Segment Information footnote (see Note 10).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Deferred revenues primarily represents unrecognized fees billed or collected for extended service arrangements. The deferred revenue balance at March 31, 2021 and December 31, 2020 was $66.2 million and $60.0 million, respectively. The short-term deferred revenue balance at March 31, 2021 and December 31, 2020 was $48.0 million and $42.5 million, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the three month period ended March 31, 2021 and 2020 were as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.076%"><tr><td style="width:1.0%"/><td style="width:72.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.906%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.798%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="6" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for warranty</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Actual warranty costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.9 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.2 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Allowance for Doubtful Accounts</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. We review our exposure to accounts receivable and reserve for amounts if collectability is no longer reasonably assured based on an assessment of various factors including historical loss rates and expectations of forward-looking loss estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes in our allowance for doubtful accounts were as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="6" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision (recovery) for expected credit losses</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Write-offs charged against the allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.6 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.9 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In March 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-04, "Facilitation of the Effects of Reference Rate Reform on Financial Reporting (Topic 848)"  The ASU provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate (e.g., LIBOR) reform if certain criteria are met, for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting.  The ASU is effective as of March 12, 2020 through December 31, 2022.  We will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis.  The ASU is currently not expected to have a material impact on our condensed consolidated financial statements. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In January 2020, the FASB issued ASU 2020-01, "Clarifying the Interactions between Topic 321 Investments—Equity Securities, Topic 323 Investments—Equity Method and Joint Ventures, and Topic 815 Derivatives and Hedging." ASU 2020-01 clarifies that a company should consider observable transactions that require a company to either apply or discontinue the equity method of accounting under Topic 323 for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. ASU 2020-01 also clarifies that, when determining the accounting for certain forward contracts and purchased options a company should not consider, whether upon settlement or exercise, if the underlying securities would be accounted for under the equity method or fair value option. The ASU is currently not expected to have a material impact on our condensed consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes," which</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">eliminates certain exceptions within ASC 740, Income Taxes, and clarifies other aspects of the current guidance to</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">promote consistency among reporting entities. ASU 2019-12 was effective for fiscal years beginning after</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">December 15, 2020, with any adjustments reflected as of January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the condensed consolidated financial statements.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recognized until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to customer specifications, which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control in relation to the equipment has occurred at that point as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon customer acceptance because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At the time revenue is recognized, a provision is recorded for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Reagent Rental Agreements </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. For purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the Company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Generally these arrangements do not contain an option for the lessee to purchase the underlying asset. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Maintenance services, along with the reagents, are allocated to the non-lease elements and are recognized as income. Generally, the terms of the arrangements result in the transfer of control for reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments.  Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales-type leases represent in aggregate an immaterial amount of lease income. Our reported lease income is primarily variable in nature and is recognized upon delivery or as the reagents are consumed by the customer.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Revenue allocated to the lease elements of these reagent rental arrangements represented approximately 2% and 3% of total revenue for the three months ended March 31, 2021 and March 31, 2020, respectively, and are included as part of Net sales in our condensed consolidated statements of income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Contract costs:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:64.912%"><tr><td style="width:1.0%"/><td style="width:48.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.134%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.731%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">247.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">195.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">168.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">111.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">271.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">229.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other (primarily Canada and Latin America)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">38.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">35.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total net sales</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">726.8 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">571.6 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenue by industry segment sources are presented in our Segment Information footnote (see Note 10).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Deferred revenues primarily represents unrecognized fees billed or collected for extended service arrangements. The deferred revenue balance at March 31, 2021 and December 31, 2020 was $66.2 million and $60.0 million, respectively. The short-term deferred revenue balance at March 31, 2021 and December 31, 2020 was $48.0 million and $42.5 million, respectively.</span></div> 0.02 0.03 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:64.912%"><tr><td style="width:1.0%"/><td style="width:48.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.134%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.731%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">247.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">195.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">168.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">111.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">271.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">229.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other (primarily Canada and Latin America)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">38.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">35.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total net sales</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">726.8 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">571.6 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 247700000 195700000 168900000 111400000 271400000 229500000 38800000 35000000.0 726800000 571600000 66200000 60000000.0 48000000.0 42500000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the three month period ended March 31, 2021 and 2020 were as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.076%"><tr><td style="width:1.0%"/><td style="width:72.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.906%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.798%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="6" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for warranty</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Actual warranty costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.9 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.2 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the three month period ended March 31, 2021 and 2020 were as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.076%"><tr><td style="width:1.0%"/><td style="width:72.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.906%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.798%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="6" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for warranty</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Actual warranty costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.9 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.2 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 9800000 9000000.0 2700000 1900000 2600000 2700000 9900000 8200000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Allowance for Doubtful Accounts</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. We review our exposure to accounts receivable and reserve for amounts if collectability is no longer reasonably assured based on an assessment of various factors including historical loss rates and expectations of forward-looking loss estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes in our allowance for doubtful accounts were as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="6" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision (recovery) for expected credit losses</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Write-offs charged against the allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.6 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.9 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes in our allowance for doubtful accounts were as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="6" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision (recovery) for expected credit losses</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Write-offs charged against the allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.6 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.9 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 19800000 20200000 -600000 -800000 600000 500000 18600000 18900000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In March 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-04, "Facilitation of the Effects of Reference Rate Reform on Financial Reporting (Topic 848)"  The ASU provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate (e.g., LIBOR) reform if certain criteria are met, for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting.  The ASU is effective as of March 12, 2020 through December 31, 2022.  We will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis.  The ASU is currently not expected to have a material impact on our condensed consolidated financial statements. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In January 2020, the FASB issued ASU 2020-01, "Clarifying the Interactions between Topic 321 Investments—Equity Securities, Topic 323 Investments—Equity Method and Joint Ventures, and Topic 815 Derivatives and Hedging." ASU 2020-01 clarifies that a company should consider observable transactions that require a company to either apply or discontinue the equity method of accounting under Topic 323 for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. ASU 2020-01 also clarifies that, when determining the accounting for certain forward contracts and purchased options a company should not consider, whether upon settlement or exercise, if the underlying securities would be accounted for under the equity method or fair value option. The ASU is currently not expected to have a material impact on our condensed consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes," which</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">eliminates certain exceptions within ASC 740, Income Taxes, and clarifies other aspects of the current guidance to</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">promote consistency among reporting entities. ASU 2019-12 was effective for fiscal years beginning after</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">December 15, 2020, with any adjustments reflected as of January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the condensed consolidated financial statements.</span></div> FAIR VALUE MEASUREMENTS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Quoted prices in active markets for identical instruments</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial assets and liabilities carried at fair value and measured on a recurring basis as of March 31, 2021 are classified in the hierarchy as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:49.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.815%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial assets carried at fair value:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">61.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">61.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total cash equivalents (a)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">70.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">41.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">111.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted investments (b)</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equity securities (c)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,524.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,524.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Available-for-sale investments:</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">162.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">162.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">71.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">71.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other foreign obligations</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total available-for-sale investments (d)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">282.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">282.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (e)</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,601.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">324.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,925.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial liabilities carried at fair value:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (f)</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contingent consideration (g)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial liabilities carried at fair value</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2020 are classified in the hierarchy as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.753%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.747%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial assets carried at fair value:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">41.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">41.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">60.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">60.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total cash equivalents (a)</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">77.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">55.1 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">132.8 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted investments (b)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equity securities (c)</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,582.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,582.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Available-for-sale investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">133.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">133.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">76.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">76.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other foreign obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total available-for-sale investments (d)</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">267.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">267.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (e)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,666.8 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">323.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,990.5 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial liabilities carried at fair value:</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (f)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contingent consideration (g)</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial liabilities carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.8pt">Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.953%"><tr><td style="width:1.0%"/><td style="width:68.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.782%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted investments</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">    Total</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">64.2 </span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">61.4 </span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,460.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,521.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">        Total</span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,524.3 </span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,582.4 </span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The change in fair market value on our equity securities for the three months ended March 31, 2021 was a $1,179.4 million gain, which was primarily due to our investment in Sartorius AG and is recorded in our condensed consolidated statements of income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">As of March 31, 2021, we own 12,987,900 ordinary voting shares and 9,588,908 preferenc</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 37% of the ordinary outstanding voting shares (excluding treasury shares) and 28% of the preference shares of Sartorius as of March 31, 2021. </span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d) Available-for-sale investments are included in the following accounts in the condensed consolidated balance sheets (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:68.247%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">282.2 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">267.5 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">282.3 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">267.6 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e) Forward foreign exchange contracts in an asset position are included in other current assets in the condensed consolidated balance sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f) Forward foreign exchange contracts in a liability position are included in other current liabilities in the condensed consolidated balance sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g) Contingent consideration liability is included in the following accounts in the condensed consolidated balance sheets (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.590%"><tr><td style="width:1.0%"/><td style="width:68.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   Total</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the fourth quarter of 2019, we recognized a contingent consideration liability for earn-out targets related to our acquisition of a foreign distributor. The first earn-out payment of $0.7 million was paid by the acquisition date and the remaining payment is anticipated to be paid in the first half of 2021. The maximum earn-out payment due is $1.4 million. The contingent consideration was accrued at its estimated fair value of $0.6 million as of March 31, 2021 which is unchanged from the fair value at December 31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the second quarter of 2020, we recognized a contingent consideration liability upon our acquisition of Celsee, Inc. which represents the future potential earn-out payments of up to $60.0 million payable in cash upon the achievement of certain net revenues for the period beginning on January 1, 2021 and ending on December 31, 2022. The fair value of the earn-out as of the Acquisition Date was approximately $0.1 million which was determined by using a Black-Scholes-Merton option-pricing valuation model that includes significant assumptions and unobservable inputs such as the projected revenues of Celsee over the earn-out period and the probability of the earn-out threshold being met. The fair value of the contingent consideration is remeasured at each reporting period based on the assumptions and inputs on the date of remeasurement. The achievement of net revenues was not met as of March 31, 2021 and therefore the fair value of the earn-out remained unchanged at approximately $0.1 million as of March 31, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To estimate the fair value of Level 2 debt securities as of March 31, 2021, our primary pricing provider uses Reuters as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Reuters does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Available-for-sale investments consist of the following (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:36.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.073%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Allowances for Credit Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">160.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">162.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">70.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">71.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Other foreign obligations</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">278.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">282.2 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">278.8 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">282.3 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a summary of the amortized cost and estimated fair value of our debt securities at March 31, 2021 by contractual maturity date (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Estimated Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mature in less than one year</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">173.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">174.1 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mature in one to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">66.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">67.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mature in more than five years</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">39.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">40.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">278.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">282.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Available-for-sale investments consist of the following (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:36.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.886%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Allowances for Credit Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">130.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">133.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">35.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">74.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">76.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Other foreign obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">262.1 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">267.5 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">262.2 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">267.6 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:35.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.078%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="24" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Greater than 12 months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Description of securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized Losses</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The unrealized losses of $0.1 million as of March 31, 2021 are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There were no significant unrealized losses as of December 31, 2020 in either the less than or greater than 12 month categories.</span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="padding-right:9pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our evaluation of credit losses for available-for-sale debt securities included t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">he extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are limited to the amount that the fair value of an instrument is less than its amortized cost basis. </span></div><div style="padding-right:9pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At March 31, 2021, we have concluded that all payments related to our available-for-sale investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> are expected to be made in full and on time at </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">par value. The diminution of value in the intervening period is due to market conditions such as illiquidity and interest rate movements and not due to significant, inherent credit concerns surrounding the issuer. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a result, we have no allowances for credit losses on our available-for-sale investments portfolio as of March 31, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Included in other current assets are $1.4 million of interest receivable as of March 31, 2021 and December 31, 2020, primarily associated with securities in our available-for-sale investments portfolio. Associated interest on these securities is typically payable semi-annually. Due to the short-term nature of our interest receivable asset, we have made an accounting policy election not to measure an allowance for credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue greater than one year to be impaired for purposes of write-off. For the three months ended March 31, 2021, we have not written-off any uncollected interest receivable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes.  We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date.  The notional principal amounts provide one measure of the transaction volume outstanding as of March 31, 2021 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties.  The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in foreign currency exchange losses, net in the condensed consolidated statements of income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a summary of our forward foreign exchange contracts (in millions): </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contracts maturing in April through June 2021 to sell foreign currency:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notional value</span></td><td style="background-color:#d6ffd2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">284.0 </span></td><td style="background-color:#d6ffd2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contracts maturing in April through June 2021 to purchase foreign currency:</span></td><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notional value</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">252.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized gain or loss</span></td><td style="background-color:#d6ffd2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#d6ffd2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Included in other investments in the condensed consolidated balance sheets are investments without readily determinable fair value measured at cost with adjustments for observable price changes in price or impairments. The carrying value of these investments was $6.5 million and $0.5 million as of March 31, 2021 and December 31, 2020, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Also included in other investments in the condensed consolidated balance sheets are our equity method investments, for which our share of the equity method investees earnings is included in other income, net in our condensed consolidated statements of income. The carrying value of these investments was $35.2 million and $38.4 million as of March 31, 2021 and December 31, 2020, respectively.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial assets and liabilities carried at fair value and measured on a recurring basis as of March 31, 2021 are classified in the hierarchy as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:49.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.815%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial assets carried at fair value:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">61.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">61.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total cash equivalents (a)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">70.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">41.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">111.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted investments (b)</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equity securities (c)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,524.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,524.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Available-for-sale investments:</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">162.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">162.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">71.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">71.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other foreign obligations</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total available-for-sale investments (d)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">282.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">282.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (e)</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,601.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">324.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,925.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial liabilities carried at fair value:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (f)</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contingent consideration (g)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial liabilities carried at fair value</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2020 are classified in the hierarchy as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.753%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.747%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial assets carried at fair value:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">41.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">41.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">60.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">60.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total cash equivalents (a)</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">77.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">55.1 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">132.8 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted investments (b)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equity securities (c)</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,582.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,582.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Available-for-sale investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">133.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">133.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">76.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">76.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other foreign obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total available-for-sale investments (d)</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">267.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">267.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (e)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,666.8 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">323.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,990.5 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial liabilities carried at fair value:</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (f)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contingent consideration (g)</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial liabilities carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.8pt">Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.953%"><tr><td style="width:1.0%"/><td style="width:68.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.782%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted investments</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">    Total</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">64.2 </span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">61.4 </span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,460.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,521.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">        Total</span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,524.3 </span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,582.4 </span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The change in fair market value on our equity securities for the three months ended March 31, 2021 was a $1,179.4 million gain, which was primarily due to our investment in Sartorius AG and is recorded in our condensed consolidated statements of income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">As of March 31, 2021, we own 12,987,900 ordinary voting shares and 9,588,908 preferenc</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 37% of the ordinary outstanding voting shares (excluding treasury shares) and 28% of the preference shares of Sartorius as of March 31, 2021. </span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d) Available-for-sale investments are included in the following accounts in the condensed consolidated balance sheets (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:68.247%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">282.2 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">267.5 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">282.3 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">267.6 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e) Forward foreign exchange contracts in an asset position are included in other current assets in the condensed consolidated balance sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f) Forward foreign exchange contracts in a liability position are included in other current liabilities in the condensed consolidated balance sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g) Contingent consideration liability is included in the following accounts in the condensed consolidated balance sheets (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.590%"><tr><td style="width:1.0%"/><td style="width:68.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   Total</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 29300000 0 29300000 0 2600000 0 2600000 8700000 10000000.0 0 18700000 61300000 0 0 61300000 70000000.0 41900000 0 111900000 6800000 0 0 6800000 10524300000 0 0 10524300000 0 162200000 0 162200000 0 71800000 0 71800000 0 4000000.0 0 4000000.0 0 2100000 0 2100000 0 14100000 0 14100000 0 28100000 0 28100000 0 282300000 0 282300000 0 600000 0 600000 10601100000 324800000 0 10925900000 0 1100000 0 1100000 0 0 700000 700000 0 1100000 700000 1800000 0 41700000 0 41700000 17600000 10000000.0 0 27600000 0 900000 0 900000 0 2500000 0 2500000 60100000 0 0 60100000 77700000 55100000 0 132800000 6700000 0 0 6700000 9582400000 0 0 9582400000 0 133200000 0 133200000 0 76900000 0 76900000 0 4000000.0 0 4000000.0 0 2100000 0 2100000 0 15200000 0 15200000 0 36200000 0 36200000 0 267600000 0 267600000 0 1000000.0 0 1000000.0 9666800000 323700000 0 9990500000 0 1000000.0 0 1000000.0 0 0 700000 700000 0 1000000.0 700000 1700000 5600000 5600000 1200000 1100000 6800000 6700000 64200000 61400000 10460100000 9521000000.0 10524300000 9582400000 1179400000 12987900 9588908 0.37 0.28 282200000 267500000 100000 100000 282300000 267600000 600000 600000 100000 100000 700000 700000 700000 1400000 600000 60000000.0 100000 100000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Available-for-sale investments consist of the following (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:36.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.073%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Allowances for Credit Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">160.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">162.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">70.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">71.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Other foreign obligations</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">278.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">282.2 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">278.8 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">282.3 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 160300000 1900000 0 0 162200000 14000000.0 100000 0 0 14100000 27700000 300000 0 0 28000000.0 70600000 1300000 100000 0 71800000 4000000.0 0 0 0 4000000.0 2100000 0 0 0 2100000 278700000 3600000 100000 0 282200000 100000 0 0 0 100000 100000 0 0 0 100000 278800000 3600000 100000 0 282300000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a summary of the amortized cost and estimated fair value of our debt securities at March 31, 2021 by contractual maturity date (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Estimated Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mature in less than one year</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">173.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">174.1 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mature in one to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">66.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">67.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mature in more than five years</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">39.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">40.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">278.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">282.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 173600000 174100000 66200000 67900000 39000000.0 40300000 278800000 282300000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Available-for-sale investments consist of the following (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:36.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.886%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Allowances for Credit Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">130.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">133.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">35.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">74.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">76.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Other foreign obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">262.1 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">267.5 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">262.2 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">267.6 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 130500000 2700000 0 0 133200000 15000000.0 200000 0 0 15200000 35800000 300000 0 0 36100000 74700000 2200000 0 0 76900000 4000000.0 0 0 0 4000000.0 2100000 0 0 0 2100000 262100000 5400000 0 0 267500000 100000 0 0 0 100000 100000 0 0 0 100000 262200000 5400000 0 0 267600000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:35.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.078%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="24" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Greater than 12 months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Description of securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized Losses</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>T 7400000 100000 0 0 7400000 100000 7400000 100000 0 0 7400000 100000 100000 1400000 1400000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a summary of our forward foreign exchange contracts (in millions): </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contracts maturing in April through June 2021 to sell foreign currency:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notional value</span></td><td style="background-color:#d6ffd2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">284.0 </span></td><td style="background-color:#d6ffd2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contracts maturing in April through June 2021 to purchase foreign currency:</span></td><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notional value</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">252.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized gain or loss</span></td><td style="background-color:#d6ffd2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#d6ffd2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 284000000.0 400000 252300000 0 6500000 500000 35200000 38400000 GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes to goodwill by segment were as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Life<br/>Science</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Clinical<br/>Diagnostics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of March 31, 2021 and December 31, 2020:</span></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">277.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">349.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">627.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accumulated impairment losses</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(41.8)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(293.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(335.2)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goodwill, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">236.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">55.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">291.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-Average Remaining Amortization Period (years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Purchase<br/>Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Customer relationships/lists</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.47</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">112.4 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(85.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">26.8 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Know how</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.50</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">192.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(172.6)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Developed product technology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.83</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">217.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(108.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">108.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.51</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">65.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(38.0)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tradenames</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.71</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Covenants not to compete</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.66</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total definite-lived intangible assets</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">598.5 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(411.3)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">187.2 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total purchased intangible assets</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">603.1 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(411.3)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">191.8 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-Average Remaining Amortization Period (years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Purchase<br/>Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Customer relationships/lists</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.51</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">116.6 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(87.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29.4 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Know how</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.75</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">196.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(175.4)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Developed product technology</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">218.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(107.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">111.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.73</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">65.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(37.4)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tradenames</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.82</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Covenants not to compete</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.87</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total definite-lived intangible assets</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">608.1 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(413.4)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">194.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total purchased intangible assets</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">612.9 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(413.4)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">199.5 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Amortization expense related to purchased intangible assets is as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes to goodwill by segment were as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Life<br/>Science</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Clinical<br/>Diagnostics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of March 31, 2021 and December 31, 2020:</span></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">277.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">349.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">627.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accumulated impairment losses</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(41.8)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(293.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(335.2)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goodwill, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">236.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">55.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">291.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 277900000 277900000 349200000 349200000 627100000 627100000 41800000 41800000 293400000 293400000 335200000 335200000 236100000 236100000 55800000 55800000 291900000 291900000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-Average Remaining Amortization Period (years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Purchase<br/>Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Customer relationships/lists</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.47</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">112.4 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(85.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">26.8 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Know how</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.50</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">192.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(172.6)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Developed product technology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.83</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">217.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(108.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">108.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.51</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">65.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(38.0)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tradenames</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.71</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Covenants not to compete</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.66</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total definite-lived intangible assets</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">598.5 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(411.3)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">187.2 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total purchased intangible assets</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">603.1 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(411.3)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">191.8 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-Average Remaining Amortization Period (years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Purchase<br/>Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Customer relationships/lists</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.51</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">116.6 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(87.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29.4 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Know how</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.75</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">196.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(175.4)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Developed product technology</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">218.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(107.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">111.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.73</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">65.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(37.4)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tradenames</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.82</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Covenants not to compete</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.87</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total definite-lived intangible assets</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">608.1 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(413.4)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">194.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total purchased intangible assets</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">612.9 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(413.4)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">199.5 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P5Y5M19D 112400000 85600000 26800000 P4Y6M 192700000 172600000 20100000 P13Y9M29D 217100000 108600000 108500000 P7Y6M3D 65200000 38000000.0 27200000 P7Y8M15D 6400000 4200000 2200000 P3Y7M28D 4600000 2200000 2400000 100000 100000 0 598500000 411300000 187200000 4600000 4600000 603100000 411300000 191800000 P5Y6M3D 116600000 87200000 29400000 P4Y9M 196600000 175400000 21200000 P14Y 218100000 107100000 111000000.0 P7Y8M23D 65600000 37400000 28200000 P7Y9M25D 6600000 4200000 2400000 P3Y10M13D 4500000 2000000.0 2500000 100000 100000 0 608100000 413400000 194700000 4800000 4800000 612900000 413400000 199500000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Amortization expense related to purchased intangible assets is as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 7200000 5900000 SUPPLEMENTAL CASH FLOW INFORMATION<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The reconciliation of net income to net cash provided by operating activities is as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.676%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">977.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">685.9 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">32.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">33.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Reduction in the carrying amount of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gains on dispositions of securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other-than-temporary impairment losses on investment</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Changes in fair market value of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,179.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(827.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Losses on dispositions of fixed assets</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Payments for operating lease liabilities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Decrease in accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Decrease (increase) in inventories</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Increase in other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(37.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Decrease in accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(44.5)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(25.6)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Increase in income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Increase in deferred income taxes</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">274.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">171.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Increase in other long term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">43.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">113.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">62.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   Purchased property, plant and equipment</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   Purchased marketable securities and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The reconciliation of net income to net cash provided by operating activities is as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.676%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">977.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">685.9 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">32.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">33.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Reduction in the carrying amount of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gains on dispositions of securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other-than-temporary impairment losses on investment</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Changes in fair market value of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,179.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(827.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Losses on dispositions of fixed assets</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Payments for operating lease liabilities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Decrease in accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Decrease (increase) in inventories</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Increase in other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(37.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Decrease in accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(44.5)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(25.6)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Increase in income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Increase in deferred income taxes</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">274.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">171.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Increase in other long term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">43.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">113.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">62.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   Purchased property, plant and equipment</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   Purchased marketable securities and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 977400000 685900000 32700000 33600000 9800000 9600000 11700000 9700000 100000 400000 800000 0 1179400000 827700000 -300000 -100000 0 -100000 -9900000 -9300000 -1300000 -2200000 -5800000 13700000 37500000 9500000 -44500000 -25600000 27300000 20900000 -274800000 -171800000 43800000 15700000 700000 400000 113600000 62800000 4700000 6000000.0 0 2700000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">5.    LONG-TERM DEBT</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The principal components of long-term debt are as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:69.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finance leases and other debt</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less current maturities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.9 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.3 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In April 2019, Bio-Rad entered into a $200.0 million unsecured revolving credit facility ("Credit Agreement"). Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> outstanding borrowings under the Credit Agreement as of March 31, 2021; however, $0.2 million was utilized for domestic standby letters of credit that reduced our borrowing availability as of March 31, 2021. The Credit Agreement matures in April 2024. If we had borrowed against our Credit Agreement, the borrowing rate would have been 1.315% at March 31, 2021, which is based on the 3-month LIBOR. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens.  We were in compliance with all of these ratios and covenants as of March 31, 2021.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The principal components of long-term debt are as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:69.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finance leases and other debt</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less current maturities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.9 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.3 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 12600000 14100000 1700000 1800000 10900000 12300000 200000000.0 0 200000 0.01315 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accumulated other comprehensive income included in our condensed consolidated balance sheets consists of the following components (in millions): </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.952%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign other post-employment benefits adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized holding gains on available-for-sale investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accumulated other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances as of January 1, 2021:</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.0)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282.4 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effects</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of income taxes</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214.3)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214.0)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances as of March 31, 2021:</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.952%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign other post-employment benefits adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized holding gains on available-for-sale investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accumulated other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances as of January 1, 2020:</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72.4)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.2)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.4)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effects</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of income taxes</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.0)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.6)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances as of March 31, 2020:</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All amounts reclassified out of accumulated other comprehensive income were reclassified into other income, net in the condensed consolidated statements of income. The reclassification adjustments are calculated using the specific identification method.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accumulated other comprehensive income included in our condensed consolidated balance sheets consists of the following components (in millions): </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.952%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign other post-employment benefits adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized holding gains on available-for-sale investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accumulated other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances as of January 1, 2021:</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.0)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282.4 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effects</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of income taxes</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214.3)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214.0)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances as of March 31, 2021:</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.952%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign other post-employment benefits adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized holding gains on available-for-sale investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accumulated other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances as of January 1, 2020:</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72.4)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.2)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.4)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effects</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of income taxes</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.0)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.6)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances as of March 31, 2020:</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 298600000 -26000000.0 9800000 282400000 -214700000 1700000 -1900000 -214900000 0 -500000 100000 -400000 -400000 300000 -400000 -500000 -214300000 1900000 -1600000 -214000000.0 84300000 -24100000 8200000 68400000 -72400000 -22200000 7200000 -87400000 -62900000 200000 0 -62700000 0 -300000 400000 100000 -900000 -200000 -100000 -1200000 -62000000.0 700000 -300000 -61600000 -134400000 -21500000 6900000 -149000000.0 .    EARNINGS PER SHARE<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect of including such securities would be anti-dilutive. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.339%"><tr><td style="width:1.0%"/><td style="width:69.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.699%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.699%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.747%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,823 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,865 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effect of potentially dilutive stock options and restricted stock awards</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">363 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">331 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted weighted average common shares</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30,186 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30,196 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Anti-dilutive shares</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.339%"><tr><td style="width:1.0%"/><td style="width:69.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.699%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.699%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.747%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,823 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,865 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effect of potentially dilutive stock options and restricted stock awards</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">363 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">331 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted weighted average common shares</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30,186 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30,196 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Anti-dilutive shares</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 29823000 29865000 363000 331000 30186000 30196000 23000 62000 .    OTHER INCOME AND EXPENSE, NET<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other (income) expense, net includes the following components (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.251%"><tr><td style="width:1.0%"/><td style="width:64.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.700%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest and investment income</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(18.3)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net realized gains on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other-than-temporary impairment loss on investment</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other expense (income) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other (income), net</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other (income) expense, net includes the following components (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.251%"><tr><td style="width:1.0%"/><td style="width:64.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.700%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest and investment income</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(18.3)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net realized gains on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other-than-temporary impairment loss on investment</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other expense (income) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other (income), net</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 18300000 2800000 100000 400000 800000 0 200000 100000 17400000 3300000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">9.    INCOME TAXES </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our effective income tax rate was 24.7% and 23.7% for the three months ended March 31, 2021 and 2020, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The realization of deferred tax assets is dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that certain foreign deferred tax assets will not be realized as of March 31, 2021, and have maintained a valuation allowance on such deferred tax assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our income tax returns are routinely audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues around the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our gross unrecognized tax benefits were $57.5 million and $55.8 million as of March 31, 2021 and December 31, 2020, respectively. The increase to our gross unrecognized tax benefits is primarily the result of a $1.7 million net increase in tax positions taken in the current year net of foreign currency translation adjustments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">As of March 31, 2021, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitations for certain jurisdictions, we believe that within the next 12 months it is reasonably possible that our previously unrecognized tax benefits could decrease by up to $16.7 million primarily related to various foreign jurisdictions.</span></div> 0.247 0.237 57500000 55800000 1700000 16700000 SEGMENT INFORMATION<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Information regarding operating segments for the three months ended March 31, 2021 and 2020 is as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:40.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.468%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.732%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.732%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.634%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Life<br/>Science</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Clinical<br/>Diagnostics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other<br/>Operations</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Segment net sales </span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">366.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">358.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">227.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">340.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Segment net profit (loss)</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">102.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">43.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. Our chief operating decision maker ("CODM") views all operating expenses, interest expense and corporate overhead as directly supporting the strategies of our segments. As a result, starting in 2021 these costs are fully allocated to our reportable segments. Prior to this change, the difference between total segment allocated interest expense, depreciation and amortization, and the corresponding consolidated amounts was attributable to our corporate headquarters.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The historical segment information has been recast to conform to the current allocation methodology of corporate operating and other expenses to the segments.  Interest expense is charged to segments based on the carrying amount of inventory and receivables employed by that segment. The following reconciles total segment profit to consolidated income before income taxes (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.451%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total segment profit </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100.5 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">68.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency exchange losses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Change in fair market value of equity securities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,179.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">827.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Consolidated income before income taxes</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,297.2 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">898.7 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Information regarding operating segments for the three months ended March 31, 2021 and 2020 is as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:40.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.468%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.732%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.732%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.634%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Life<br/>Science</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Clinical<br/>Diagnostics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other<br/>Operations</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Segment net sales </span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">366.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">358.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">227.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">340.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Segment net profit (loss)</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">102.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">43.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div> 366500000 358500000 1800000 227200000 340300000 4100000 102300000 -1900000 100000 23700000 43800000 1100000 The following reconciles total segment profit to consolidated income before income taxes (in millions):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.451%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total segment profit </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100.5 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">68.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency exchange losses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Change in fair market value of equity securities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,179.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">827.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Consolidated income before income taxes</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,297.2 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">898.7 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 100500000 68600000 -100000 -900000 1179400000 827700000 17400000 3300000 1297200000 898700000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">11.    LEGAL PROCEEDINGS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are a party to various claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.</span></div> RESTRUCTURING COSTSIn February 2021, we announced our strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance. The restructuring plan primarily impacts our operations in Europe and includes the elimination of certain positions, the consolidation of certain functions, and the relocation of certain manufacturing operations from Europe to Asia. The restructuring plan will be implemented in phases and is expected to be substantially complete by the end of 2022. The liability of $71.2 million as of March 31, 2021 consisted of $35.2 million recorded in Accrued payroll and employee benefits and $36.0 million recorded in Other long-term liabilities in the condensed consolidated balance sheets. The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense were $23.9 million, $34.7 million and $17.0 million in the condensed consolidated statements of income for the three months ended March 31, 2021, respectively. The amounts are preliminary estimates based on the information currently available to management. It is possible that additional adjustments and future cash payments could occur in relation to the restructuring actions.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions): </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Life Science</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Clinical Diagnostics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of December 31, 2020:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Charged to expense - employee termination benefits</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">62.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">75.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency translation gains</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of March 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">58.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">71.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 71200000 35200000 36000000.0 23900000 34700000 17000000.0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions): </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Life Science</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Clinical Diagnostics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of December 31, 2020:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Charged to expense - employee termination benefits</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">62.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">75.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency translation gains</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"/><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of March 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">58.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">71.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 0 12900000 62700000 75600000 100000 1900000 2000000.0 400000 2000000.0 2400000 12400000 58800000 71200000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">13.    LEASES: FINANCE AND OPERATING WHERE WE ACT AS LESSEE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For operating leases where we act as lessor in reagent rental agreements, see Note 1. We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. For operating leases, we have elected not to separate lease and non-lease components for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 18 years, which includes our determination to exercise renewal options.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception. Right-of-use (ROU) assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Operating lease ROU assets also include any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.046%"><tr><td style="width:1.0%"/><td style="width:69.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.751%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.751%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="9" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">        Total finance lease cost</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sublease income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The sublease is for a building with a term that ends in 2025, with no options to extend or renew.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease cost includes original reduction in the carrying amount of ROU assets, the impact of remeasurements, modifications, impairments and abandonments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our short-term leases are expensed as incurred, reflecting leases with a lease term of one year or less, and are not significant for both the three months ended March 31, 2021 and 2020. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial for both the three months ended March 31, 2021 and 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:62.280%"><tr><td style="width:1.0%"/><td style="width:38.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.183%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Operating cash flows from operating leases</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Operating cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Financing cash flows from finance leases</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new lease obligations:</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Finance leases</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:60.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.688%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Operating lease liabilities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:60.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.688%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Finance Leases</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Property, plant and equipment, gross</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Property, plant and equipment, net</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current maturities of long-term debt and notes payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Long-term debt, net of current maturities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Total finance lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"/><td style="width:60.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.307%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Operating leases - in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Finance leases - in years</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Finance leases</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Maturities of lease liabilities were as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance Leases</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the three months ended March 31, 2021)</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total lease payments</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.4 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Total</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.6 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles, and other equipment with shorter terms and higher-turn over.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">13.    LEASES: FINANCE AND OPERATING WHERE WE ACT AS LESSEE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For operating leases where we act as lessor in reagent rental agreements, see Note 1. We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. For operating leases, we have elected not to separate lease and non-lease components for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 18 years, which includes our determination to exercise renewal options.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception. Right-of-use (ROU) assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Operating lease ROU assets also include any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.046%"><tr><td style="width:1.0%"/><td style="width:69.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.751%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.751%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="9" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">        Total finance lease cost</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sublease income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The sublease is for a building with a term that ends in 2025, with no options to extend or renew.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease cost includes original reduction in the carrying amount of ROU assets, the impact of remeasurements, modifications, impairments and abandonments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our short-term leases are expensed as incurred, reflecting leases with a lease term of one year or less, and are not significant for both the three months ended March 31, 2021 and 2020. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial for both the three months ended March 31, 2021 and 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:62.280%"><tr><td style="width:1.0%"/><td style="width:38.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.183%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Operating cash flows from operating leases</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Operating cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Financing cash flows from finance leases</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new lease obligations:</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Finance leases</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:60.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.688%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Operating lease liabilities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:60.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.688%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Finance Leases</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Property, plant and equipment, gross</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Property, plant and equipment, net</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current maturities of long-term debt and notes payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Long-term debt, net of current maturities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Total finance lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"/><td style="width:60.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.307%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Operating leases - in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Finance leases - in years</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Finance leases</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Maturities of lease liabilities were as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance Leases</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the three months ended March 31, 2021)</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total lease payments</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.4 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Total</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.6 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles, and other equipment with shorter terms and higher-turn over.</span></div> P1Y P18Y <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.046%"><tr><td style="width:1.0%"/><td style="width:69.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.751%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.751%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="9" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">        Total finance lease cost</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sublease income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The sublease is for a building with a term that ends in 2025, with no options to extend or renew.</span></div> 11700000 12600000 100000 100000 200000 200000 300000 300000 700000 700000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:62.280%"><tr><td style="width:1.0%"/><td style="width:38.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.183%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Operating cash flows from operating leases</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Operating cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Financing cash flows from finance leases</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new lease obligations:</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Finance leases</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 11800000 11400000 100000 200000 200000 100000 4200000 10800000 0 0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:60.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.688%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Operating lease liabilities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:60.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.688%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Finance Leases</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Property, plant and equipment, gross</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Property, plant and equipment, net</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current maturities of long-term debt and notes payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Long-term debt, net of current maturities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Total finance lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"/><td style="width:60.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.307%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Operating leases - in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Finance leases - in years</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Finance leases</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 196200000 202100000 39300000 36500000 168300000 175100000 207600000 211600000 12200000 12200000 5100000 5000000.0 7100000 7200000 500000 500000 10900000 11000000.0 11400000 11500000 P8Y P8Y P16Y P16Y 0.039 0.039 0.062 0.062 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Maturities of lease liabilities were as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance Leases</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the three months ended March 31, 2021)</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total lease payments</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.4 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Total</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.6 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"/><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 35300000 1000000.0 38600000 1300000 32400000 1200000 26400000 1100000 23100000 1100000 90600000 14000000.0 246400000 19700000 38800000 8300000 207600000 11400000 Contingent consideration liability is included in the following accounts in the condensed consolidated balance sheets (in millions):March 31, 2021December 31, 2020Other current liabilities$0.6 $0.6 Other long-term liabilities0.1 0.1    Total$0.7 $0.7  Forward foreign exchange contracts in a liability position are included in other current liabilities in the condensed consolidated balance sheets. Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):March 31, 2021December 31, 2020Restricted investments$5.6 $5.6 Other investments1.2 1.1     Total$6.8 $6.7  Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets. Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):March 31, 2021December 31, 2020Short-term investments$64.2 $61.4 Other investments10,460.1 9,521.0         Total$10,524.3 $9,582.4  Forward foreign exchange contracts in an asset position are included in other current assets in the condensed consolidated balance sheets. Available-for-sale investments are included in the following accounts in the condensed consolidated balance sheets (in millions): March 31, 2021December 31, 2020Short-term investments$282.2 $267.5 Other investments0.1 0.1 Total$282.3 $267.6  XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document and Entity Information - shares
 3 Months Ended
Mar. 31, 2021
Apr. 23, 2021
Document Transition Report false  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Shell Company false  
City Area Code (510)  
Document Quarterly Report true  
Entity Incorporation, State or Country Code DE  
Entity File Number 1-7928  
Entity Registrant Name BIO-RAD LABORATORIES, INC.  
Entity Central Index Key 0000012208  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Document Type 10-Q  
Document Period End Date Mar. 31, 2021  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Entity Small Business false  
Entity Tax Identification Number 94-1381833  
Entity Address, Address Line One 1000 Alfred Nobel Drive,  
Entity Address, City or Town Hercules,  
Entity Address, Country CA  
Entity Address, Postal Zip Code 94547  
Local Phone Number 724-7000  
Entity Emerging Growth Company false  
Common Class A [Member]    
Title of 12(b) Security Class A Common Stock, Par Value $0.0001 per share  
Trading Symbol BIO  
Security Exchange Name NYSE  
Entity Common Stock, Shares Outstanding   24,692,554
Common Class B [Member]    
Title of 12(b) Security Class B Common Stock, Par Value $0.0001 per share  
Trading Symbol BIOb  
Security Exchange Name NYSE  
Entity Common Stock, Shares Outstanding   5,071,060
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2021
Dec. 31, 2020
ASSETS:    
Cash and cash equivalents $ 673,470,000 $ 662,205,000
Short-term investments 346,398,000 328,913,000
Restricted investments 5,560,000 5,560,000
Accounts receivable, net 408,137,000 419,424,000
Inventories:    
Raw materials 122,605,000 126,911,000
Work in process 150,628,000 151,931,000
Finished goods 331,923,000 343,411,000
Total inventories 605,156,000 622,253,000
Prepaid expenses 110,271,000 90,621,000
Other current assets 26,325,000 10,859,000
Total current assets 2,175,317,000 2,139,835,000
Property, plant, and equipment 1,420,284,000 1,452,761,000
Less: accumulated depreciation and amortization 937,572,000 961,390,000
Property, plant and equipment, net 482,712,000 491,371,000
Operating lease right-of-use assets 196,224,000 202,136,000
Goodwill, net 291,916,000 291,916,000
Purchased intangibles, net 191,764,000 199,497,000
Other investments 10,503,038,000 9,561,140,000
Other assets 92,189,000 86,723,000
Assets 13,933,160,000 12,972,618,000
LIABILITIES AND STOCKHOLDERS' EQUITY:    
Accounts payable 138,494,000 139,451,000
Accrued payroll and employee benefits 174,889,000 222,875,000
Current maturities of long-term debt and notes payable 1,738,000 1,798,000
Income and other taxes payable 89,074,000 57,335,000
Current operating lease liabilities 39,235,000 36,507,000
Other current liabilities 166,462,000 173,570,000
Total current liabilities 609,892,000 631,536,000
Long-term debt, net of current maturities 10,901,000 12,258,000
Deferred income taxes 2,306,112,000 2,076,785,000
Operating lease liabilities 168,326,000 175,128,000
Other long-term liabilities 228,870,000 196,971,000
Total liabilities 3,324,101,000 3,092,678,000
Stockholders' equity:    
Additional paid-in capital 445,101,000 429,376,000
Retained earnings 10,245,426,000 9,268,012,000
Accumulated other comprehensive loss 68,434,000 282,456,000
Total stockholders' equity 10,609,059,000 9,879,940,000
Total liabilities and stockholders' equity 13,933,160,000 12,972,618,000
Accounts receivable allowance for doubtful accounts 18,553,000 19,807,000
Common Class A [Member]    
Stockholders' equity:    
Common stock $ 2,000 $ 2,000
Common Stock, Shares, Issued 25,086,359 25,072,619
Common Stock, Shares, Outstanding 24,692,104 24,767,870
Common Class B [Member]    
Stockholders' equity:    
Common stock $ 1,000 $ 1,000
Common Stock, Shares, Issued 5,071,060 5,076,186
Common Stock, Shares, Outstanding 5,071,060 5,076,186
Treasury Class A [Member]    
Stockholders' equity:    
Treasury stock $ (149,905,000) $ (99,907,000)
Treasury Stock, Shares 394,255 304,749
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Balance Sheets Parenthetical - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Accounts receivable allowance for doubtful accounts $ 18,553 $ 19,807
Common Class A [Member]    
Common Stock, Shares, Issued 25,086,359 25,072,619
Common Stock, Shares, Outstanding 24,692,104 24,767,870
Common Class B [Member]    
Common Stock, Shares, Issued 5,071,060 5,076,186
Common Stock, Shares, Outstanding 5,071,060 5,076,186
Treasury Class A [Member]    
Treasury Stock, Shares 394,255 304,749
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Net sales $ 726,796 $ 571,644
Cost of goods sold 326,169 254,276
Gross profit 400,627 317,368
Selling, general and administrative expense 225,853 193,692
Research and Development Expense 73,912 49,303
Segment profit (loss) 100,862 74,373
Interest expense 398 5,690
Foreign exchange (gains) losses, net 71 928
Marketable Securities, Unrealized (Gain) Loss (1,179,403) (827,671)
Other Nonoperating Income (Expense) 17,407 3,273
Income before income taxes 1,297,203 898,699
(Provision) benefit for income taxes (319,789) (212,787)
Net income attributable to Bio-Rad $ 977,414 $ 685,912
Basic earnings per share:    
Net income per share basic attributable to Bio-Rad $ 32.77 $ 22.97
Weighted average common shares - basic 29,823 29,865
Diluted earnings per share:    
Net income per share diluted attributable to Bio-Rad $ 32.38 $ 22.72
Weighted average common shares - diluted 30,186 30,196
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Net Income (Loss) Attributable to Parent $ 977,414 $ 685,912
Foreign currency translation adjustments (214,323) (62,011)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent 1,857 731
Net unrealized holding gains (losses) on available-for-sale investments net of tax expense (1,556) (327)
Total other comprehensive income (loss) net of tax (214,022) (61,607)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest $ 763,392 $ 624,305
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Cash flows from operating activities:    
Cash received from customers $ 728,013 $ 569,001
Cash paid to suppliers and employees (612,803) (509,683)
Interest paid, net (309) (231)
Income tax payments, net (14,727) (4,528)
Investment proceeds and miscellaneous receipts, net 12,193 3,912
Proceeds from forward foreign exchange contracts, net 1,243 4,337
Net cash provided by operating activities 113,610 62,808
Cash flows from investing activities:    
Capital expenditures (19,547) (21,591)
Proceeds from dispositions of property, plant and equipment 12 38
Payments for purchases of marketable securities and investments (74,925) (98,151)
Proceeds from maturities of marketable securities and investments 30,509 67,710
Proceeds from Sale of Debt Securities, Available-for-sale 15,624 39,672
(Payments for) recovery of purchases of intangible assets 0 (100)
Net cash used in investing activities (48,327) (12,422)
Cash flows from financing activities:    
Payments on long-term borrowings (1,401) (1,415)
Payments of contingent consideration 0 (1,265)
Proceeds from Issuance of Common Stock 4,052 4,068
Payments for purchases of treasury stock (49,998) (100,005)
Net cash used in financing activities (47,347) (98,617)
Effect of Exchange Rate on Cash and Cash Equivalents (7,347) (5,977)
Beginning Cash, Cash Equivalents, and Restricted Cash 667,115 662,651
Cash and cash equivalents 673,470 603,551
Ending Cash, Cash Equivalents, and Restricted Cash 677,704 608,443
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 10,589 (54,208)
Other Current Assets    
Cash flows from financing activities:    
Restricted Cash, Current 3,354 3,110
Other Assets    
Cash flows from financing activities:    
Restricted Cash, Noncurrent $ 880 $ 1,782
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Stockholders' Equity Statement - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Treasury Stock [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Total Stockholders' Equity at Dec. 31, 2019 $ 5,755,057 $ 3 $ 410,020 $ (38,397) $ 5,470,779 $ (87,348)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net Income (Loss) Attributable to Parent 685,912 0 0 0 685,912 0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (61,607) 0 0 0 0 (61,607)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9,654 0 9,654 0 0 0
Proceeds from Issuance of Common Stock 4,068 0 4,068 0 0 0
Treasury Stock, Value, Acquired, Cost Method (100,005) 0 0 (100,005) 0 0
Total Stockholders' Equity at Mar. 31, 2020 6,293,079 3 423,742 (138,402) 6,156,691 (148,955)
Total Stockholders' Equity at Dec. 31, 2020 9,879,940 3 429,376 (99,907) 9,268,012 282,456
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net Income (Loss) Attributable to Parent 977,414 0 0 0 977,414 0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (214,022) 0 0 0 0 (214,022)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition 11,673 0 11,673 0 0 0
Proceeds from Issuance of Common Stock 4,052 0 4,052 0 0 0
Treasury Stock, Value, Acquired, Cost Method (49,998) 0 0 (49,998) 0 0
Total Stockholders' Equity at Mar. 31, 2021 $ 10,609,059 $ 3 $ 445,101 $ (149,905) $ 10,245,426 $ 68,434
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.1
1. Basis of Presentation and Use of Estimates
 3 Months Ended
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization, Consolidation and Presentation of Financial Statements Disclosure BASIS OF PRESENTATION AND USE OF ESTIMATES
Basis of Presentation

In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries.  The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented.  All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year.  The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2020.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.

Use of Estimates

The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.

Revenue Recognition

We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.
Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recognized until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to customer specifications, which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control in relation to the equipment has occurred at that point as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon customer acceptance because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service.

At the time revenue is recognized, a provision is recorded for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns.

Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately.

The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.

We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.

Reagent Rental Agreements

Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. For purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the Company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Generally these arrangements do not contain an option for the lessee to purchase the underlying asset.
We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606.

Maintenance services, along with the reagents, are allocated to the non-lease elements and are recognized as income. Generally, the terms of the arrangements result in the transfer of control for reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer.

Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments.  Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales-type leases represent in aggregate an immaterial amount of lease income. Our reported lease income is primarily variable in nature and is recognized upon delivery or as the reagents are consumed by the customer.
Revenue allocated to the lease elements of these reagent rental arrangements represented approximately 2% and 3% of total revenue for the three months ended March 31, 2021 and March 31, 2020, respectively, and are included as part of Net sales in our condensed consolidated statements of income.

Contract costs:

As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income.

Disaggregation of Revenue:

The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions):
Three Months Ended
March 31,
20212020
Europe$247.7 $195.7 
Asia168.9 111.4 
United States271.4 229.5 
Other (primarily Canada and Latin America)38.8 35.0 
Total net sales$726.8 $571.6 

The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenue by industry segment sources are presented in our Segment Information footnote (see Note 10).

Deferred revenues primarily represents unrecognized fees billed or collected for extended service arrangements. The deferred revenue balance at March 31, 2021 and December 31, 2020 was $66.2 million and $60.0 million, respectively. The short-term deferred revenue balance at March 31, 2021 and December 31, 2020 was $48.0 million and $42.5 million, respectively.
We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income.  

Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the three month period ended March 31, 2021 and 2020 were as follows (in millions):
Three Months Ended
March 31,
20212020
Balance at beginning of period$9.8 $9.0 
Provision for warranty2.7 1.9 
Actual warranty costs(2.6)(2.7)
Balance at end of period$9.9 $8.2 

Allowance for Doubtful Accounts

We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. We review our exposure to accounts receivable and reserve for amounts if collectability is no longer reasonably assured based on an assessment of various factors including historical loss rates and expectations of forward-looking loss estimates.

Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer.

Changes in our allowance for doubtful accounts were as follows (in millions):
Three Months Ended
March 31,
20212020
Balance at beginning of period$19.8 $20.2 
Provision (recovery) for expected credit losses(0.6)(0.8)
Write-offs charged against the allowance(0.6)(0.5)
Balance at end of period$18.6 $18.9 
Recent Accounting Pronouncements Adopted

In March 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-04, "Facilitation of the Effects of Reference Rate Reform on Financial Reporting (Topic 848)"  The ASU provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate (e.g., LIBOR) reform if certain criteria are met, for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting.  The ASU is effective as of March 12, 2020 through December 31, 2022.  We will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis.  The ASU is currently not expected to have a material impact on our condensed consolidated financial statements. 
In January 2020, the FASB issued ASU 2020-01, "Clarifying the Interactions between Topic 321 Investments—Equity Securities, Topic 323 Investments—Equity Method and Joint Ventures, and Topic 815 Derivatives and Hedging." ASU 2020-01 clarifies that a company should consider observable transactions that require a company to either apply or discontinue the equity method of accounting under Topic 323 for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. ASU 2020-01 also clarifies that, when determining the accounting for certain forward contracts and purchased options a company should not consider, whether upon settlement or exercise, if the underlying securities would be accounted for under the equity method or fair value option. The ASU is currently not expected to have a material impact on our condensed consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes," which
eliminates certain exceptions within ASC 740, Income Taxes, and clarifies other aspects of the current guidance to
promote consistency among reporting entities. ASU 2019-12 was effective for fiscal years beginning after
December 15, 2020, with any adjustments reflected as of January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the condensed consolidated financial statements.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.1
2. Fair Value Measurements
 3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements FAIR VALUE MEASUREMENTS
We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:

•Level 1: Quoted prices in active markets for identical instruments
•Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)
•Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)
Financial assets and liabilities carried at fair value and measured on a recurring basis as of March 31, 2021 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Commercial paper$— $29.3 $— $29.3 
U.S. government sponsored agencies— 2.6 — 2.6 
Time deposits8.7 10.0 — 18.7 
Money market funds61.3 — — 61.3 
Total cash equivalents (a)70.0 41.9 — 111.9 
Restricted investments (b)6.8 — — 6.8 
Equity securities (c)10,524.3 — — 10,524.3 
Available-for-sale investments:
Corporate debt securities— 162.2 — 162.2 
U.S. government sponsored agencies— 71.8 — 71.8 
Foreign government obligations— 4.0 — 4.0 
Other foreign obligations— 2.1 — 2.1 
Municipal obligations— 14.1 — 14.1 
Asset-backed securities— 28.1 — 28.1 
Total available-for-sale investments (d)— 282.3 — 282.3 
Forward foreign exchange contracts (e)— 0.6 — 0.6 
Total financial assets carried at fair value$10,601.1 $324.8 $— $10,925.9 
Financial liabilities carried at fair value:   
Forward foreign exchange contracts (f)$— $1.1 $— $1.1 
Contingent consideration (g)— — 0.7 0.7 
Total financial liabilities carried at fair value$— $1.1 $0.7 $1.8 
Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2020 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Commercial paper$— $41.7 $— $41.7 
Time deposits17.6 10.0 — 27.6 
Asset-backed securities— 0.9 — 0.9 
U.S. government sponsored agencies— 2.5— 2.5 
Money market funds60.1 — — 60.1 
Total cash equivalents (a)77.7 55.1 — 132.8 
Restricted investments (b)6.7 — — 6.7 
Equity securities (c)9,582.4 — — 9,582.4 
Available-for-sale investments:
Corporate debt securities— 133.2 — 133.2 
U.S. government sponsored agencies— 76.9 — 76.9 
Foreign government obligations— 4.0 — 4.0 
Other foreign obligations— 2.1 — 2.1 
Municipal obligations— 15.2 — 15.2 
Asset-backed securities— 36.2 — 36.2 
Total available-for-sale investments (d)— 267.6 — 267.6 
Forward foreign exchange contracts (e)— 1.0 — 1.0 
Total financial assets carried at fair value$9,666.8 $323.7 $— $9,990.5 
Financial liabilities carried at fair value:
Forward foreign exchange contracts (f)$— $1.0 $— $1.0 
Contingent consideration (g)— — 0.7 0.7 
Total financial liabilities carried at fair value$— $1.0 $0.7 $1.7 

(a)Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.

(b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):
March 31, 2021December 31, 2020
Restricted investments$5.6 $5.6 
Other investments1.2 1.1 
    Total$6.8 $6.7 

(c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):
March 31, 2021December 31, 2020
Short-term investments$64.2 $61.4 
Other investments10,460.1 9,521.0 
        Total$10,524.3 $9,582.4 
The change in fair market value on our equity securities for the three months ended March 31, 2021 was a $1,179.4 million gain, which was primarily due to our investment in Sartorius AG and is recorded in our condensed consolidated statements of income.

As of March 31, 2021, we own 12,987,900 ordinary voting shares and 9,588,908 preference shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 37% of the ordinary outstanding voting shares (excluding treasury shares) and 28% of the preference shares of Sartorius as of March 31, 2021.

(d) Available-for-sale investments are included in the following accounts in the condensed consolidated balance sheets (in millions):
 March 31, 2021December 31, 2020
Short-term investments$282.2 $267.5 
Other investments0.1 0.1 
Total$282.3 $267.6 

(e) Forward foreign exchange contracts in an asset position are included in other current assets in the condensed consolidated balance sheets.

(f) Forward foreign exchange contracts in a liability position are included in other current liabilities in the condensed consolidated balance sheets.

(g) Contingent consideration liability is included in the following accounts in the condensed consolidated balance sheets (in millions):
March 31, 2021December 31, 2020
Other current liabilities$0.6 $0.6 
Other long-term liabilities0.1 0.1 
   Total$0.7 $0.7 

During the fourth quarter of 2019, we recognized a contingent consideration liability for earn-out targets related to our acquisition of a foreign distributor. The first earn-out payment of $0.7 million was paid by the acquisition date and the remaining payment is anticipated to be paid in the first half of 2021. The maximum earn-out payment due is $1.4 million. The contingent consideration was accrued at its estimated fair value of $0.6 million as of March 31, 2021 which is unchanged from the fair value at December 31, 2020.

During the second quarter of 2020, we recognized a contingent consideration liability upon our acquisition of Celsee, Inc. which represents the future potential earn-out payments of up to $60.0 million payable in cash upon the achievement of certain net revenues for the period beginning on January 1, 2021 and ending on December 31, 2022. The fair value of the earn-out as of the Acquisition Date was approximately $0.1 million which was determined by using a Black-Scholes-Merton option-pricing valuation model that includes significant assumptions and unobservable inputs such as the projected revenues of Celsee over the earn-out period and the probability of the earn-out threshold being met. The fair value of the contingent consideration is remeasured at each reporting period based on the assumptions and inputs on the date of remeasurement. The achievement of net revenues was not met as of March 31, 2021 and therefore the fair value of the earn-out remained unchanged at approximately $0.1 million as of March 31, 2021.
To estimate the fair value of Level 2 debt securities as of March 31, 2021, our primary pricing provider uses Reuters as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Reuters does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source.

Available-for-sale investments consist of the following (in millions):
 March 31, 2021
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Allowances for Credit Losses
Fair
Value
Short-term investments:    
Corporate debt securities$160.3 $1.9 $— $— $162.2 
Municipal obligations14.0 0.1 — — 14.1 
Asset-backed securities27.7 0.3 — — 28.0 
U.S. government sponsored agencies70.6 1.3 (0.1)— 71.8 
Foreign government obligations4.0 — — — 4.0 
  Other foreign obligations2.1 — — — 2.1 
 278.7 3.6 (0.1)— 282.2 
Long-term investments:    
Asset-backed securities0.1 — — — 0.1 
 0.1 — — — 0.1 
Total$278.8 $3.6 $(0.1)$— $282.3 

The following is a summary of the amortized cost and estimated fair value of our debt securities at March 31, 2021 by contractual maturity date (in millions):
Amortized
Cost		Estimated Fair
Value
Mature in less than one year$173.6 $174.1 
Mature in one to five years66.2 67.9 
Mature in more than five years39.0 40.3 
Total$278.8 $282.3 
Available-for-sale investments consist of the following (in millions):
 December 31, 2020
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Allowances for Credit LossesEstimated
Fair
Value
Short-term investments:    
Corporate debt securities$130.5 $2.7 $— — $133.2 
Municipal obligations15.0 0.2 — — 15.2 
Asset-backed securities35.8 0.3 — — 36.1 
U.S. government sponsored agencies74.7 2.2 — — 76.9 
Foreign government obligations4.0 — — — 4.0 
  Other foreign obligations2.1 — — — 2.1 
 262.1 5.4 — — 267.5 
Long-term investments:    
Asset-backed securities0.1 — — — 0.1 
 0.1 — — — 0.1 
Total$262.2 $5.4 $— $— $267.6 

The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):
March 31, 2021
Less than 12 monthsGreater than 12 monthsTotal
Description of securities:Fair ValueUnrealized LossesFair ValueUnrealized LossesFair ValueUnrealized Losses
U.S. government sponsored agencies7.4 0.1 — — 7.4 0.1 
Total$7.4 $0.1 $— $— $7.4 $0.1 

The unrealized losses of $0.1 million as of March 31, 2021 are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others.  

There were no significant unrealized losses as of December 31, 2020 in either the less than or greater than 12 month categories.
Our evaluation of credit losses for available-for-sale debt securities included the extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are limited to the amount that the fair value of an instrument is less than its amortized cost basis.

At March 31, 2021, we have concluded that all payments related to our available-for-sale investments are expected to be made in full and on time at par value. The diminution of value in the intervening period is due to market conditions such as illiquidity and interest rate movements and not due to significant, inherent credit concerns surrounding the issuer. As a result, we have no allowances for credit losses on our available-for-sale investments portfolio as of March 31, 2021.
Included in other current assets are $1.4 million of interest receivable as of March 31, 2021 and December 31, 2020, primarily associated with securities in our available-for-sale investments portfolio. Associated interest on these securities is typically payable semi-annually. Due to the short-term nature of our interest receivable asset, we have made an accounting policy election not to measure an allowance for credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue greater than one year to be impaired for purposes of write-off. For the three months ended March 31, 2021, we have not written-off any uncollected interest receivable.

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes.  We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date.  The notional principal amounts provide one measure of the transaction volume outstanding as of March 31, 2021 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties.  The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in foreign currency exchange losses, net in the condensed consolidated statements of income.

The following is a summary of our forward foreign exchange contracts (in millions):
 March 31,
 2021
Contracts maturing in April through June 2021 to sell foreign currency: 
Notional value$284.0 
Unrealized loss$0.4 
Contracts maturing in April through June 2021 to purchase foreign currency: 
Notional value$252.3 
Unrealized gain or loss$— 

Included in other investments in the condensed consolidated balance sheets are investments without readily determinable fair value measured at cost with adjustments for observable price changes in price or impairments. The carrying value of these investments was $6.5 million and $0.5 million as of March 31, 2021 and December 31, 2020, respectively.

Also included in other investments in the condensed consolidated balance sheets are our equity method investments, for which our share of the equity method investees earnings is included in other income, net in our condensed consolidated statements of income. The carrying value of these investments was $35.2 million and $38.4 million as of March 31, 2021 and December 31, 2020, respectively.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.1
3. Intangible Assets, Goodwill and Other
 3 Months Ended
Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Disclosure GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS
Changes to goodwill by segment were as follows (in millions):
Life
Science		Clinical
Diagnostics		Total
Balances as of March 31, 2021 and December 31, 2020:
Goodwill277.9 349.2 627.1 
Accumulated impairment losses(41.8)(293.4)(335.2)
Goodwill, net$236.1 $55.8 $291.9 

Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions):
March 31, 2021
Weighted-Average Remaining Amortization Period (years)Purchase
Price		Accumulated
Amortization		Net
Carrying
Amount
Customer relationships/lists5.47$112.4 $(85.6)$26.8 
Know how4.50192.7 (172.6)20.1 
Developed product technology13.83217.1 (108.6)108.5 
Licenses7.5165.2 (38.0)27.2 
Tradenames7.716.4 (4.2)2.2 
Covenants not to compete3.664.6 (2.2)2.4 
Other—0.1 (0.1)— 
     Total definite-lived intangible assets598.5 (411.3)187.2 
In-process research and development4.6 — 4.6 
     Total purchased intangible assets $603.1 $(411.3)$191.8 
 December 31, 2020
Weighted-Average Remaining Amortization Period (years)Purchase
Price		Accumulated
Amortization		Net
Carrying
Amount
Customer relationships/lists5.51$116.6 $(87.2)$29.4 
Know how4.75196.6 (175.4)21.2 
Developed product technology14.00218.1 (107.1)111.0 
Licenses7.7365.6 (37.4)28.2 
Tradenames7.826.6 (4.2)2.4 
Covenants not to compete3.874.5 (2.0)2.5 
Other—0.1 (0.1)— 
     Total definite-lived intangible assets608.1 (413.4)194.7 
In-process research and development4.8 — 4.8 
     Total purchased intangible assets $612.9 $(413.4)$199.5 
Amortization expense related to purchased intangible assets is as follows (in millions):
Three Months Ended
 March 31,
 20212020
Amortization expense$7.2 $5.9 
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.1
4. Statement of Cash Flows, Supplemental Disclosures
 3 Months Ended
Mar. 31, 2021
Supplemental Cash Flow Elements [Abstract]  
Cash Flow, Supplemental Disclosures [Text Block] SUPPLEMENTAL CASH FLOW INFORMATION
The reconciliation of net income to net cash provided by operating activities is as follows (in millions):
Three Months Ended
March 31, 2021March 31, 2020
Net income$977.4 $685.9 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization32.7 33.6 
Reduction in the carrying amount of right-of-use assets9.8 9.6 
Share-based compensation11.7 9.7 
Gains on dispositions of securities(0.1)(0.4)
Other-than-temporary impairment losses on investment0.8 — 
Changes in fair market value of equity securities(1,179.4)(827.7)
Losses on dispositions of fixed assets0.3 0.1 
Changes in fair value of contingent consideration— (0.1)
Payments for operating lease liabilities(9.9)(9.3)
Decrease in accounts receivable1.3 2.2 
Decrease (increase) in inventories5.8 (13.7)
Increase in other current assets(37.5)(9.5)
Decrease in accounts payable and other current liabilities(44.5)(25.6)
Increase in income taxes payable27.3 20.9 
Increase in deferred income taxes274.8 171.8 
Increase in other long term liabilities43.8 15.7 
Other(0.7)(0.4)
Net cash provided by operating activities$113.6 $62.8 
Non-cash investing activities:
   Purchased property, plant and equipment$4.7 $6.0 
   Purchased marketable securities and investments$— $2.7 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.1
5. Long-Term Debt
 3 Months Ended
Mar. 31, 2021
Debt Disclosure [Abstract]  
Long-term Debt
5.    LONG-TERM DEBT

The principal components of long-term debt are as follows (in millions):
March 31,
2021		December 31,
2020
Finance leases and other debt$12.6 $14.1 
Less current maturities(1.7)(1.8)
Long-term debt$10.9 $12.3 

Credit Agreement

In April 2019, Bio-Rad entered into a $200.0 million unsecured revolving credit facility ("Credit Agreement"). Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of March 31, 2021; however, $0.2 million was utilized for domestic standby letters of credit that reduced our borrowing availability as of March 31, 2021. The Credit Agreement matures in April 2024. If we had borrowed against our Credit Agreement, the borrowing rate would have been 1.315% at March 31, 2021, which is based on the 3-month LIBOR.

The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens.  We were in compliance with all of these ratios and covenants as of March 31, 2021.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.1
6. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Notes)
 3 Months Ended
Mar. 31, 2021
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Stockholders' Equity Note Disclosure [Text Block]
6.    ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Accumulated other comprehensive income included in our condensed consolidated balance sheets consists of the following components (in millions):
Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains on available-for-sale investmentsTotal accumulated other comprehensive income (loss)
Balances as of January 1, 2021:$298.6 $(26.0)$9.8 $282.4 
Other comprehensive (loss) income, before reclassifications(214.7)1.7 (1.9)(214.9)
Amounts reclassified from Accumulated other comprehensive income— 0.5 (0.1)0.4 
Income tax effects0.4 (0.3)0.4 0.5 
Other comprehensive (loss) income, net of income taxes(214.3)1.9 (1.6)(214.0)
Balances as of March 31, 2021:$84.3 $(24.1)$8.2 $68.4 
Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains on available-for-sale investmentsTotal accumulated other comprehensive income (loss)
Balances as of January 1, 2020:$(72.4)$(22.2)$7.2 $(87.4)
Other comprehensive (loss) income, before reclassifications(62.9)0.2 — (62.7)
Amounts reclassified from Accumulated other comprehensive income— 0.3 (0.4)(0.1)
Income tax effects0.9 0.2 0.1 1.2 
Other comprehensive (loss) income, net of income taxes(62.0)0.7 (0.3)(61.6)
Balances as of March 31, 2020:$(134.4)$(21.5)$6.9 $(149.0)

All amounts reclassified out of accumulated other comprehensive income were reclassified into other income, net in the condensed consolidated statements of income. The reclassification adjustments are calculated using the specific identification method.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.1
7. Earnings Per Share
 3 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
Earnings Per Share .    EARNINGS PER SHARE
Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect of including such securities would be anti-dilutive.

The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands):
Three Months Ended
March 31,
 20212020
Basic weighted average shares outstanding29,823 29,865 
Effect of potentially dilutive stock options and restricted stock awards
363 331 
Diluted weighted average common shares30,186 30,196 
Anti-dilutive shares23 62 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.1
8. Other Income and Expenses
 3 Months Ended
Mar. 31, 2021
Other Income and Expenses [Abstract]  
Other Income and Other Expense Disclosure .    OTHER INCOME AND EXPENSE, NET
Other (income) expense, net includes the following components (in millions):
Three Months Ended
March 31,
 20212020
Interest and investment income$(18.3)$(2.8)
Net realized gains on investments(0.1)(0.4)
Other-than-temporary impairment loss on investment0.8 — 
Other expense (income) 0.2 (0.1)
Other (income), net$(17.4)$(3.3)
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.1
9. Income Taxes
 3 Months Ended
Mar. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes
9.    INCOME TAXES

Our effective income tax rate was 24.7% and 23.7% for the three months ended March 31, 2021 and 2020, respectively.

The realization of deferred tax assets is dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that certain foreign deferred tax assets will not be realized as of March 31, 2021, and have maintained a valuation allowance on such deferred tax assets.

Our income tax returns are routinely audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues around the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

Our gross unrecognized tax benefits were $57.5 million and $55.8 million as of March 31, 2021 and December 31, 2020, respectively. The increase to our gross unrecognized tax benefits is primarily the result of a $1.7 million net increase in tax positions taken in the current year net of foreign currency translation adjustments.

As of March 31, 2021, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitations for certain jurisdictions, we believe that within the next 12 months it is reasonably possible that our previously unrecognized tax benefits could decrease by up to $16.7 million primarily related to various foreign jurisdictions.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.1
10. Segment Information Segment Reporting
 3 Months Ended
Mar. 31, 2021
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block] SEGMENT INFORMATION
Information regarding operating segments for the three months ended March 31, 2021 and 2020 is as follows (in millions):
Life
Science		Clinical
Diagnostics		Other
Operations
Segment net sales 2021$366.5 $358.5 $1.8 
 2020$227.2 $340.3 $4.1 
Segment net profit (loss)2021$102.3 $(1.9)$0.1 
 2020$23.7 $43.8 $1.1 
Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. Our chief operating decision maker ("CODM") views all operating expenses, interest expense and corporate overhead as directly supporting the strategies of our segments. As a result, starting in 2021 these costs are fully allocated to our reportable segments. Prior to this change, the difference between total segment allocated interest expense, depreciation and amortization, and the corresponding consolidated amounts was attributable to our corporate headquarters.

The historical segment information has been recast to conform to the current allocation methodology of corporate operating and other expenses to the segments.  Interest expense is charged to segments based on the carrying amount of inventory and receivables employed by that segment. The following reconciles total segment profit to consolidated income before income taxes (in millions):

Three Months Ended
March 31,
 20212020
Total segment profit $100.5 $68.6 
Foreign currency exchange losses, net(0.1)(0.9)
Change in fair market value of equity securities1,179.4 827.7 
Other income, net17.4 3.3 
Consolidated income before income taxes$1,297.2 $898.7 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.1
11. Legal Proceedings
 3 Months Ended
Mar. 31, 2021
Loss Contingency, Information about Litigation Matters [Abstract]  
Legal Proceedings.
11.    LEGAL PROCEEDINGS

We are a party to various claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.1
12. Restructuring Costs (Notes)
 3 Months Ended
Mar. 31, 2021
Restructuring Costs [Abstract]  
Restructuring and Related Activities Disclosure [Text Block] RESTRUCTURING COSTSIn February 2021, we announced our strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance. The restructuring plan primarily impacts our operations in Europe and includes the elimination of certain positions, the consolidation of certain functions, and the relocation of certain manufacturing operations from Europe to Asia. The restructuring plan will be implemented in phases and is expected to be substantially complete by the end of 2022. The liability of $71.2 million as of March 31, 2021 consisted of $35.2 million recorded in Accrued payroll and employee benefits and $36.0 million recorded in Other long-term liabilities in the condensed consolidated balance sheets. The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense were $23.9 million, $34.7 million and $17.0 million in the condensed consolidated statements of income for the three months ended March 31, 2021, respectively. The amounts are preliminary estimates based on the information currently available to management. It is possible that additional adjustments and future cash payments could occur in relation to the restructuring actions.
The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions):

Life ScienceClinical DiagnosticsTotal
Balances as of December 31, 2020:$— $— $— 
Charged to expense - employee termination benefits12.9 62.7 75.6 
Cash payments(0.1)(1.9)(2.0)
Foreign currency translation gains(0.4)(2.0)(2.4)
Balances as of March 31, 2021:$12.4 $58.8 $71.2 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.1
13. Leases (Notes)
 3 Months Ended
Mar. 31, 2021
13. Leases [Abstract]  
Leases of Lessee Disclosure [Text Block]
13.    LEASES: FINANCE AND OPERATING WHERE WE ACT AS LESSEE

For operating leases where we act as lessor in reagent rental agreements, see Note 1. We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. For operating leases, we have elected not to separate lease and non-lease components for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 18 years, which includes our determination to exercise renewal options.

We determine if an arrangement is a lease at inception. Right-of-use (ROU) assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Operating lease ROU assets also include any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

The components of lease expense were as follows (in millions):
Three Months Ended
March 31,
20212020
Operating lease cost$11.7 $12.6 
Finance lease cost:
  Amortization of right-of-use assets$0.1 $0.1 
  Interest on lease liabilities0.2 0.2 
        Total finance lease cost$0.3 $0.3 
Sublease income$0.7 $0.7 
The sublease is for a building with a term that ends in 2025, with no options to extend or renew.

Operating lease cost includes original reduction in the carrying amount of ROU assets, the impact of remeasurements, modifications, impairments and abandonments.
Our short-term leases are expensed as incurred, reflecting leases with a lease term of one year or less, and are not significant for both the three months ended March 31, 2021 and 2020. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial for both the three months ended March 31, 2021 and 2020.

Supplemental cash flow information related to leases was as follows (in millions):

Three Months Ended
March 31,
20212020
Cash paid for amounts included in the measurement of lease liabilities:
  Operating cash flows from operating leases$11.8 $11.4 
  Operating cash flows from finance leases$0.1 $0.2 
  Financing cash flows from finance leases$0.2 $0.1 
Right-of-use assets obtained in exchange for new lease obligations:
  Operating leases$4.2 $10.8 
  Finance leases$— $— 
Supplemental balance sheet information related to leases was as follows (in millions):
March 31, 2021December 31, 2020
Operating Leases
  Operating lease right-of-use assets$196.2 $202.1 
  Current operating lease liabilities$39.3 $36.5 
  Operating lease liabilities168.3 175.1 
     Total operating lease liabilities$207.6 $211.6 

Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities (in millions):
March 31, 2021December 31, 2020
Finance Leases
  Property, plant and equipment, gross$12.2 $12.2 
  Less: accumulated depreciation and amortization(5.1)(5.0)
      Property, plant and equipment, net$7.1 $7.2 
  Current maturities of long-term debt and notes payable$0.5 $0.5 
  Long-term debt, net of current maturities10.9 11.0 
      Total finance lease liabilities$11.4 $11.5 
March 31, 2021December 31, 2020
Weighted Average Remaining Lease Term
  Operating leases - in years88
  Finance leases - in years1616
Weighted Average Discount Rate
  Operating leases3.9 %3.9 %
  Finance leases6.2 %6.2 %

Maturities of lease liabilities were as follows (in millions):
Year Ending December 31,Operating LeasesFinance Leases
2021 (excluding the three months ended March 31, 2021)$35.3 $1.0 
202238.6 1.3 
202332.4 1.2 
202426.4 1.1 
202523.1 1.1 
Thereafter90.6 14.0 
   Total lease payments246.4 19.7 
Less imputed interest(38.8)(8.3)
    Total$207.6 $11.4 

The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles, and other equipment with shorter terms and higher-turn over.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.1
1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Policies)
 3 Months Ended
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]
Allowance for Doubtful Accounts

We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. We review our exposure to accounts receivable and reserve for amounts if collectability is no longer reasonably assured based on an assessment of various factors including historical loss rates and expectations of forward-looking loss estimates.

Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer.

Changes in our allowance for doubtful accounts were as follows (in millions):
Three Months Ended
March 31,
20212020
Balance at beginning of period$19.8 $20.2 
Provision (recovery) for expected credit losses(0.6)(0.8)
Write-offs charged against the allowance(0.6)(0.5)
Balance at end of period$18.6 $18.9 
Standard Product Warranty, Policy [Policy Text Block]
We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income.  

Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the three month period ended March 31, 2021 and 2020 were as follows (in millions):
Three Months Ended
March 31,
20212020
Balance at beginning of period$9.8 $9.0 
Provision for warranty2.7 1.9 
Actual warranty costs(2.6)(2.7)
Balance at end of period$9.9 $8.2 
New Accounting Pronouncements, Policy [Policy Text Block]
Recent Accounting Pronouncements Adopted

In March 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-04, "Facilitation of the Effects of Reference Rate Reform on Financial Reporting (Topic 848)"  The ASU provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate (e.g., LIBOR) reform if certain criteria are met, for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting.  The ASU is effective as of March 12, 2020 through December 31, 2022.  We will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis.  The ASU is currently not expected to have a material impact on our condensed consolidated financial statements. 
In January 2020, the FASB issued ASU 2020-01, "Clarifying the Interactions between Topic 321 Investments—Equity Securities, Topic 323 Investments—Equity Method and Joint Ventures, and Topic 815 Derivatives and Hedging." ASU 2020-01 clarifies that a company should consider observable transactions that require a company to either apply or discontinue the equity method of accounting under Topic 323 for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. ASU 2020-01 also clarifies that, when determining the accounting for certain forward contracts and purchased options a company should not consider, whether upon settlement or exercise, if the underlying securities would be accounted for under the equity method or fair value option. The ASU is currently not expected to have a material impact on our condensed consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes," which
eliminates certain exceptions within ASC 740, Income Taxes, and clarifies other aspects of the current guidance to
promote consistency among reporting entities. ASU 2019-12 was effective for fiscal years beginning after
December 15, 2020, with any adjustments reflected as of January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the condensed consolidated financial statements.
Revenue from Contract with Customer [Policy Text Block]
Revenue Recognition

We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.
Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recognized until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to customer specifications, which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control in relation to the equipment has occurred at that point as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon customer acceptance because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service.

At the time revenue is recognized, a provision is recorded for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns.

Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately.

The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.

We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.

Reagent Rental Agreements

Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. For purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the Company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Generally these arrangements do not contain an option for the lessee to purchase the underlying asset.
We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606.

Maintenance services, along with the reagents, are allocated to the non-lease elements and are recognized as income. Generally, the terms of the arrangements result in the transfer of control for reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer.

Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments.  Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales-type leases represent in aggregate an immaterial amount of lease income. Our reported lease income is primarily variable in nature and is recognized upon delivery or as the reagents are consumed by the customer.
Revenue allocated to the lease elements of these reagent rental arrangements represented approximately 2% and 3% of total revenue for the three months ended March 31, 2021 and March 31, 2020, respectively, and are included as part of Net sales in our condensed consolidated statements of income.

Contract costs:

As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income.

Disaggregation of Revenue:

The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions):
Three Months Ended
March 31,
20212020
Europe$247.7 $195.7 
Asia168.9 111.4 
United States271.4 229.5 
Other (primarily Canada and Latin America)38.8 35.0 
Total net sales$726.8 $571.6 

The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenue by industry segment sources are presented in our Segment Information footnote (see Note 10).

Deferred revenues primarily represents unrecognized fees billed or collected for extended service arrangements. The deferred revenue balance at March 31, 2021 and December 31, 2020 was $66.2 million and $60.0 million, respectively. The short-term deferred revenue balance at March 31, 2021 and December 31, 2020 was $48.0 million and $42.5 million, respectively.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.1
1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables)
 3 Months Ended
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Revenue from External Customers by Geographic Areas [Table Text Block]
The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions):
Three Months Ended
March 31,
20212020
Europe$247.7 $195.7 
Asia168.9 111.4 
United States271.4 229.5 
Other (primarily Canada and Latin America)38.8 35.0 
Total net sales$726.8 $571.6 
Schedule of Product Warranty Liability [Table Text Block]
Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the three month period ended March 31, 2021 and 2020 were as follows (in millions):
Three Months Ended
March 31,
20212020
Balance at beginning of period$9.8 $9.0 
Provision for warranty2.7 1.9 
Actual warranty costs(2.6)(2.7)
Balance at end of period$9.9 $8.2 
Accounts Receivable, Allowance for Credit Loss [Table Text Block]
Changes in our allowance for doubtful accounts were as follows (in millions):
Three Months Ended
March 31,
20212020
Balance at beginning of period$19.8 $20.2 
Provision (recovery) for expected credit losses(0.6)(0.8)
Write-offs charged against the allowance(0.6)(0.5)
Balance at end of period$18.6 $18.9 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.1
2. Fair Value Measurements (Tables)
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Fair Value Disclosures [Abstract]    
Debt Securities, Available-for-sale [Table Text Block]
Available-for-sale investments consist of the following (in millions):
 March 31, 2021
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Allowances for Credit Losses
Fair
Value
Short-term investments:    
Corporate debt securities$160.3 $1.9 $— $— $162.2 
Municipal obligations14.0 0.1 — — 14.1 
Asset-backed securities27.7 0.3 — — 28.0 
U.S. government sponsored agencies70.6 1.3 (0.1)— 71.8 
Foreign government obligations4.0 — — — 4.0 
  Other foreign obligations2.1 — — — 2.1 
 278.7 3.6 (0.1)— 282.2 
Long-term investments:    
Asset-backed securities0.1 — — — 0.1 
 0.1 — — — 0.1 
Total$278.8 $3.6 $(0.1)$— $282.3 
Available-for-sale investments consist of the following (in millions):
 December 31, 2020
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Allowances for Credit LossesEstimated
Fair
Value
Short-term investments:    
Corporate debt securities$130.5 $2.7 $— — $133.2 
Municipal obligations15.0 0.2 — — 15.2 
Asset-backed securities35.8 0.3 — — 36.1 
U.S. government sponsored agencies74.7 2.2 — — 76.9 
Foreign government obligations4.0 — — — 4.0 
  Other foreign obligations2.1 — — — 2.1 
 262.1 5.4 — — 267.5 
Long-term investments:    
Asset-backed securities0.1 — — — 0.1 
 0.1 — — — 0.1 
Total$262.2 $5.4 $— $— $267.6 
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]  
Summary of fair value of gross unrealized losses for investments with unrealized losses
The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):
March 31, 2021
Less than 12 monthsGreater than 12 monthsTotal
Description of securities:Fair ValueUnrealized LossesFair ValueUnrealized LossesFair ValueUnrealized Losses
U.S. government sponsored agencies7.4 0.1 — — 7.4 0.1 
Total$7.4 $0.1 $— $— $7.4 $0.1 
T 		 
Discussion of current derivative risk management
The following is a summary of our forward foreign exchange contracts (in millions):
 March 31,
 2021
Contracts maturing in April through June 2021 to sell foreign currency: 
Notional value$284.0 
Unrealized loss$0.4 
Contracts maturing in April through June 2021 to purchase foreign currency: 
Notional value$252.3 
Unrealized gain or loss$— 
  
Summary of amortized cost and estimated fair value of debt securities by contractual maturity date
The following is a summary of the amortized cost and estimated fair value of our debt securities at March 31, 2021 by contractual maturity date (in millions):
Amortized
Cost		Estimated Fair
Value
Mature in less than one year$173.6 $174.1 
Mature in one to five years66.2 67.9 
Mature in more than five years39.0 40.3 
Total$278.8 $282.3 
  
Fair Value Measurements, Recurring and Nonrecurring
Financial assets and liabilities carried at fair value and measured on a recurring basis as of March 31, 2021 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Commercial paper$— $29.3 $— $29.3 
U.S. government sponsored agencies— 2.6 — 2.6 
Time deposits8.7 10.0 — 18.7 
Money market funds61.3 — — 61.3 
Total cash equivalents (a)70.0 41.9 — 111.9 
Restricted investments (b)6.8 — — 6.8 
Equity securities (c)10,524.3 — — 10,524.3 
Available-for-sale investments:
Corporate debt securities— 162.2 — 162.2 
U.S. government sponsored agencies— 71.8 — 71.8 
Foreign government obligations— 4.0 — 4.0 
Other foreign obligations— 2.1 — 2.1 
Municipal obligations— 14.1 — 14.1 
Asset-backed securities— 28.1 — 28.1 
Total available-for-sale investments (d)— 282.3 — 282.3 
Forward foreign exchange contracts (e)— 0.6 — 0.6 
Total financial assets carried at fair value$10,601.1 $324.8 $— $10,925.9 
Financial liabilities carried at fair value:   
Forward foreign exchange contracts (f)$— $1.1 $— $1.1 
Contingent consideration (g)— — 0.7 0.7 
Total financial liabilities carried at fair value$— $1.1 $0.7 $1.8 
Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2020 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Commercial paper$— $41.7 $— $41.7 
Time deposits17.6 10.0 — 27.6 
Asset-backed securities— 0.9 — 0.9 
U.S. government sponsored agencies— 2.5— 2.5 
Money market funds60.1 — — 60.1 
Total cash equivalents (a)77.7 55.1 — 132.8 
Restricted investments (b)6.7 — — 6.7 
Equity securities (c)9,582.4 — — 9,582.4 
Available-for-sale investments:
Corporate debt securities— 133.2 — 133.2 
U.S. government sponsored agencies— 76.9 — 76.9 
Foreign government obligations— 4.0 — 4.0 
Other foreign obligations— 2.1 — 2.1 
Municipal obligations— 15.2 — 15.2 
Asset-backed securities— 36.2 — 36.2 
Total available-for-sale investments (d)— 267.6 — 267.6 
Forward foreign exchange contracts (e)— 1.0 — 1.0 
Total financial assets carried at fair value$9,666.8 $323.7 $— $9,990.5 
Financial liabilities carried at fair value:
Forward foreign exchange contracts (f)$— $1.0 $— $1.0 
Contingent consideration (g)— — 0.7 0.7 
Total financial liabilities carried at fair value$— $1.0 $0.7 $1.7 

(a)Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.

(b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):
March 31, 2021December 31, 2020
Restricted investments$5.6 $5.6 
Other investments1.2 1.1 
    Total$6.8 $6.7 

(c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):
March 31, 2021December 31, 2020
Short-term investments$64.2 $61.4 
Other investments10,460.1 9,521.0 
        Total$10,524.3 $9,582.4 
The change in fair market value on our equity securities for the three months ended March 31, 2021 was a $1,179.4 million gain, which was primarily due to our investment in Sartorius AG and is recorded in our condensed consolidated statements of income.

As of March 31, 2021, we own 12,987,900 ordinary voting shares and 9,588,908 preference shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 37% of the ordinary outstanding voting shares (excluding treasury shares) and 28% of the preference shares of Sartorius as of March 31, 2021.

(d) Available-for-sale investments are included in the following accounts in the condensed consolidated balance sheets (in millions):
 March 31, 2021December 31, 2020
Short-term investments$282.2 $267.5 
Other investments0.1 0.1 
Total$282.3 $267.6 

(e) Forward foreign exchange contracts in an asset position are included in other current assets in the condensed consolidated balance sheets.

(f) Forward foreign exchange contracts in a liability position are included in other current liabilities in the condensed consolidated balance sheets.

(g) Contingent consideration liability is included in the following accounts in the condensed consolidated balance sheets (in millions):
March 31, 2021December 31, 2020
Other current liabilities$0.6 $0.6 
Other long-term liabilities0.1 0.1 
   Total$0.7 $0.7 
  
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.1
3. Intangible Assets, Goodwill and Other (Tables)
 3 Months Ended
Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Changes to goodwill by segment
Changes to goodwill by segment were as follows (in millions):
Life
Science		Clinical
Diagnostics		Total
Balances as of March 31, 2021 and December 31, 2020:
Goodwill277.9 349.2 627.1 
Accumulated impairment losses(41.8)(293.4)(335.2)
Goodwill, net$236.1 $55.8 $291.9 
Schedule of identifiable purchased intangible assets with definite lives
Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions):
March 31, 2021
Weighted-Average Remaining Amortization Period (years)Purchase
Price		Accumulated
Amortization		Net
Carrying
Amount
Customer relationships/lists5.47$112.4 $(85.6)$26.8 
Know how4.50192.7 (172.6)20.1 
Developed product technology13.83217.1 (108.6)108.5 
Licenses7.5165.2 (38.0)27.2 
Tradenames7.716.4 (4.2)2.2 
Covenants not to compete3.664.6 (2.2)2.4 
Other—0.1 (0.1)— 
     Total definite-lived intangible assets598.5 (411.3)187.2 
In-process research and development4.6 — 4.6 
     Total purchased intangible assets $603.1 $(411.3)$191.8 
 December 31, 2020
Weighted-Average Remaining Amortization Period (years)Purchase
Price		Accumulated
Amortization		Net
Carrying
Amount
Customer relationships/lists5.51$116.6 $(87.2)$29.4 
Know how4.75196.6 (175.4)21.2 
Developed product technology14.00218.1 (107.1)111.0 
Licenses7.7365.6 (37.4)28.2 
Tradenames7.826.6 (4.2)2.4 
Covenants not to compete3.874.5 (2.0)2.5 
Other—0.1 (0.1)— 
     Total definite-lived intangible assets608.1 (413.4)194.7 
In-process research and development4.8 — 4.8 
     Total purchased intangible assets $612.9 $(413.4)$199.5 
Finite-lived Intangible Assets Amortization Expense [Table Text Block]
Amortization expense related to purchased intangible assets is as follows (in millions):
Three Months Ended
 March 31,
 20212020
Amortization expense$7.2 $5.9 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.1
4. Supplemental Cash Flow Information Cash Flow, Supplemental Disclosure - (Tables)
 3 Months Ended
Mar. 31, 2021
Supplemental Cash Flow Elements [Abstract]  
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]
The reconciliation of net income to net cash provided by operating activities is as follows (in millions):
Three Months Ended
March 31, 2021March 31, 2020
Net income$977.4 $685.9 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization32.7 33.6 
Reduction in the carrying amount of right-of-use assets9.8 9.6 
Share-based compensation11.7 9.7 
Gains on dispositions of securities(0.1)(0.4)
Other-than-temporary impairment losses on investment0.8 — 
Changes in fair market value of equity securities(1,179.4)(827.7)
Losses on dispositions of fixed assets0.3 0.1 
Changes in fair value of contingent consideration— (0.1)
Payments for operating lease liabilities(9.9)(9.3)
Decrease in accounts receivable1.3 2.2 
Decrease (increase) in inventories5.8 (13.7)
Increase in other current assets(37.5)(9.5)
Decrease in accounts payable and other current liabilities(44.5)(25.6)
Increase in income taxes payable27.3 20.9 
Increase in deferred income taxes274.8 171.8 
Increase in other long term liabilities43.8 15.7 
Other(0.7)(0.4)
Net cash provided by operating activities$113.6 $62.8 
Non-cash investing activities:
   Purchased property, plant and equipment$4.7 $6.0 
   Purchased marketable securities and investments$— $2.7 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.1
5. Long-Term Debt (Tables)
 3 Months Ended
Mar. 31, 2021
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Instruments [Table Text Block]
The principal components of long-term debt are as follows (in millions):
March 31,
2021		December 31,
2020
Finance leases and other debt$12.6 $14.1 
Less current maturities(1.7)(1.8)
Long-term debt$10.9 $12.3 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.1
6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Tables)
 3 Months Ended
Mar. 31, 2021
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]
Accumulated other comprehensive income included in our condensed consolidated balance sheets consists of the following components (in millions):
Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains on available-for-sale investmentsTotal accumulated other comprehensive income (loss)
Balances as of January 1, 2021:$298.6 $(26.0)$9.8 $282.4 
Other comprehensive (loss) income, before reclassifications(214.7)1.7 (1.9)(214.9)
Amounts reclassified from Accumulated other comprehensive income— 0.5 (0.1)0.4 
Income tax effects0.4 (0.3)0.4 0.5 
Other comprehensive (loss) income, net of income taxes(214.3)1.9 (1.6)(214.0)
Balances as of March 31, 2021:$84.3 $(24.1)$8.2 $68.4 
Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains on available-for-sale investmentsTotal accumulated other comprehensive income (loss)
Balances as of January 1, 2020:$(72.4)$(22.2)$7.2 $(87.4)
Other comprehensive (loss) income, before reclassifications(62.9)0.2 — (62.7)
Amounts reclassified from Accumulated other comprehensive income— 0.3 (0.4)(0.1)
Income tax effects0.9 0.2 0.1 1.2 
Other comprehensive (loss) income, net of income taxes(62.0)0.7 (0.3)(61.6)
Balances as of March 31, 2020:$(134.4)$(21.5)$6.9 $(149.0)
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.1
7. Earnings Per Share (Tables)
 3 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares
The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands):
Three Months Ended
March 31,
 20212020
Basic weighted average shares outstanding29,823 29,865 
Effect of potentially dilutive stock options and restricted stock awards
363 331 
Diluted weighted average common shares30,186 30,196 
Anti-dilutive shares23 62 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.1
8. Other Income and Expenses (Tables)
 3 Months Ended
Mar. 31, 2021
Other Income and Expenses [Abstract]  
Schedule of other income (expense), net
Other (income) expense, net includes the following components (in millions):
Three Months Ended
March 31,
 20212020
Interest and investment income$(18.3)$(2.8)
Net realized gains on investments(0.1)(0.4)
Other-than-temporary impairment loss on investment0.8 — 
Other expense (income) 0.2 (0.1)
Other (income), net$(17.4)$(3.3)
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.1
10. Segment Information Segment Reporting (Tables)
 3 Months Ended
Mar. 31, 2021
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Information regarding operating segments for the three months ended March 31, 2021 and 2020 is as follows (in millions):
Life
Science		Clinical
Diagnostics		Other
Operations
Segment net sales 2021$366.5 $358.5 $1.8 
 2020$227.2 $340.3 $4.1 
Segment net profit (loss)2021$102.3 $(1.9)$0.1 
 2020$23.7 $43.8 $1.1 
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] The following reconciles total segment profit to consolidated income before income taxes (in millions):
Three Months Ended
March 31,
 20212020
Total segment profit $100.5 $68.6 
Foreign currency exchange losses, net(0.1)(0.9)
Change in fair market value of equity securities1,179.4 827.7 
Other income, net17.4 3.3 
Consolidated income before income taxes$1,297.2 $898.7 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.1
12. Restructuring Costs (Tables)
 3 Months Ended
Mar. 31, 2021
Restructuring Cost and Reserve [Line Items]  
Restructuring and Related Costs [Table Text Block]
The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions):

Life ScienceClinical DiagnosticsTotal
Balances as of December 31, 2020:$— $— $— 
Charged to expense - employee termination benefits12.9 62.7 75.6 
Cash payments(0.1)(1.9)(2.0)
Foreign currency translation gains(0.4)(2.0)(2.4)
Balances as of March 31, 2021:$12.4 $58.8 $71.2 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.1
13. Leases (Tables)
 3 Months Ended
Mar. 31, 2021
13. Leases [Abstract]  
Lease, Cost [Table Text Block]
The components of lease expense were as follows (in millions):
Three Months Ended
March 31,
20212020
Operating lease cost$11.7 $12.6 
Finance lease cost:
  Amortization of right-of-use assets$0.1 $0.1 
  Interest on lease liabilities0.2 0.2 
        Total finance lease cost$0.3 $0.3 
Sublease income$0.7 $0.7 
The sublease is for a building with a term that ends in 2025, with no options to extend or renew.
Lessee Supplemental Cash Flow Information [Table Text Block]
Supplemental cash flow information related to leases was as follows (in millions):

Three Months Ended
March 31,
20212020
Cash paid for amounts included in the measurement of lease liabilities:
  Operating cash flows from operating leases$11.8 $11.4 
  Operating cash flows from finance leases$0.1 $0.2 
  Financing cash flows from finance leases$0.2 $0.1 
Right-of-use assets obtained in exchange for new lease obligations:
  Operating leases$4.2 $10.8 
  Finance leases$— $— 
Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block]
Maturities of lease liabilities were as follows (in millions):
Year Ending December 31,Operating LeasesFinance Leases
2021 (excluding the three months ended March 31, 2021)$35.3 $1.0 
202238.6 1.3 
202332.4 1.2 
202426.4 1.1 
202523.1 1.1 
Thereafter90.6 14.0 
   Total lease payments246.4 19.7 
Less imputed interest(38.8)(8.3)
    Total$207.6 $11.4 
Lessee Supplemental Balance Sheet Information [Table Text Block]
Supplemental balance sheet information related to leases was as follows (in millions):
March 31, 2021December 31, 2020
Operating Leases
  Operating lease right-of-use assets$196.2 $202.1 
  Current operating lease liabilities$39.3 $36.5 
  Operating lease liabilities168.3 175.1 
     Total operating lease liabilities$207.6 $211.6 

Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities (in millions):
March 31, 2021December 31, 2020
Finance Leases
  Property, plant and equipment, gross$12.2 $12.2 
  Less: accumulated depreciation and amortization(5.1)(5.0)
      Property, plant and equipment, net$7.1 $7.2 
  Current maturities of long-term debt and notes payable$0.5 $0.5 
  Long-term debt, net of current maturities10.9 11.0 
      Total finance lease liabilities$11.4 $11.5 
March 31, 2021December 31, 2020
Weighted Average Remaining Lease Term
  Operating leases - in years88
  Finance leases - in years1616
Weighted Average Discount Rate
  Operating leases3.9 %3.9 %
  Finance leases6.2 %6.2 %
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.1
1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Line Items]        
Net sales $ 726,796 $ 571,644    
Cost of goods sold 326,169 254,276    
Deferred Revenue 66,200   $ 60,000  
Retained earnings 10,245,426   9,268,012  
Accumulated other comprehensive loss 68,434   282,456  
Total stockholders' equity $ 10,609,059 $ 6,293,079 9,879,940 $ 5,755,057
Revenue Allocation Percent To Lease Elements 2.00% 3.00%    
Additional paid-in-capital $ 445,101   429,376  
Selling, general and administrative expense 225,853 $ 193,692    
Research and Development Expense 73,912 49,303    
Interest expense 398 5,690    
Other Nonoperating Income (Expense) 17,407 3,273    
Deferred Revenue, Current 48,000   $ 42,500  
Europe [Member]        
Organization, Consolidation and Presentation of Financial Statements [Line Items]        
Net sales 247,700 195,700    
Asia Pacific [Member]        
Organization, Consolidation and Presentation of Financial Statements [Line Items]        
Net sales 168,900 111,400    
UNITED STATES        
Organization, Consolidation and Presentation of Financial Statements [Line Items]        
Net sales 271,400 229,500    
Americas [Member]        
Organization, Consolidation and Presentation of Financial Statements [Line Items]        
Net sales $ 38,800 $ 35,000    
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.1
1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Warranty accrual, beginning of period $ 9.8 $ 9.0
Provision for warranty 2.7 1.9
Actual warranty costs (2.6) (2.7)
Warranty accrual, end of period $ 9.9 $ 8.2
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.1
1. Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Accounts Receivable, Allowance for Credit Loss $ 18.6 $ 18.9 $ 19.8 $ 20.2
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) (0.6) (0.8)    
Allowance for Loan and Lease Losses, Write-offs $ (0.6) $ (0.5)    
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.1
2. Fair Value Measurements Fair Value Level Table (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Unrealized Gain on Securities $ 1,179.4  
Debt Securities, Available-for-sale 282.3  
Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted Investments, at Fair Value [1] 6.8 $ 6.7
Equity Securities [2] 10,524.3 9,582.4
Debt Securities, Available-for-sale [3] 282.3 267.6
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [4] 0.6 1.0
Assets, Fair Value Disclosure 10,925.9 9,990.5
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [5] 1.1 1.0
Business Combination, Contingent Consideration, Liability [6] 0.7 0.7
Liabilities, Fair Value Disclosure 1.8 1.7
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted Investments, at Fair Value [1] 6.8 6.7
Equity Securities [2] 10,524.3 9,582.4
Debt Securities, Available-for-sale [3] 0.0 0.0
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [4] 0.0 0.0
Assets, Fair Value Disclosure 10,601.1 9,666.8
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [5] 0.0 0.0
Business Combination, Contingent Consideration, Liability [6] 0.0 0.0
Liabilities, Fair Value Disclosure 0.0 0.0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted Investments, at Fair Value [1] 0.0 0.0
Equity Securities [2] 0.0 0.0
Debt Securities, Available-for-sale 282.3 267.6 [3]
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [4] 0.6 1.0
Assets, Fair Value Disclosure 324.8 323.7
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [5] 1.1 1.0
Business Combination, Contingent Consideration, Liability [6] 0.0 0.0
Liabilities, Fair Value Disclosure 1.1 1.0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted Investments, at Fair Value [1] 0.0 0.0
Equity Securities [2] 0.0 0.0
Debt Securities, Available-for-sale [3] 0.0 0.0
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [4] 0.0 0.0
Assets, Fair Value Disclosure 0.0 0.0
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [5] 0.0 0.0
Business Combination, Contingent Consideration, Liability [6] 0.7 0.7
Liabilities, Fair Value Disclosure 0.7 0.7
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure 0.0 0.0
Asset-backed Securities [Member] | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [7]   0.9
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [7]   0.0
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [7]   0.9
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [7]   0.0
Commercial Paper [Member] | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [7] 29.3 41.7
Commercial Paper [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [7] 0.0 0.0
Commercial Paper [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [7] 29.3 41.7
Commercial Paper [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [7] 0.0 0.0
Time Deposits [Member] | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [7] 18.7 27.6
Time Deposits [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [7] 8.7 17.6
Time Deposits [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [7] 10.0 10.0
Time Deposits [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [7] 0.0 0.0
Money Market Funds [Member] | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [7] 61.3 60.1
Money Market Funds [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [7] 61.3 60.1
Money Market Funds [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [7] 0.0 0.0
Money Market Funds [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [7] 0.0 0.0
Cash Equivalents [Member] | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [7] 111.9 132.8
Cash Equivalents [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [7] 70.0 77.7
Cash Equivalents [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [7] 41.9 55.1
Cash Equivalents [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [7] 0.0 0.0
US Treasury Securities | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure 2.6 2.5
US Treasury Securities | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure 2.6 2.5
US Treasury Securities | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure 0.0 0.0
Foreign Government Debt [Member] | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 2.1 [3] 2.1
Foreign Government Debt [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 0.0 [3] 0.0
Foreign Government Debt [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 2.1 [3] 2.1
Foreign Government Debt [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 0.0 [3] 0.0
Municipal Obligations (Member) | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale [3] 14.1 15.2
Municipal Obligations (Member) | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale [3] 0.0 0.0
Municipal Obligations (Member) | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale [3] 14.1 15.2
Municipal Obligations (Member) | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale [3] 0.0 0.0
Foreign Government Obligations [Member] | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale [3] 4.0 4.0
Foreign Government Obligations [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale [3] 0.0 0.0
Foreign Government Obligations [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale [3] 4.0 4.0
Foreign Government Obligations [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale [3] 0.0 0.0
Corporate Debt Securities [Member] | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale [3] 162.2 133.2
Corporate Debt Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale [3] 0.0 0.0
Corporate Debt Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale [3] 162.2 133.2
Corporate Debt Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale [3] 0.0 0.0
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale [3] 71.8 76.9
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale [3] 0.0 0.0
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale [3] 71.8 76.9
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale [3] 0.0 0.0
Asset-backed Securities [Member] | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale [3] 28.1 36.2
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale [3] 0.0 0.0
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale [3] 28.1 36.2
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale [3] 0.0 0.0
Other Current Liabilities [Member] | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Business Combination, Contingent Consideration, Liability [6] 0.6 0.6
Other Noncurrent Liabilities [Member] | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Business Combination, Contingent Consideration, Liability [6] 0.1 0.1
Short-term Investments [Member] | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities [2] 64.2 61.4
Debt Securities, Available-for-sale [3] 282.2 267.5
Short-term Investments [Member] | Foreign Government Debt [Member] | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 2.1 2.1
Short-term Investments [Member] | Municipal Obligations (Member) | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 14.1 15.2
Short-term Investments [Member] | Foreign Government Obligations [Member] | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 4.0 4.0
Short-term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 162.2 133.2
Short-term Investments [Member] | US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 71.8 76.9
Short-term Investments [Member] | Asset-backed Securities [Member] | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 28.0 36.1
Other Investments [Member] | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted Investments, at Fair Value 1.2 1.1
Equity Securities [2] 10,460.1 9,521.0
Debt Securities, Available-for-sale [3] 0.1 0.1
Restricted investment [Member] | Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted Investments, at Fair Value $ 5.6 $ 5.6
[1] Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):
March 31, 2021December 31, 2020
Restricted investments$5.6 $5.6 
Other investments1.2 1.1 
    Total$6.8 $6.7 
[2] Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):
March 31, 2021December 31, 2020
Short-term investments$64.2 $61.4 
Other investments10,460.1 9,521.0 
        Total$10,524.3 $9,582.4 
[3] Available-for-sale investments are included in the following accounts in the condensed consolidated balance sheets (in millions):
 March 31, 2021December 31, 2020
Short-term investments$282.2 $267.5 
Other investments0.1 0.1 
Total$282.3 $267.6 
[4] Forward foreign exchange contracts in an asset position are included in other current assets in the condensed consolidated balance sheets.
[5] Forward foreign exchange contracts in a liability position are included in other current liabilities in the condensed consolidated balance sheets.
[6] Contingent consideration liability is included in the following accounts in the condensed consolidated balance sheets (in millions):
March 31, 2021December 31, 2020
Other current liabilities$0.6 $0.6 
Other long-term liabilities0.1 0.1 
   Total$0.7 $0.7 
[7] Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.21.1
2. Fair Value Measurements 3. Contingent Consideration (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Apr. 01, 2020
Distributor [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Contingent consideration milestone payments $ (1.4) $ (0.7)  
Business Combination, Contingent Consideration, Liability 0.6    
Celsee      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 60.0    
Business Combination, Contingent Consideration, Liability 0.1   $ 0.1
Fair Value, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Business Combination, Contingent Consideration, Liability [1] 0.7 0.7  
Other Noncurrent Liabilities [Member] | Fair Value, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Business Combination, Contingent Consideration, Liability [1] 0.1 0.1  
Other Current Liabilities [Member] | Fair Value, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Business Combination, Contingent Consideration, Liability [1] $ 0.6 $ 0.6  
[1] Contingent consideration liability is included in the following accounts in the condensed consolidated balance sheets (in millions):
March 31, 2021December 31, 2020
Other current liabilities$0.6 $0.6 
Other long-term liabilities0.1 0.1 
   Total$0.7 $0.7 
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.21.1
2. Foreign Exchange Forward Contracts (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2021
USD ($)
Forward foreign exchange contract to sell foreign currency [Member]  
Derivatives, Fair Value [Line Items]  
Derivative, Notional Amount $ 284.0
Loss on Foreign Currency Derivative Instruments not Designated as Hedging Instruments 0.4
Forward foreign exchange contract to purchase foreign currency [Member]  
Derivatives, Fair Value [Line Items]  
Derivative, Notional Amount 252.3
Loss on Foreign Currency Derivative Instruments not Designated as Hedging Instruments $ 0.0
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.1
2. Available-for-Sale Investments (Details) - USD ($)
$ in Millions
Mar. 31, 2021
Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost $ 278.8  
Debt Securities, Available-for-sale 282.3  
Fair Value, Recurring [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 278.8 $ 262.2
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 3.6 5.4
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (0.1) 0.0
Debt Securities, Available-for-sale, Allowance for Credit Loss 0.0 0.0
Debt Securities, Available-for-sale [1] 282.3 267.6
Fair Value, Recurring [Member] | Corporate Debt Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale [1] 162.2 133.2
Fair Value, Recurring [Member] | Municipal obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale [1] 14.1 15.2
Fair Value, Recurring [Member] | US Government Sponsored Agencies [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale [1] 71.8 76.9
Fair Value, Recurring [Member] | Foreign Government Obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale [1] 4.0 4.0
Fair Value, Recurring [Member] | Foreign Government Debt [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale 2.1 [1] 2.1
Fair Value, Recurring [Member] | Asset-backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale [1] 28.1 36.2
Fair Value, Recurring [Member] | Other Long-term Investments [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 0.1 0.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0 0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Debt Securities, Available-for-sale, Allowance for Credit Loss 0.0 0.0
Debt Securities, Available-for-sale 0.1 0.1
Fair Value, Recurring [Member] | Other Long-term Investments [Member] | Asset-backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 0.1 0.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0 0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Debt Securities, Available-for-sale, Allowance for Credit Loss 0.0 0.0
Debt Securities, Available-for-sale 0.1 0.1
Fair Value, Recurring [Member] | Short-term Investments [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 278.7 262.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 3.6 5.4
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (0.1) 0.0
Debt Securities, Available-for-sale, Allowance for Credit Loss 0.0 0.0
Debt Securities, Available-for-sale [1] 282.2 267.5
Fair Value, Recurring [Member] | Short-term Investments [Member] | Corporate Debt Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 160.3 130.5
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 1.9 2.7
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Debt Securities, Available-for-sale, Allowance for Credit Loss 0.0 0.0
Debt Securities, Available-for-sale 162.2 133.2
Fair Value, Recurring [Member] | Short-term Investments [Member] | Municipal obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 14.0 15.0
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.1 0.2
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Debt Securities, Available-for-sale, Allowance for Credit Loss 0.0 0.0
Debt Securities, Available-for-sale 14.1 15.2
Fair Value, Recurring [Member] | Short-term Investments [Member] | US Government Sponsored Agencies [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 70.6 74.7
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 1.3 2.2
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (0.1) 0.0
Debt Securities, Available-for-sale, Allowance for Credit Loss 0.0 0.0
Debt Securities, Available-for-sale 71.8 76.9
Fair Value, Recurring [Member] | Short-term Investments [Member] | Foreign Government Obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 4.0 4.0
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0 0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Debt Securities, Available-for-sale, Allowance for Credit Loss 0.0 0.0
Debt Securities, Available-for-sale 4.0 4.0
Fair Value, Recurring [Member] | Short-term Investments [Member] | Foreign Government Debt [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 2.1 2.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0 0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Debt Securities, Available-for-sale, Allowance for Credit Loss 0.0 0.0
Debt Securities, Available-for-sale 2.1 2.1
Fair Value, Recurring [Member] | Short-term Investments [Member] | Asset-backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 27.7 35.8
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.3 0.3
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Debt Securities, Available-for-sale, Allowance for Credit Loss 0.0 0.0
Debt Securities, Available-for-sale 28.0 36.1
Fair Value, Recurring [Member] | Other Investments [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale [1] $ 0.1 $ 0.1
[1] Available-for-sale investments are included in the following accounts in the condensed consolidated balance sheets (in millions):
 March 31, 2021December 31, 2020
Short-term investments$282.2 $267.5 
Other investments0.1 0.1 
Total$282.3 $267.6 
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.1
2. Amortized Cost and Fair Value of Debt Securities (Details)
$ in Millions
Mar. 31, 2021
USD ($)
Fair Value Disclosures [Abstract]  
Mature in less than one year $ 173.6
Mature in one to five years 66.2
Mature in more than five years 39.0
Total Amortized Cost 278.8
Mature in less than one year 174.1
Mature in one to five years 67.9
Mature in more than five years 40.3
Estimated Fair Value $ 282.3
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.1
2. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details)
$ in Millions
Mar. 31, 2021
USD ($)
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax $ 0.1
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss 0.0
Debt Securities, Available-for-sale, Unrealized Loss Position 7.4
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months 7.4
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer 0.0
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss 0.1
US Government Sponsored Agencies [Member]  
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax 0.1
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss 0.0
Debt Securities, Available-for-sale, Unrealized Loss Position 7.4
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months 7.4
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer 0.0
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss 0.1
Fair Value, Recurring [Member] | Debt Securities [Member]  
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax $ 0.1
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.21.1
2. Fair Value Financial Instruments (Details) - USD ($)
$ in Millions
Mar. 31, 2021
Dec. 31, 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Interest Receivable, Current $ 1.4 $ 1.4
Equity Securities without Readily Determinable Fair Value, Amount 6.5 0.5
Equity Method Investments $ 35.2 $ 38.4
Ordinary voting shares [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Investment ownership percentage 37.00%  
Investment Owned, Balance, Shares 12,987,900  
Preference shares [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Investment ownership percentage 28.00%  
Investment Owned, Balance, Shares 9,588,908  
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.21.1
3. Intangible Assets, Goodwill and Other (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Goodwill [Line Items]    
Goodwill $ 627,100 $ 627,100
Accumulated impairment loss (335,200) (335,200)
Goodwill, net 291,916 291,916
Clinical Diagnostics [Member]    
Goodwill [Line Items]    
Goodwill 349,200 349,200
Accumulated impairment loss (293,400) (293,400)
Goodwill, net 55,800 55,800
Life Science [Member]    
Goodwill [Line Items]    
Goodwill 277,900 277,900
Accumulated impairment loss (41,800) (41,800)
Goodwill, net $ 236,100 $ 236,100
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.21.1
3. Intangible Assets, Goodwill and Other Intangible Assets (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Finite-Lived Intangible Assets, Net [Abstract]      
Purchase Price $ 598.5   $ 608.1
Accumulated Amortization (411.3)   (413.4)
Net Carrying Amount 187.2   194.7
Amortization [Abstract]      
Amortization expense 7.2 $ 5.9  
Intangible Assets, Gross (Excluding Goodwill) $ 603.1   $ 612.9
Customer Relationships [Member]      
Acquired Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Assets, Remaining Amortization Period 5 years 5 months 19 days   5 years 6 months 3 days
Finite-Lived Intangible Assets, Net [Abstract]      
Purchase Price $ 112.4   $ 116.6
Accumulated Amortization (85.6)   (87.2)
Net Carrying Amount $ 26.8   $ 29.4
Know How [Member]      
Acquired Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Assets, Remaining Amortization Period 4 years 6 months   4 years 9 months
Finite-Lived Intangible Assets, Net [Abstract]      
Purchase Price $ 192.7   $ 196.6
Accumulated Amortization (172.6)   (175.4)
Net Carrying Amount $ 20.1   $ 21.2
Developed Technology Rights [Member]      
Acquired Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Assets, Remaining Amortization Period 13 years 9 months 29 days   14 years
Finite-Lived Intangible Assets, Net [Abstract]      
Purchase Price $ 217.1   $ 218.1
Accumulated Amortization (108.6)   (107.1)
Net Carrying Amount $ 108.5   $ 111.0
Licensing Agreements [Member]      
Acquired Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Assets, Remaining Amortization Period 7 years 6 months 3 days   7 years 8 months 23 days
Finite-Lived Intangible Assets, Net [Abstract]      
Purchase Price $ 65.2   $ 65.6
Accumulated Amortization (38.0)   (37.4)
Net Carrying Amount $ 27.2   $ 28.2
Trade Names [Member]      
Acquired Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Assets, Remaining Amortization Period 7 years 8 months 15 days   7 years 9 months 25 days
Finite-Lived Intangible Assets, Net [Abstract]      
Purchase Price $ 6.4   $ 6.6
Accumulated Amortization (4.2)   (4.2)
Net Carrying Amount $ 2.2   $ 2.4
Noncompete Agreements [Member]      
Acquired Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Assets, Remaining Amortization Period 3 years 7 months 28 days   3 years 10 months 13 days
Finite-Lived Intangible Assets, Net [Abstract]      
Purchase Price $ 4.6   $ 4.5
Accumulated Amortization (2.2)   (2.0)
Net Carrying Amount $ 2.4   $ 2.5
Other Intangible Assets [Member]      
Acquired Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Assets, Remaining Amortization Period  
Finite-Lived Intangible Assets, Net [Abstract]      
Purchase Price $ 0.1   $ 0.1
Accumulated Amortization (0.1)   (0.1)
Net Carrying Amount 0.0   0.0
In Process Research and Development [Member]      
Amortization [Abstract]      
Indefinite-lived Intangible Assets (Excluding Goodwill) $ 4.6   $ 4.8
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.21.1
4. Supplemental Cash Flow Information - (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Supplemental Cash Flow Elements [Abstract]    
Net Income Attributable to Parent $ 977,414 $ 685,912
Share-based Compensation 11,700 9,700
(Gain) Loss on Sale of Securities, Net (100) (400)
Other than temporary impairment losses on investments 800 0
Changes in fair market value of equity securities (1,179,400) (827,700)
Loss on Disposition of Property Plant Equipment 300 100
Changes in fair value of contingent consideration 0 (100)
Decrease in accounts receivable 1,300 2,200
Decrease (increase) in inventories 5,800 (13,700)
Increase in other current assets (37,500) (9,500)
Decrease in accounts payable and other current liabilities (44,500) (25,600)
Increase in income taxes payable 27,300 20,900
Increase in deferred income taxes 274,800 171,800
Increase in other long term liabilities 43,800 15,700
Reduction in the carrying amount of right-of-use assets 9,800 9,600
Depreciation and amortization 32,700 33,600
Other (700) (400)
Payments of operating lease liabilities (9,900) (9,300)
Net cash provided by operating activities 113,610 62,808
Noncash or Part Noncash Acquisition, Investments Acquired 0 2,700
Noncash or Part Noncash Acquisition, Fixed Assets Acquired $ 4,700 $ 6,000
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.21.1
5. Long-Term Debt (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Debt Instrument [Line Items]    
Other Long-term Debt, Current $ 1,700 $ 1,800
Long-term debt, net of current maturities 10,901 12,258
Outstanding borrowings 0  
Finance Lease Obligations [Member] | Finance Leases and Other Debt [Member]    
Debt Instrument [Line Items]    
Other Long-term Debt 12,600 $ 14,100
Line of Credit [Member]    
Debt Instrument [Line Items]    
Line of credit maximum borrowing capacity $ 200,000  
Line of Credit Facility, Interest Rate at Period End 1.315%  
Standby Letters of Credit [Member]    
Debt Instrument [Line Items]    
Line of credit maximum borrowing capacity $ 200  
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.21.1
6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Beginning balance, Accumulated other comprehensive income $ 282,456  
Total other comprehensive income (loss) net of tax (214,022) $ (61,607)
Ending balance, Accumulated other comprehensive income 68,434  
Other (income) expense, net (17,407) (3,273)
Accumulated Translation Adjustment [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Beginning balance, Accumulated other comprehensive income 298,600 (72,400)
Other Comprehensive Income (Loss), before Reclassifications, before Tax (214,700) (62,900)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax 0 0
Other Comprehensive Income (Loss), Tax 400 900
Total other comprehensive income (loss) net of tax (214,300) (62,000)
Ending balance, Accumulated other comprehensive income 84,300 (134,400)
Accumulated Defined Benefit Plans Adjustment [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Beginning balance, Accumulated other comprehensive income (26,000) (22,200)
Other Comprehensive Income (Loss), before Reclassifications, before Tax 1,700 200
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax 500 300
Other Comprehensive Income (Loss), Tax (300) 200
Total other comprehensive income (loss) net of tax 1,900 700
Ending balance, Accumulated other comprehensive income (24,100) (21,500)
Accumulated Net Unrealized Investment Gain (Loss) [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Beginning balance, Accumulated other comprehensive income 9,800 7,200
Other Comprehensive Income (Loss), before Reclassifications, before Tax (1,900) 0
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax (100) (400)
Other Comprehensive Income (Loss), Tax 400 100
Total other comprehensive income (loss) net of tax (1,600) (300)
Ending balance, Accumulated other comprehensive income 8,200 6,900
AOCI Attributable to Parent [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Beginning balance, Accumulated other comprehensive income 282,400 (87,400)
Other Comprehensive Income (Loss), before Reclassifications, before Tax (214,900) (62,700)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax 400 (100)
Other Comprehensive Income (Loss), Tax 500 1,200
Total other comprehensive income (loss) net of tax (214,000) (61,600)
Ending balance, Accumulated other comprehensive income $ 68,400 $ (149,000)
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.21.1
7. Earnings Per Share (Details) - shares
shares in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Basic weighted average shares outstanding 29,823 29,865
Effect of potentially dilutive stock options and restricted stock awards 363 331
Diluted weighted average common shares 30,186 30,196
Anti-dilutive shares 23 62
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.21.1
8. Other Income and Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Interest and investment income $ (18,300) $ (2,800)
Net realized (gain) loss on investments (100) (400)
Other Nonoperating (Income)   (100)
Other Nonoperating Expense 200  
Equity Method Investment, Other than Temporary Impairment 800 0
Other Nonoperating Income (Expense) $ 17,407 $ 3,273
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.21.1
9. Income Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Effective tax rate 24.70% 23.70%  
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit $ 16.7    
Unrecognized Tax Benefits 57.5   $ 55.8
Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions $ 1.7    
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.21.1
Segment Reporting (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Segment Reporting Information [Line Items]    
Net sales $ 726,796 $ 571,644
Income before income taxes 1,297,203 898,699
Life Science [Member]    
Segment Reporting Information [Line Items]    
Net sales 366,500 227,200
Income before income taxes 102,300 23,700
Clinical Diagnostics [Member]    
Segment Reporting Information [Line Items]    
Net sales 358,500 340,300
Income before income taxes (1,900) 43,800
Other Segments [Member]    
Segment Reporting Information [Line Items]    
Net sales 1,800 4,100
Income before income taxes $ 100 $ 1,100
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.21.1
10. Segment Information Segment Profit Reconciliations (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Income before income taxes $ 1,297,203 $ 898,699
Marketable Securities, Unrealized Gain (Loss) 1,179,403 827,671
Operating Segments [Member]    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Income before income taxes 100,500 68,600
Segment Reconciling Items [Member]    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Marketable Securities, Unrealized Gain (Loss) 1,179,400 827,700
Foreign Currency Gain (Loss) [Member] | Segment Reconciling Items [Member]    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Income before income taxes (100) (900)
Other Nonoperating Income (Expense) [Member] | Segment Reconciling Items [Member]    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Income before income taxes $ 17,400 $ 3,300
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.21.1
10. Segment Information Segment Asset Reconciliation (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Segment Reporting, Asset Reconciling Item [Line Items]    
Assets $ 13,933,160 $ 12,972,618
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.21.1
12. Restructuring Costs (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Restructuring Cost and Reserve [Line Items]      
Cost of goods sold $ 326,169 $ 254,276  
European Reorganization      
Restructuring Cost and Reserve [Line Items]      
Restructuring Reserve 71,200   $ 0
Restructuring Charges 75,600    
Payments for Restructuring (2,000)    
Restructuring Reserve, Foreign Currency Translation (Gain) Loss (2,400)    
European Reorganization | Accounts Payable and Accrued Liabilities [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Reserve 35,200    
European Reorganization | Other Noncurrent Liabilities [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Reserve 36,000    
European Reorganization | Selling, General and Administrative Expenses [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Reserve, Accrual Adjustment 34,700    
European Reorganization | Cost of Sales [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Reserve, Accrual Adjustment 23,900    
European Reorganization | Research and Development Expense [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Reserve, Accrual Adjustment 17,000    
European Reorganization | Life Science [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Reserve 12,400   0
Restructuring Charges 12,900    
Payments for Restructuring (100)    
Restructuring Reserve, Foreign Currency Translation (Gain) Loss (400)    
European Reorganization | Clinical Diagnostics [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Reserve 58,800   $ 0
Restructuring Charges 62,700    
Payments for Restructuring (1,900)    
Restructuring Reserve, Foreign Currency Translation (Gain) Loss $ (2,000)    
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.21.1
13. Leases (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Lessee, Lease, Description [Line Items]      
Operating Lease, Cost $ 11,700 $ 12,600  
Finance Lease, Right-of-Use Asset, Amortization 100 100  
Finance Lease, Interest Expense 200 200  
Finance Lease Cost 300 300  
Sublease Income 700 700  
Operating Lease, Payments 11,800 11,400  
Finance Lease, Interest Payment on Liability 100 200  
Finance Lease, Principal Payments 200 100  
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 4,200 10,800  
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability 0 $ 0  
Operating lease right-of-use assets 196,224   $ 202,136
Current operating lease liabilities 39,235   36,507
Operating lease liabilities 168,326   175,128
Operating Lease, Liability 207,600   211,600
Finance Lease, Right-Of-Use Asset, before Accumulated Amortization 12,200   12,200
Finance Lease, Right-Of-Use Asset, Accumulated Amortization 5,100   5,000
Finance Lease, Right-Of-Use Asset, after Accumulated Amortization 7,100   7,200
Finance Lease, Liability, Current 500   500
Finance Lease, Liability, Noncurrent 10,900   11,000
Finance Lease, Liability $ 11,400   $ 11,500
Operating Lease, Weighted Average Remaining Lease Term 8 years   8 years
Finance Lease, Weighted Average Remaining Lease Term 16 years   16 years
Operating Lease, Weighted Average Discount Rate, Percent 3.90%   3.90%
Finance Lease, Weighted Average Discount Rate, Percent 6.20%   6.20%
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year $ 35,300    
Finance Lease, Liability, Payments, Remainder of Fiscal Year 1,000    
Lessee, Operating Lease, Liability, to be Paid, Year One 38,600    
Finance Lease, Liability, to be Paid, Year One 1,300    
Lessee, Operating Lease, Liability, Payments, Due Year Two 32,400    
Finance Lease, Liability, Payments, Due Year Two 1,200    
Lessee, Operating Lease, Liability, Payments, Due Year Three 26,400    
Finance Lease, Liability, Payments, Due Year Three 1,100    
Lessee, Operating Lease, Liability, Payments, Due Year Four 23,100    
Finance Lease, Liability, Payments, Due Year Four 1,100    
Lessee, Operating Lease, Liability, Payments, Due after Year Five 90,600    
Finance Lease, Liability, Payments, Due after Year Five 14,000    
Lessee, Operating Lease, Liability, Payments, Due 246,400    
Finance Lease, Liability, Payment, Due 19,700    
Lessee, Operating Lease, Liability, Undiscounted Excess Amount (38,800)    
Finance Lease, Liability, Undiscounted Excess Amount (8,300)    
Current liability      
Lessee, Lease, Description [Line Items]      
Current operating lease liabilities $ 39,300   $ 36,500
Minimum [Member]      
Lessee, Lease, Description [Line Items]      
Lessee Operating And Finance Leases Remaining Lease Term 1 year    
Maximum [Member]      
Lessee, Lease, Description [Line Items]      
Lessee Operating And Finance Leases Remaining Lease Term 18 years    
EXCEL 67 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�="GY7X4="JU[A]012[/.<),$2Q@I8TEMU:D(O9<(;%1JQ/T M&JP5]%B]%0P:Y0I^Q[DN**$7'\PE-3H_5 Z__-2/6M%O+ Q.6#T,6@T<=;;/ MR.&[@33%^FW],AJT2P,R/R C5;X_L0L'53)M2F9 R72K9,(?&,;:$6>[XD$$ M]]'1\]LAH#@/(OSM]A'0_TEL(7%1[Z&J&IZ-*(AHT/-LU/L]6O]74C*]2K[UKA?=1V(K"6ZU M.UN&6\$)#;H(B38Z PHYEGBK;Q&"K1>%//#&-[!W";XR.UUYO,X,JRN5WG<* MMG7X*06WHR!@B^S'"][3-L?#8R[C"F=A2=ETC%U#3"Y,X&GNQ3D'E^DD>.M/ MM/FJ"\K!K'RO1_\=2%'9$.U6=^WDN.RB7LS+7A2O8T6O2T**KGAYV!"8LK\K M)TZO?4^UU X[-#_,L"4&0P:XGVK\-ZXF=,"NR1[]#5!+ P04 " 7AYY2 M=NZ5]I,# #%" &0 'AL+W=O=355O!):XUF+HLF7Y8HE#-+!@'^X,-WQ76 M'83S:<5VN$7[M5IKVH4]2L9+E(8K"1KS6; 87R\OG+P7^,:Q,0=K<)XD2MVZ MS:=L%HP<(1286H? Z'.';U$(!T0T?G6806_2*1ZN]^COO>_D2\(,OE7B.\]L M,0NN L@P9[6P&]5\Q,Z?2X>7*F'\+S2M;#P*(*V-566G3 Q*+MLON^_B<*!P M=4XAZA0BS[LUY%F^8Y;-IUHUH)TTH;F%=]5K$SDN75*V5M,M)ST[?SV$%=.2 MRYV!-6K8%DSC-+0$[03"M(-9MC#1&9@8;I2TA8&5S#![JA\2I9Y7M.>UC)X% MO&%Z"/%X -$H&C^#%_=^QA[O\@S>L9/P8Y$8J^E9_'P&_Z+'O_#X\3_CGPKB MLQBN_JY-Q5*4Z$Z,YG3I5(E&U(2L.>.]':[TB2>SX8D>7#%$A6]147\X;=_/H=:4L,>!, M_.&_]]<[I" A,QD]?+?^2Q"/HS>$]1D3#AWO4U$[Z%RKTH-GYV.;,I'6@OE^ MQ_,_XDKY)R3GH(^EP;36W'*RTZA:9-X)8O%J'_\A?/G?]T#!]['8\T'7.>G% MNL24=UNHVI!9\_*:W-6(3QH94!NB M4.W[D/L9=<5W%)<388C>#*ZBV'\FE[#J,]$_*?'P^-K__K"!-4QG!N))#'$\ M[HOLB,K3Q,2CP?AJXC]O)K X%5HB.8G@5!L,#T9+B7KG!ZAK,E2W[93I3_L9 MO6A'TZ-X.^ IECLJ:1"8D^IH^)IZM6Z'9KNQJO*#*E&6QIY?%O0_ [43H/M< M4=RZC3/0_W.9_P902P,$% @ %X>>4J,.A'"W @ X 4 !D !X;"]W M;W)K&ULC51M3]LP$/XKIVR:J 1)FI91L;92"YG@ M Z4"]B)-^^ FU\;"L3/;I6R_?F9X[^VZX4?K1%(@6GDLA MS2@HK*W.H\AD!9;,A*I"27^62I?,TE:O(E-I9+D/*D64Q/''J&1 2YQK,NBR9_CU%H3:CH!ML#^[XJK#N(!H/*[;">[1?JKFF7=2BY+Q$ M:;B2H'$Y"B;=\VG?^7N'KQPW9L<&E\E"J4>WNP$H<#,.@1&GR>\0"$< M$,GXU6 &+:4+W+6WZ)]][I3+@AF\4.(;SVTQ"@8!Y+AD:V'OU.8*FWQ.'5ZF MA/$K;&K??A) MC96E4TP*2BYK+_LN:G#3L @WA.0- &)UUT3>967S++Q4*L- M:.=-:,[PJ?IH$L>ENY1[J^DOIS@['H1P:PO4<"TS52(PF4/Z3%=NT PC2PS. M+\H:M&F-ENQ!Z\&-DK8PD,H<\]?Q$2EKY25;>=/D(. -TR'TNL>0Q$GW %ZO M3;?G\4[WX.W-%7Y,%L9J>B0_#]#T6YJ^I^G]+TU]T)#!)3>94&:M\:T2'X:F M^WJX2N_@>G9Q>Y/"9'8)Z?=Y.KM/CV&6/C1,1]QS=P!KRF.0U.!T*-8Y)4L^ ML%2".I++%9!GI21*:UP"HWXZDZ!;B0KVBMQ2TR)6M1HK$^5 MRRSCJ#L)>QQE)..C C+30!!'\#P&N:'(8H 9]"20=<=CMN+7? MJ3,ZL063)Q9)J:;A ;RL&->>A2KY3SS$X0 ^O!LDW>134Y"F#B^%B<.D87E= ML;I23O*9(R>C1]+?>A/13M>5J%=^MABJYEK:N@';TW9\3>JN?7&O9Q\5=>6J M('!)H7%X1N]7U_.DWEA5^1Y>*$L3P9L%C6#4SH'^+Y6RVXTC:(?Z^"]02P,$ M% @ %X>>4IUF'S+7!0 [0T !D !X;"]W;W)K&ULC5?;9%( +M[]G86/-]8=^<;HB#N6VW\Q:0)H7L]G?JRH5;Z MPG9DL%-;U\J 5[>:^LZ1K))0JZ?SV>S%M)7*3"[/T]H'=WEN8]#*T &%Z>=[)%=U2^-Q]<'B;CEHJU9+QRAKAJ+Z87)V\ MOC[E\^G 7XHV?N=9L"=+:^_XY8_J8C)C0*2I#*Q!XF]-;TAK5@08WWJ=D]$D M"^X^#]I_2[[#EZ7T],;J+ZH*S<7DU4145,NHPT>[^9UZ?\Y87VFU3[]BD\\N M%A-11A]LVPL#0:M,_I?W?1QV!%[-#@C,>X%YPIT-)90W,LC+O#4558_EIP S(IH/B*[GSRI\)UTA%B?'8CZ;GSRC;S%ZN$CZS@[H>W!/ MW"A?:NNC(_'/U=('AYKX]QD3IZ.)TV1B\4,3^R/XO#2GX,\W[]^]%9^N_GY[ M*]Y')ZBN*=6K4%EW 'PG XF-]&)^6KS\14A3B?F"G]";(C0XU#@BT>9\$.=# M()IE,X8SR\SFLV,TE.^R";TMQ"=(HZ>U^BY3L]B:2YN<@PHV+;VGX(7R6.Y8 MLPDB=CC(9E=DR(UR/M:U*A6?@*18_24?@$+Y1DBQECIF MI%*#CZ0I@:X6*K!KK85UK>X0$0"51A@;^"$(S_ [ZUCR6"#:D#YF?P[9W2BM MD_ARB"M5W&F]&\JL4BCZD/?^'-9W+#;(/#,,6Q9R+95.D>VL5ZE,V%%#*YE> M:*V0H9(*<1.)P\2VDGA(1I9?A\R+-8)=JZ3KB7BRNB2M:$TY#C^*4TDN2,XD M3JB5^>G08(^!/2[6X^14(V&L5(#@%J*E"42/+J)Z0XSMXE73'T%B'V%,N5%961I@V \/14"5K093V50O<[KA%X30[#-B0E*48LI^4FEW9N MC[27HX4X2FYMS"0@!U@DMY1HQ4KY+@9"\B1\=0H(-BHT^\' [MKJ=4+@?22. ME85/F614RQO)6HO5D,FBBF7&F#:0F/(!4VE+9HPJP^9=5E"C\3>EI99UP,0GKS5JDKH:A28*5DL MU2FN2\P64B.7D=G"C.H01JOCP-+6$/-8:N6Q)@_!Q +[E8DY5=#_,:NVDQEK MIC4NP)1ZW!Y=7PAY2H$ELI[J'L[#AIC@Z>UFIZ%-C1V5GQ MZF%E#WND8S=44KM$*_:K>^<>JA,\Y!-1VI^ ! ;$],(55B7^&]QE"%((+4F7Y*!MX)N\5\*8D\;KGONJK[@=IGP7XFHO M??)MM1IR@EZ"V_P>PS"-AVSO$)5/T^V!18:A#7&U,^-1:XE-\*S!!V$GQ8/2 M1[W]=)1P&_>^&[H/XF0^7%SRD.&@68/!M.60><43*@ERBD"):R:11+6'\E3: MJ"LP4Q]_,'#L.,=')R]VV,#XA7?Y'U!+ P04 " 7AYY2H6?U1.$$ "P"@ &0 M 'AL+W=O!%P=Q]6^\%-)HU%$G=MIZ7WZ^\9.PF%9=%^:!/;,\_,//,2GVZT M>;(%D1//55G;LZAP;G4R'-JTH$K:6*^HQDFN324=EF8YM"M#,O-*53E,1J/# M8255'X%_%&WLSKO@2!9:/_'B*CN+1NP0 ME90Z1I!XK.F2RI*!X,:/%C/J3;+B[GN'_M7'CE@6TM*E+O]5F2O.HEDD,LIE M4[I[O?F3VG@.&"_5I?7_8A-DITDDTL8Z7;7*\*!2=7C*YY:''879Z!<*2:N0 M>+^#(>_E9^GD_-3HC3 L#31^\:%Z;3BG:D[*@S,X5=!S\_$H%@^T!,U.7-4A MRG0P=SK#1,6^B+ )W\ GHBKG7M"BN^U!EEK_6'<+/W->E\ MO4@^!+R6)A:3\4 DHV3\ =ZDCWWB\0Y^@?=3C.+;^<(Z@TKY_@'\M(>?>OC) M;\-_5C8MM6T,B6^/].S$1:G3I^_O4?LA-'?JB5W)E,XBM*(ELZ9H_O#EC^LO M-X_BZN;K[?WU^>/5[)%]X;Q\?[>(Z@U.%-XB.&F< $&WI! X_H9,2$['A2:X?@$1738F4% M5F1=(PP$O>E%A&Y,QR?OY.MH7:YY0 J9V9.D9TQJP@^ (6==M>9.I-JA% MZ>#4FDR!(<[19,I@1L)CVZRZ4O5!.Q9=*B1*YS[0KEQB<0[++64#",J@!;9\ M"J -BZFV+9]YPX3 59U*9A74,)SQG2$7)>T@WQG%M:@!@@I+"UDO:>#]R52> M(R80)1;D-D3(C78HKU9YQ\#;Z =@$1E+56@%3W_%H?[G-P9^AVV (>BM=.T; M)46N=*DRCPF%AEME \JDN"CA-1!AFL\#$?"K@5\O(?IR(%?H3)=ZN>7\[.2V+P>.2OO>ZPJC MPWOA^^IMH036S3+DJ9\0_.T#6NB'5!JS]18\*6Q?U6O(:;/U5A$(J373@S%2 MK4J]A?("35%(UV$&:L( 82SHZ#I5I?=R-Z]MDP=67A*BZE177 L@BKJ5D\_T MTS1Z]%-M]W/T=JKY\?#XGE4>)R,_E@YG\:' 70!?^KI-2+H%;:%&!8\@[CP> M2WL8.?O\C_ES&8[A42Z501>;)TBL9=D0\T8_&N70>P1$Y;C9QH/QT7$\%3/, MOJ-V=H;H OCX"(<33+C+WV0#(0R2XS!(9\1ONW"(J0O[YKH1:X 2' M"T6_VU_'SL,MY$4\W.5 [E)AS)640W44'^$3;,+]*"R<7OD[R4([W'#\*S<- M&1; >:ZUZQ9LH+^DSO\'4$L#!!0 ( !>'GE)(63[#8 , !H' 9 M>&PO=V]R:W-H965T(LZ%XE%:N;,-\/A:+5W_GMH MF".]M,:&==;$V'W*\U TW*HP=1U;O*F<;U7$TM=YZ#RK,CFU)E_,9I=YJ[3- M-JNTM_6;E>NCT9:WGD+?MLJ_7K-Q^W4VSPX;C[INHFSDFU6G:G[B^'>W]5CE M1Y52MVR#=I8\5^OL:O[I^D+LD\$_FO?AY)DDDYUSWV5Q5ZZSF0"QX2**@L+/ M,]^P,2($C!^C9G8,*8ZGSP?UWU/NR&6G M\X\U67L5EG'S,JN5*]B8]N_P>/ M^7P0O<*9D/[3?K"]O,RHZ$-T[>@,@E;;X5>]C'4X@--6#N4I>KS5\(N;^7Q*]UPK0UOO"N92VSJL\@AI M,9ZD%F4QSV72^W!&[]Z%0#=@1'YLB]<)W=FAI5-O[-"O=*^CKH>-!Q4C^T#?KG8A M>K3.O^\P7!P9+A+#\AS#SW6>_JK0[VND\[K]_;FYO/]_]^>6)OC(I MCS_JE(^O%!T]*Z]='Z@P2K=A0B;%5NDJ!%*VI,*U'5[:B*77 3RD+<6&R7G0 MX8;"I/24.V%%1<+Q"M<6? M7SH7>L\3TA6BH_S8E%B=BXQ# 9O1:J>-!OY>QP:"HL2 M+!/)9*QHK24.8%1 L> E=:V5'$>=JG5,!>V*\^-SU'*^V- )RID^1<5IFA+5 M>LL#M17PD18Q#BG@9B0.:2==]$9Y@HUVY003#]^#!.2&;C&HO1$0;1.2^*:3 M30[37]V;_&1>M>SK-)6# -HXC*[C[G'P7PWS[LU\^&I@3M0:'6VX@NML^AL& M@!\F\;"(KDO3;^%\Y=."XD #'S^'F/U!+ P04 " 7 MAYY2#T%-72D% D"P &0 'AL+W=OQG"M@\[^Z#8Q[&*;+F23,C^^GY' M%L97T MV-K%P#669!Z8*CU(A\.C0255W9N*\=S$ZO3Q@^D#PEZ*E MVUH+MF1NS#UO;O+SWI !D:;,LP2)WP--26L6!!C_=C)[&Y7,N+U>2W\?;(>^D)W(J9*O]K5G^09T]ARPO,]J%KUA&VB-HS%KG3=4Q8U^I M.O[E8^>'+8:3X2L,:<>0!MQ144!Y);V<@LHKSN]LOT[LOMSD5\R,< M+HJ/,DSM6/]U:W$0_*KJ3+A)HC%.!=Y^H,JP,EKE M/]$5\$-'QZ)] (B8_$0("]I"KF%O82NLJ=;HX($+I^2KABZ5UF).;*8F]#C. M#@9;HL&X:)L3]-B@=^$&TD#K6B2IK+V2&@[*#+-Z$O-5-!\\0(G0IE&K5G*N MM/(K/MXY'B4I^H?6H14Z/D-A9>6FLH)GE&-U3#\^W**WE!F;1X@7669;+!NY ML@9&,%8"%+,B8*&:"N6C!3OCHV3XHHQ/G$!"(VWV/=EJ Y4+ ]==G'*T?M _ M10R;N=0A\4+#<]%062&'H1/M7$=_00;7-1NR,"9W @+ROIBA]R,"?;$ 3"LC M=IDC:U1(?21]\#G4=F7K*/B(-SD](!T:CM6&:$DHWYUTG+Q;F]F'U0?)\9.G MV0^CXRT_O&T? NQ#/H0((;]-10)E$WA\:>'C*K97XO;Z0PS[G&J<,[!$KYY[ M1P(J&D0L$O0 Y"1J#3T^/&H(>L2EZOC0,]2LM190D&SR02HMYSHD-@H SS6# M3,2-YT1%C3D5;DOIX=$\5!P[./\'3UBTAUU1M)X[7B9=R0D4+S+3:NC/H(Z] M8[E9LGJH\C]5CXQ%&FTKD(!FR<<^@(N3A?K>=009V^UJW:9B;4I6@2E&UNI[ M5/1<0]=$77"[0]1CJ]OETH\Q='NGXD]5D)AEBOANBK12&>R]4G)1(_-4YL2= M\3BYC GKNIJ[HHRJ.9*_"]GP5.R(7W\Y24?I;R^NIJ6TB]@"UEFW_U1O7#WK MGK>I/3SI[\11BBP\/DR.Q/29LW>'R6A/[(Z2=_BFR7!/8+C!Z+*.=H9N H-= M%X,%.EY@.EB3XXOU#V8]3T.V"2 .\#L\24[P"]WGI:=UL#6Y5 1+>3X+*5'[ M.,1L3C'GE+/HG6=L0@ +P7 9 M>&PO=V]R:W-H965T;*>7%4Y&7[FQKYOW\I-MUZ4P5TG7,7)68F1A;2(^AG7;=W"J9\:8B[R:] MWD&WD+K<.C_E;S?V_-14/M>ENK'"544A[?.%RLWB;*N_57^XU=.9IP_=\].Y MG*H[Y7^;WUB,N@V53!>J=-J4PJK)V=:H?W*Q3^MYP;^U6KC6;T&:C(WY08.O MV=E6CP12N4H]49!X/:I+E>=$"&+\&6EN-2QI8_MW3?T+ZPY=QM*I2Y,_Z,S/ MSK:.MD2F)K+*_:U9_**B/D.BEYK<\5,LPMI]<$PKYTT1-V-^5#4G7YJS4)86@UJ](-5Y=T03I?DE#MO,:NQSY_W!QWQ MJX):3FQ?&Z_'[2OX^&CMO$0M_O$%WOZ&[SW0'K]"- M-,T$U)U32GS6+LV-JZP2O]^K)R\NZN[D[$EZ_7H^O+ M*S&Z_BR^WUS=CNZ_7O\L'GZYNKT2#_A\>2]&=UA]=W=U)1"J AEKI=?E5.1! MP,5,0:*%HAP0TN&S:7'N_0R%W)JE4+*>;$\_. M1N%W26YFSIFL,E$:3SR=FDNLC$R85&G*O3!*33$W)2GR4=[?*ULKQ=RL(DAK MY!!>V8)=W1?/2EJ2H'_$/TE$T)S!GFE>9100H)4IV@$[,/A@M7I2-M6.*)=J M 6.;.4TYMFZ]6@D]@61"6BO+*;M":,?V924],5&\L2,80??,9*_"U/;M]]]V MX%RGH+-50&A'FTD42^M(A(KM)"JDJSR;R,]72E*T3AKF68YUKK]4J M73/.];31KY _:@IS^:7(:2MRF4>UJG%'C(+C8A!DA@-M M;LVCSMALNICG.M5(%O#CL"1[TA;XQ+(H\.K86* (J6;7Q-)EJ*)E,"7;/(E762[T,$GZ&L B$=H/GUWDA)E]8;3#TV]PB MC&[F**/4']5PVS B,LU:D)VV)&7$R(9=-&ZDI(E%Z:W)\Q<$VU$QE_H?@>X%BM;M"SUZ:VF9&N?%)]'O=P[IE70.Q)=VS>0%)V)4 M&.OU7P$Q()IM(WZ,]4^BU^G'Y]<22BF0QO)U].YU$OZ_-P14DS5^3&00GW?5 MN$E_4RC^>AB?9#/7S(<2*YLB&S)$AOSEJ$*$. H!F&*X&Z9+LQDON#BNPQB+ M]U)?80=(GV-U5H7N/D)$BL(9"EMAJ@ 3+[ 0$@DP3FT065.U$ 6SAYM!S2B.]"R[36;S-D M'(77_AL;EQOP%D8D$6<^N"F)6V\W (\94QT)BJ)EF%'#RI9 !D2I\'O%M9\5>K Q*D7\T@;O M>.!;S:#-L-P_/F#U0 ,6O"0V3\XPL+^X1"4 M YR_33?I':+$X(VX.5BU-6=B*VIO8O8BCW-"FJ63TFZC"TZHVZZ^VS#U#CU[.^^Q(S4_B4/.N$.P^HC!XOG58PYM#<,Q9=XP/C]N M2233,:%#;V.97XX*!A%^#=\W^0-?<,%.([11$JE^VYR00X-V3^*M)?D>110? MD\616$OSUFS_@/[6N-"5"I?R6^IMU\@/H.U/\;E"F[+OI_C\MFSZ-5N\T^7] MARHR"@$Q7K+,&C2L!";; 7C>[IUD=.$#7BN$>[]YN@6.F?DWVF<(S6CM*" M.I_*,Q;$=G(;[(\0_0"=G4CB!5,XBJ@E; ZE?#FP@D=SY!*LJTWL,%""YC)' MCT$58R+3QA/4%5%N0.RLLC+VB*@NS9D ,X%5?9<3T,;P\:S)PT")6S1EXW&5 MELT08,KN(1Y*/A%T-ET$=ELWJH6R4[XWIC,*(C%[K7A M6S2K=)B>8"O:Y^%6*!CUP)LYW\^B^_&FX)\SA;.XI068GQC 0AP0@^;"_OR_ M4$L#!!0 ( !>'GE('J>HQN1, "\Y 9 >&PO=V]R:W-H965T !2+^Z<_Q(6QG3J MZ[)IP\N#1=>MGA\?AVIAECJ,W')R/6"GWWPKUZXOFML:SYX%?KE4OO[UZ9Q=R\/3@_2@X]VONCHP?&K%RL] M-S>F^[SZX/'7<9ZEMDO3!NM:Y/+D&!I6_FI MOT8[?,\+D_C"A.66A5C*GW6G7[WP[DYY&HW9Z!=6E=^&<+:E3;GI/#ZU>*][ M=3I6KW6P0;F9^N!-,&VGQ5QMK3X'0\_?A,Y"?Q-^9.CA!]?8RIIP].*X@Z"T MW'$5A7HM0DUV"'6F?G%MMPCJ35N;>OW]8RB8M9PD+5]/]D[XB_9C=78Z4I.3 MR>F>^5U8VZP4,# MI^Z"^M?5-'0>;OGO/1(]R1(]88G.=DCTT53&WNII8\)(??*Z-BS(^VYAO+JJ M*M?3DF742%TU"$A(911"6_WL^FDWZYL\=J1X ^_5O^+/3^9KIUXWKOKR[VT[ MNE<\@I;G8:4K\_)@1;;QM^;@U3M$^]-5B,#@H[3'4M8]MVQF(T:FIT=ZV\S&M56$;;0US#=]8:8RJ M,1^%?JVPG;0 M; 2]E"%VAC4:@BX]M8WM[A7BKG6J<>V<)=3!M9CA7NE \]=%/MW2,Q,"2P7G MNX6*K@]J!H&=Q]QMU?0UM%8+"WSQMH(6C0L0C".79(+K?@5?BVTO:+^A,-MA;VUM"^ X%)1P"=]R1M;6[DQ\>L3VP41SX^9>KQ9X M&T&10SW-/U;7"XW-8D7(#'K-V^OD[5G,.R@.C?$I#02 XKVE;1K:@J/GZM/" M&[.&BPJH!O].L$;_G0"A&UY#DV_/;=O2;D$L,KFKU2-U^FQ\B1^3D_$$,.5N M+:?70PHTZ OUQ(BT_5BB@FO9CO>-,/UD?'%$_U\>J=^\[*;VX.%YQL/SO7@(G&UK>"SI6/=PL=^T M][KM[G\4U_8NLQW7 %WLIJJC.]@%&7^Z.V*?2L9"R.'(&T@=XO?*_&4 M'PW__4L1GX+_[%Q-7=5N17[QKHWF)ZN/>,<+)QR\GF +5-L1>AV^O;IY?82X M##UFV3KP\XI<3QU>W7P^4K^Z,2_Q^.3)2!V\U15Y6 ._OQH8K)5 M'VD&_(DZA^*]B/;1K)SG!0\_N15"_?+)Y=$!A;+">DB-\ G EX*66"/B0VU9 M=^$1E5D)BV#@6JV:>YKMKU=7'X@?@$6U05[ MU^\_'M&')"F1I(BO%64C8"<'^M)THXB3C5U:FK'@I6"?4V!0@H$KUU%FA^S3 M'G#4,O$HAJ9Y#IW/N$C/Z#63[7BT*:S/AIQE0_IDR'$V'L!6)D%92I$,X<1' M3BGM.M >UH9 $)ZO[A:&D9'(+.TD&R)O_;P'"-($0D*!GH[6 MF5+-N*9UA%V\W[JN< W,NM!DBIP(E5VN2 6W-PT4(Y>$,*:(^[MN>^WOAS&' M:,K!!&$D5@^L&+'EVGW;W'14(R9I3T]T9.(9$P!FP\UU[:R+5_<__N)R< M3GYZ@P0/U+LQ4(X3Q2@//]L]_!?8$VY)5OX[C-6I?V(,Z#S>IF:O>HSHR M[/D9&>B#)8(35A"^U& G6E8]1:87-R/:,-@3NUP">> $'!*WFO*I%BP7\&+ MBM0YC(=RC]>L"2+F-DPZHA!H(99BG&U_9 "YF!=W9U*)SR*X(*DFS3K.@%#1D$MZ7+;L' MUJ:MCX6T2/G_$L 9]R8GI\]V1?#IL\<$F ,WBC58PU.]1L+GE S\D39>%V+&]" H4RU%6_=O>][R/+6?=]# M )]F OCT&ZQ,JID93$W-.Q) XD M1">!9ALZW(QR BV4W*&R ;;13WG#Q-AHB5_E';X1F/ M"9WO8_RL6:% $)LA56=AH^)CB.&,,*,L,9/W7!/E6UK:PR0HX402E3Q[,*ET MH;B7E7(*.UE([L#0)KSTSD0$H3FD5\-(CT"4XDG2!1+%UI6E[J5T329R TUY MX4JWJ?#+C3!$\92B/C6W\K3<,\S&%X@@0EFJ[W4 1<#4U(9J(3SV@X](F !- M&SN7^$>=_[@F(_#S)GRFO;7R1EDJ- @V_9678[YL\'F2Z8E?9"#6)3KW-S67VI M[S/CH38,^GI.U!.AIE)/!!'<1WF(O)=;,*=A]08.R^SH$5UF&/8[ MTA :,* ^UP]:55FHM76H&4X. -UG8H3851J@#^_>U+!A&/6DZP)/ (12'^FX MT5.'YZ2J:6\MJN9B[#197C([1<7;&XL6:G@,:IN4=(O\U'7QM=0K@%%NP^\2 MEKIMG#N97S*'*(B6.UWB:QOQ]GO$+@1G.@,"H<"\C*9Q3P8"#E5CFM-Q8XP; M)_/4I9 5DF-N\PKA0S4H#/5M'VJ_U9(L<@R&W9"UEL/8R4N10.WP2OJ[E8[8 MLKZP:Q%FHOLV%]2A3+F196PK'4DVX>:T0V^51B;^6W'5%*?,RRWB@]1DPUPU MS!@CMI>$2O9Q4W9Y LU.=< S!EFB"]WFUSKUD/\!?1AE,QI:@X M>39"_#O.#YHZZ"MO[26/J&>=&XCQ(V[^\G%#;%MG;H&/4093:40;2:QNQ"IE-4=DII-V[J _FHO"-6&H_<('>Y2O>5$4-6;#XDK/O8GU,=6/Y+WU M8[J4<;\CJL?J+1&6 <9( *7L: \IVFFI-8\WNEKL$*2<*HC0NJ$3C !N M2V'&T\5N4:Q&^R!SEC84&V+GR^Q1:5,&PI?]@+1KI[F#;DB<@KV&6Q1QGB'5 MY5IG2@TA/J,HW$+$QA1TO25U-_B,IO?Q=)H3"Q^2V!"K06J@#B@7LX- M:RD M\16=P-$Q<),L(IQ5N@B<8?L='&K$K*$T;])BSN?@CB68I#NJ*+E0(4J8!!H/ MCN%S3W%X(,*VJG18I)/P[-&T G<3B#)0^J]OQ1G$(@/_X$5JQ_)2CZ9QL3D; M6Q S$)X ]PFHM>N=%'#F_&:A0WU(8(=-K6DFV(UIY_AL<'A&0H)D1SJ\=J)/ M,'.?XI_/C,G$PQ/?H;D*@=G.:AV?;]Q.M3E$\V]O=KJ>>OH#!U+UQ ?6DJE$>-.\FMJ M\.>D.6!.0C-A^7XIER4.O2P:CM9Y/W>$:=N8& TZPL$,!2-VS>DP@1(E7^!F MBTULZ6.#S ]V5F !^+DT\^,$*"SJ?0VW+:)&7B&;EBRE4(N^9?$1OM]2> M6$([Z)$Z5)2 9?FJ 0DI!)B!;UM/%;]X!UPBTC?H5790M/:BAP! MW(:!NASHE(523<>A'UL&/(YXPRV3ANGPT(*QD3/S8!8[6Z=#S +R=9NT"?RF M-%]E2V5&29!;%F7S9F++5DKG]#^R; +TK4MGZ/E.G>E8*TZ8)3H:BM2F-FE: M+IH[SB1TC)A[4U:YEE8V18"EE!4/]0DD=T=62-Z?4M5@E7B0!W0V9B \E#UV M3%;A$T.S%[&'-[7XM*W%7)5A_R'&HKAP"@OGN_1N-*&7\X,-'Z:R@O-^.E6, MW'ZK:X[57W/7Z&&!EY)=4KNX1SH<*0JG X/-!G\L0.3F6KS:D.O;/FR!3 )H MY!\OHD,;.HV:G/PD.AHY5^ CJLGI3T)3)FP6#U)E#V;[NYM?)29G%2.MY$:[J:5":36 MF@8/IG:[4%)T,^Q)"SG[AAW&YHS(^M5_;B>]?< M^,&V8YU[^<)O%='FS&4IF34\G#AV)N@+L?-X-E(U#$ZX/9:^!L%+(G<GC#+>R^V[;VZ&1$D;>2$T^*TA3.^2J?IAO:GK?@ M5]/% N;/W!J\+C0^=.&YN@K14=RPF42$=2[KM1%2T]Q4%_ M)R1@]5W\SD"B&W(P7QH*#^O13X-+DXD.2SN!KT4T464F-I*A(E,DL[34NHXF MH8MJE!VQ:W.OE^O0.+R&>2,Y,]\YE8$U12=]78$G20;X,Y;^V8843S&'1A]] MSNE9[C-R?1 [,NQQ(49_;.'491*S>1L;3TN?J41;A*UAY;Y!E!XV>_[DKD%W7 ^/3T=/U&?6Z:1_)V0H"9/Z=ED\FQ\ M'F^@'A;IKW6K:\U[\0_",'6%\(9K'JFSR_&E.CL?GZA/''=MCH-'ZNGD@N]O MGF/J"V$_#ZP_L.MV0^9VV?_,EJ-T<;ZT&XP0JP 1"CW[EH"[7D_P'_$INN9- M'/2NE2^P"<5V74MW, Z)8?]*OYV>'-'A9"3'VDOZ@!?)W)%_]-U!+ P04 " 7AYY2?68DJWH$ #Q"@ M&0 'AL+W=O)"?-?OTH.76:@S;H]K 7V[J0_$A^ MI#G9:O-L&O 5D7!S&Z!4F^GK;CUNG$GLMSYC&5IU&2RH*5%9H!0;7T]8\OEH,_/UPX0^!6_OF&[PG*ZV?_>+W=-KJ M>D HD3NO@=%K@TN4TBLB&'_M=;8:DU[P[?>K]J_!=_)EQ2PNM7P2JP8%98T&NX-6A1 M.5:'2Z7P:-'O7ULGR'^T_^;J^0-;2;3M2<<13&^LP_>0%C6DY -(/?BFE]I$HK2S\.=\99TA4OXX@>BR0709$/4^ M0'2'&U05PMKH JY?'!I%UI:!/F@LK';P*^K,L#(7'.94O00@) @>\,7!0FK^ M_..]5)VTZSO&E2T9QVFK]$Z;#;9F#SD!T9+*7:@,7+!2UB$A[E2&:CF@M9 * MR[+,8$9123W([ "2=GWX?,6E)$ZL,D+N@+8\37C]NJKIYS]+H].*.]#4 M>@B0X CG0E'M2$D"MGT%#[E!/"(9$$5XWG#$/[IP71GJ?7 &R>4P&M(['O?I M/;>"03P816.(XSBZA$V!/G)#()07%8^'Q2: M.GB\,H:(?2JVR+\3VXNA9DQ2-2*$GFDC6.9, M9=YTX.;V9V@[XK()^ER@3>%I R6E3:> [Y''PPL$VB*Y1)56%X/]CS1<[/$R M!RNJ":5\55'B]A#.8!S(,2;J4"XW(OPN/>;&E818&Q-=Y]Q51*UFGVM+%7F> M1(.V?P[;;VV1:S]9&=-S%"6G"#AH"#@X2< YY[KR[> ..8J-I]D%S'V4@GF/ M?FDP%0YNM/ULJSII\GTBUKFWK\EG1PA27:WS1_D\)C>N,)ET*]B&E MYP:YWJ#9M0,Z?"EIL/'DK@,E*5#^M]L-V>Q&HS8\&6I,7_1Z;8'GS&1TF64T MIUD7^'SPMA'JGZ1 /*+V$U[C=TG0>3.&4%_+PK!%MGWPZHFDV6WFN7D]QARN MU\,@Q8TB8T'BFD2[T9"ZC*D'K'KA=!F&FI5V](\+GSG-I&C\!3I?:^U>%]Y M,^7._@%02P,$% @ %X>>4@A/<1@*"@ ]"8 !D !X;"]W;W)K&ULU5I9<^.X$?XK*,5)V542&:FC*U4@EDM'0+-I$(]>V_=&&\GAP M0;UBLN(B)9,OKP:US>3_'^6;"SYQM5>6=H"0+(9ZP\4-X/;"1(1:Q M0.,.%![/[)Y%$6X$;/R>[SDH2>+"ZGNQ^WLC.\BRH(K=B^@7'NKU]6 V("%; MTC32G\7V'RR79X+[!2)2YI=L\[GV@ 2ITF*3+P8.-CS.GO0EU\,Q"]Q\@7OL M B]?X!E!,\Z,6&^IIC=74FR)Q-FP&[X8W9C5( V/\10?M811#NOTC3LD[RF7 MY&<:I8P\,*I2R>"4M"+G7^@B8NKB:J2!$$X?!?FF=]FF[H%-/?(@8KU6Y%T< MLK"^?@0,EERZ!9=W;N^&#U0.B>=8Q+5=IX.?^^.7VSWL>*72/+/?Y,!^%8V] MY2J(!"I-D5]O%TI+,,S?>FB,2QIC0\,[0.,M6VCRR()46$0CP8J6)6!*]9F0I(@ #'J_(.8_!2*,('%1=7!+0>[ NSXW<;H34_%\L M)%]C0)RH^7J+V] X %4"67(O6<@U^2B4@AZC\\#VE2I-G)&'-\>>O@Y,]CNZ_!Q2%;BF^0<:%^4RZ?.<$8 O@"VW\ MB]!P5&>&J1D\D:VSG+'JX2)S'NG"C._G%V]9P#8+.(4"D_XSUWBG-(<+#:9] MDW]X]G""BH*S/6NI&L>]P]XQ,=[AMKUC IV'CMZ;P(EU>8?GP\$>XQUCX-7M M(#OUPB:/,7=&!JZBQY7K= MGM8E82\CW1)^J>$05X06 3NRV&+C$,\T#@VD4:5$P W65(3MO_8_,MA2KVE, M')=LLL#P Q 3VAV9R;[EJE \L0VQO6MK>M#](A.@S52I7%/H5L5H[LMY<+.E!BY@_FTB M>01&(T6Z6I-_IC'+9FL!5A)%);E,$\'NDOPHT(S@9#)+Q7@ 0?YKW<+-B8Q/ M)YJDP#0DD4<1GF @4B&\@AR; !;D#!0FTF,6L](L9L="$BT#BT! 9()^S,IP MH8Y7S=!@L2M/*P4Y,I7H'0EA;9B9.5<3WX6J& MVW=>F05$6;9E9:(W!ZL=8]#4#'R[ MR:U7G7Z@!6Y<9&]?\HP(3S MCBXSZ"72;0;O>0RQ+0>Q*,9"V7435>*'@ (Y1&-=/7.H,(*/$E[@D:1T-;!L;M+71L<1-]8^-/5K[U_X!O. 1"@. M3&)*Y]B5F-C!G@"V:+J7>Y MO8.MS^#$D@?:Z'\?@YPO+H@/5MTB WWO8&OPTXISGP<7P+HU<<<=G)4#_3E; M7VY4;N5751 BSK=0FG$2%B&^,/ "^T!U-*@$ N2X#.5QU M]R[X[DI>_'WFT@W?6,><3*HPX;E@);WP/>V [^D!^)Y;$T" =L&DZ/\O@+!8VP_$S,/XUJ:%S] HT2=9+X30(1'HJO5>* M!>U;Y0!K6 3U\]_,(:NC#KB$4RGE9':&X(50U0:P/X.@W15_9'MLBKX0H(^[ M1+6ML0%_ %IW[X9G^[#YK,1@3-)SGP#FC#'F-TN>>L)C^)=P4ZXMQ=3_S+&M81&(%FD^3).)85!5&[0LN]J,6 M28#>!A+O5/. 1A;![T'PS;"X%"(T+PL(HB0U1QVFZ$,,G/V73%J: -474P>! M(_"F?RV*-*7L(M6@Q3A$!=3U< ZX"HZ"/5J:0'&7#UT8NNZLW*U44K>.NG+Z MH;FE7OEW[D_MKME_J&?Y/T5MARW^\"FK/R9Q*OZZP0OVB(L,F*5Q=L,2$ZN: M#VD::A&&=E%+SJ_C$R^'Y='LE'?>[EB.JI?DB6S!57SPGM[SP=5W-Y.?#DI\ M9C+>[#>;%97_*E;G->TE"Q/PMZM2.*I\0 2YS\I\5X7_9X.HV5>4JHGC&ULO5=M;]LV$/XK!RT8;""1 M]2XYY MN^=.S&PCU6==4VK@J>%"7WBU,>WY9*++FC9$^[*E M\LI6J(P5NUFNA645(Y MHX9/HB#()@UAPKN\4Z'73$/5\1;G<7'BAMWMPSU:UL0\F ME[.6K.A[:GYO[Q3>37HO%6NHT$P*4'1YXUTC$-5@)*QV#!;/H.D* M16^.Y7G0GVW?<]V2DEYXV)^:JD?J_0,(;"A&130L)$$U&B2S232\!BE'5?#9?"&UK29H&:V3X-SE\$%>6Y M/X4XF?H19%'NAS ORW6SYL30"EC3$J8<,\RX1I!1$OK%&$;1-/83O,9QZD?C MWM\I"!Q<)Q#%&;HZ@33U"WL[#1%EH$9I7Z-TL$;O<0A6:]0"1LHJY,66S/8! MM&L,&Z2.587]U;.^H8K*" MT3,E2H_A;LOPH/J_8BFOWTFQ!TK\!F%:U-MG/V^^^**(Q^ M ,MXA#_C_DG7?KM:G=E:'2MP.K6LL6]"/\88"DOR5IQAS-BT&JR67 EMZ:LN M):[A+)D=E%UW<$-2.H$LB%W;[="P-MAYQ=<3X/_621HZG608A]5);G-LQP*F M>4\G>8I\[1[426K'2Q1BLH9UDOA!@/N*3B>Y+5"(P0?[.LECJQ-T&^?.:_&E M3@H!^(Z\U3:TL$']U9!A[HDX$K+LO/ MGX[-YT'' MGE+"87-T< 0 /<) 9 >&PO=V]R:W-H965TW01!'R21%&?FS)D+>?JDS8,M$!T\EZJRLT[A7'TR&-BLP%+82-=8T9^E M-J5P-#6K@:T-BMP+E6J0#(='@U+(JC,_]6LW9GZJ&Z=DA3<&;%.6PJS/4>FG M62?N;!=NY:IPO#"8G]9BA7?H_JAO#,T&K99<0+5(H5$8RO&YV=UB0+[HZWVC]Z MW\F7A;!XH=5?,G?%K'/<@1R7HE'N5C_]BAM_QJPOT\KZ-SQM]@X[D#76Z7(C M3 A*686O>-[P\!Z!9".0>-S!D$=Y*9R8GQK]!(9WDS8>>%>]-(&3%0?ESAGZ M*TG.S4<1W#5UK9"(=D+!A; %?*10P5450L[,C5IC(V\L? M* 2]? ?Q9-SS#O?X[.!SARX\B\*9-+OT36XL,9QVJ;8OF$3OS^P*I[C)= M95+)D @$J:).(:M,EPA.^UG&(&NC'R5%#Q9KH)9A:'^U"D4GG228TH*PL-2* MO+'0E16ELU*DU/9.X+XPB'M9 !3#K&B#N#\=PO4+B@.83B;1B+Y'Q^-H"F?Y M/U0W(3"$<.L!_E_D)W")1$JVH4!4.8A2&R?_#0MI$DT@3:,CN*6XA69#WCEB M+Q/&K+VV4C>58_H,MXF^7O8;BT2(14(YC8[I.8*[0ACL_$XH3-\5HNH[+&MMJ/&" M+&LA#1,$E$,6O4)9/6)@#88$Y^>?CI,X^04N2'3%T:M@24+4>LP#$?'\63*QKO'R22:]."WULBWJ)?RF5S=L#",4GKB[TRVMBB.'!J& M2$-+,3.!GBW8X/F-6(?@4__:":A"XA4HD1>4S0'I-)KV^)WV*,29\1LDGQ09 M1\MRZJ!\]-45$[@D2E[V40*'48]%F+W*:<-JQT1?-T[9\ZOJ1:OF4%!+-X8= MV/C<32?1V&,8OX*A%FL/@--N7\6>*Z.1UY.,HZ-]L]N$%\_XHHSB0NX,J5AV MM])AAJ0ZWY=))B-R*)[$]/[>'Z6)6H>FW(,S2EED3 GK$Y #,]FFY/6[.\8! MY3V7%15V0OJN==7W@B%5ORW2FX8:A"\=4DSJW/H0:B68:Z*.\[3VV7T (\)% M.J/ACDS(:T_.3BZSY$MA,*)MJAT 5_V/NOU@YS NT:S\E<."#VBBX(<%W'GE)E$)LPC ( % % 9 >&PO=V]R M:W-H965T9)N.AU=0=1-F_9!I_0_F@?-%G1P%+R!J7A2H+& M:A%<);/EQ/E[AY\S I*#ALE_9^ZX.!X#+^ @@W0%2K[L/Y%6NF&797*LM:.=-;&[C M4_5H$L>E^RE/5M,M)YS-IB'<*;GYLD;=P IS"V=KE@LTHWEDB=]Y1<6.:]ES MI4>XQG"OI*T-?),EEO_C(](UB$OWXI;I2<)[ID,8)Y\AC=/D!-]X2';L^:9' M^'Q^*VX*H4RG$9ZOB@1GN"./S:\XSAH_\1'71Y@WKC9YG"J$[:ON&'T^&YN.JGY)][_]90BALN M#>52$30.+ZAC=#^_O6%5ZVO)0.P>ZKY2R>\,%&![1["]02P,$ M% @ %X>>4CR]9^C5 P ;PH !D !X;"]W;W)K&ULY599;^,V$/XKA%H4,K#103L^4MM G+9HBMTV2-+V8;$/M#2RV/!P M22I.^NL[I&2M@R:&>[SUQ>(QQS5Z!T+M%E$?[@UN^J9T_2)?S+=O ';B?MS<&=VEOI>02E.5:$0/5(KK,+U8C M+Q\$?N&PLP=KXB-9:_W@-]?E(LH\(!!0.&^!X><1KD (;PAA_-[9C'J77O%P MO;?^78@=8UDS"U=:_,I+5R^B:41*J%@CW*W>?0]=/.?>7J&%#;]DU\EF$2D: MZ[3LE!&!Y*K]LJ,[]E:@!W, M4X<(O9^TZ-"L6C3T#31#\D$K5UORK2JA?*F?8F1]>'0?WHH>-?B!F80,\W>$ M9C0_8F_8IVL8[)V_8>\6"L&LY14O6;?D;%@E9Z@A2GNCJU"1]?(^FR;4# M:3\= 3;J@8T"L.$;P.[PM9:-@+^!('ZOK1V0CZ%:Y!Z>'%D)73Q\>JUNQ[T? M>M3!8_'"(V\]XD)[5/B"C %5/!-GF+*BK1GK:V9[ MP1;U5EMW!G(K]',HZ1H45!S%#E5^Q%;9*.R @O^!:&LM2@]F@QT0,:+Y1\:% MS^D9]LPSRX0/_!'VZO?:,8'=Z*2,Q2+4:-5F!'&$+/S 5(,=E'2\OB!?$CJ; M)F/\QG2<9 -G8X]$:@J M;-XV'*/ L!7PXB=$I" \1]Z;@RZ8H0]FYH,9=\%D?\DP]HVB[AN'3_ 4%4-^ M1QXH[A.*O^,I OH_D2WSN8@GR*I!R 9-J%],0C;BZ<2?_RNZC:GG5H;V]O3P M1Y/_E&Y#SR8$VI+N5<+- @2\1Z[0?TPW1)[Y8"8=?>-Q(-TQLK4)SH>C?8;S MY-POQ@C)7XQF:/*U/XST8 B08#9AU/'=$[/6S@/]:3]-7;9#Q&?Q=A1#0!O/ M+P$5JB)\_#LT[7C3;IS>AI%BK1T.*&%9XT0(Q@O@?:6UVV^\@W[&7/X)4$L# M!!0 ( !>'GE*X/5HNX0( ,L& 9 >&PO=V]R:W-H965T/)M%'ZR12(%EY*(JMH)+7&DP=5DR_;I$ MH9I9, IV&P]\6UBW$06W[)9$#E"*#"U#H'1\(PW*(0#(AI_.LR@3^D"W\]WZ%^\ M=M*R809OE/C),UO,@JL ,LQ9+>R#:KYBI^?"X:5*&/^%IO.- DAK8U79!1.# MDLMV9"_=.?Q+0-P%Q)YWF\BSO&66S:=:-:"=-Z&YB9?JHXD76P HUK NF$4X>V4:@.9V&EG(XSS#M\)8M7GP +X%[)6UAX$YF MF'V,#XE;3S#>$5S&1P'OF1Y",AI ',6C(WA)+SCQ>!<'\/:H_;78&*NI/GX? MP3_O\<\]?G( ?TW/)JL%@LJA\36!V1E[1DTE#JDJ2RI%X](:H#=B+),9T8': M8 960D(N^,^V[O*'G7 M 2:F8BG. GKB!O4S!O-'@M\I@9T269<;8D$B_[>FP5%-9& 6W*WA2RIJJC'( MM2J]_V',GH)O!+1F!G(EJ",9..&2HE5M**TYG7,6)'\87<)?GU)#/%)-%@=#7VP_48%ON.EDB.8]CW!L)W#:9$ MO?5MU%"&6MJVU_2[?:=>M WJS;UM\W266T[2!.84&@TOZ:'JMG6V"ZLJWZXV MRE+S\]."_C:HG0/9'GE(#%-&PO=V]R:W-H965T 2;S28==,P_6>!0FUFT3#:'MSR56W=03J?MFR% M=VB_M3>:=FF/4O(&I>%*@L9J%IT/SQ9CY^\=OG/HG_RN5,N2V;P0HD?O+3U+)I$4&+% MUL+>JLUG[/(Y<7B%$L:OL F^XRR"8FVL:KI@4M!P&;[LJ:O#3L!D7T#>!>1> M=R#R*C\RR^93K3:@G3>A.<.GZJ-)')?N4NZLIK^%RN@#Q;)5%:X^+H,0E!?6'B,[BO->*+&P.J=U'W!7=+1M6RJ-%87R\N'\FD M]K3;E-["8#A)1K$S\F02PQ?20H-"\+\$N*(!88#Z\#F0=&3),';K. [/\-C6 M3!Y;)*6:9@3PIF5<>Q:AS'_QD"43>/=FD@_S#]TK[NKP7)@LR3N6EQ4+E7*2 M3QTY&2.2_MJ-ISO-U:!>^1%BJ)IK:4.?]:?]E#H/S?GL'D8<%77EJB"PHM L M.:77J'GE(\]4@+@0, "P( 9 >&PO=V]R:W-H965TXVL\$ZUB-(XGD0UXS)8SOW<@U[.U<$*+O%!@SG4-=.O*Q3JN B2 MH)MXY+O*NHEH.=^S'3ZA_6?_H&D4]2@%KU$:KB1H+!?!?7*W&CM[;_"5X]&< M]<'M9*O4LQM\+!9![ BAP-PZ!$;-"ZY1" =$-'ZVF$$?TCF>]SOTO_S>:2]; M9G"MQ#=>V&H1S (HL&0'81_5\6]L]^,)YDH8_X5C:QL'D!^,577K3 QJ+IN6 MG=H\O,F\AQZ41YLII6.?G991*' M\(0[2K.%C[(1V66KFWO$O=*6RQW<;-A6H!G,(TMQG7>4MS%638STC1@9?%;2 M5@;^E 46O_I'Q+^ V\WS?[_7YK MK*:2^7$%?M3#CSQ\]A8\G:3B(!!4>2&O9UD?PO:UM_CN\PT;/%E8"94__[B4 M^:N1W8F^,WN6XR*@(VM0OV"P/)=9XX[IPM&@8ZZ9)V0: @;(#&R%]-.(4#<: MHM,02(&\ZB4 )@O7B8$;8,Y1T&$W<,,EU:P0%,D,[N 3+Q'6Q)'G3, 7@M;] M;B7=/X91?36 'R";3,*Q:\\QO@_]7C9=A4_\>;)6EU\5W*WK.43L#6B^5LMW !>C_("S_!5!+ M P04 " 7AYY2_Q,LBP,# !%!@ &0 'AL+W=OYY[:#[G^<[8!U_&+N>F(R4UWEAP7=,( MNU^A,KM%E$7'C5NYK?"+ZW(1I;X@5%B01Q \/.(:E?) 7,:/ V8T4/K$T_D1 M_4/0SEHVPN':J#]E2?4BFD908B4Z1;=F]Q$/>B8>KS#*A2_L^M@),Q:=(],< MDGG=2-V/XNEP#R<)T_2%A/R0D(>Z>Z)0Y94@L9Q;LP/KHQG-3X+4D,W%2>U_ ME#NR?"HYCY99'L,M.K)=09V5>@MKX\C!V;W8*'3G\X28Q<P/NO M7!"Z]+> ]A'AVR>.AVO"QGU_A6T\L(T#V^A_L?5$2A"6AXO^%BX:[O&)8*5, M\?#]N2M_E<,;=^9:4> B8F<&&='ROD:HC&+7>6(*++WUY$]T0'P<+"%I#Z8" MTUEXWUEVN_!N8YL++7\*ZLUWJN' X!B=W8V/:(4N$,ZDY@>J%">X\QE\DA7" M72'1GZVY8ED(!5=2;#7KEH6#>T.\LQ+*ISL0SI=QA04V&[3''SR=P2_PZYMI MGN5_/#M;U\)N^3;) #YQJW((OP,VK3)[1""T;)I>Q08U5I*OG-_\6[C(XTNX MG,07L!:NAE;LN=7XAY_&V3F<9?%;_N9Q>@[L?O:V9C=:RVKV0"S8J1YTRWTO M)(V/X?SE^;]D\1LNZN$1>TU\G"9Q3D\]]J2$VLWR$I] W-0F$Y3 M[_)A=^B1[_K6\'=XWV"YAJTO5F'%J6E\R0:Q?=/J%V3:T"@VAKCMA&G-?1ZM M#^#SRA@Z+CS!\,^Q_ M02P,$% @ %X>>4I6*0,*!!0 N0\ !D !X M;"]W;W)K&ULI5=M;]LV$/XK!R\=8B"Q+9&JAPT+BY:E\'D:L3SW81_)*Y,XQW8DIE27[GS;G[1ZK%" MF&)L&4'0XQ&O,4T9B-3X5F&V:I&\L/F^1K]QMI,M,V'P6J6?Y-PF%ZUQ"^:X M$&5J[]3J+ZSL&3!>K%+C6EA5*K\\)H%8;4@='I[ M04[+M\**Z;E6*] \F]#XQ9GJ5I-R,N>@W%M-HY+6V6D0=> ]DED&CA_$+$73 M/N]: N;A;ER!7'F0\ <@$7Q0N4T,_)G/<;ZYODL*U5J%:ZVNPH. 'X3N0!2< M0-@+@P-X46UEY/ &+UOY^7)FK"8R?#F VZ]Q^PXW^@&NPSR!:V4L?';N@P=\ MLG"5JOCKEWV./(SWD"#$*BM4CKDUH!:0L@3 )TI">JY0(P@#"Y52-E'(9$ZD M2%/BMVE/X"'1B!NQ /)DG-2NY*8''PO4PLI\6:''K/X1!$%GQ(^P,X0;F8L\ MQL:$"5QF2EOYGW#91*II)ORI6IR6AI4R2!H?0:\35.V[W)*Z!$W3/4XJQ4RF MTDJ*0Z\3NO^#LB*%Q8X\!Q)5[7TY\R,R)_>@^SJJ6O:9J$+N03*C*%*DDL8F7PN3P V%D1SEBRO[]74L.BB-Z_C$%"+&BQ85:H/Z$5O3 M#=DQRUZP;-F0K3$5ECA#/DA]LJR(:[],-V=H(>3!J&-)_/8/_H'%F[0KLG>L,J 5RX*JZ5W M>U)"S2SMC=Y0?(H3D2_1>8*X59FI9JE#KL.;K\"!?/PA;:I^G'Q>^JI#_HM!,55;[+<:8S5 [NGZWIK)@RR!'YV.*'Y&69S%EK>-_YOF/ M>_C?IJA$ U?%@DZ//X40C:F\!O2->A%$(?$SH/!2KP_AT/5U3A MZ+RUH!(&9SU>W2] PKQG+D-(^P[A#,JBUQR0&9%:1WUJE)\3.+';3@> M=Z)V!7%$TD:$6B7+ ?:,:O:,?KK:78G4N?/>G31_ON(=EK@A:E:)\H?:7REP M6]5L@S!;.VE%D^VM=?\>&9P-7483!H7WNM3:5;VMM4U:$X_.'(^B86>P(Z4Y M,QA2;"$8#9@X+L"'<=?!#RGZP^WR(C1N%.I;S6#V^00*\K%UF8_?2EFPZT]J M2[+-)%7Y\M3MOW.]'[K6XZNZL>[ #\;DJV\?4'CI5;&^$-/N'XP?2=T M78C+K/1\F2,5H%AZ$C&":!Z%CLG5;6Y[[9?$L9E','*;S(A$O<9A#B-7EL8H MSUVN\&8SJ-K7>Y+VCS/.\=[>,]NDNC0:<,'^SJK_6]])+?QW[/MU?:LEW2TG'RA07M)2. MJW1RT_ZBZ#M6%>YR-E.6KGKN-:&[-6J>0.,+19&O.BR@OJU/_P=02P,$% M @ %X>>4L'7NR9E!0 -A4 !D !X;"]W;W)K&ULS5A=;]LV%/TKA-%A+=#&(O5=. 8$E&^]^K<#YU#]9LR@I[(0^GRP-F;S<3C4V9J5 M5)_)#1/PRU*JDAI8JM50;Q2C>>U4%D/B>=&PI%P,QJ/ZWK4:C^36%%RP:X7T MMBRI^GG!"OEX/L"#YQLW?+4VU8WA>+2A*[9@YFYSK6 U;*/DO&1"]=HRJ5>RF_5XO+_'S@58A8P3)3A:#P[X%-65%4D0#' MCR;HH'UFY;A__1S]4YT\)'-/-9O*XB^>F_7Y(!F@G"WIMC W\O$/UB045O$R M6>CZ+WIL;+T!RK;:R+)Q!@0E%[O_]*DIQ)X#Q.EW((T#.78(3CCXC8/_4H>@ M<0A>ZA V#G7JPUWN=>%FU-#Q2,E'I"IKB%9=U-6OO:%>7%2#LC *?N7@9\;X M#%U0S3622W2MF&;"T%T'18[N-*ONS[7AT!*FT5>UHH+_4UN\1U,IM"QXWCD< M1 #/3UQ0D7%:H 7<9#!@1J.W,V8H+_0[] '=+6;H[9MWZ WB MVNY59#&#T: M&DBM CC,FC0N=FF0$VGXZ$H*L]9H+G*6'_H/H21M7VF9AC*,@:,T. MD(4MLM");"JUJ:JPDC+7"$J5]T'W,*+G?!N*H(0 (]1 M);A8]?8XMO!ACP10G*,NSVS#E$2)ATD_R*0%F3A!3K)L6VX+F.\<2;-F"F6R M!+%>5RKZP% A=2_NQ*YK$OC!$6C;BB20W8F^IRWFU(GY5AIX*4%4LN]KF$NF M].^(_=AR\[,/:6KU%GN1EWKA\9#:AA%)?2\^LINE=B>2.$V#HZ&:V_'". R] M,.[/'GN=V'F_&*QZW-&D*&2VHZMKIC+@)W0KT6<&.PXT+W:$U2M"[O#DS/-^ MZQ.+7_CYMM]A@GMJCMU#F>>\2@NZO*$\_\#%AXQN.'2]-QUL%3H(0NSAH[XU M=ON-"Z#!IU@(DPXN<<)=P 81WN_W:,4$4P"Z4A.:PSZ':Z-HM8=$[ DVQ;J7 MHIKH!V\)"9/0/YK/QNY@DE,_2D\P .YT$?N_F"<-%)6M:]PS&*Y";JKA07,' M:-\"'?OI'ALUF&VS -XI_P3D3C:Q6SJ[7LBV4.(X\.)CT'VR&Y\J:B>G M^+_I*6R2MK 6IA>JK:Q!XEG*BFUI#4AX2EIQIZW8+:[SK8+2HF]7K+QGRK45 MPYT4XN35;!!Q)W;8K7;.+2*VQ8@$<7S]NKO0\[41'U2WZ4*/'4E/)2X>712 M,L4SJE_T/G2,1^+7TXF.,XG[^\'=B<0B?S])[$;TF(7VY]=P[WP(*KRJ#^8T M?*]LA=D=B;1WV\._27WD=73_ G^<[H[PNC"[$\4KJE9<:%2P)83TSF)HAMH= MTNT61F[J4ZA[:8PLZ\LUH_ )4AG [TLIS?.B>D![5#K^%U!+ P04 " 7 MAYY2>5.#T-H" !^!P &0 'AL+W=O,R&/2\;:('/;6V@DN<:##K+&/Z?81";?M!/=@9 MGOAB:9TA&O16;(%3M,^KB:995+*D/$-IN)*@<=X/AO7;<=OY>XT'-2<(!2;6,3#Z;'",0C@BDO&[X S*)1UP?[QC?_"Q4RPS9G"L MQ M/[;(?= )(<<[6PCZI[5EIM03MO8G,#GQN/IFBX=%6< M6DU_.>'LH!["B!EN0,UAHM&@M"S/KTSAV:"SWQO+*6%HX(5IS:1]ARYEB>HB/*,(RS'@7YB@^2_C(= B-^A7$M;A>H6?\[_#:&3F-,NL-S]<\ MP?==+YCD?WRFKV!,.5*"IQ^)/Z@$5>"!2R83S@1,R8ATBJR!G\.9L9K.P:\S MBFY*13=>4>.$HK*R+$GTFHDKF.&"2\GEP@E8H>8JK2ID3MOQM*YE; ;=L%/; M?RC?F_U4YXC6/J+T.-#>++4WSVJ?:+7AOJW0EH1M$4F5V)RGN[=T'+:/Y'WV MJ8)I926RB!1QE:>BM:GM:_CL'4DL-*I7:VP72IL_V?YD;;A MV<*W*PK?/9+ZV:<3UKL'SY'N:*^59:@7OL,;RMA:VORXE];R$AGZWGED']'E MDM\%'S3YS42'F7:V 8%SHJR%;:JXSKM]/K%JY1OF3%EJOWZXI L2M7.@_W.E M[&[B%BBOW,%?4$L#!!0 ( !>'GE*G2OI)^ ( %D( 9 >&PO=V]R M:W-H965TR'V9-[XS?-DANY6Z6>S0K3PF@EI M>L'*VO5-&)IDA1DS-;5&26\62F?,TE8O0[/6R%(/RD081U$[S!B70;_K;5/= M[ZJ-%5SB5(/99!G3?X8HU+87U(,WPP-?KJPSA/WNFBUQAO9Q/=6T"\LH*<]0 M&JXD:%ST@D']9M)V_M[A!\>MV5F#RV2NU+/;?$M[0>0(H<#$N@B,'B\X0B%< M(*+QNX@9E$>&I7O: 30(H+MA'V06V_8I%/R\5+ ME##^%[:%;Q1 LC%69068&&1#3H[!-C.5T)&A@DB=I(:^ !$^0O;"Z<45"Q,9D@4-G" M2&/*+=PI8^!\C)9Q82[@"AYG8S@_NX SX!+NN1!TB.F&EG)P3,*DX#O,^<8' M^#;@7DF[,C"1*:;[^)!R+P6(WP08QD<#WC-=@T;]$N(HKE?P&9T.CRK@X^/P M,29'X9.3X?7K(V(TRFIH^'BM _&^ZR63_*^O@$L8T0TIP=/W@MBK$*J,6R[I MXCD3,",C4O^@VO@YF!NKJ0/\.L*H63)J>D:- XPJ*N[R<,55U5,>O^/CNZ[Y MTJ]W:NUN^+)[R95.U_M.XPJGZUIGWVGRV2F.:G'IM"="JQ2A]1]%N(0I:JY2 M^"83&AWT#=-WF*\NJ@3*S[[>87P5?1*HTJE3G5:[3*M]/*V]#.X4RXOLSG-V MF2#E\J2YQ2NU6%1>;ON3VA7<*YU:'[B'.STT0[WTP\N %S[O)J6UG(\#/Q8^ MV(?UFU$^YM[#Y$.7>L622P,"%Q0RJGTA474^R/*-56O?J>?*4M_WRQ7-?M3. M@=XOE+)O&W= ^6^B_P]02P,$% @ %X>>4FSA5ER $@ 7K, !D !X M;"]W;W)K&ULS5UK;YQ(%OTKR,J'1'+:5/&V'$O3 MMC,;:;(3Y3'[P9H/N%VQ4>C& ]A.5OOCMZ ?=8&JNJ1-.17-)'9SZWVH<[C MZ9/'HOQ6W3)6.]^7^:IZ;9B'TJGNE\NT_+'G.7%XYL# M[6JZS)5M56;%R2O;US<%OY/@M M];RF1!OR5\8>*_"STXSEJBB^-;^\NWYSX#9=8CE;U$T=*?_G@9VQ/&^JXAWY M9U/KP:[1IB#\>5O[VW;T?#17:<7.BOP_V75]^^8@/G"NV=?T/J\_%H__8IL1 M!4U]BR*OVK^=QTVL>^ L[JNZ6&X*\QXLL]7ZW_3[9B;&%*"; K17@# M6.Y\3J]RYKP\9W6:Y=4KY[7SY=.Y\_+%*^>%DZV<]UF><[!4)THHA.>\[Y8U;>5<[&Z9M?=\D=\0+M1T>VHSJBVPO=I.7,\3@F)DIE_DK]E2Q@/EC"Q8E$7+&INP9.I3E2ZZ4G'>RFE/H,7(]5%A9& MLU Q5D!@1'^J%N5C6EX[_%\N(U;.Q??%;;JZ8^O*)((,1NF!\FVE8!_D0&XHIH&(*J+8_ZPUD_/C.-O5U 9K0 M8);T>SL,3)+$G06*+@M&)-Z35VV[&?[XF973-WL9R%?.&\['C/3GPAN]%*B!/D07._QP8\&YU=]_" MN!7/9(QZ($(^$"OU Q$"@AA2$$B]"@E!QF@(:9 *%$)%D ED!%*'0D>0L4)" M$JA3$E0H"6I$22"U*I3$IA3<8=W>0+4AW3$*!4&?7T$@32H4!!V*@\$$Z$*Z M$R#T YU8/U"9?@C=(6=* I,PY"==(OXH>B^D!/TU4@)I5B$EZ% E#)90%]*= M!"$DZ#,*":0MA9#8E-*.7!?2';D0$=2$B-A4JNVL+J3;62$@J#$!0<<(""H$ M!+520% A(*@A 8'4JQ 0FU):0.A"NJ,4XH%.(!Z0.A3B85-*.R)=2#?5*12# M9T(QG'GCL@BRL$X6H0U[B_1QH#^Z8Q7*P7M^Y8 TJ5 .WIC<@S!- MK!V\H23PN*+M:W5IF*=2ZQY(Q?\:M8 TJU +WIC$@S )O> ]HUY VE+H M!0_7"]J0[LB%7O!,Z 5/ED\8+-10,:@62B@&SYAB\,8H!D\H!L]*Q> )Q> 9 M4@Q(O0K%X.&*01O2':50#-X$B@&I0Z$8/%PQ:$.Z=Q^%8O"-Y!B06A4Y!A_/ M,6A#NF,42L%_?J6 -*E0"CZ>8]"&="= Z 1_8IVPJ4_;3UU(MY]"'_B_1A\@ MS2KT@8]G$[0AW4D #P0\HSI VE*H W_,;0DDJ#MZH1!\$PK!'RH$28?U0=T. M"XW@ZS7"ET_.[\4#*U<-X3F?[OCB% T+_\;7:M'PLD(NF+B%X0L]X5NI)WRA M)WP][Y^EU6W;6/M#P[L/G(I6/[>+X2)!&]+MNA )OI[@V_E\?94NOO')$]0Z M'@B:"0P$L0>NC2L<"%8.]!0YP0K/D28N(]GV=A'(KM<5J?! D&PP@F2?LNQ/ M/_\#P;2!E4_%!8(% STS38(.A/P4Z!A]W1N I^OTK&86&Z.RTX%@M""T$AN" MO(+(/#;T3:BP$?W$SB&X+M!SG5ETC,I$!(+=@L1&=(2"^$+]M><4Z$":4* C M''WM&@J6#!&6+)9+5BZR-'<^I'>LG$1%A(+40FKE:@LB"_77;I.L-G)Y*%WM MLW"8/J;)X)Z)),I7/@P5"GH,$7K<&Q9/5QFAH+TPL!(]X$ES_<7;).C1-Z%" M3XA>FVA#N@,6U!DBU&D&-Z,42"@(,8RMQ(T@P5!_B3<);I TL0(WPX?-9+O. M,$J]ZT2"6B.$6LV@9Y1"B01E1L1&]$2"5"/]E>(4Z$&:4* GPO.ZVI#N@ 5) M1WH&_9PM^7C875%E]31YD$@P9>1;B09!DI'^VG 2-.B;4*%!I()*@WTO/BGIAXNGR)P&MB5B9)(\&3D?$DZ1QI0@6=X=/<\2Q,.G_Z.!H6 M(6H<"2J.]#QI D>CY$PL:#.V,A4;"\:,S:=BD284.(HE3T7U&4D?TQVRX.!8 M3Y F8#-*Q\2"-6,K<[2QH-;8?(X6:4(%&_SQ)6U(=\""JF,]C[XO5NR'\SXM MO[':>7N_NIY&S,2"-&,K4[.QH,S8?&H6:4(%B6%J-B2#"R-9E#M3/"@6@S>V M]2SY%& \7='$@BQC*Y.WB:#*Q'SR%FE"@9]D^'"S!#^R*"5^$D' B9X=C>%G ME)))!&LF5J:#$\&9B?ET,-*$"C_XTT+:D.Z !0H(TAIQ18B81U)E8F0I. M!+4FYE/!2!,JY."I8&U(=\""JI,15 W&.8F4201E)E;F>!-@4&(^QXLTH0*$ MY,UC0@;^$+(PCX*7.7H&)M#!9 0+[P6-"5[#=X'[B&MEII>X%'31?*X7:T,! MHVTQN&M$_9UE&P11%$7*%_-=8#+BCJ#BZ4$T2M$0%[B N%8FB(D+K#I<\REB MK TEB(;I7W^X%\G"@D EC(D+7#_<$;P\/8Q&R1OB D\0U\ID,7&!*XAK/EV, MM:&$$?XLKCZF-VK@$.+J2?;+)^=SV[9M0[OK:V-ZW0=P;W7LL^QQJ7OREZ@57>&RP@.]QO MZFFXF. *%YA#$6IEPI4 !RB">#'M#1\T87J.-:T$S^A$*P$N3P2Q7C(+G7%R M U@S$6IEQI4 0R:".#+M#9UPU,Z#9&-5X-%7WALL(%2J)U2S\!DG48 #%*%6 MYF<)L&\BB/?2WO!!K1;.L::5X!EMT4" JQ-!+)/>WZ^R17:7YLZ?5WEVT[[X M73DOUPO^ZDE2!O@M$<_.;"OP0R*((=*^WMM(M2KS;8E/$O$EWL62L&!&5;B M/LYZ_GLB+B:0,L#TB'AVYEF!.Q%![(GVA@^26E7!!_=!U,?T!@J(%S$V,@F< M<4(&6!\1.[V/"# _(HA+T=[ 09*I*N!('J65[3N2,,V^ X@7L3 R"9]Q0@88 M'!'?S@PL\"W, MR/KP.PKT%YU[0P-YKE8%C>%3L_X &KJ8WD !]R+&/U-!8P)1 \Q_B&]G(ACHX)Y TP)B*!G4E@8$=$ A-)X#E6K1)$ MN$VO/J8[4&!K1#!?(\/@&:=L@',1">W,%X> .D,S^6*D6A5X0DDB6+8#R>(T M.Q!P2R*879)A$(T3-\#GB(1V9HV!R1$)S62-D6J5(!J1-=;&] 8*OX#ON:QN MM3,/^#2T,S,,G(Q(:"8SC%2K!,"U3@Y!$R32&1GOCF"7XYK M)M^,5*N$U8A\LS:F-U! [8@UDDF?=P(,D$AD9P89&""1V$P&&:E6A8E8]GUV MP_OCDC O5%YE 3LE@I@=66 %3X 5$HGM3" #*R02FTD@(]4J 30B@:R-Z0T4 MD#)B>&2!4SP!AD@DMC/+#"R32&PFRXQ4JX2.Y/%AV=XS#-/M/8!^$7LD"\SD M20R_J=[.##/P3"*QF0PS4JT20",RS-J8[D"!]Q)!G)'^K&]9Z9SQ^6Q$,5R" M220-L$,BB9VI8^"$1!+]A>FD7].%-:;XGJYM,?TWSV)1O2D I(PX(:WQPJ=[ M80PR@#@3.Q/%P *))/J+SHDA@Z2/59"1?0O:@)Z0J-X4 #)&+) ^W19E_;IF MY1)^3>A$8 $DF=B9. ;V2"317UV.^JI1K!+%=XUNBW5L[/SA?2A9&)FI'K0! MUDH$,3[:EU(Q/R4%I4JZ]D2AX"YU[PH\$.B=OHA4>"' M1!&OHKT!(#&\'[XW(0U3OC=!@9<11;R,]MH%IGY G@)3(VJGJ1$%ID84,1S: M&PM#LZ'^4Z;ZF%Z/$]!C/4OA*##[%"$%]D743OLB"NR+*&)?M"\ )%Y$LH=Q MI''JAW$H<"VBB&L1#H1G>>*" @\C:J>'$04>1A3Q,-H;#Z/N3TK#QMV?I,#% MB"(N1C@T3-Y]HL#*B-II942!E1%%K(SV1L3PMB$=XF'H*.^%2KT('(PHXF"T MSJY,?95,@7<1M=.[B +O(HK8!WWDDU-FBYKW ,S4H9/68(JDBRLQ&"+#S5\: MI5I<8$-$$1NB45?W6"6*J_MML4ZG73\B%([K]N )1&E>E9[PMFZKC@&2Q<, M$MU85*_?#?[,C^N[M(%>W-P5[**E0_L0(X?OGHE MX[\O\OOK]H##^<#Y6N1Y\=BNVF)1W#=AFR.+8G7-5A4/730J,<^NTZ;"JS1/ M5POF5+>L0<1+'KW,\KRYFGQUW'QOP.+6\/6SW>2D.5),OA9#DK#NA% N3)M0;OYM$L:2I6E6Q04G11/O;>)#[6( HRB*&$5= M^O+%0(J]+<]DO3^(0-%J1H M1[V]&YBN2>AGEF.FG0<@KSQ$&06*>4#?_QTS#TZ^O3$W=BIR0,+3S0>08YB! ME?1FX!PI)C])P?W*!;Q?"68EJW[Y>?JG-EP!"_#[V=<^^B'_EDZ!VUQ\[3.CT]6;+R MAIVQ/*^<=D$;"Z$#\+%3LJ_-K<#C.3TX&GQ^1H[/B>3S"W+\5O;Y&3T^E]5S M08_?RC[GO!4>7S0B;WBL46G-L4A^+&Z.Q?)C27,LD1[S7'Z,;[328Z0Y)AM7 M>XY*+WS*[N=W]4A=W M?$T.G*NBKHME^^,M2_GIV@3PXU^+HM[^TC3P6)3?VO4]_3]02P,$% @ M%X>>4G&UL MS5C;;MLX$/T50LA# B36Q9@#+8UMHI3H):FX ?KQ M.Z1D7;RR$BRR11XLB]1NVDJ@D56*N1MXWL"-*4NR6[7-9S2)@J M+>)<&1'$+,G^Z<]\(5ZC$.0*P8$".FY6Z.8*W4.%WA&%7J[0>ZU"/U>PH;M9 M[';AYE33R4B*'9%&&JV9&[OZ5AO7BR6&* ]:XE.&>GH2=,@'RB3Y1GD*9 %4 MI1*0"%J1;H?,1*)9LL:AN54L DEM?D_GH"GCZHQ]Q@[R%,I41* M6*D_1"*+B2E53)''S^B ?-(0JS9X_0)>OS7J"@'#&@%CQ@$W!_K:TF?+UR;& M9<:OK'%S9#Y-+OQ.;^0^56G0(.1U+@NA&NY!@7O0BGN:*IQ1"K=-O&2)Q7Q^ M=#N=%^O]W!1%YNJZ M#K#)KQ71;X+MO7%;@":$G056'HZCWRY[J =_V&>2 W M4E*ET/BM<5294M+@%4>9'Y0N@O=(1K\\P_WV0_PMC_[V1 =T&!EP>'(DO"-6C+TN-WVM%]$5O0)IU-JMLHJTF9D\$\HO\=Z:4 M9<7OOTNFE/7#_WT%9/J"KV-,::H[_B%3VH7JT9?5R6\O3QE39O\73?+^&!#/*DI"GV*^8W@=)2U:"8^]M*1"&(C5]5/X$ MC4388*.H,2,,Y4N#?3S"+^"3[@E"ZSCYHX#JM M6:((AQ7"0/"XHV7VC2 ;:+&U3?!2:&RI[>T&*.;4".#SE1!Z/S .BB\UDW\ M4$L#!!0 ( !>'GE*AU/0@PP( .L' 9 >&PO=V]R:W-H965TTE\6/F/S]/)N/A5NDWDR!:>$^%-",OL79]Z?LF M2C!EIJ76*&EGJ73*+$WURC=KC2S.G5+AAT'0\U/&I3<>YFL/>CQ4F15M?#(5XEU"_YXN&8K?$+[O'[0-/-KE9BG* U7$C0N1]Y5 M^W+2#IQ#;O'"<6L:8W!'62CUYB9W\<@+'!$*C*R38/3:X!2%<$K$\:T4]>J8 MSK$YKM1O\L/381;,X%2)+SRVRQ#CDF7"/JKM+98'ZCJ]2 F3/V%;V@8> M1)FQ*BV=B2#ELGBS]S(1#8>P?< A+!W"G+L(E%/.F&7CH59;T,Z:U-P@/VKN M37!MA=F#/XK-S/P@1\H MP;TR!N@?K4IQ6B5SAP9WTEB=44.@>I3*TI8A4V8Q!F;@%N,5EZNFU3[V F/0 M8 ]:!]@O:O:+/R^5=:9IU>!OE4N_)NG_RW(9U&$&?[-# M7=\*_H^2*3F:]1[\!.\W^F^*>I7?,H8*@%)2M.)ZM;[)KHK^O3,OKD'J9P1E M0."27(/6!7UL7=PLQ<2J==[-%\K2W9 /$[J-43L#VE\J9:N)"U#?[^/O4$L# M!!0 ( !>'GE)A%2D[20D -A% 9 >&PO=V]R:W-H965TY#=1\PWMBH MO/@ )[W3_?A;,&58=MG%H7"16AL\^S([, ^S.^S%U3XFW*0E&XT)=+O(B\()Y=793G M/J=7%\DA#X.8?$Y1=H@B+_W[AH3)\^5,F_TX\278[O+BQ.+J8N]MR3W)'_:? M4WJTJ&O9!!&)LR")44H>+V?7VOD[URX*E!*_!^0Y:WQ'A2KK)/E6''S87,Z6 M18](2/R\J,*C'T]D1<*PJ(GVXZ^JTEG=9E&P^?U'[;^4RE-EUEY&5DGX1[#) M=YN+M+D M&:6%-*VM^%*.?EF:CE<0%Q?*?9[27P-:+K_2Y^CZR0M";QV2,WK=G=U[(4$? MXB>2Y?1ZR#/T^I;D5"![@\[0P_TM>OWJ#7J%@AC=!6%(;9U=+'+:D:*ZA5\U MNCHVJGN>E(+JGX]!GH]!GI9G]59WSI' M]\0_I$$>D.QM:T2R8D2^?J2%T(><1-F?DB:-NDFC;-+H:/(Z2M(\^(=LT"K) M_S1L?ZW-=/.!.W3E'WCE>?69T?/\0'4(OI[U_GR99AAYBBIZP5.<]1=]%JCF<:L85R73Y;SK667DJ_1<2$GOQ3Y!]!Q:I603Y*560J>\E/2RC:@U+'T\ MGP9XT8RI?)\&<-'&H,N-HM8N0_-0TA@?61E:(&887:Y4 WAI0^A%#7UWB ,_ MV'LA2M9AL/6*Q^)^1@:^:9,!3@/":7+$O=3(\EJ[C,SC4C,YYRN2LCI-#+C4 MY+Q4FOCA'KU/GD@:%P_*Z'Y/#4PYLD'76Q+[?6]IP)SF3F5M'2"D#X:0R-J* M6CNL795JVM'6N&N\O&GR8VO0[(TN5P49J>!JDT!(V;]O]TVFVN-Z*3 MR<(3'0"BRP.4EQI>7FN7X0WNJ<-L6UTFPNH(O-+E9'F)E((EN369> M0(>.QP@$JUJ9QZ:V.[Y5-"V^!MXIJF;U!%KIND=+*^UZP[FHR3=X4 MD#)P%Z@-@)0AQXG2R)_R'4EI M6!1OSW*21LST5@]#&\ -0YML)@GX8,ACCAYS23HW[GP(JQ!B.]>8YU),=(T\ MZ6#P7&C'M%(15BU AR%'Q]B3#E7S4K5D(JQ:P")#'M7\_#F'JD&I(C(15A'@ MFS$*WPP>0H(;12[$]AA(90PD51\G-@QH!@#-F QH!@#-4$STJ?T!^>1" M[+PZ,,B4,VAL/V>JY^ZD(JQ: #13'@B-[>>JYJ5JR418M0"9IAR9/]_/50U* M%9&)L(H 7LTQPK155:O\1E$(L3UNK$ -#+KN=_0V?]%SF@F<,R>+N4Q@DBEG MDMI_F8(8R';F=MLP C'<&2R9@"!3L7HUM@_CY^GX%2*!4.<2D0G ,L=;^^KE MQ_B%+<$J4275QP, %B,2P/;TI+'1!*15BU +[6 MX(#P1#=9-2A51";"*@*0ML98?UM9@C4RP7*I2*Q[N=0"_EH#U]+4#N_%"ZH6 ML-2:;(D- _>P(G)4.CO,!W9:>WU$)-/AYC!@"H\7_?5Q 9O9X@6 ?WV>K T&I"*L6,,]6S,*.[/=L=5@H%6'5:KQX M,#@L/-7IV6I%9"*L(H!<6X[+B^268.,-%9 M3N7:'."7HP@?E:[-$:3A<\\("B&V<\ F9[P L-?;,.H 4"K"J@4,<\;+M^GC MWAQU."@58=4"2CJ#P\$3W9NCSK"1BK"* %6=P1DVPMY:?6X4N1#;8P"F(P?F M3W!Q W)2'""@8T_FXAJOU"D"1+6+$T1O-K>D*Y RK*ZW/1W DS->D-?+R8ER M:=KQJT*(?>D/B.:.EW#3Z[4_=\DS4VZ&KRV>J&KC+T;F 3E>.SIX9>"I94+L7H6%&// "_S;<9[M/9]($;V,Z(U;W,/%!>;Y?G(HQ*I?_"3>D#BCHGXQ^QL& MF]*)K;VPO./+K1XR])I*1]4&#&_.T9V7^KMZ2P4:0/CEA5GODM"$=+-KKU"9 M]E!\%GD-U27>E*!C7_[[+C\M8O/;ZGI^5^H]>@OY:XE"VCZN.<)':)M$&>4M[0)@>A @ F < !D !X;"]W;W)K&ULK95=;YLP%(;_BH5ZT4H3GPF0*D%JFU7;1:6H6;N+:1<.'()5 M@S/[I&GWZV>;E+&%1+UH+H(-/N_['',XGNZ$?%(5 )*7FC=JYE2(FTO/4WD% M-56NV$"CGY1"UA3U5*X]M9% "QM4X N36*' MY%N%HMX':X*:->V5ONPWHA<0!D<"PGU :+E;(TLYITBSJ10[(LUJK68&-E4; MK>%88][*$J5^RG0<9J%+KFHAD?V&@MP(A80V!;FE3))'RK= 1$GFL$*RA'PK M&3)0Y'P.2!E7%^2,L(;<,<[U!JNIAQK(R'KYWORZ-0^/F-]1Z9(H^$1"/PP> MEG-R?G;QKXJGT^ER"KN<0BL[/B+;HY\SE7.AME)C_[A:*92Z#'Z>\(@ZC\AZ M1$?148N:]#DH1;"B#1$-D%>@X8XI,, MWP12_E\9#SG'!_F'2>JFP^9)9YY\:"$D!Q!!,G*#88BT@T@_LA#2PT)(W(G? M^QWAF70\DP^NBLD!TLAWHV&*P/_;W/R3')\5,MVYH=_1!MN4?_!YAFEXX._U M^JPYLW3_6K-&Z3=?ZCC?371MR_88:"%PFL#-L\R;GZS:4"VLO(Q% MALH*K<#@I!^079N$+?A@@L#=USF"%R-X8/1UL*MHCV6 MXB>.X9+J:$F72VN:=\[1<2'M+KP#H>!*2$FK;7NA(W5^CC IE9PNE<0;E%QQ MTX8]UH(XBMGM\!QVWNT^]1(26P485X!QX79O@]MS'#D88I(;X03:%IS,22X? M27Q/9_J]Y1*I+4GR+)?RX6?:>6$RG7^3#%<:RO\P6\!B^&*QJ46M*$^-47S%-F/KZ-:"MQ?IZIG MVJ^8]E_.M FD3N%RNJ,UA=WV?KW&@TKCP3]:]TNDJDNY6NU '<-!E*Z%4%W*\%SP4]X_G;]FYW[[K,=V?@U'U8\AUMY;H?P0<_1*,IH MM#4S"I$43L9P,D65$!)\O<)LA.;;EI!W5,UU]!^$O*/FB\2B53:*_O>@5RIL M<);96I)E_S;NE?,U"AILE2K9*^3*UPQ]I9YF&*O$R=XP<]9B-$Z4;)4IV?94 M^:8!D#W/JYL_[E5B9=LSZ^JBV8(;SV*$FE:!#W[!'QO7)":R54IDKY 37QP5 M2Q';;X+AVGW=OWWHZCL5RH+$"5E%[2ZMHUD^)Y85IV?%%7ZD'3T(BF)*3S T M?@#U3[1VCQ7_*J@>=8/?4$L#!!0 ( !>'GE(7Q:N,/@, %(* 9 M>&PO=V]R:W-H965T?>XW./CS]&&ZGN M=8)HX"$5F1X[B3'Y9]?548(ITQV98T9?EE*ES%!7K5R=*V1QF90*-_"\8S=E M/',FHW+L2DU&LC""9WBE0!=IRM3C*0JY&3N^\S1PS5>)L0/N9)2S%<[1W.17 MBGINC1+S%#/-908*EV/GQ/\\];LVH8RXY;C1C3;84A92WMO.+!X[GF6$ B-C M(1C]K7&*0E@DXO%K"^K4<]K$9OL)_;PLGHI9,(U3*7[PV"1C)W0@QB4KA+F6 MFV^X+:AO\2(I=/D+FRIV0,%1H8U,M\G$(.59]<\>MD(T$OS>GH1@FQ"\-Z&[ M32B5ME-'P\0\.XT(?P"6[F9_#QX! .@&=PP86@M= CUQ 5 M"^A&VVE/JVF#/=->,-6!KG\$@1?X.]*G[>EG&-7IWLMTEP2H50AJ%8(2K[\' M[UF"(SAE@C1 F)>[Z*N21)7:&%)9K=N.N)W^F-W'53T?:8 M%S1[-*\TOOPIN'F&.4:&XX:C)O":APX)XLYB+1R#GH"+;V@J@J?))*HO= MM513#AL\CSO]5[7\&>,U8E[4TJ]KZ;^GE@ND F*R_YKD+^V_BV/_#RV[_4[P MBN2.H'"?XL"3ACY!.XN,%V@:K/>H)YA\%]LA;#F M$[ZQ%9Y6 N0F0Z43GD..*J(1NF=VK4X[8'?0\;P/+YE=$K.XUNN( M!+/+LHM;!=EK[L)@& Z&GK?;&+[W?)![K72NZ/ZC0\.NU_M=X3?N"?^_\(7_ M?&;[P;]VQAN(0?B&-?SG ]Q_ZP3_"W-L,9ON&/;#<.B%K\SA-BY\^]JBZW3% M26.!2\KT.@-:154]8*J.D7GY!EA(0R^*LIG0$8W*!M#WI93FJ6.?%?4S'GE(?M?7E_@( /@* 9 >&PO=V]R:W-H965T'+@$ MJP9GMM-T__ULH 1&&JJV+^ ?]WW^[GP<-]IR\2@3 (6>4Y;)L94HM3ZW;1DE MD!+9XVO(],Z2BY0H/14K6ZX%D#@'IP4T(S:S+*UV[%9,0WBM$,;@62 MFS0EXN\E,+X=6]AZ6;BCJT29!7LR6I,5S$'=KV^%GMD52TQ3R"3E&1*P'%L7 M^'R*?0/(+7Y2V,K:&!E7%IP_FLE5/+8T4):[-2.*3$:";Y$P MUIK-#/+8Y&CM#LC#I\AU7+P'/CT,GT%4P9TFW-9AJ&+A5K%PK^+U?Y;DMLMUU#K5^I]=\4QE.4@=JGSV^= MZX8XQ,%_\CK-&NJ"2EUP4-U4+]"(,#2C9)5QJ6@DT<,-I L0AY)H4/$//C4Y MAQ7O\-W).6Q%RNN'[?ON-&L("RMAX6#L!W/3KNFN%WQQ)]:/?&>LMC'>^Z_TZZI=U<^\0?K9XFO_V5<+VC_C+KM M"H5VK2TQ/:'^W:]H)A&#I08ZO8'F$46;54P47^>=RH(KW??DPT2WIB",@=Y? M)J;YJ9K=R3]02P,$% @ %X>>4B &,:D&!P JB@ !D !X;"]W M;W)K&ULO9K;;MLX$(9?A3!ZT0*-+9*B+ >)@21N MM\$VW2!M=R^*O5!DQA8JB2Y)Y[!/OY2LB)))T3)J.$ 2'X;#X>G[.13/GAC_ M*9:42O"TBP20[:BN?KF@?$LDNHM7XS$BM-H7A;*TA'R MO&"414D^F)Z5G]WRZ1E;RS3)Z2T'8IUE$7^YI"E[.A_ P>L'=\EB*8L/1M.S M5;2@7ZG\OKKEZMVH]C)/,IJ+A.6 TX?SP04\G05E@=+B[X0^B<9K4#3EGK&? MQ9OK^?G *R*B*8UEX2)2_Q[I%4W3PI.*XU?E=%#7611LOG[U_K%LO&K,?23H M%4O_2>9R>3X(!V!.'Z)U*N_8TR=:-8@4_F*6BO(O>*ILO0&(UT*RK"JL(LB2 M?/,_>JXZHE$ !1T%4%4 ;16 ?D@S\8FS\E M:0JB? [^DDO*32OP=D9EE*3B'3@!W[_.P-LW[\ ;D.3@1I548RK.1E)%6-0S MBJMH+C?1H*YHP W+Y5* #_FO)9+;6Y;=R_*-#\ MN+@7DJOU^*^C0K^NT"\KQ!T5WJYYO%3+$MSR)*:V";$I'Y;E"T@]3LDD')*S MT6.SFTRKP N'L+9J!4?JX(@SN(LX7F?K-)*J,RXRQF7R7U3 R!;FQM.D$<") M#^$0;\5I-<-#WQYH4 <:. ,MAN4JXOPER1=%I.MIZ9D^*[T3UGD4<RFGX5FG-M.+$W?%*' M-W&&9X,G9T+1\<-SG*[GQ8B]TO2=+>Z)96;CQLS>#)K%"J*NV*&GX>\YH[\J M!4;1_8ZF90^+9;(2X,<-S>XI=PT?; @,=$^-^-$#?GQ6!<&UI)EP M5HQTQ,)OV7.ZHCX 7&G$!",@V&@0G8!Z]V&1P MUM-5\.H*6SRUNT5+ #R2!D M O!W50":@(=J@OM;R\!J%@R#CG6@A0 >3@F@ MA?$A&9))\V<[;EN9)I_:<6M=@ <1ALI+L]M0, RW@[183;JD"VIE@&-GC'_F MJL0G]=N'*EH58'A4JFC>0S?P#T\5=WW^%@JL-.GG8F)UT=X6:^E WG$P@K22 M(/B;&*D,;^Q&8%N_B&M' @MW#,Z"--V4IUYS<:+W.6LL4+*,\F>FU2 MD!8 1(Z)$Z0)CMP$/SA.=M0'\18, .K>I>SR58'%U1%:)I [@S@<3[2&('=J MT8,G9L: X-B<_3:SSO04::U!;G#OQ9.)A1,J1S9X8K4;=P6+M2!@=R[1DR>5 MEQ9[/3/AK\R"UDZO*T:M(-BM()_5..>B#'#!*P)M+.; =K!<'^<;""M99@=S*Q&RN5@U8Z3XR#&KM5 M1Y[1CE7+#W8C?!_"5*[\)CGP=A*!S>.E$SSNVJU@+0_8G47TIS2GX$F6T'U2T#N#),:'B:Z;[;J8?'"H[ZC-0 $DG57JZ MTOLZ$HB=&?/.<"9DAVHPZ0.=K]?#=ZO&%Y3'+5E32/?)N[[77&=<,R#LQDD_5]"KT;1SE^)KY?#=IUF'XXG6 M%-^=6_3@B?G0P3?2":L1L2\"HG6'N.&]UY,YSR2%N5@KJ];FI8,F1,L <:<3 M/6E"S.,F\VC;:M35D5HUB%LUNI[=]^ )T?0G[B<*!^8)T30G;IH?G"?N^HH[ M.*=B%<7T?+#B5%#^2 =38*/) 1RU^Z3Q3-M]DG4PE!"M)\2=1.Q&"3$?+9AG MB#N,VL%IS2%N<.^%DK&)$DN<.ZS:@6H-(.[LH2],0@-DWG: +I-V=%HNR*[G MW&IT64R%4*M**"F,E^7EH.J$MMBE](%*H"4@<#]?V/]&0:"Y';BY?9W/Z<-F MG:0=K.K[^#XPL6V*I-4HW!J24>,25T;YHKP,)T!<3(3-?:7ZT_K"W45YS6SK M\TMX>K6Y-J?=;&[QW41\D>0"I/1!N?2&8]7Y?',Q;O-&LE5Y5>R>2N+T?U!+ P04 " 7AYY2HT][NF,% "R$P M&0 'AL+W=O ME^3B4=D 75\"KW(U5)1C/; MJ,A')(HFHX+R\9&N)5%T45#[?LEP\7@_PX.7#%[X_:/-A MM%Q4=,\V3'^MUA+>1JV7C!>L5%R42++=]> &?UB1Q#2P%G]R]JC.GI$)92O$ M-_-RGUT/(D/$S 8H8SM:Y_J+>/R5G0(:&W^IR)7]BQX;V^EX@-)::5&<&@-!P/ZZN4,7[R[1.\1+],=!U(J6F5J,-/ 8KZ/TU/=MTS<)]!VC!U'J@T(?RXQE MK]N/((XV&/(2S"WI=?A Y16*\7M$(H(]/*N?;Q[UX,3MV,;6WSC@+S"P'YMO M"OU]LU5:0B+_T]-9TG:6V,[B0&>?8DV9T@+M*82^O/- M3^-R8EV:!7]+T?%\V%RSR6P\QZ0U>T4\;HG'O<2; W -S1K,T$H4 M4)B4S38?:.,I.2/ >!I%;SA=J_FYT2O*24LYZ:6\^ 5JX27Z32B%8"5L*(RI MV*$-2VO)-6?J/8*A]S%/')HA=I ]1DD(>=HB3WN1?]<')I$^T!)I5E1"0GU& MO*@HER;Q4 ZQ,!L-+X],:9N-O@BF#MS,"<"U"=#/6OI9+_T*N/> ![5E!\10 M[.0WR.TCS6L[\NQ[S?4S4NT$^,AGGK''TWGBX'L,9V0:S)IY&\2\-XB7=+GC MJA**VR(*[&L)^BN!?IU3F(B/$$I5!-;FW"&+'7K7!H?(<=0I0O2_)J =^12J M-8>?@!P>%<^8#"[84Q_^O&C@/2;#,/Z9H.%>_#N6PGY&,<-/TU34IM1*EC)^ M- 71"XO=<70'VV-%2)"7=+SDYW@O>-D\71ITLS1++60@P4].SV'&[N+T6 UQ M',QNW"D;CGNA[\MND(4M-[ :C3P%OA%_3 M)]:&Y(5V%9),/9GN,8OF0>1.2G&_EIXCPU:;P4!GK]B]S*Y$DFGBR777#D_Q M+$C=J2GNEU,WUW-1[D%:9?'#)''5,8D]Z*X9'H=7::>DN%]*O["L;DY+@ [D M**52/D,)1[0PZ6^*NC3GG*'8#6N(L&?QND(Y]P3BL0JG>B>FN%]-[Q@<45/> MG$7,2@5\J?F_8?7QB"=Q]XL^LSC(2SH%)?T*:C=@/B[BD3P7RV<5W!223AA) MOS"NZ7-S[H!9-]L0:L03F[M1KSY0;X]$)^"<;71B<,U(<%:0CKU)#\X7_Y,&)_X$TS. MC:TB_7&X1\K$LQ \!\_("65T=OM1,+FWET(*68%O[@[:K^W%TXV];GGS_19_ M6#771YV;YC;K@\>R%5J+PCX>&(4-LC& MWW="Z)<7TT%[3;?\#U!+ P04 " 7AYY2H$4.UC@# ","@ &0 'AL M+W=OAF:MD6<>5.1A'$7]L.!" M!I.1OW:I)R-5VEQ(O-1@RJ+@^NX]YFHS#EBPNW EEBOK+H23T9HO\1KMU_6E MIEU8LV2B0&F$DJ!Q,0[>L;=3ECB C_@F<&,.UN!*F2OURVW.LW$0.4688VH= M!:>_&YQBGCLFTO%[2QK4.1WP<+UC/_/%4S%S;G"J\N\BLZMQ, P@PP4OPDZ<"%DLLW7U 7 M,,.YA5/T'^V*]156^VNK2O4_=;49T)R MF2)<( T/^#S/Q9*[@63@QRMT6?*RK8_[@=A]&^V"(*=E)XJYM2G=_ M_3H)C0.^#*LR] 5R^6R?X\\^QXY'*\:_B06E$KSF62'..PLIG\]Z/3%;T)R( M4_9,"_5FSGA.I+KE3SWQS"E)JD)YUD-!$/5RDA:=\:AZ=LO'([:465K06P[$ M,L\)_^>29FQUWH&=MP=WZ=-"E@]ZX]$S>:+W5#X^WW)UUVMJ2=*<%B)E!>!T M?MZY@&<3/"P+5!&_IW0E6M>@I#)E[%MY5'U355:L4F+,HWWDJNWJ2HGQ]$IN)C-EODR M(Y(FX(M<4 XF+%=C8E$FZX6"ZV+&<@IVCSRZHI*DF3@&7?!X?P6./AV#3R M MP,."+04I$C'J286]1-";K7%>UCB1 R<&-ZR0"P%^*A*:;);O* )0@* %SV3WXH$'#F[R@*OZ^H[Z=NW:STRH?OWZ614'UY+FXD]/ MXV'3>%@UCAV-7]*GM"C2XDG-B(P4,WJRD6I6X9EMX$DK/+8\UDU%55.EB+R, MT0"%_6C4>[% [#<0^UZ(#TR2S(,$'&55SQ1*^=@<2/)JPU:W$;:P=1$, X0: M<'7N^P:';@2C(+9SB!H.D9>#&KI[ZN/(X!$-0AS:X<4-O-@+KQYV1W6KQX"^ M*JL0"J;J4AN&V.Q+&(>M/JJ[TA*&48SM4 <-U($7:KOG'C@IA+HL3>$B^4M) MIG(9";[>T'Q*N6]Z#)O6AH>?FS#0"AT<;G:NVVKG PT'41!LI".SC(B1#I/9U5V1?/FP3Z[URUO3^_8)&<)C-#0 M20YI4IRSY+EMDD#!X^D(V*6J?@OB]^7,! MQ@::T$R-&>3.B_8WZ#>X_;C'NI'M\85-$I; 2"VL73RT"4*_"^[/0:!IA0,; M$XMC0ARZ=4![(?2;81OZ%9VKMPFXI(6Z4A- T1/_4\RAMCD8?X"<:^N"?N_: MKYP/+$,R"LP\VN(0B_R>>T@A1Z;5]@V: MEB#LI*G-&+W;C%V@+19JRH=CB8-])15LK\EMK&_IOJL,?"TY)EOZK;J^+%[H6\%^(VOZ_ M*>KWQ1QI1T3]PXLYTBZ&_"ZV5S%'YK9N.# S:4;%[DFE71'MLOO[(4*.;%M% MRU0SPURLM-DBO]D>5,Q M<]9C[7[8OQ_\@:*-[=]*3=FV!4;(N4C"VENQWUL/J=W8-%5+&LV@KEL%M?/B M=SNO"[7IF.;.P1($G>L%K)T5^YUU3]IMVY?"T-S V@*C#97?Y*&-$_N->4O\_4@&D @ Z@8 !D !X M;"]W;W)K&ULC55=;YLP%/TK%D^;M 8""?T006K2 M3MM#I:CMMF<7+L&JL9EM0OOO=VT(31,2[07\<<_Q.1??2])*]:I+ $/>*B[T MPBN-J6]\7VV5FDB M&\.9@+4BNJDJJMZ7P&6[\*;>;N&1;4IC%_PTJ>D&GL#\JM<*9_[ DK,*A&92 M$ 7%PKN=WJQB&^\"?C-H]=Z86"4 F8G %$/B)S13IFS=4<- M31,E6Z)L-++9@2*B!?[L!0 MQO577QL_ZT97=:>.*TB#Q(84I-[D4.^6>\ MC\H'^>%._C(\2_A U81$TV\D#,+IB)[5_\.#,W*B(9N1XXM.\"VI9AEIW=V! MG- M*"R%7>ZPB+3!Q&&RQU+74<\7X51XF_W#8U&Q?,AZI/NV:![ M=E;W?5%@61%9D%H:$(91SM])SGACBXS@+B:QMX6F"#K!^M5$LLR:[3=I2 M-7XC9D>"H_C0U$A,-!VW-!\LS<]:NK/B4=[1Q\AD56'_Z+[)F.#YL9A@>A4? M2!Z-NH['1<>#Z/BLZ%M,_<5'VD]*C(\OP6%*CT/B\$"N3QVL+[&1=WWW@Z;["V"!;1C>&0X%4@:32TR;ZCIK-S&R=LWI M11IL=6Y8XL\(E W _4+BA>PG]H#A]Y;^ U!+ P04 " 7AYY2XT0QC=@" M #I!P &0 'AL+W=OH J1"NUHNVJW:[>ZU2P9B-;&I;:#=I]^Q$U(. 6UOP'9F?G\S M]HP'&ZE>=8IHX#W/A!YZJ3'+*]_7LQ1SIEMRB8*^S*7*F:&I6OAZJ9 ESBG/ M_# (>G[.N/!& [?VH$8#N3(9%_B@0*_RG*F/,69R,_3:WG;AD2]28Q?\T6#) M%OB$YGGYH&CF5RH)SU%H+@4HG ^]Z_;5)+;VSN WQXW>&8.-Y$7*5SN9)D,O ML$"8XQ4RPO3.-$9G]X8M*A%WN0 MX)RM,O,H-S^PC*=K]68RT^X7-H5MK^/!;*6-S$MG(LBY*/[9>YF''0?2J7<( M2X?PT.'4#E'I$+E "S(7U@TS;#10<@/*6I.:';C<.&^*A@M[BD]&T5=.?F84 MM^"G25'!5,QDCL!$ K?O=$G&VA\:\(WX )^I7*ER50/ M?$,05LJ?E1N.BPW#$QM&<">%237S^G9HEN/ M+MMQ%!#,>C>,&K,PWK':H^U4M)VSM/?4)ZCX,_X7$V@LJ.J;D$FM@2KL$[[V MF OASA[V$72-4><4<[=B[IYE+N[KO134RA0S7"R@4=S>9MWQ=\]S[B'T*H3> M5Q'*HJG+5.^((#P%T*\ ^FF#]3&]8\6S\RE3/(+47!9< M:,AP3I)!JT^7414/2S$QH7O?1/U!+ M P04 " 7AYY2]CG#Z\$" !=!P &0 'AL+W=O$A$!; 5*!3NM#)536[=DD-XE5QV:V M*>U^_6PG9+0$5NTE\=W8ZWF[@0=:E-H.!)/1FA2X1/VX7DC3"UJ6C%;(%14<).9C[Z9W/1_8]6[! M#XI;M=<&F\E*B"?;NL7]U MN9M<5D3A3+"?--/EV+OT(,.<;)A^$-MOV.236+Y4,.6^L&W6AAZD&Z5%U8"- M@HKR^D]>&A_V (:G&Q U@.@]H'\$$#> ^*. ?@/H.V?J5)P/B@KA.WE!!6=SU(0R=0Y?X'$YA[-/ MY_ )*(=[RIC9*#4*M EKP4':A)C6(:(C(6*X%UR7"FYYAME;?&#DMIJCG>9I M=)+PGD@?XMX%1&'4Z] S^S@\[(#/3\/GF!Z#O\DF;G<@=GSQ$;[;/$=W^$&3 M%Y!$8Y?%ISFBOC\,/W=9\0]P$TE-H9"Y U6FA.S0W79 M4JNZ=*ILA7N>] ;^6$OM'D!%!J+E2E_E!>02U'!0E(A88'F5T.,[U0?N]2#0VL/ MG WV"D^%LG %7$%J-[&^S^UH^T;5L);8JE:Y;F_4-I%YCY7 B]Z]@ [8LZ^0-02P,$% M @ %X>>4A]64Z$\ P [0L !D !X;"]W;W)K&ULO5;?;],P$/Y7K(@'D&")G=]36XEU("8QF%8&#X@'-[TV%HE=;'<=_SVV MDZ7=TD83&KPTL7/?W7?GS]<;;87\J4H C>[JBJNQ5VJ]/O5]59104W4BUL#- MEZ60-=5F*5>^6DN@"P>J*Y\$0>+7E'%O,G)[5W(R$AM=,0Y7$JE-75/Y^PPJ ML1U[V+O?N&:K4ML-?S):TQ7,0-^LKZ19^9V7!:N!*R8XDK <>V_QZ12G%N L MOC+8JKUW9%.9"_'3+BX68R^PC*""0EL7U#QN80I593T9'K]:IUX7TP+WW^^] MOW?)FV3F5,%45-_80I=C+_/0 I9T4^EKL?T ;4*Q]5>(2KE?M&ULX]!#Q49I M4;=@PZ!FO'G2N[80>P#CYS" M #R&! = 80M('2)-LQ<6N=4T\E(BBV2UMIX MLR^N-@YMLF'<'N-,2_.5&9R>S&!E#D6C:U@+J1E?H9?GH"FKU"OT!MW,SM'+ M%Z_0"\0X^E**C:)\H4:^-I$MWB_:*&=-%'(D2H@N!=>E0N_X A8/\;YAW-$F M][3/R*##2RI/4(A?(Q(0?(#/].GP8(!.V%4Q=/[B)U?Q@C=7S$KU^T=CCBXT MU.K'0+"H"Q:Y8.&18)_,Y5:T@H/GT$ 3![57^':2DB3-DY%_NU^>OEF)7E^ MF&O2<4T&N7YD2T"S@@$O 'V_A'H.U;T;"]!A3'.Q:8##(=6HV6$$K=,[H MB@NE6:&>(@F\UV3QOQ<%)KMPY.]ET6(?Z"+.^KHX9!<%X=%R[WHE#I]1&JVS M?1IO<-YGVS>+PNPHV5VOQ'ACC>LBJ1_ M!;-^E?M6$3Y:Y%W+Q.ES*B+M_7GA/M,#1GVF_M[@5(-'GE*-&PO=V]R:W-H965TB#[1TMHA(I$?2<3KLQ_=(R9(2V4:!I4!>;)&\ M^_3=?2+O.-E*=:]S $,>RT+HJ9<;LW[O^SK-H63Z3*Y!X,I2JI(9'*J5K]<* M6.:KM)F[X*C=V MPI]-UFP%MV#NUM<*1WZ#DO$2A.92$ 7+J?>!OI_3Q#HXB[\X;'7GF=A0%E+> MV\%E-O4"RP@*2(V%8/CW ',H"HN$//ZI0;WFG=:Q^[Q#_\T%C\$LF(:Y+/[F MFV,#$HNJG_V6">B MXX X^QW"VB%\[C XX!#5#I$+M&+FPKI@ALTF2FZ)LM:(9A]<;IPW1L.%E?'6 M*%SEZ&=F-#@CM[!"80RY%-5G8=.[F[M6N(;I&=?XJ\ #>+J4WL);* M<+$Z;=,J5N320$E0 /)E#8K9]5WR3SY)C9E>*EDVNAA)YBB$+'C&#&3DZR=\ MF\/0WXYP'31J8 MD$F#GKSZCV[4"9:WRP>Q1VK)TS'#=/Q4:9M5I^F\J>D MHT%[-@>O7CS:J23TU^[#&K^_$9]KNL<0=V)R2%4:MB&$1T/ S@#KOB#SC5(@ MTN]=QHVTY#_R__1O"P9]_16#MB6#OF3-J,&Z&KZC?:7W6(T/ZMQ6#'J\9'PQ M.2CR60K99*YF?_+Q$3MD#2\H=UL(:/SZY6X+"TU>4NZDWR,D>W9VWRR*>GK[ MG7ZW!+5RUP!-4KD1IFH/F]GFJO'!-=C/YL_M%<3UT2U,=7_!PVS%L=$M8(F0 MP5F"HJGJ2E -C%R[KGHA#?;H[C'':Q0H:X#K2RG-;F!?T%S,9C\ 4$L#!!0 M ( !>'GE(W1FD$&@( )@$ 9 >&PO=V]R:W-H965TH%CH$TP+, &!,FZ/0Q[4&S&%BI+GJ3$ M[=^/DAW#&Y)B+S8I\1R21Y325ND74P%8\EH+:69!96WS0*G)*ZB9F:@&).[L ME*Z915>7U#0:6.%!M:!Q&$YIS;@,LM2OK726JKT57,)*$[.O:Z;?GD"H=A9$ MP7%ASS!64'/9_=EK MK\,($'T\ XA[0/R_@*0'>.5H5YEO:\$LRU*M6J)=-+(YPVOCT=@-E^X4-U;C M+D>"=YN7"[","W-%/I#GS8)< M7ER1"\(E^5:IO6&R,"FU6)Q+0?.^D*>ND/A,(5^9GI DNB9Q&$'3>=PV.4 M_0%02P,$% @ %X>>4@XX)=G2! L18 !D !X;"]W;W)K&ULO5A=;^(X%/TK%IJ'5FJ;V(9 *XK40G=VI':W*C.[#Z-] M,(D![R0Q:QMH5_OCUPXAADELP7SP OGPO??XW-SC:_?77'R1,W27-ZV MYDHM;H) QG.:$7G%%S37;Z9<9$3I6S$+Y$)0DA1&61J@,(R"C+"\->@7SY[% MH,^7*F4Y?19 +K.,B+=[FO+U;0NVM@]>V&RNS(-@T%^0&1U3]6GQ+/1=4'E) M6$9SR7@.!)W>MN[@S0AWC4$QX@]&UW+G&IBI3#C_8FX^)+>MT""B*8V5<4'T MWXH.:9H:3QK'/Z735A73&.Y>;[W_4DQ>3V9")!WR]$^6J/EMJ]<""9V29:I> M^/I76DZH8_S%/)7%+UB78\,6B)=2\:PTU@@REF_^R6M)Q(Z!]M-L@$H#]+5! MVV& 2P-\J$&[-&@7S&RF4O P(HH,^H*O@3"CM3=S49!96.OIL]SD?:R$?LNT MG1I = 5>J%1B&:NE8/D,#+E4$IR-J"(LE>?@$GP:C\#9NW/P#K >*[F$CSD"4WV[0.-NP*/MN#OD=?A$Q%7 ,,+ M@$($&_ ,#S[/!52IPX:_C\%=/ ] \F^Q0L:+@\Z,>#SXH MFLF_/-':5;1V$0T[HA7^^13,.$\DD#Q-FA*Z\1$5/HR$K 8813"Z[@>K79[K MPU"GC;I1-6P/8J>"V/%"?%@*K6\DUQ1H82,Y^Y<8K?!,/JH\1R>@NEM%ZWKG ML1^M#-+$]L9->X?&+M0"OD_VJ%LC.VSFN5?AZQV!;S@G8D8;R[M7Q]>)0D?T MZRKZM3?Z,WG3ZXB6'+V([4M1$X3K&H1+S9 # @RM"H;'I^@"Z*5%+QPY&"Z% MH'G\!CX*DLNT^ S!V7N]K)Z#1RZ;M3!L@-IV0MT1;/@M50'^ W=QS)>&24TI MF:2T^*;U0[&D"7AD9,)2IAB5X/,3S294^+YMB"P>=():@E8E(?XQU53ZV4T M[B!G JQP0K]RNA/PNYI3 7[C>5Q\+^IHTJTRPLXI2+=Z":,?1'I4)SUR%ZB5 M4.C74#?I8]TS:E 7X#W-J2#IYJM/=*_$-&9BVDKP\*K[9'E@$JQLPMXIDF"% M$OJ5TB%2187K>=\E?^M^T6AI8V+JRHG;75=BD%5.Y%=.=V*V'<:8I(ZATZID_T+ *HWBC"O=:GW%[5A[GR8#42':.1GEX6U?40(F=58JN'V*^' MQ[6SN*%)A$X05A^QOT?\">UL&7$/J;.;Q599L5]9/NH'UX4T M0LY^ ELAQ7XA/;)^ZNWF)717L956_ U;]N\LH/J^O6GK&NRE><-G[U_![>##>GI];-YC#W22>5Y1*D=*I=AE==G4JQ.1_= MW"B^*$X,)UPIGA67F #5*?7@?U!+ P04 " 7AYY2 M((WD*,T& !J)0 &0 'AL+W=O68<'S]3]H,O"!'@)<\*?C)8"+'\-!SR9$'RF!_1)2GD MDSEE>2SD)7L<\B4C\:Q6RK,A\KQPF,=I,3@]KN_=LM-C6HHL+<@M [S,\YB] MGI.,/I\,X&!UXRY]7(CJQO#T>!D_DGLB'I:W3%X-UU9F:4X*GM(",#(_&9S! M3U& *H5:XJ^4//.-WZ!R94KIC^KB9VG1?,_?FD#L:$@[9@54*N MA5\BP)N%?"N"GZK MX->1:5RIXQ#%(CX]9O09L$I:6JM^U,&LM:7[:5&]]WO!Y--4ZHE3B(_ %9&! MX^!#1$2<9OPC. 0/]Q'X\-M'\!M("_!U04L>%S-^/!1RR$IQF+3FSQOSR&(> M@VM:B 4'GXL9F77UAQ+J&B]:X3U'3H/7,3L"&!X Y"%HP'.QN[IG4(_>=/9I,\H&*11N2'4P!FN, M@1/CE[2(BX2L$-8YZ)#.#Q\X 6:-X#^Y*?$UJ M82OO2GD15]Z9IY6O!W<2(N1W(4=09\*J,L&A!;?B0N@FPXN2L7J];N'/VABG MQ(Q;9S<\03C8AFT0"P-O9$&M>!"ZB7 [VF^AU1D.AF.,PFVX!KE1 -'8@E>Q M(733H9;7W5-8YSSDC<+ME1F9Y""TUD=0\2-T$Z2Q0KKI5$A3(M>EO$J2,B^S M6,A%^U;1!'7"A$C+-]&;8EVG%+5"-[?NX%0O;W1B#30&BTQ2GLT7I-@7]6)? MDR_Q7#)R+X^0SK8CW2.3E/7M($7*J!'["":#&5$K/-MH -V"W7Q*E)& M;E*VX_V3%HD#LHE-)SIH@QBT3QQ%NLA-NC;81J@Z379+QQ:J2

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

' MGE*UH*83K 0 /0D / " 7U) 0!X;"]W;W)K8F]O:RYX M;6Q02P$"% ,4 " 7AYY2O '6P> ! #L( &@ @ %6 M3@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " 7AYY2 M%-1QY- ! "M( $P @ %N4 $ 6T-O;G1E;G1?5'EP97-= :+GAM;%!+!08 /P _ # 1 !O4@$ ! end XML 68 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 69 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 70 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 285 363 1 true 74 0 false 4 false false R1.htm 0001001 - Document - Document and Entity Information Sheet http://www.bio-rad.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets Parenthetical Sheet http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets Parenthetical Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Income (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited Condensed Consolidated Statements of Income (Unaudited) Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited Condensed Consolidated Statements of Comprehensive Income (Unaudited) Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity Statement Sheet http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement Condensed Consolidated Statements of Stockholders' Equity Statement Statements 7 false false R8.htm 2101101 - Disclosure - 1. Basis of Presentation and Use of Estimates Sheet http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimates 1. Basis of Presentation and Use of Estimates Notes 8 false false R9.htm 2108102 - Disclosure - 2. Fair Value Measurements Sheet http://www.bio-rad.com/role/A2FairValueMeasurements 2. Fair Value Measurements Notes 9 false false R10.htm 2117103 - Disclosure - 3. Intangible Assets, Goodwill and Other Sheet http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOther 3. Intangible Assets, Goodwill and Other Notes 10 false false R11.htm 2121104 - Disclosure - 4. Statement of Cash Flows, Supplemental Disclosures Sheet http://www.bio-rad.com/role/A4StatementofCashFlowsSupplementalDisclosures 4. Statement of Cash Flows, Supplemental Disclosures Notes 11 false false R12.htm 2124105 - Disclosure - 5. Long-Term Debt Sheet http://www.bio-rad.com/role/A5LongTermDebt 5. Long-Term Debt Notes 12 false false R13.htm 2127106 - Disclosure - 6. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Notes) Notes http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeNotes 6. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Notes) Notes 13 false false R14.htm 2130107 - Disclosure - 7. Earnings Per Share Sheet http://www.bio-rad.com/role/A7EarningsPerShare 7. Earnings Per Share Notes 14 false false R15.htm 2133108 - Disclosure - 8. Other Income and Expenses Sheet http://www.bio-rad.com/role/A8OtherIncomeandExpenses 8. Other Income and Expenses Notes 15 false false R16.htm 2136109 - Disclosure - 9. Income Taxes Sheet http://www.bio-rad.com/role/A9IncomeTaxes 9. Income Taxes Notes 16 false false R17.htm 2138110 - Disclosure - 10. Segment Information Segment Reporting Sheet http://www.bio-rad.com/role/A10SegmentInformationSegmentReporting 10. Segment Information Segment Reporting Notes 17 false false R18.htm 2143111 - Disclosure - 11. Legal Proceedings Sheet http://www.bio-rad.com/role/A11LegalProceedings 11. Legal Proceedings Notes 18 false false R19.htm 2145112 - Disclosure - 12. Restructuring Costs (Notes) Notes http://www.bio-rad.com/role/A12RestructuringCostsNotes 12. Restructuring Costs (Notes) Notes 19 false false R20.htm 2148113 - Disclosure - 13. Leases (Notes) Notes http://www.bio-rad.com/role/A13LeasesNotes 13. Leases (Notes) Notes 20 false false R21.htm 2202201 - Disclosure - 1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Policies) Sheet http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesPolicies 1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Policies) Policies 21 false false R22.htm 2303301 - Disclosure - 1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables) Sheet http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesTables 1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables) Tables 22 false false R23.htm 2309302 - Disclosure - 2. Fair Value Measurements (Tables) Sheet http://www.bio-rad.com/role/A2FairValueMeasurementsTables 2. Fair Value Measurements (Tables) Tables http://www.bio-rad.com/role/A2FairValueMeasurements 23 false false R24.htm 2318303 - Disclosure - 3. Intangible Assets, Goodwill and Other (Tables) Sheet http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherTables 3. Intangible Assets, Goodwill and Other (Tables) Tables http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOther 24 false false R25.htm 2322304 - Disclosure - 4. Supplemental Cash Flow Information Cash Flow, Supplemental Disclosure - (Tables) Sheet http://www.bio-rad.com/role/A4SupplementalCashFlowInformationCashFlowSupplementalDisclosureTables 4. Supplemental Cash Flow Information Cash Flow, Supplemental Disclosure - (Tables) Tables 25 false false R26.htm 2325305 - Disclosure - 5. Long-Term Debt (Tables) Sheet http://www.bio-rad.com/role/A5LongTermDebtTables 5. Long-Term Debt (Tables) Tables http://www.bio-rad.com/role/A5LongTermDebt 26 false false R27.htm 2328306 - Disclosure - 6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Tables) Sheet http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeTables 6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Tables) Tables 27 false false R28.htm 2331307 - Disclosure - 7. Earnings Per Share (Tables) Sheet http://www.bio-rad.com/role/A7EarningsPerShareTables 7. Earnings Per Share (Tables) Tables http://www.bio-rad.com/role/A7EarningsPerShare 28 false false R29.htm 2334308 - Disclosure - 8. Other Income and Expenses (Tables) Sheet http://www.bio-rad.com/role/A8OtherIncomeandExpensesTables 8. Other Income and Expenses (Tables) Tables http://www.bio-rad.com/role/A8OtherIncomeandExpenses 29 false false R30.htm 2339309 - Disclosure - 10. Segment Information Segment Reporting (Tables) Sheet http://www.bio-rad.com/role/A10SegmentInformationSegmentReportingTables 10. Segment Information Segment Reporting (Tables) Tables http://www.bio-rad.com/role/A10SegmentInformationSegmentReporting 30 false false R31.htm 2346310 - Disclosure - 12. Restructuring Costs (Tables) Sheet http://www.bio-rad.com/role/A12RestructuringCostsTables 12. Restructuring Costs (Tables) Tables http://www.bio-rad.com/role/A12RestructuringCostsNotes 31 false false R32.htm 2349311 - Disclosure - 13. Leases (Tables) Sheet http://www.bio-rad.com/role/A13LeasesTables 13. Leases (Tables) Tables http://www.bio-rad.com/role/A13LeasesNotes 32 false false R33.htm 2404401 - Disclosure - 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) Sheet http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) Details 33 false false R34.htm 2405402 - Disclosure - 1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details) Sheet http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesWarrantyRollforwardDetails 1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details) Details 34 false false R35.htm 2407404 - Disclosure - 1. Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details) Sheet http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesAccountsReceivablesAllowanceforCreditLossDetails 1. Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details) Details 35 false false R36.htm 2410405 - Disclosure - 2. Fair Value Measurements Fair Value Level Table (Details) Sheet http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails 2. Fair Value Measurements Fair Value Level Table (Details) Details 36 false false R37.htm 2411406 - Disclosure - 2. Fair Value Measurements 3. Contingent Consideration (Details) Sheet http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails 2. Fair Value Measurements 3. Contingent Consideration (Details) Details 37 false false R38.htm 2412407 - Disclosure - 2. Foreign Exchange Forward Contracts (Details) Sheet http://www.bio-rad.com/role/A2ForeignExchangeForwardContractsDetails 2. Foreign Exchange Forward Contracts (Details) Details 38 false false R39.htm 2413408 - Disclosure - 2. Available-for-Sale Investments (Details) Sheet http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails 2. Available-for-Sale Investments (Details) Details 39 false false R40.htm 2414409 - Disclosure - 2. Amortized Cost and Fair Value of Debt Securities (Details) Sheet http://www.bio-rad.com/role/A2AmortizedCostandFairValueofDebtSecuritiesDetails 2. Amortized Cost and Fair Value of Debt Securities (Details) Details 40 false false R41.htm 2415410 - Disclosure - 2. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) Sheet http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails 2. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) Details 41 false false R42.htm 2416411 - Disclosure - 2. Fair Value Financial Instruments (Details) Sheet http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails 2. Fair Value Financial Instruments (Details) Details 42 false false R43.htm 2419412 - Disclosure - 3. Intangible Assets, Goodwill and Other (Details) Sheet http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherDetails 3. Intangible Assets, Goodwill and Other (Details) Details http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherTables 43 false false R44.htm 2420413 - Disclosure - 3. Intangible Assets, Goodwill and Other Intangible Assets (Details) Sheet http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails 3. Intangible Assets, Goodwill and Other Intangible Assets (Details) Details 44 false false R45.htm 2423414 - Disclosure - 4. Supplemental Cash Flow Information - (Details) Sheet http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails 4. Supplemental Cash Flow Information - (Details) Details http://www.bio-rad.com/role/A4SupplementalCashFlowInformationCashFlowSupplementalDisclosureTables 45 false false R46.htm 2426415 - Disclosure - 5. Long-Term Debt (Details) Sheet http://www.bio-rad.com/role/A5LongTermDebtDetails 5. Long-Term Debt (Details) Details http://www.bio-rad.com/role/A5LongTermDebtTables 46 false false R47.htm 2429416 - Disclosure - 6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Details) Sheet http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails 6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Details) Details http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeTables 47 false false R48.htm 2432417 - Disclosure - 7. Earnings Per Share (Details) Sheet http://www.bio-rad.com/role/A7EarningsPerShareDetails 7. Earnings Per Share (Details) Details http://www.bio-rad.com/role/A7EarningsPerShareTables 48 false false R49.htm 2435418 - Disclosure - 8. Other Income and Expenses (Details) Sheet http://www.bio-rad.com/role/A8OtherIncomeandExpensesDetails 8. Other Income and Expenses (Details) Details http://www.bio-rad.com/role/A8OtherIncomeandExpensesTables 49 false false R50.htm 2437419 - Disclosure - 9. Income Taxes (Details) Sheet http://www.bio-rad.com/role/A9IncomeTaxesDetails 9. Income Taxes (Details) Details http://www.bio-rad.com/role/A9IncomeTaxes 50 false false R51.htm 2440420 - Disclosure - Segment Reporting (Details) Sheet http://www.bio-rad.com/role/SegmentReportingDetails Segment Reporting (Details) Details 51 false false R52.htm 2441421 - Disclosure - 10. Segment Information Segment Profit Reconciliations (Details) Sheet http://www.bio-rad.com/role/A10SegmentInformationSegmentProfitReconciliationsDetails 10. Segment Information Segment Profit Reconciliations (Details) Details 52 false false R53.htm 2442422 - Disclosure - 10. Segment Information Segment Asset Reconciliation (Details) Sheet http://www.bio-rad.com/role/A10SegmentInformationSegmentAssetReconciliationDetails 10. Segment Information Segment Asset Reconciliation (Details) Details 53 false false R54.htm 2447424 - Disclosure - 12. Restructuring Costs (Details) Sheet http://www.bio-rad.com/role/A12RestructuringCostsDetails 12. Restructuring Costs (Details) Details http://www.bio-rad.com/role/A12RestructuringCostsTables 54 false false R55.htm 2450425 - Disclosure - 13. Leases (Details) Sheet http://www.bio-rad.com/role/A13LeasesDetails 13. Leases (Details) Details http://www.bio-rad.com/role/A13LeasesTables 55 false false All Reports Book All Reports bio-20210331.htm bio-20210331.xsd bio-20210331_cal.xml bio-20210331_def.xml bio-20210331_lab.xml bio-20210331_pre.xml ex31133121.htm ex31233121.htm ex32133121.htm ex32233121.htm http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 true true JSON 73 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bio-20210331.htm": { "axisCustom": 0, "axisStandard": 20, "contextCount": 285, "dts": { "calculationLink": { "local": [ "bio-20210331_cal.xml" ] }, "definitionLink": { "local": [ "bio-20210331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "bio-20210331.htm" ] }, "labelLink": { "local": [ "bio-20210331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "bio-20210331_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "bio-20210331.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 550, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 2, "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 7 }, "keyCustom": 9, "keyStandard": 354, "memberCustom": 15, "memberStandard": 57, "nsprefix": "bio", "nsuri": "http://www.bio-rad.com/20210331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentTransitionReport", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document and Entity Information", "role": "http://www.bio-rad.com/role/DocumentandEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentTransitionReport", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117103 - Disclosure - 3. Intangible Assets, Goodwill and Other", "role": "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOther", "shortName": "3. Intangible Assets, Goodwill and Other", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121104 - Disclosure - 4. Statement of Cash Flows, Supplemental Disclosures", "role": "http://www.bio-rad.com/role/A4StatementofCashFlowsSupplementalDisclosures", "shortName": "4. Statement of Cash Flows, Supplemental Disclosures", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124105 - Disclosure - 5. Long-Term Debt", "role": "http://www.bio-rad.com/role/A5LongTermDebt", "shortName": "5. Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127106 - Disclosure - 6. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Notes)", "role": "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeNotes", "shortName": "6. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130107 - Disclosure - 7. Earnings Per Share", "role": "http://www.bio-rad.com/role/A7EarningsPerShare", "shortName": "7. Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2133108 - Disclosure - 8. Other Income and Expenses", "role": "http://www.bio-rad.com/role/A8OtherIncomeandExpenses", "shortName": "8. Other Income and Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2136109 - Disclosure - 9. Income Taxes", "role": "http://www.bio-rad.com/role/A9IncomeTaxes", "shortName": "9. Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2138110 - Disclosure - 10. Segment Information Segment Reporting", "role": "http://www.bio-rad.com/role/A10SegmentInformationSegmentReporting", "shortName": "10. Segment Information Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2143111 - Disclosure - 11. Legal Proceedings", "role": "http://www.bio-rad.com/role/A11LegalProceedings", "shortName": "11. Legal Proceedings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2145112 - Disclosure - 12. Restructuring Costs (Notes)", "role": "http://www.bio-rad.com/role/A12RestructuringCostsNotes", "shortName": "12. Restructuring Costs (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "if3e7ee922c3a46cda61c5afd41a8052d_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ife0d0f39fa834ef0a337516adae572f1_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2148113 - Disclosure - 13. Leases (Notes)", "role": "http://www.bio-rad.com/role/A13LeasesNotes", "shortName": "13. Leases (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - 1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Policies)", "role": "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesPolicies", "shortName": "1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - 1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables)", "role": "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesTables", "shortName": "1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - 2. Fair Value Measurements (Tables)", "role": "http://www.bio-rad.com/role/A2FairValueMeasurementsTables", "shortName": "2. Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318303 - Disclosure - 3. Intangible Assets, Goodwill and Other (Tables)", "role": "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherTables", "shortName": "3. Intangible Assets, Goodwill and Other (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2322304 - Disclosure - 4. Supplemental Cash Flow Information Cash Flow, Supplemental Disclosure - (Tables)", "role": "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationCashFlowSupplementalDisclosureTables", "shortName": "4. Supplemental Cash Flow Information Cash Flow, Supplemental Disclosure - (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325305 - Disclosure - 5. Long-Term Debt (Tables)", "role": "http://www.bio-rad.com/role/A5LongTermDebtTables", "shortName": "5. Long-Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2328306 - Disclosure - 6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Tables)", "role": "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeTables", "shortName": "6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331307 - Disclosure - 7. Earnings Per Share (Tables)", "role": "http://www.bio-rad.com/role/A7EarningsPerShareTables", "shortName": "7. Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2334308 - Disclosure - 8. Other Income and Expenses (Tables)", "role": "http://www.bio-rad.com/role/A8OtherIncomeandExpensesTables", "shortName": "8. Other Income and Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "if3e7ee922c3a46cda61c5afd41a8052d_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets Parenthetical", "role": "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets Parenthetical", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2339309 - Disclosure - 10. Segment Information Segment Reporting (Tables)", "role": "http://www.bio-rad.com/role/A10SegmentInformationSegmentReportingTables", "shortName": "10. Segment Information Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2346310 - Disclosure - 12. Restructuring Costs (Tables)", "role": "http://www.bio-rad.com/role/A12RestructuringCostsTables", "shortName": "12. Restructuring Costs (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2349311 - Disclosure - 13. Leases (Tables)", "role": "http://www.bio-rad.com/role/A13LeasesTables", "shortName": "13. Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404401 - Disclosure - 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details)", "role": "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "shortName": "1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "if3e7ee922c3a46cda61c5afd41a8052d_I20210331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DeferredRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:StandardProductWarrantyPolicy", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ife0d0f39fa834ef0a337516adae572f1_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - 1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details)", "role": "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesWarrantyRollforwardDetails", "shortName": "1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:StandardProductWarrantyPolicy", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ife0d0f39fa834ef0a337516adae572f1_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "if3e7ee922c3a46cda61c5afd41a8052d_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - 1. Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details)", "role": "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesAccountsReceivablesAllowanceforCreditLossDetails", "shortName": "1. Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "if3e7ee922c3a46cda61c5afd41a8052d_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGain", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - 2. Fair Value Measurements Fair Value Level Table (Details)", "role": "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails", "shortName": "2. Fair Value Measurements Fair Value Level Table (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGain", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "i99b11cac20c54b21a8f952e91e8d5236_D20210101-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411406 - Disclosure - 2. Fair Value Measurements 3. Contingent Consideration (Details)", "role": "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails", "shortName": "2. Fair Value Measurements 3. Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "i99b11cac20c54b21a8f952e91e8d5236_D20210101-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "i322ddef711e94493b646bd85f93bedff_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412407 - Disclosure - 2. Foreign Exchange Forward Contracts (Details)", "role": "http://www.bio-rad.com/role/A2ForeignExchangeForwardContractsDetails", "shortName": "2. Foreign Exchange Forward Contracts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "i322ddef711e94493b646bd85f93bedff_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "if3e7ee922c3a46cda61c5afd41a8052d_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413408 - Disclosure - 2. Available-for-Sale Investments (Details)", "role": "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails", "shortName": "2. Available-for-Sale Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "i311f0394a3344ca7a989361d491d23e0_I20210331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Income (Unaudited)", "role": "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "shortName": "Condensed Consolidated Statements of Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "if3e7ee922c3a46cda61c5afd41a8052d_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414409 - Disclosure - 2. Amortized Cost and Fair Value of Debt Securities (Details)", "role": "http://www.bio-rad.com/role/A2AmortizedCostandFairValueofDebtSecuritiesDetails", "shortName": "2. Amortized Cost and Fair Value of Debt Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "if3e7ee922c3a46cda61c5afd41a8052d_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "if3e7ee922c3a46cda61c5afd41a8052d_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415410 - Disclosure - 2. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details)", "role": "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails", "shortName": "2. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "if3e7ee922c3a46cda61c5afd41a8052d_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "if3e7ee922c3a46cda61c5afd41a8052d_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InterestReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416411 - Disclosure - 2. Fair Value Financial Instruments (Details)", "role": "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails", "shortName": "2. Fair Value Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "if3e7ee922c3a46cda61c5afd41a8052d_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InterestReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "if3e7ee922c3a46cda61c5afd41a8052d_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419412 - Disclosure - 3. Intangible Assets, Goodwill and Other (Details)", "role": "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherDetails", "shortName": "3. Intangible Assets, Goodwill and Other (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "if3e7ee922c3a46cda61c5afd41a8052d_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "if3e7ee922c3a46cda61c5afd41a8052d_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420413 - Disclosure - 3. Intangible Assets, Goodwill and Other Intangible Assets (Details)", "role": "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails", "shortName": "3. Intangible Assets, Goodwill and Other Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "if3e7ee922c3a46cda61c5afd41a8052d_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423414 - Disclosure - 4. Supplemental Cash Flow Information - (Details)", "role": "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails", "shortName": "4. Supplemental Cash Flow Information - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "if3e7ee922c3a46cda61c5afd41a8052d_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherLongTermDebtCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426415 - Disclosure - 5. Long-Term Debt (Details)", "role": "http://www.bio-rad.com/role/A5LongTermDebtDetails", "shortName": "5. Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "if3e7ee922c3a46cda61c5afd41a8052d_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherLongTermDebtCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ife0d0f39fa834ef0a337516adae572f1_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429416 - Disclosure - 6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Details)", "role": "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails", "shortName": "6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "i8f250775f8634b43825a2e99af0cff8a_I20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432417 - Disclosure - 7. Earnings Per Share (Details)", "role": "http://www.bio-rad.com/role/A7EarningsPerShareDetails", "shortName": "7. Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentIncomeInterestAndDividend", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435418 - Disclosure - 8. Other Income and Expenses (Details)", "role": "http://www.bio-rad.com/role/A8OtherIncomeandExpensesDetails", "shortName": "8. Other Income and Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentIncomeInterestAndDividend", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "role": "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437419 - Disclosure - 9. Income Taxes (Details)", "role": "http://www.bio-rad.com/role/A9IncomeTaxesDetails", "shortName": "9. Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440420 - Disclosure - Segment Reporting (Details)", "role": "http://www.bio-rad.com/role/SegmentReportingDetails", "shortName": "Segment Reporting (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "i45fcb1c0687448d0a8833ed62fcdca74_D20210101-20210331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441421 - Disclosure - 10. Segment Information Segment Profit Reconciliations (Details)", "role": "http://www.bio-rad.com/role/A10SegmentInformationSegmentProfitReconciliationsDetails", "shortName": "10. Segment Information Segment Profit Reconciliations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ie0d92f4df03f47928db863698e7ab6d6_D20210101-20210331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "if3e7ee922c3a46cda61c5afd41a8052d_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442422 - Disclosure - 10. Segment Information Segment Asset Reconciliation (Details)", "role": "http://www.bio-rad.com/role/A10SegmentInformationSegmentAssetReconciliationDetails", "shortName": "10. Segment Information Segment Asset Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447424 - Disclosure - 12. Restructuring Costs (Details)", "role": "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "shortName": "12. Restructuring Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "i94db384a5db24dc3983842bfb44f6348_I20210331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450425 - Disclosure - 13. Leases (Details)", "role": "http://www.bio-rad.com/role/A13LeasesDetails", "shortName": "13. Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "i3222bab2b5334584936c521027034cb7_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity Statement", "role": "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement", "shortName": "Condensed Consolidated Statements of Stockholders' Equity Statement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "i3aab0f297122499490179d107c4987f3_I20191231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - 1. Basis of Presentation and Use of Estimates", "role": "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimates", "shortName": "1. Basis of Presentation and Use of Estimates", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108102 - Disclosure - 2. Fair Value Measurements", "role": "http://www.bio-rad.com/role/A2FairValueMeasurements", "shortName": "2. Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bio-20210331.htm", "contextRef": "ib538243a0d5741ca95ec72abc7a767fa_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 74, "tag": { "bio_A13LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "13. Leases [Abstract]", "label": "13. Leases [Abstract]", "terseLabel": "14. Leases [Abstract]" } } }, "localname": "A13LeasesAbstract", "nsuri": "http://www.bio-rad.com/20210331", "xbrltype": "stringItemType" }, "bio_AnalyticalFlowCytometerPlatformMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Analytical Flow Cytometer Platform", "label": "Analytical Flow Cytometer Platform [Member]", "terseLabel": "Analytical Flow Cytometer Platform [Member]" } } }, "localname": "AnalyticalFlowCytometerPlatformMember", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "bio_BusinessAcquisitionContingentConsiderationPotentialPercentagePayout": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "business acquisition contingent consideration percentage payout", "label": "Business Acquisition, Contingent Consideration, Potential Percentage Payout", "terseLabel": "Business Acquisition, Contingent Consideration, Potential Percentage Payout" } } }, "localname": "BusinessAcquisitionContingentConsiderationPotentialPercentagePayout", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails" ], "xbrltype": "percentItemType" }, "bio_CelseeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Celsee", "label": "Celsee [Member]", "terseLabel": "Celsee" } } }, "localname": "CelseeMember", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_ClinicalDiagnosticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Clinical Diagnostics [Member]", "label": "Clinical Diagnostics [Member]", "terseLabel": "Clinical Diagnostics [Member]" } } }, "localname": "ClinicalDiagnosticsMember", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherDetails", "http://www.bio-rad.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bio_CurrentLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Current liability", "label": "Current liability [Member]", "terseLabel": "Current liability" } } }, "localname": "CurrentLiabilityMember", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "domainItemType" }, "bio_DistributorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distributor [Member]", "label": "Distributor [Member]", "terseLabel": "Distributor [Member]" } } }, "localname": "DistributorMember", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_DocumentAndEntityInformationParentheticalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Document and Entity Information (Parenthetical) [Abstract]", "label": "Document and Entity Information (Parenthetical) [Abstract]", "terseLabel": "Document and Entity Information (Parenthetical) [Abstract]" } } }, "localname": "DocumentAndEntityInformationParentheticalAbstract", "nsuri": "http://www.bio-rad.com/20210331", "xbrltype": "stringItemType" }, "bio_EuropeanReorganizationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "European Reorganization", "label": "European Reorganization [Member]", "terseLabel": "European Reorganization" } } }, "localname": "EuropeanReorganizationMember", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "bio_FinanceLeaseCost": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance Lease Cost", "label": "Finance Lease Cost", "totalLabel": "Finance Lease Cost" } } }, "localname": "FinanceLeaseCost", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "bio_FinanceLeaseObligationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Finance Lease Obligations [Member]", "label": "Finance Lease Obligations [Member]", "terseLabel": "Finance Lease Obligations [Member]" } } }, "localname": "FinanceLeaseObligationsMember", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "bio_FinanceLeaseRightOfUseAssetafterAccumulatedAmortization": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Right-Of-Use Asset, after Accumulated Amortization", "label": "Finance Lease, Right-Of-Use Asset, after Accumulated Amortization", "totalLabel": "Finance Lease, Right-Of-Use Asset, after Accumulated Amortization" } } }, "localname": "FinanceLeaseRightOfUseAssetafterAccumulatedAmortization", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "bio_FinanceLeasesandOtherDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Finance Leases and Other Debt [Member]", "label": "Finance Leases and Other Debt [Member]", "terseLabel": "Finance Leases and Other Debt [Member]" } } }, "localname": "FinanceLeasesandOtherDebtMember", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "bio_ForwardforeignexchangecontracttopurchaseforeigncurrencyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Forward foreign exchange contract to purchase foreign currency [Member]", "label": "Forward foreign exchange contract to purchase foreign currency [Member]", "terseLabel": "Forward foreign exchange contract to purchase foreign currency [Member]" } } }, "localname": "ForwardforeignexchangecontracttopurchaseforeigncurrencyMember", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A2ForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "bio_ForwardforeignexchangecontracttosellforeigncurrencyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Forward foreign exchange contract to sell foreign currency [Member]", "label": "Forward foreign exchange contract to sell foreign currency [Member]", "terseLabel": "Forward foreign exchange contract to sell foreign currency [Member]" } } }, "localname": "ForwardforeignexchangecontracttosellforeigncurrencyMember", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A2ForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "bio_Investmentownershippercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investment ownership percentage", "label": "Investment ownership percentage", "terseLabel": "Investment ownership percentage" } } }, "localname": "Investmentownershippercentage", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "percentItemType" }, "bio_KnowHowMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Know how [Member]", "label": "Know How [Member]", "terseLabel": "Know How [Member]" } } }, "localname": "KnowHowMember", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "bio_LesseeOperatingAndFinanceLeasesRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee Operating And Finance Leases Remaining Lease Term", "label": "Lessee Operating And Finance Leases Remaining Lease Term", "terseLabel": "Lessee Operating And Finance Leases Remaining Lease Term" } } }, "localname": "LesseeOperatingAndFinanceLeasesRemainingLeaseTerm", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "durationItemType" }, "bio_LesseeSupplementalBalanceSheetInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee Supplemental Balance Sheet Information [Table Text Block]", "label": "Lessee Supplemental Balance Sheet Information [Table Text Block]", "terseLabel": "Lessee Supplemental Balance Sheet Information [Table Text Block]" } } }, "localname": "LesseeSupplementalBalanceSheetInformationTableTextBlock", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A13LeasesTables" ], "xbrltype": "textBlockItemType" }, "bio_LesseeSupplementalCashFlowInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee Supplemental Cash Flow Information [Table Text Block]", "label": "Lessee Supplemental Cash Flow Information [Table Text Block]", "terseLabel": "Lessee Supplemental Cash Flow Information [Table Text Block]" } } }, "localname": "LesseeSupplementalCashFlowInformationTableTextBlock", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A13LeasesTables" ], "xbrltype": "textBlockItemType" }, "bio_LifeScienceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Life Sciences [Member]", "label": "Life Science [Member]", "terseLabel": "Life Science [Member]" } } }, "localname": "LifeScienceMember", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherDetails", "http://www.bio-rad.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bio_MaturitiesOfLeaseLiabilitiesForOperatingandFinanceLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block]", "label": "Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block]", "terseLabel": "Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block]" } } }, "localname": "MaturitiesOfLeaseLiabilitiesForOperatingandFinanceLeasesTableTextBlock", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A13LeasesTables" ], "xbrltype": "textBlockItemType" }, "bio_OrdinaryVotingSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ordinary voting shares", "label": "Ordinary voting shares [Member]", "terseLabel": "Ordinary voting shares [Member]" } } }, "localname": "OrdinaryVotingSharesMember", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "bio_Paymentsforproceedsfromderivativeinstrumentsoperatingactivities": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for (proceeds from) derivative instruments, operating activities", "label": "Payments for (proceeds from) derivative instruments, operating activities", "negatedTerseLabel": "Proceeds from forward foreign exchange contracts, net" } } }, "localname": "Paymentsforproceedsfromderivativeinstrumentsoperatingactivities", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bio_PreferenceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preference shares", "label": "Preference shares [Member]", "terseLabel": "Preference shares [Member]" } } }, "localname": "PreferenceSharesMember", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "bio_PriceChangeDebtSecurity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price Change Debt Security", "label": "Price Change Debt Security", "terseLabel": "Price Change Debt Security" } } }, "localname": "PriceChangeDebtSecurity", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "xbrltype": "percentItemType" }, "bio_RestrictedInvestmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted investment", "label": "Restricted investment [Member]", "terseLabel": "Restricted investment [Member]" } } }, "localname": "RestrictedInvestmentMember", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "bio_RevenueAllocationPercentToLeaseElements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue Allocation Percent To Lease Elements", "label": "Revenue Allocation Percent To Lease Elements", "terseLabel": "Revenue Allocation Percent To Lease Elements" } } }, "localname": "RevenueAllocationPercentToLeaseElements", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "xbrltype": "percentItemType" }, "bio_SalesmilestoneminimumamountMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales milestone minimum amount [Member]", "label": "Sales milestone minimum amount [Member]", "terseLabel": "Sales milestone minimum amount [Member]" } } }, "localname": "SalesmilestoneminimumamountMember", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "bio_SalesmilestonepercentageofannualinvoicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales milestone percentage of annual invoices [Member]", "label": "Sales milestone percentage of annual invoices [Member]", "terseLabel": "Sales milestone percentage of annual invoices [Member]" } } }, "localname": "SalesmilestonepercentageofannualinvoicesMember", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_SalesmilestonepercentageofannualinvoiceslowMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales milestone percentage of annual invoices low [Member]", "label": "Sales milestone percentage of annual invoices low [Member]", "terseLabel": "Sales milestone percentage of annual invoices low [Member]" } } }, "localname": "SalesmilestonepercentageofannualinvoiceslowMember", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_SeniorNotes4.875due2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 4.875% [Member]", "label": "Senior Notes 4.875% due 2020 [Member]", "terseLabel": "Senior Notes 4.875% due 2020 [Member]" } } }, "localname": "SeniorNotes4.875due2020Member", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "bio_TolerablevarianceLevel2debtsecuritypricing": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tolerable variance Level 2 debt security pricing", "label": "Tolerable variance Level 2 debt security pricing", "terseLabel": "Tolerable variance Level 2 debt security pricing" } } }, "localname": "TolerablevarianceLevel2debtsecuritypricing", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "xbrltype": "percentItemType" }, "bio_TreasuryClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Treasury Class A [Member]", "label": "Treasury Class-A [Member]", "terseLabel": "Treasury Class A [Member]" } } }, "localname": "TreasuryClassAMember", "nsuri": "http://www.bio-rad.com/20210331", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails", "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r622" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r624" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r624" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r624" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r625" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r624" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r624" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r624" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r624" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r620" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_AmericasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Americas [Member]", "terseLabel": "Americas [Member]" } } }, "localname": "AmericasMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific [Member]" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r172", "r185", "r186", "r187", "r188", "r190", "r192", "r196" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A10SegmentInformationSegmentProfitReconciliationsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables", "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r172", "r185", "r186", "r187", "r188", "r190", "r192", "r196" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A10SegmentInformationSegmentProfitReconciliationsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables", "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Europe [Member]", "terseLabel": "Europe [Member]" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r350", "r353", "r501", "r502", "r503", "r504", "r505", "r506", "r525", "r572", "r574" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r350", "r353", "r501", "r502", "r503", "r504", "r505", "r506", "r525", "r572", "r574" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r340", "r350", "r353", "r501", "r502", "r503", "r504", "r505", "r506", "r525", "r572", "r574" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails", "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r340", "r350", "r353", "r501", "r502", "r503", "r504", "r505", "r506", "r525", "r572", "r574" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails", "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A5LongTermDebtDetails", "http://www.bio-rad.com/role/A7EarningsPerShareDetails", "http://www.bio-rad.com/role/A8OtherIncomeandExpensesDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r199", "r200", "r336", "r337", "r573", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails", "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r199", "r200", "r336", "r337", "r573", "r608", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails", "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r302", "r351", "r494" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Statement, Scenario [Axis]", "verboseLabel": "Statement, Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A5LongTermDebtDetails", "http://www.bio-rad.com/role/A7EarningsPerShareDetails", "http://www.bio-rad.com/role/A8OtherIncomeandExpensesDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable and Accrued Liabilities [Member]", "terseLabel": "Accounts Payable and Accrued Liabilities [Member]" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]" } } }, "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r5", "r23", "r205", "r206" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r58", "r64", "r65", "r414" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Accumulated Defined Benefit Plans Adjustment [Member]" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r55", "r56", "r57", "r64", "r65" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "terseLabel": "Accumulated Net Unrealized Investment Gain (Loss) [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r26", "r61", "r63", "r64", "r560", "r582", "r586" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "periodEndLabel": "Ending balance, Accumulated other comprehensive income", "periodStartLabel": "Beginning balance, Accumulated other comprehensive income", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r463", "r464", "r465", "r466", "r467", "r469" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r60", "r64", "r65", "r128", "r129", "r130", "r414", "r577", "r578" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r54", "r64", "r65", "r414", "r464", "r465", "r466", "r467", "r469" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Accumulated Translation Adjustment [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r24", "r363" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "verboseLabel": "Additional paid-in-capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r128", "r129", "r130", "r360", "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortizationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Amortization [Abstract]", "terseLabel": "Amortization [Abstract]" } } }, "localname": "AdjustmentForAmortizationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r354", "r355", "r364", "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllOtherSegmentsMember": { "auth_ref": [ "r168", "r185", "r186", "r187", "r188", "r190" ], "lang": { "en-us": { "role": { "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.", "label": "Other Segments [Member]", "terseLabel": "Other Segments [Member]" } } }, "localname": "AllOtherSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r208", "r242", "r244", "r246" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Accounts Receivable, Allowance for Credit Loss" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesAccountsReceivablesAllowanceforCreditLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r30", "r208", "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)", "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)" } } }, "localname": "AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesAccountsReceivablesAllowanceforCreditLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": { "auth_ref": [ "r245" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.", "label": "Accounts Receivable, Allowance for Credit Loss, Recovery", "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Recovery" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesAccountsReceivablesAllowanceforCreditLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForLoanAndLeaseLossesWriteOffs": { "auth_ref": [ "r207" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loans and leases that have been written off from both loan receivables and allowance reserve for credit loss.", "label": "Allowance for Loan and Lease Losses, Write-offs", "negatedTerseLabel": "Allowance for Loan and Lease Losses, Write-offs" } } }, "localname": "AllowanceForLoanAndLeaseLossesWriteOffs", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesAccountsReceivablesAllowanceforCreditLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r111", "r272", "r279" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A7EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r224", "r341" ], "lang": { "en-us": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "Asset-backed Securities [Member]" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails", "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r123", "r180", "r187", "r194", "r235", "r411", "r416", "r457", "r534", "r558" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Assets", "totalLabel": "Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r9", "r51", "r123", "r235", "r411", "r416", "r457" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r439" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Assets, Fair Value Disclosure" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r218" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r219" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r215", "r251" ], "calculation": { "http://www.bio-rad.com/role/A2AmortizedCostandFairValueofDebtSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Total Amortized Cost", "verboseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AmortizedCostandFairValueofDebtSecuritiesDetails", "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax", "terseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss": { "auth_ref": [ "r229" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale in a continuous loss position.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss", "terseLabel": "Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities in an unrealized loss position which are categorized neither as held-to-maturity nor trading securities.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value", "terseLabel": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale that have been in a continuous loss position for less than twelve months.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "terseLabel": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for less than twelve months.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value", "terseLabel": "Fair Value of Investments with Gross Unrealized Losses in loss position less than 12 months" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for twelve months or longer.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value", "terseLabel": "Fair Value of Investments with Gross Unrealized Losses in loss position 12 months or more" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "auth_ref": [ "r223" ], "calculation": { "http://www.bio-rad.com/role/A2AmortizedCostandFairValueofDebtSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "terseLabel": "Mature in more than five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "auth_ref": [ "r220", "r223", "r552" ], "calculation": { "http://www.bio-rad.com/role/A2AmortizedCostandFairValueofDebtSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "terseLabel": "Mature in more than five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "auth_ref": [ "r222" ], "calculation": { "http://www.bio-rad.com/role/A2AmortizedCostandFairValueofDebtSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "terseLabel": "Mature in one to five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r220", "r222", "r551" ], "calculation": { "http://www.bio-rad.com/role/A2AmortizedCostandFairValueofDebtSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "terseLabel": "Mature in one to five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r221" ], "calculation": { "http://www.bio-rad.com/role/A2AmortizedCostandFairValueofDebtSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Mature in less than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r220", "r221", "r550" ], "calculation": { "http://www.bio-rad.com/role/A2AmortizedCostandFairValueofDebtSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Mature in less than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r211", "r216", "r251", "r540" ], "calculation": { "http://www.bio-rad.com/role/A2AmortizedCostandFairValueofDebtSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Debt Securities, Available-for-sale", "totalLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AmortizedCostandFairValueofDebtSecuritiesDetails", "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Available-for-sale Securities [Table Text Block]", "terseLabel": "Schedule of available-for-sale investments" } } }, "localname": "AvailableForSaleSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A13LeasesDetails", "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails", "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r426", "r429" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A13LeasesDetails", "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails", "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]", "terseLabel": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]", "terseLabel": "Time Deposits [Member]" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r349", "r352" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsTables", "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails", "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherDetails", "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r349", "r352", "r393", "r394" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsTables", "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails", "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherDetails", "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r110", "r407" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Changes in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r406" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow": { "auth_ref": [ "r406" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r402", "r403", "r405" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Business Combination, Contingent Consideration, Liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r402", "r404" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Business Combination, Contingent Consideration, Liability, Noncurrent" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r395", "r396" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r455", "r456" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying (Reported) Amount, Fair Value Disclosure [Member]" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r33", "r113" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and Cash Equivalents, Fair Value Disclosure" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r104", "r113", "r118" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Ending Cash, Cash Equivalents, and Restricted Cash", "periodStartLabel": "Beginning Cash, Cash Equivalents, and Restricted Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r104", "r462" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash Equivalents [Member]" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "terseLabel": "Cash Flow, Supplemental Disclosures [Text Block]" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4StatementofCashFlowsSupplementalDisclosures" ], "xbrltype": "textBlockItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r122", "r123", "r147", "r151", "r152", "r154", "r156", "r165", "r166", "r167", "r235", "r457" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common Class A [Member]", "verboseLabel": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "terseLabel": "Common Class B [Member]", "verboseLabel": "Common Class B [Member]" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r128", "r129" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r22", "r318" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r22" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r68", "r70", "r75", "r409", "r418", "r545", "r567" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r74", "r87", "r544", "r566" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]", "verboseLabel": "Contingent Consideration by Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r341", "r348", "r587" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails", "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r81", "r526" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of Sales [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtAndCapitalLeaseObligations": { "auth_ref": [ "r541", "r564" ], "calculation": { "http://www.bio-rad.com/role/A5LongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term and long-term debt and lease obligation.", "label": "Debt and Lease Obligation", "totalLabel": "Debt and Lease Obligation" } } }, "localname": "DebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtAndEquitySecuritiesGainLoss": { "auth_ref": [ "r77", "r79" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in debt and equity securities.", "label": "Debt and Equity Securities, Gain (Loss)", "negatedTerseLabel": "(Gain) Loss on Sale of Securities, Net" } } }, "localname": "DebtAndEquitySecuritiesGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r16", "r18", "r19", "r535", "r536", "r555" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r472", "r474" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount of debt sold" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r41", "r316", "r472" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Debt Instrument, Redemption Price, Percentage" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r42", "r125", "r319", "r320", "r321", "r322", "r471", "r472", "r474", "r554" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r314", "r473" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "auth_ref": [ "r217", "r251", "r257", "r258" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss", "terseLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r229", "r255", "r260" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer", "terseLabel": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r229", "r255" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "terseLabel": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r229", "r255", "r260" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months", "terseLabel": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Debt Securities, Available-for-sale [Table Text Block]" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r226", "r252", "r260" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position", "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "auth_ref": [ "r227", "r253" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss", "terseLabel": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesMember": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.", "label": "Debt Securities [Member]", "terseLabel": "Debt Securities [Member]" } } }, "localname": "DebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r369", "r370" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r32" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "terseLabel": "Deferred Revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r32" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred Revenue, Current" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2ForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r427", "r428", "r432", "r434" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2ForeignExchangeForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r421", "r423" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Derivative, Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2ForeignExchangeForwardContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r420", "r422", "r423", "r424", "r425", "r430", "r432", "r435", "r436", "r438" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2ForeignExchangeForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2ForeignExchangeForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed Technology Rights [Member]" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r76", "r137", "r138", "r139", "r140", "r141", "r145", "r147", "r154", "r155", "r156", "r161", "r162", "r546", "r568" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net income per share basic attributable to Bio-Rad" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic earnings per share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r76", "r137", "r138", "r139", "r140", "r141", "r147", "r154", "r155", "r156", "r161", "r162", "r546", "r568" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net income per share diluted attributable to Bio-Rad" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted earnings per share:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r157", "r159", "r160", "r163" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A7EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r462" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of Exchange Rate on Cash and Cash Equivalents" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A9IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued payroll and employee benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r128", "r129", "r130", "r133", "r142", "r144", "r164", "r239", "r318", "r323", "r360", "r361", "r362", "r382", "r383", "r463", "r464", "r465", "r466", "r467", "r469", "r577", "r578", "r579" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": { "auth_ref": [ "r233" ], "calculation": { "http://www.bio-rad.com/role/A8OtherIncomeandExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.", "label": "Equity Method Investment, Other than Temporary Impairment", "terseLabel": "Equity Method Investment, Other than Temporary Impairment" } } }, "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A8OtherIncomeandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r34", "r181", "r234" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity Method Investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r452" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI", "terseLabel": "Equity Securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGain": { "auth_ref": [ "r232" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain", "terseLabel": "Unrealized Gain on Securities" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Equity Securities without Readily Determinable Fair Value, Amount" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Estimate of Fair Value, Fair Value Disclosure [Member]" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r439", "r440", "r441", "r449" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r439", "r440", "r441", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r439", "r455", "r456" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r439", "r455" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Estimated fair value of financial instruments" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r440", "r498", "r499", "r500" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r439", "r450" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r439", "r440", "r443", "r444", "r451" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]", "verboseLabel": "Fair Value by Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails", "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r341", "r342", "r347", "r348", "r440", "r498" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r341", "r342", "r347", "r348", "r440", "r499" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r440", "r500" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r439", "r440" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.", "label": "Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]", "terseLabel": "Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r445", "r449" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails", "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r446" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "negatedLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r446" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedTerseLabel": "Contingent consideration milestone payments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r445" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r498", "r499", "r500" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r447", "r451" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails", "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r478", "r483", "r492" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": 2.0, "parentTag": "bio_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Finance Lease, Interest Expense" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r480", "r486" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Finance Lease, Interest Payment on Liability" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r477", "r491" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "totalLabel": "Finance Lease, Liability" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r477" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance Lease, Liability, Current" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r477" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance Lease, Liability, Noncurrent" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r491" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Finance Lease, Liability, Payment, Due" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r491" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, after Year Five", "terseLabel": "Finance Lease, Liability, Payments, Due after Year Five" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r491" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "Finance Lease, Liability, to be Paid, Year One" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r491" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "Finance Lease, Liability, Payments, Due Year Four" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r491" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "Finance Lease, Liability, Payments, Due Year Three" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r491" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "Finance Lease, Liability, Payments, Due Year Two" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r491" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Finance Lease, Liability, Payments, Remainder of Fiscal Year" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r491" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Finance Lease, Liability, Undiscounted Excess Amount" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r479", "r486" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Finance Lease, Principal Payments" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": { "auth_ref": [ "r478", "r483" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": 2.0, "parentTag": "bio_FinanceLeaseRightOfUseAssetafterAccumulatedAmortization", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization", "terseLabel": "Finance Lease, Right-Of-Use Asset, Accumulated Amortization" } } }, "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r478", "r483", "r492" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": 1.0, "parentTag": "bio_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Finance Lease, Right-of-Use Asset, Amortization" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "auth_ref": [ "r476" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": 1.0, "parentTag": "bio_FinanceLeaseRightOfUseAssetafterAccumulatedAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization", "terseLabel": "Finance Lease, Right-Of-Use Asset, before Accumulated Amortization" } } }, "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r489", "r492" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Finance Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r488", "r492" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Finance Lease, Weighted Average Remaining Lease Term" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r224", "r225", "r243", "r247", "r248", "r249", "r250", "r254", "r256", "r259", "r260", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails", "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r278" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]", "terseLabel": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r273", "r275", "r278", "r281", "r527", "r531" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Acquired Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r278", "r531" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Purchase Price" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r273", "r277" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r278", "r527" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Net Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]", "terseLabel": "Finite-Lived Intangible Assets, Net [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r527" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Finite-Lived Intangible Assets, Remaining Amortization Period" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "terseLabel": "Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure" } } }, "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "terseLabel": "Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure" } } }, "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyGainLossMember": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing foreign currency gain (loss).", "label": "Foreign Currency Gain (Loss) [Member]", "terseLabel": "Foreign Currency Gain (Loss) [Member]" } } }, "localname": "ForeignCurrencyGainLossMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentProfitReconciliationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r458", "r459", "r460", "r461" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedTerseLabel": "Foreign exchange (gains) losses, net" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignGovernmentDebtMember": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Debt securities (such as bonds) issued by a national, local, or municipal government not within the country of domicile of the entity.", "label": "Foreign Government Debt [Member]", "terseLabel": "Foreign Government Debt [Member]" } } }, "localname": "ForeignGovernmentDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": { "auth_ref": [ "r341", "r587" ], "lang": { "en-us": { "role": { "documentation": "Debt security issued by government not domiciled in United States of America (US).", "label": "Debt Security, Government, Non-US [Member]", "terseLabel": "Foreign Government Obligations [Member]" } } }, "localname": "ForeignGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r111" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedTerseLabel": "Gain on sale of land" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": { "auth_ref": [ "r427", "r431" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.", "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "terseLabel": "Loss on Foreign Currency Derivative Instruments not Designated as Hedging Instruments" } } }, "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2ForeignExchangeForwardContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfBusiness": { "auth_ref": [ "r111", "r415" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.bio-rad.com/role/A8OtherIncomeandExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.", "label": "Gain (Loss) on Disposition of Business", "negatedTerseLabel": "Gain on Disposition of a division" } } }, "localname": "GainLossOnSaleOfBusiness", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/A8OtherIncomeandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfOtherAssets": { "auth_ref": [ "r111" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of other assets.", "label": "Gain (Loss) on Disposition of Other Assets", "negatedTerseLabel": "Gain on divestiture of a division" } } }, "localname": "GainLossOnSaleOfOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r111" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedTerseLabel": "Loss on Disposition of Property Plant Equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r263", "r264", "r532" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill, net" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r266" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill, Acquired During Period" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherDetails", "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets Disclosure" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOther" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillGross": { "auth_ref": [ "r265", "r268" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Gross", "terseLabel": "Goodwill" } } }, "localname": "GoodwillGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r265", "r268" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "negatedTerseLabel": "Accumulated impairment loss" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillOtherIncreaseDecrease": { "auth_ref": [ "r267" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Other Increase (Decrease)", "negatedTerseLabel": "Goodwill, Other Increase (Decrease)" } } }, "localname": "GoodwillOtherIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r80", "r123", "r180", "r186", "r190", "r193", "r196", "r235", "r457" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r227", "r229" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity), in continuous loss position for less than 12 months.", "label": "Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "terseLabel": "Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss" } } }, "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfInvestments": { "auth_ref": [ "r213" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.", "label": "Other than Temporary Impairment Losses, Investments", "terseLabel": "Other than temporary impairment losses on investments" } } }, "localname": "ImpairmentOfInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In Process Research and Development [Member]" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r126", "r180", "r186", "r190", "r193", "r196" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "terseLabel": "Income before income taxes", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentProfitReconciliationsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentProfitReconciliationsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentProfitReconciliationsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A9IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A9IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r373", "r378", "r379", "r384", "r386", "r390", "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A9IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r124", "r143", "r144", "r178", "r371", "r385", "r388", "r569" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "(Provision) benefit for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r114" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "negatedTerseLabel": "Income tax payments, net" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": { "auth_ref": [ "r110" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.", "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities", "terseLabel": "Decrease in accounts payable and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r110" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Decrease in accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r110" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Increase in income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r110" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedTerseLabel": "Increase in deferred income taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredLiabilities": { "auth_ref": [ "r110" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.", "label": "Increase (Decrease) in Deferred Liabilities", "terseLabel": "Payments of operating lease liabilities" } } }, "localname": "IncreaseDecreaseInDeferredLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r110" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Decrease (increase) in inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingLiabilities": { "auth_ref": [ "r110" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities that result from activities that generate operating income.", "label": "Increase (Decrease) in Operating Liabilities", "negatedTerseLabel": "Payments for Operating Lease Liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r110" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedTerseLabel": "Increase in other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Increase in other long term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r110" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedTerseLabel": "Other" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r110" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Increase (Decrease) in Other Operating Liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r148", "r149", "r150", "r156" ], "calculation": { "http://www.bio-rad.com/role/A7EarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Effect of potentially dilutive stock options and restricted stock awards" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A7EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r274", "r280" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r280" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r274", "r280" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Intangible Assets, Gross (Excluding Goodwill)" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r271", "r276" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Purchased intangibles, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r72", "r174", "r470", "r473", "r547" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r102", "r108", "r114" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "negatedTerseLabel": "Interest paid, net" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivableCurrent": { "auth_ref": [ "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Interest Receivable, Current", "terseLabel": "Interest Receivable, Current" } } }, "localname": "InterestReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r46" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r4", "r49" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventories:" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r48" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r47" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r84" ], "calculation": { "http://www.bio-rad.com/role/A8OtherIncomeandExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Interest and Dividend", "negatedTerseLabel": "Interest and investment income" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A8OtherIncomeandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedBalanceShares": { "auth_ref": [ "r589", "r594" ], "lang": { "en-us": { "role": { "documentation": "Balance held at close of period in number of shares.", "label": "Investment Owned, Balance, Shares", "terseLabel": "Investment Owned, Balance, Shares" } } }, "localname": "InvestmentOwnedBalanceShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r591", "r592", "r593", "r595", "r596", "r597", "r598", "r599", "r600", "r602", "r603", "r604", "r605", "r606", "r607" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r591", "r592", "r593", "r595", "r596", "r597", "r598", "r599", "r600", "r602", "r603", "r604", "r605", "r606", "r607" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Summary of amortized cost and estimated fair value of debt securities by contractual maturity date" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]", "terseLabel": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]", "terseLabel": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r490" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease, Cost [Table Text Block]" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases of Lessee Disclosure [Text Block]", "terseLabel": "Leases of Lessee Disclosure [Text Block]" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Legal Proceedings." } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A11LegalProceedings" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r491" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Lessee, Operating Lease, Liability, Payments, Due" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r491" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due after Year Five" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r491" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Lessee, Operating Lease, Liability, to be Paid, Year One" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r491" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Four" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r491" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Three" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r491" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Two" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r491" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r491" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r38", "r123", "r188", "r235", "r412", "r416", "r417", "r457" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r29", "r123", "r235", "r457", "r537", "r562" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY:" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r40", "r123", "r235", "r412", "r416", "r417", "r457" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r439" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "terseLabel": "Liabilities, Fair Value Disclosure" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licensing Agreements [Member]" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r19", "r536", "r555" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Outstanding borrowings" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "The effective interest rate at the end of the reporting period.", "label": "Line of Credit Facility, Interest Rate at Period End", "terseLabel": "Line of Credit Facility, Interest Rate at Period End" } } }, "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r36" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit [Member]" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LinesOfCreditCurrent": { "auth_ref": [ "r16", "r535" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Line of Credit, Current", "terseLabel": "Line of Credit, Current" } } }, "localname": "LinesOfCreditCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r19", "r315", "r536", "r559" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, including portion classified as current.", "label": "Long-term Debt and Lease Obligation, Including Current Maturities", "terseLabel": "Long-term Debt and Lease Obligation, Including Current Maturities" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Total long-term debt, excluding capital leases and current maturities" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.bio-rad.com/role/A5LongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_DebtAndCapitalLeaseObligations", "weight": 1.0 }, "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, net of current maturities" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "Long-term Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r34" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term Investments", "terseLabel": "Other investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r42", "r313" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loss Contingency, Information about Litigation Matters [Abstract]", "terseLabel": "Loss Contingency, Information about Litigation Matters [Abstract]" } } }, "localname": "LossContingencyInformationAboutLitigationMattersAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "auth_ref": [ "r77" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security.", "label": "Marketable Securities, Unrealized Gain (Loss)", "negatedTerseLabel": "Marketable Securities, Unrealized (Gain) Loss", "terseLabel": "Marketable Securities, Unrealized Gain (Loss)" } } }, "localname": "MarketableSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentProfitReconciliationsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security, excluding other-than-temporary impairment (OTTI).", "label": "Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss", "negatedTerseLabel": "Changes in fair market value of equity securities" } } }, "localname": "MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Segment Reconciling Items [Member]" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A10SegmentInformationSegmentProfitReconciliationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MunicipalBondsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds [Member]", "terseLabel": "Municipal Obligations (Member)", "verboseLabel": "Municipal obligations [Member]" } } }, "localname": "MunicipalBondsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r104" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r104" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r104", "r109", "r112" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r66", "r69", "r73", "r112", "r123", "r132", "r137", "r138", "r139", "r140", "r143", "r144", "r153", "r180", "r186", "r190", "r193", "r196", "r235", "r457", "r543", "r565" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income attributable to Bio-Rad", "verboseLabel": "Net Income Attributable to Parent" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r131", "r132", "r133", "r134", "r135", "r136", "r139", "r161", "r236", "r237", "r238", "r239", "r240", "r241", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r380", "r381", "r382", "r383", "r528", "r529", "r530", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "Revenue from external customers [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "auth_ref": [ "r115", "r116", "r117" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "terseLabel": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired" } } }, "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1": { "auth_ref": [ "r115", "r116", "r117" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of investments that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Investments Acquired", "terseLabel": "Noncash or Part Noncash Acquisition, Investments Acquired" } } }, "localname": "NoncashOrPartNoncashAcquisitionInvestmentsAcquired1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]", "terseLabel": "Noncompete Agreements [Member]" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r85" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 6.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTerseLabel": "Nonoperating (Income( Expense", "terseLabel": "Nonoperating Income (Expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A8OtherIncomeandExpensesDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesAndLoansPayableCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer.", "label": "Notes and Loans Payable, Current", "terseLabel": "Current maturities of long-term debt and notes payable" } } }, "localname": "NotesAndLoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r180", "r186", "r190", "r193", "r196" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Segment profit (loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r484", "r492" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating Lease, Cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r477" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Operating Lease, Liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r477" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r477" ], "calculation": { "http://www.bio-rad.com/role/A13LeasesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r481", "r486" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating Lease, Payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r476" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r111" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Reduction in the carrying amount of right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r489", "r492" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r488", "r492" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r185", "r186", "r187", "r188", "r190", "r196" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments [Member]" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A10SegmentInformationSegmentProfitReconciliationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r419" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements Disclosure" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimates" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r15", "r533", "r557" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "terseLabel": "Other assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r426", "r437" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other Assets" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r59", "r61", "r409", "r413" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedTerseLabel": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location in other comprehensive income.", "label": "Other Comprehensive Income Location [Axis]", "terseLabel": "Other Comprehensive Income Location [Axis]" } } }, "localname": "OtherComprehensiveIncomeLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in other comprehensive income.", "label": "Other Comprehensive Income Location [Domain]", "terseLabel": "Other Comprehensive Income Location [Domain]" } } }, "localname": "OtherComprehensiveIncomeLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "auth_ref": [ "r64", "r463", "r465", "r469" ], "calculation": { "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "terseLabel": "Other Comprehensive Income (Loss), before Reclassifications, before Tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r53" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r67", "r70", "r71", "r74", "r318", "r463", "r468", "r469", "r544", "r566" ], "calculation": { "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive income (loss) net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r67", "r70", "r409", "r410", "r413" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r62", "r74", "r371", "r387", "r389", "r463", "r466", "r469", "r544", "r566" ], "calculation": { "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Tax", "negatedTerseLabel": "Other Comprehensive Income (Loss), Tax" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r55", "r61" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Net unrealized holding gains (losses) on available-for-sale investments net of tax expense" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r426", "r437" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other Current Assets" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other Current Liabilities [Member]" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherDepreciationAndAmortization": { "auth_ref": [ "r82", "r111", "r283" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.", "label": "Other Depreciation and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "OtherDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r339", "r366" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "Other Income and Other Expense Disclosure" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A8OtherIncomeandExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other Intangible Assets [Member]" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherInvestments": { "auth_ref": [ "r34", "r563" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments classified as other.", "label": "Other Investments", "terseLabel": "Other Investments" } } }, "localname": "OtherInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other investments.", "label": "Other Investments [Member]", "terseLabel": "Other Investments [Member]" } } }, "localname": "OtherInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r11", "r12", "r39" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermDebt": { "auth_ref": [ "r19", "r536", "r559" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt classified as other.", "label": "Other Long-term Debt", "terseLabel": "Other Long-term Debt" } } }, "localname": "OtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermDebtCurrent": { "auth_ref": [ "r16", "r18" ], "calculation": { "http://www.bio-rad.com/role/A5LongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_DebtAndCapitalLeaseObligations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt classified as other, payable within one year or the operating cycle, if longer.", "label": "Other Long-term Debt, Current", "terseLabel": "Other Long-term Debt, Current" } } }, "localname": "OtherLongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermInvestmentsMember": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Long-term investments classified as other.", "label": "Other Long-term Investments [Member]", "terseLabel": "Other Long-term Investments [Member]" } } }, "localname": "OtherLongTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities [Member]" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingExpense": { "auth_ref": [ "r86" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to nonoperating activities, classified as other.", "label": "Other Nonoperating Expense", "terseLabel": "Other Nonoperating Expense" } } }, "localname": "OtherNonoperatingExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A8OtherIncomeandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncome": { "auth_ref": [ "r78" ], "calculation": { "http://www.bio-rad.com/role/A8OtherIncomeandExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income", "negatedTerseLabel": "Other Nonoperating (Income)" } } }, "localname": "OtherNonoperatingIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A8OtherIncomeandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r86" ], "calculation": { "http://www.bio-rad.com/role/A8OtherIncomeandExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedTerseLabel": "Other (income) expense, net", "terseLabel": "Other Nonoperating Income (Expense)", "totalLabel": "Other Nonoperating Income (Expense)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8OtherIncomeandExpensesDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other Nonoperating Income (Expense) [Member]" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentProfitReconciliationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r99" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedTerseLabel": "Payments of contingent consideration" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForPreviousAcquisition": { "auth_ref": [ "r94" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow representing an adjustment to the purchase price of a previous acquisition.", "label": "Payments for Previous Acquisition", "negatedLabel": "Payments for Acquisitions, net of cash received" } } }, "localname": "PaymentsForPreviousAcquisition", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r91", "r94", "r127" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedTerseLabel": "(Payments for) recovery of purchases of intangible assets" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r96" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Payments for purchases of treasury stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r103", "r290" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Payments for Restructuring" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r98" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Payments for credit agreement renewal fees" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r96" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Tax payments from net share settlement" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r94" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedTerseLabel": "Payments for purchases of marketable securities and investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r93" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToFundLongtermLoansToRelatedParties": { "auth_ref": [ "r92", "r493" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.", "label": "Payments to Fund Long-term Loans to Related Parties", "negatedTerseLabel": "Payments to Fund Long-term Loans to Related Parties" } } }, "localname": "PaymentsToFundLongtermLoansToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToSuppliersAndEmployees": { "auth_ref": [ "r100", "r101", "r107" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to suppliers for goods and services provided and to employees for services provided.", "label": "Payments to Suppliers and Employees", "negatedTerseLabel": "Cash paid to suppliers and employees" } } }, "localname": "PaymentsToSuppliersAndEmployees", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r6", "r8", "r261", "r262" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromCustomers": { "auth_ref": [ "r105" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services.", "label": "Proceeds from Customers", "terseLabel": "Cash received from customers" } } }, "localname": "ProceedsFromCustomers", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r95" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from Issuance of Common Stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r88", "r89", "r212" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale", "terseLabel": "Proceeds from maturities of marketable securities and investments" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromOtherOperatingActivities": { "auth_ref": [ "r106" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from operating activities classified as other.", "label": "Proceeds from Other Operating Activities", "terseLabel": "Investment proceeds and miscellaneous receipts, net" } } }, "localname": "ProceedsFromOtherOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "auth_ref": [ "r127" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Proceeds from (Repayments of) Lines of Credit", "terseLabel": "Net payments on line-of-credit arrangements and notes payable" } } }, "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r88", "r89", "r212" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-sale", "terseLabel": "Proceeds from Sale of Debt Securities, Available-for-sale" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r90" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from dispositions of property, plant and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfTreasuryStock": { "auth_ref": [ "r95" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of an equity stock that has been previously reacquired by the entity.", "label": "Proceeds from Sale of Treasury Stock", "terseLabel": "Proceeds from Reissuance of Treasury Stock" } } }, "localname": "ProceedsFromSaleOfTreasuryStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrual": { "auth_ref": [ "r308", "r309", "r542" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.", "label": "Standard and Extended Product Warranty Accrual", "periodEndLabel": "Warranty accrual, end of period", "periodStartLabel": "Warranty accrual, beginning of period" } } }, "localname": "ProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesWarrantyRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualPayments": { "auth_ref": [ "r305" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.", "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments", "negatedLabel": "Actual warranty costs" } } }, "localname": "ProductWarrantyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesWarrantyRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "auth_ref": [ "r306" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued.", "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued", "verboseLabel": "Provision for warranty" } } }, "localname": "ProductWarrantyAccrualWarrantiesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesWarrantyRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r285", "r478", "r483" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "terseLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r52", "r286", "r483" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r14", "r284", "r476" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "terseLabel": "Property, plant, and equipment" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealizedInvestmentGainsLosses": { "auth_ref": [ "r570" ], "calculation": { "http://www.bio-rad.com/role/A8OtherIncomeandExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment.", "label": "Realized Investment Gains (Losses)", "negatedTerseLabel": "Net realized (gain) loss on investments" } } }, "localname": "RealizedInvestmentGainsLosses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A8OtherIncomeandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "auth_ref": [ "r31", "r120", "r209" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.", "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]", "terseLabel": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "auth_ref": [ "r64", "r65", "r463", "r467", "r469" ], "calculation": { "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "negatedTerseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "verboseLabel": "Reclassification Out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "verboseLabel": "Reclassification Out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification Out Of Accumulated Other Comprehensive Income [Member]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "verboseLabel": "Reclassification Out of Accumulated Other Comprehensive Income [Table Text Block]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable": { "auth_ref": [ "r187", "r190" ], "lang": { "en-us": { "role": { "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table]", "terseLabel": "Reconciliation of Assets from Segment to Consolidated [Table]" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "auth_ref": [ "r187", "r190" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "auth_ref": [ "r186", "r190" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentProfitReconciliationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r186", "r190" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r97" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Payments on long-term borrowings" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r367", "r619" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r3", "r13", "r118" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted Cash, Current" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r10", "r15", "r118", "r609" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted Cash, Noncurrent" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedInvestmentsAtFairValue": { "auth_ref": [ "r590", "r601" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate value of all restricted investments.", "label": "Restricted Investments, at Fair Value", "terseLabel": "Restricted Investments, at Fair Value" } } }, "localname": "RestrictedInvestmentsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedInvestmentsCurrent": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.", "label": "Restricted Investments, Current", "terseLabel": "Restricted investments" } } }, "localname": "RestrictedInvestmentsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring and Related Activities Disclosure [Text Block]" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r111", "r289", "r294", "r299" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring Charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring Costs [Abstract]", "terseLabel": "Restructuring Costs [Abstract]" } } }, "localname": "RestructuringCostsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r290", "r296" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "terseLabel": "Restructuring Reserve" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "auth_ref": [ "r289", "r295" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.", "label": "Restructuring Reserve, Accrual Adjustment", "terseLabel": "Restructuring Reserve, Accrual Adjustment" } } }, "localname": "RestructuringReserveAccrualAdjustment1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveCurrent": { "auth_ref": [ "r289", "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.", "label": "Restructuring Reserve, Current", "terseLabel": "Restructuring Reserve, Current" } } }, "localname": "RestructuringReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveTranslationAdjustment": { "auth_ref": [ "r290", "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve.", "label": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)", "negatedTerseLabel": "Restructuring Reserve, Foreign Currency Translation (Gain) Loss" } } }, "localname": "RestructuringReserveTranslationAdjustment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r25", "r323", "r363", "r561", "r581", "r586" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings", "verboseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r128", "r129", "r130", "r133", "r142", "r144", "r239", "r360", "r361", "r362", "r382", "r383", "r577", "r579" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r171", "r172", "r185", "r191", "r192", "r198", "r199", "r203", "r335", "r336", "r526" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r121", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r338" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue from Contract with Customer [Policy Text Block]" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r487", "r492" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r487", "r492" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r64", "r468", "r469" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "verboseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "terseLabel": "Schedule of identifiable purchased intangible assets with definite lives" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationCashFlowSupplementalDisclosureTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r42", "r125", "r319", "r320", "r321", "r322", "r471", "r472", "r474", "r554" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt Instruments [Table Text Block]" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r420", "r422", "r423", "r424", "r425", "r430", "r432", "r435", "r436" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Discussion of current derivative risk management" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r439", "r440" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of financial assets and liabilities carried at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r269", "r270" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r269", "r270" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Changes to goodwill by segment" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Schedule of other income (expense), net" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A8OtherIncomeandExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Product Warranty Liability [Table Text Block]", "terseLabel": "Schedule of Product Warranty Liability [Table Text Block]" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r292", "r293", "r297" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r292", "r293", "r297" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Restructuring and Related Costs [Table Text Block]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r180", "r183", "r189", "r269" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r180", "r183", "r189", "r269" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table Text Block]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).", "label": "Schedule of Unrealized Loss on Investments [Table Text Block]", "terseLabel": "Summary of fair value of gross unrealized losses for investments with unrealized losses" } } }, "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A7EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r168", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r185", "r186", "r187", "r188", "r190", "r191", "r192", "r193", "r194", "r196", "r203", "r571" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]", "verboseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables", "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherDetails", "http://www.bio-rad.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingAssetReconcilingItemLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Asset Reconciling Item [Line Items]", "terseLabel": "Segment Reporting, Asset Reconciling Item [Line Items]" } } }, "localname": "SegmentReportingAssetReconcilingItemLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r168", "r169", "r170", "r180", "r184", "r190", "r194", "r195", "r196", "r197", "r198", "r202", "r203", "r204" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting Disclosure [Text Block]" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]" } } }, "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentProfitReconciliationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r83" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expense" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r110" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based Compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r17", "r538", "r539", "r556" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r604", "r605", "r606", "r607" ], "lang": { "en-us": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short-term Investments [Member]", "terseLabel": "Short-term Investments [Member]" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": { "auth_ref": [ "r374" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.", "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit", "terseLabel": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit" } } }, "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A9IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyPolicy": { "auth_ref": [ "r120", "r307" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.", "label": "Standard Product Warranty, Policy [Policy Text Block]", "terseLabel": "Standard Product Warranty, Policy [Policy Text Block]" } } }, "localname": "StandardProductWarrantyPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StandbyLettersOfCreditMember": { "auth_ref": [ "r304", "r311", "r408", "r588" ], "lang": { "en-us": { "role": { "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.", "label": "Standby Letters of Credit [Member]", "terseLabel": "Standby Letters of Credit [Member]" } } }, "localname": "StandbyLettersOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r168", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r185", "r186", "r187", "r188", "r190", "r191", "r192", "r193", "r194", "r196", "r203", "r269", "r288", "r291", "r300", "r571" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]", "verboseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables", "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherDetails", "http://www.bio-rad.com/role/SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r20", "r21", "r22", "r122", "r123", "r147", "r151", "r152", "r154", "r156", "r165", "r166", "r167", "r235", "r318", "r457" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r45", "r128", "r129", "r130", "r133", "r142", "r144", "r164", "r239", "r318", "r323", "r360", "r361", "r362", "r382", "r383", "r463", "r464", "r465", "r466", "r467", "r469", "r577", "r578", "r579" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A7EarningsPerShareDetails", "http://www.bio-rad.com/role/A8OtherIncomeandExpensesDetails", "http://www.bio-rad.com/role/A9IncomeTaxesDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement", "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r128", "r129", "r130", "r164", "r526" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A7EarningsPerShareDetails", "http://www.bio-rad.com/role/A8OtherIncomeandExpensesDetails", "http://www.bio-rad.com/role/A9IncomeTaxesDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement", "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r22", "r27", "r28", "r123", "r210", "r235", "r457" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Total Stockholders' Equity", "periodStartLabel": "Total Stockholders' Equity", "terseLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r485", "r492" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "terseLabel": "Sublease Income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "Supplemental Cash Flow Elements [Abstract]" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Income and other taxes payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade Names [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r224", "r225", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails", "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r44", "r325" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockReissuedAtLowerThanRepurchasePrice": { "auth_ref": [ "r22", "r318", "r323", "r324" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "In cases when treasury stock is reissued at a price lower than the cost to repurchase, the excess difference between the selling price and cost to repurchase is charged against retained earnings (assuming that all APIC arising from treasury stock transactions has first been exhausted).", "label": "Treasury Stock Reissued at Lower than Repurchase Price", "terseLabel": "Treasury Stock Reissued at Lower than Repurchase Price" } } }, "localname": "TreasuryStockReissuedAtLowerThanRepurchasePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r44", "r325" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury Stock, Shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r44", "r325", "r326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury stock" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r318", "r323", "r325" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Treasury Stock, Value, Acquired, Cost Method" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r341", "r549", "r587" ], "lang": { "en-us": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "US Government Sponsored Agencies [Member]" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableforSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails", "http://www.bio-rad.com/role/A2FairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r341", "r348", "r549" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "US Treasury Securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r368", "r376" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized Tax Benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A9IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r377" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A9IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebt": { "auth_ref": [ "r19", "r536", "r559" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Unsecured Debt", "terseLabel": "Unsecured Debt" } } }, "localname": "UnsecuredDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.", "label": "Unsecured Debt [Member]", "terseLabel": "Unsecured Debt [Member]" } } }, "localname": "UnsecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r146", "r156" ], "calculation": { "http://www.bio-rad.com/role/A7EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares - diluted", "totalLabel": "Diluted weighted average common shares" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A7EarningsPerShareDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r145", "r156" ], "calculation": { "http://www.bio-rad.com/role/A7EarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares - basic", "verboseLabel": "Basic weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-rad.com/role/A7EarningsPerShareDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r119": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "http://asc.fasb.org/topic&trid=2134446" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r163": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5144-111524" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=SL6284422-111562" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL6283291-111563" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=121548190&loc=d3e32787-111569" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922890-210455" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(i)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r282": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r301": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r303": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(2))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(3))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(5)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121596127&loc=d3e12803-110250" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r317": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=64906022&loc=d3e23086-112654" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r338": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r339": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "http://asc.fasb.org/topic&trid=49130413" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r366": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "http://asc.fasb.org/topic&trid=2122503" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e39076-109324" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r392": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r419": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r475": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13,16)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=121551529&loc=d3e60009-112784" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f,g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.16)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.3(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12.6(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611133-123010" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Footnote 11(c)))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580" }, "r620": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r621": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r622": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r623": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r624": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r625": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" } }, "version": "2.1" } ZIP 74 0000012208-21-000024-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000012208-21-000024-xbrl.zip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end

MB1HD;F0VK@>MV#ZOES.W%ZK?NQ> QM_Z0SME]C'E79X$;A MG2WG3YE&1OFJS>K( .4_ZVCEBSCV6S_/CW6F\L!PA_&H.ZY%YX/!YSCL%]G# M3F!!A^6,V>J<\5*=-2Z>L1E>Z("L?6%KX8,D^'(GY/WX$Q>T]W[7?GOFS$@F MP46::?B1,R\T7 H'?/ D&9J$W+CD/=\_:\Z<31@[G90(-)>MLEY'+H4-TGMB M HSX;DZCBS=];S*< Y8S_#F #9Z!3(V3E:FF@=(C$,:R-?)BJ,F7VND# 3&> MU5IN%A*_',8BXEU\9^;X!D]C^"X:59@XLSB=AK-1I>1$ Z BM$D#^P@UA+V M2:/%E.(;66K!M7%Q=9V=&QKW05$S#R9F:[00&$>UAQ&@B \ M 4DCZB<5/F5QY6^5)TCM2(%] '*P4DY\P"8:[(;U8+R[$ # NN=NVAJP2LZ M=;WLM74XK]AF-BXTYH3-8I <^&Q2S?:6SE,X>FT^H*9#FX[JU(L"3*G]! ZYS]WAH#];[N9ATU=.R:(2 M^RLE(#_P:!#*CLTKL+/Q9POA,%0F?Q X)L4X<\E@OPR&1;&I;.]%OYL=_9U& M ZNH[ ^I3%@S*F)I7 M-+1Y$5U42EL 70^H^N3\]"]''@VY1@RL1K'G=8?U% MI7,6'T6 =:RY=E()GT6==H7HLW0!HQM76N2<$1TD#5L!E@-A*74;F"P/S]IM M;1F_QOI<3-+ M[8W&IP35R]8.1B"MWGL&4*F6O>5]#6'J$6F[I4!7?3L4\L' M&%@C3A%;LS#7&(>;5:C_KI\/J_ 0U)CM*6K/M)A3XBL09V4T']68FG\:AOH@ MF=DUZU,+?AY/AOU117_Y\ORR"HNGAU<6SXOQY92"4&P:-=;T3C*_%R]@\]C& M\'3*?+UY"2N6<<*-E4?GM 6V5E=FZD SY@>R976S^]F2#/J5$3MORI>"F<#? M,R'FC,$?%AO6'LCW[BRM= M,D/446DXE,'OC,NA+,6E=Q?*;VAG;O2S'8'A3D=1/,8N7U)(OGY$(>[QX51. M/*5CSYS@H"J%.6EM59P!US"C [/!$7P\&1X/JK,ENR:[_<^#KB^R!*QT62=8 M]\8G-Q.TBT0XZF8<+PM\#,S<]27$N-ZT2IV?##V<:T6HFEPB.&\623&33+>1 MKLO+!L,IF-?&\$K"@>\K*TY6!)H!S<[_89ARUBD#;ME/;T= E?9D)D35KPCY ML5E,S")?^%Q1;+4D*6RIS!P [T:NM1'!_+_8/X+>\4OW::0UW]N(H;TC6U.JUKJGI.OKY MM+:?SP*;6:+H0I4#J:*N49P?6=:IB_S;G)Q9W(;3O0&-L[K:<<_Z2OJ?OJFA M^5,NO6Y6P6$1@.N*^%YA6OTMR .G'.ZV,SRS=+.#O8DXR8)!+]I1Z6DU!44X MY8^R_RY?F5\!F!NSZ;><:=-WU"M;!3CUKWSZ9KZ[#P).YPCF!S/QM5J>9>[J M_;X'BL=,[2W'<BS_P;PYQ9IXA899@%1(JP :.OL?'T%6IZ;_:6.@"S\$ WRRV M,\TA=#ES3>.Y&GEE[C7%$5&.OQCG1@^S_650-%0@BOEUGXV[=L94' JCC3D0 MSL="0%FT[A1[R>@P!XPU@8+5&@YG(3QS1#R-W.MUC[IS"OV%M DK\,?4K7+> ML-.($\V\9P321*O-9EP+?-5XBN>^9NS*[G#>P7':H7&ABV.A!*RU\G^0E?)_ M7.AZ^*[+XHSK(6@L%-4):Y*X)-A8[&RDR03*1,+A4A?'"KLL_BV\70Z(,#/G M3D872 M9. &QMHZ= R:N0\(KUHZ]BB/KZ/"?&S$VGR)UF.#!I!L:063[[=.. MQ+)$^L%YF<$J?Z5A@\]:WQS/IZSDYX.W=3]&L,O^<0_FAS-J8 S\6LN MXBE=80 K(97U,DV/T9G%:GKC[!7S9I%:BH"3!^9>@M>[\'9WROY31$&XI E] MJO>LV-=[<;'WS7;CNN^\()B_IJ.S\+V:&L7.G# ^,S%D6CN817 W&L!FI6:< M-7M?0,,E(G!X\9K-GY^U?:RHNS7=GCI+9XZ@R_P):3 5/VI_3"UH_-3]>6:5 MFE=H\KAJGTIER/BI>]6EU=\S.6CJ[7P(V[OW'>$L3S ;HP89/4K@12;\80F7 MF6>7:GNG3%-0.?4F.:IGG%?S& 2W8K:JUO S2 1'L7*:UEO3B#K9 #^J I:+ MD)9@HG!=UIRJ;R\4'L]CTND1U=GHG1>38=[\S>]*I1=,O-95*E*=ZDS5BW)* M4AE_QYM9$LI>! #U+#4U\E6WT9, XYM2+KMQ7!M]ZP2Z2Q(^3B>LUD?1 MB@@U"YKUFUA[F.!H//IU129Q=:#"J 0B9,)I$D5"MP1(U7'%.7ZZDIFK<)@R MM>+1JP):YASBHT;+&8[KF@F-U>M+":>:^5\O\#OMUY5_\M,;NVSEVP2A);NO M*EHJ!K9*8:Q-EIG>^CETJJ:U#"I96X5C[6!HCTXK 27"HE:\WU8Z[&83G5Q= M&+)D!XI]I?(V*W #$EX5O6M!&G[6'35B8ZV(U\B]"#G?67;+\Z\5=329+:/? M3_Z(>=^/#[M^.QNX][.@NMZI+ML?-(%#6PF%%,Z== 3WR*6(4>2&6SA(K.3V M/E)7+H]T2 ,0%+X4-TX=WU$$UE&M4=4!(6%&K)4.<3#=_)Q".@M;F>DNM6HX M[[\^8]<['SH"JGF_ Q/M9>??S^<986J.M<.#;K]I'92ML?4WN5^0.-U:;&J# MKN8WM6N7_D(YE<$>C^*OS8??F@IQW7Y9KW+3V69"\);:_"OYEB$T6X#K"H+U MXVOC\%8Q#C?UZ$[]QO665/S2G_$6N?2WJQZKMPA;_E.)W,)$W>BQ5_U&MQ2] MV5-_T&"O>BP,EEU[FO==SO#R>I:7=?Z[R:7FW*47M/:K^.]N6ME]WS.$*]S+ MLOE.)9L_S[+YV=YEMUNX=EMNM"U%#^J "O2H=N/\I0]C-[)0N-R->'#SQS^> M$._A!/AN4]A[[<_Z?=&U[,[S24XMOL;^_*@6N.<[4^+5:G1[S86\::?;:\S_ MGOK97G/B"S2T!0W.L6B943YRRK 67$1C-3$"-&RIOF-^1V+!LA'/OV:S#*SC M]FB48X?"OOTZM=?*AZE:U_UMM[_N[>]\@]^^[!S]V=W]^)KM'H$:_<=S^/M- M[]W^<[SS[9W8V]]F9_O;PGQ$[IJ[^W'[Y-W12[K[S-/W1\_QN]S?]H]_#G?V M7W_;_?A)[#P+:><$GTR;@%,3B,&&HV2$!9V<,60)?$H4=M7A8*3$ /=<;:GE M=K;]/HL\C&[?+=2M#]0Q&ABV5.)$-">.&VNT4M(HG8+WBG['$]5"W3U '9Y" M'1/:+T>.'8F_+Q-=D8DR3 MY#1BEFL,I>BMD)HD4"R=E#J9V$I7J\?$,^E*ZD@\3A;)8$&Z"I@B'9-!1!29 MV0HK5$X[(5O\$3/Q Q"@'J ]\U2%_Q]AUKP6"%^P<(\/A)/@P+N>2THC%]$Z MS2-)@0G*+"<6MY+4JH'PVSE)R@C%F0;Y*2@940ZJ008^HD0H2401+6S:>$+5 M$D#X8AA9"2UV[9F8:T=44IH$CH$(M-&)&"*HD5$2KT4K2:T>$\\D*8!5#<(2 M108SC6 O'7*2:&2#(]Q0KD'+!2:F9DL\8B9^ )+4 S1%[579@+- Q*>V;X,M M0<=_Y12OIGG2SZW!ZDTH]8U5U['B9P$GL/+)H"Y8(F M#9\MPSP&0U,TK)6R5H^'9U*6#5%AT(00HQI4)1PITB3!)V<,#\YC+C#PL-C" MCYB''X"0]0#-5?LEY['?9![>8QQ>G0/"CG/KQ$G.\&AFWT:O+&V!'LV!=LM$ M^O9 N_,#;3Z23QG!,>P8(I8$.,9H3LF7&'$N*>/"!J'5QA-%Y>VETJ7ST,,( M]6O1M$73ZZ/I+>M!305 MBFS)%DU72[OXI:0E/YDK%#K?"6TU"V#L5UU>S]0\F,LROSBM?-J*X':9Y54) M%7SG5N;[JV=W[*56%W\R>" M?UZ52BQ7UZQHJF]."P/,=F5:ZVH$1\9<>;(4X3+7+:6%2]W\:?/ W'^EZ?LQ M;=PQ5SYK6NWR]$NGW;KM^-*2.A=WA>]\L:/._RP2*L"BBM%0ZIGET@^0]: M!,]B8,C91!%7!"-++$.24N$Y5]$XL?%$RJWSE;>:RA&% A;:YH@#3LPDJQF/ M"5O&E"#2!AN%HHF4;<:$MMN\G&W>?_TA,8EMH Y%'1GB6$7D< R(::=(3"KZ M ,*'Q!?8)IMM/ETCJP:+4@,D*I.,/R5)ML53(& -" M;>XZ;6P2B*ADHV=">LHWGG!]J%5I.O_6;?->@<;L3]8."."Z9\\_Y!@3A1U' MDMF >)(&F20X(BP$CWE(3*Q0\;5_8]/L<%IA<:[3ZT%N(30N,HPOA1KA8V[' MM=EIBDM7]19SEUL8RNBP>[PYU_V]:K4RZZW3U(&LF]#7M?SK^N=57Y=Z,+D9 MG)UKJEE5DJZZC%[88'/6O^"P.QH/AM/REL-N+,UAFU:[L]Z.5?WW4SV-04L, MV0QSID#E1>4DG]8#/ACDWCBEP^!-JD:>,6'==ZW%M_XPADDO[J4S+/U7W:7O MI"VP^ UX/%F9)%L(1EU(CRQ)&P-Y680Y@[=D*\7A#\?.M%D_5\07*K0(6 M?27-G;X2.*3Z-?=GJ+2:^=^[TPX&%Y%]H^Z,#F,LQI2GA]FTTC#+E[-C.[FH M=G&#(5=7,*Z4I-PIS8[JBI*C9=5R_$&5&XW:PDK>I'*CHEO&R.67+83'XA_P M6+REC+[68V\;N'*IE5S>*OCE3FN#73/\Y>H"@K<-L[[10GX_5'L%%_+BDG\_ MC!!O%X6U@NMWS2)]CV>V>*F,=LU(!3@U[FG&O\],EB["H5@Z547C0^ M_Z,)T;BY6?*T>G)&*=GV?CC)%LJ';7NL@B^.WGS:^^/%I[W]]T?O M/Q["6%Y_!76$[WX[P#L?__X":@>!^_#.T8NCL\$7[_]XS=_]^UKL'KT_@F=\ MW'WVXA/,@>T]>WVRN[_];6?_'U!C7I^\^_=]KM3T=580A!A+G<*@#^8T5LP3 MTKE:O-&1<:\5_+_8>&*6EEYQ%Y$5+?RT\'.NG!RESKJ<]<6XT-PPZ04EF"H, M9.Y4AA]B6OBY&_B91=)B1X5EAJ- %$?<.H)TC!YIQY+4R:J40H:?966&_'#X M65+2104\=(N*598*@1L^=T=-B^G&D'.I'O##B@7'0&6<D-M7)5P6 MKRW)XO,PSOGMW&^Y-_/4%)_HC8[Y6V6KW]\"_+1ZY_RKN@-UBSF+8,[;N?-= M:>OA%!<(2Y\K>.&L=G",I,/"*$ )JT,^W\]GG9RKV/)C$M)O<+2O 7_=T=G> M\M?-^&MVIEO*A!$R(>(X'.P.*V2ETTAAHH.6CJ<< GN1_'SW_'5'M1)6PH$3 M^^$&KILV/[?-S[VQ\^?&:0BM]779"-V=DX"8D-%8PQ"./B%. DA S%)DA3." M&TD-4=GZNBRM:R7R;EN$:Q%N^07UI544:T49,5P$Y7SV<0?%DO8F1ENYMUN$ MNQN$F\F@1*6@05= 06?_$HL1&:$4#X3-8TW&:])JK MUC;;9.?;S@>%%8],212B$]ET*I'6V" .XI47QN*D\'U$HJNSF%JZS$^WL;@, MFXWL-#NYXL4'B*@29JI4D,XXDVS'UF//W];$VF2NY,)TW?[G0:XH\-GV)K%$ MJ8\F_G#NXBH2'Y@,=7.D8QSE&#L[!"#8RDDR.9:^"YAQZHYCFY-R2BYQG?12 M!^"76C796'MU1=TDU-X80F5K\[@J&7O( R1#L:].$))QT[RL^?R\J!C;*E7$X9%BB@GV&. M@\FHDV#$@^&HSD7(@85S"3R]P0@&EIM1E#'E?!YX=T;HDD0#8_MBAP'U!H-/ M^9-6-'H0M2RV^[!8X>-D-*Y2@XXR3<&VY&TZNQ"S="98ZI2W89JO$;HI M ?'T?96/D9<:QM&D/ V[HT\=?V@S=< 38('\:'.VXIMU$0Q[=-S+)4HNH AW M,DN2&I\.I="%A)16!_K*%*QUFX:PBL@42 MQ8_(*N(_)EF)F^N-MLTJ:K.*VJRB![5^;591FU6TA-C>1VV476SRC\;@NJQ\ MHJO,2C.I_[$88'N[^_]\S,_>>?;ZR\[^:_[N"'[[^)KN?GO1VWWFX;MM_.[? MY]_.&V#_)KO_[HA<&';W&8SUV6'W_1\ONKO/8/;__HUWOVU_W7D&]^SOIIWY M(%KN##..!623L(@'$9#&,2*5DG,8"TUXRIW@?WR"T;UG%[4P]/A@:%EY12T, M+1^&9K%(=&?_Y0?+DR26$"1P"3&6"=D@*)*14ARU,@!560B[O2_H3I!H31.- M?LJF=QC7R<^UR?*X*N+KBRVN6$FO: /S"+,B[C@T.=?^@D\WPZ]71:Y_V??9 M3Q"?Q>J_+:HMAFIS\3M:2!H$1REQ@;C)D&9T[F$:+(T@#VL>-Y[@6T4P/ZCD MI'L5&^XXB+GEQ'OFQ.Z\?.$_",R,,3&@7 6V"J8SE!I$G%,R46EAJS,SGE=T M[H@9;RD_/.0$IG^'W7%$@Y1&Q0EZ )#4]DR^\VGSI^[SVEZ,(BU]+2F>:#Z M:V#[V_WP5P:AOXH(5W9L#S:LQ:3%,&DF'4ALI'':(VFX05S&B)SA("P8KKU0 MB?N@;RL=_*"&FRV[+3W+J66W'\!N)W,BP,?GN0*\T3IR) 23B L>D?$4HQ09 MPQI'#,B9.>Y\ ?A[X;@VZ:E-"6A3 E8]Z:DU#2\=MT^5>8DT26ZE0DGCW %( MQEQZ@B!-(H[$TX@-W7A"]./J/MA"7@MY*YL%U4+>\B%O9JWZMKO_^LL':US" MQ!M$G0?8TYHA1QQ#@5HL@[96BE1@[_$D?]X@-6KQ#DLW_[%9P;7LS<16JC?3 MS??QPJY.]]ZE"7:IQD_@H5?#01\^^JH5394[5_V[SAD,.Q___F!C"$2PA(+( MP4J,**2Q#@",6DM,&,CN=]O4I3SQU^X8.-1?G5Q7N"B?C?UQ9[;5G=-[W=D. M@^/Q7#CW"J=%O>Q775Y*3Y?-8J9_T>V#4-"UO?D9-@W(1IW?!_"?SD\OMM_^ M_G.G6PKR77SAW\>Y,4WGI^VW?__#X;EA3_M#XZ!ES77/V]41V;U;VX/"J_. MS:$_=P.L&.P)O*[N5A6Z9:>J9#OG[WIN?\X]YT#F3KV[WY;/Q;]BU)0_Q M*(XWZ[9=O>Y1-S]QUKZKZL0UZ&3#8=7@>C#.N5TP=C>!T[M?4L]F:YZ?\]-@ M..W2E;_+M\7IDOY\=K##Z9JFZ9H.FS7=NF@=NZ/Z>7 VYA0=&&=%.836;5/' MAR"0'!Q.NZIVZJ9!]-3SQ9><]*P MQ,LL?37$YN+X2P1NJA"$40(_?XYUANC_^_]H2NAOS_\[R9F6;R-L>&G#M3F] MG%U^^0Z0&_!R)L(_@9;&G7_@FLDPWYV_JR&+"."5DKL)/%6!T?^-X2!SX$9G M?AX=7V:1FX"-#^T8J,L/@*KZ)[D!\J079MG+ Y>SB4NNVRF^*K<-<\?!G& W MO3V#3+=P1L46.2FO.VJ:7U8@4LWHJ)H1\-L<\(#Z ;?.UJ/I*'8\&8)P' M( M3/$T_W $D ;+4#4][,%6],O<&SP;5FR8.__-;4KWZ CP&K@"!N@R=\?90^&% MDV-@K=FHI^ W/^ZMT\L)"O'@S)IN9HSH3R&C>G-(LWV:HVG-MOGW84![@]-9&JJ^>4D085E)3>RJ-&L&M2YZ>G['BP(A,'T? ( M)*N*(4<@8OF37((!=FPJ"E4Y]3"W*8*4_2XMXF?B4-[@U,UVLM)V=3279U4T MZ!69[Y2>B=BL#\\"M?9,;82ZZ$$.WRF[V)RW=0_(&C!LJ/ C7S&_-*%;P=SE M>'%%%\L+\>)\@^X?:#RJ='+CF+:8*$:#Y\%;DV1@PGH:E$U4FP\<;UQ@5"J& MGFZ>&:RY+OFCJZ&SGI;!Y__]P3:1%W#<_)-/FV? '[U2#66T(@80O-,80(Y> M?WFW#V^FK^'W3VQW_\W'=T>OQ[+[QVX7GO%E[]F;3SL?=[Z\._KS:/?H3WC>;FYACW<^^@\R M 6$)89#GAB#.J4*:AX!B]"8DI;'R]&P+ :[HH*@ M9PTF+[9?ONG\L_W7W\\[.\^!/=\\WWF^N__V//??WJW4DB'1?2;E^BGNLM%;ZC+(LT+ MVQE=FR;8&;R[&:*FVG6>WOD'G9K.U(QB*[VX*N Q)RU_R?/M]H\G=1]OD!A! M+)V,:HFTF6BT_O""F39CVYY?],,NZ&H@4I_ 69+/5)@NJ%N@W'1'A[E!>):A M.@=%=SK.-71"K,2+^6?,+0*(-[;G)U5S\\FHJ \S=:D>>LYZ@=4#[:6^9-(_ M=]$6G'^P K/AP>0&62#_5I2)Z;- \1O4W97=<&!#IQ<_Q]S)?5K@Y'Q)DVOY M+FHW#C7\[M3:$;Y7R+W_EA>^0 M7SN=UY-!,;8!.=8EG"H1KB+_BJPKYLC27(Y='DX*\;2;L=S-H+ 95;?SG&)1 MH"AKON<8\J=9P;+_7F/O1J#+@#XROW,_MUNWW*UCL'5OYS;M HB]=BK?Q-,M(-]6(.]WF._D_BQ0*&YAU5AK5:VKE%2[I$O M 6V7@*WS$NP/QK:W2*W!!5.^[G5RYX2;"X697Z^Q_]>*2%Z .*Y3N;-]Y87/ MN:- Z Y^D%O3!9GO5^-0)] MN%_:CY]G-/J%C?Y521V[JGOK.'7LY_?/_W[^X>GCK8];KW\W6\]^?__BV2\[ M6Z]W=K?_?BZW_O[9;OW]EW[!WWDV=>PY?Z[= Y_Y8?MQ?K_]^)==_OR'IT_^ M4B]>__[^^;,W?*T7_#R_M2H'LVS9ELAB:R+AT1@!:$FDUNG!9"Q@4J&JU'23 M0.E_+ZB0XJ*KBURC5GTGIC4E)G162_"ZI>A#!8Q6)NN+-1&#=MI>-%N_4]"2 M*.CC*07%2,Y[;T2NE 44K46LW@L53$TR)",M/MC4<<-T_NG\ UH9*DE/:Q*T:W3$'FE(+:)'@*0:"M M18"T200;4%@?,>F@M:QNY12C6ZAC?ZO0^VOCSXWYAIGCMRW+9#2I2$O[>7@; MU>OO"A=9JAZ5MD5G#1EML."K*F 1"LJHNY*T>@RU/5^PGFUL8Y(O@F?1"S"% MN2J[)#2;V\[%7%/K!K0@)6F!Q;(7O4]P[Y$<6$X5A561"Q I8P K)6#V*!." MZ5K%+6-VYF[)6?)2)!":$@G04HH$X(2NGE+R32]L?7,65AZQXW4%\5IC-#I0 M,MXS2@E2\TU0RJY0+:Z]\B6=K%&">3]*NK6>[7ZF=Q>[7U+T$YNABMT#NI M0()-.F!4SMA4"YORDD*GG%NEG/F>,3$KJ5QEML&DV$#/("(:+U(QQF$,IA(\ MV P;_E8]B%]I*W>-[8N.U.DN9%1):B-HG=GB"-E.BJ(9GUJKY:0%.H^B M$-A00S+&^TF[C)71C._;QOK6P3Y]."D65OFY[E4;^,N8XT1993 ^5U[1+@=K MC9'>9C;*M<;46>=666<^V\)YE:6N7KCD,IOC,HO(DR4(O RL]R<#Y<&F4]>/ MZ%E&F_>5]M??":A2(/)87*ZL+"9'P5?*TKE2,@*4R*;+MU#"\K@-862ZWT;-$.4DD1C4M9!V.UKWRU MCN&5Q/#,4'=15ZM3%;PQ7IW726$E:,(K! M''7,B@"]KLI@5YEO&:TS0QU*SHFM&1%L30(<>1%,=*(EYZCL02NO5DME7N26 MN;;3ZI>K;*A/B@\-\IEB)X/O\%_7V3^_7C_B.QW2(R.A9X4R:INAF)HR4@*5 MC-)0O7.=G6Z3G9[.-QO701+K?T4$1"4@8!8I-Z=_PFH=!*6H/MCTB]NUNXE> MXC>](W"/H>ZL-#92JQ)LP%0=V)#,EB(I2$8JZ%"_9:C/3/]0 7(L5C@7K "I MM,!HVR)1R))#:0K5L:3KE+&;O<@H^]5)) MJTD ,[]!#ED5,EYH[;4 \$$DI,IO72K55(L B][@[QRP7AQ@M#,2,5>=@<^. MQ7NK@L^Q%AFA;]7=-MKGDN\C54I6"Y>(6-R7(J)%UUK)DU.E9$#6[)6Z0_+^ M/M1<_8/&AZ/AI*7D7&.7P7?I:LZ(XQ%8 F7="3\I.LQ0% 87%.AJHW,N60R@ M;-#!^(ORU6Q6YAI9/SP\):Q.4Y>AJ?D,?$"9F)N4P)B, )6UB)%?6$=!:S7; M)*%%%&R$!7E'ET!2M[O+<5^A[8*+5?F GC0 EJ"K5KGF5!VJFJ^YC=D!OUC MS^4)(*:*58EH%.LE/J) :F=EO ^K M#?T[(>];SI\T$= 8 %XQ&$,T;,A"5$6;\PJ2=H0O$^%S'@=IHRTQ"*;F)""P M%I^TT2SC*TS^)W^5I!#VO,/U=W M)^7@\/CX66J:3L>?I[/QRS_;PTY'EZD^^NQAHZ*I=^'ARV*MCDA& MA&*] %?8U*C:"U.K5$D:2 I;2O+W5L,MUR#M*8UWTDW0$;L(Q'XX12RZ[!-8 M%%2#%& 5BF!9A0C8ZKH996-=7&CSO0-L-_$[9A>$V>V9E(TZ1!=L%I8B",B, MV92::Z\:S_]'Z>2*U VX]C-PG?-/R9B5MU(D K9PR441 M:XXB.1_1QHP,6U:9'2&Q]8HJ7 @T445.(**4NP>D5D[CWK=#E M*G:0O!,\%#RQ-E' UEI DPH^%E)(DARJ>-WVD9V=EL).6_/FNVE-< (R,07? MJO J+V++L"6GC38J&<+%-=GNI;A6$L0Z*PF8(%( :6V2@1$LO3=5I807KH#1 MX;HLN,Z4":W15EZ*K01&$J P,%R+$XQ29;VRV7M\L.G5PD)4.U97"JLFVN2J M]4$I!] T2 ,4*>F$Q814N\!=203/6>\UEL@39@0%PU)71RL")!(A>"B),AL" M"\\>ZR!>*1!;1Q*\RLE+MMZ]338F1(:OUUH;=^':EQVNRX+K3."F$C-/C6JA MG*W<-* (Q2@AG4M.960RAM42N/=MRYT7/[_=G[??#Q+?%K9)Z/ON7RF#7YPI M2FJ/WD%2K/!KT@5]\3F8'*Y9!K\3TU*(Z?=YPUT534P^02B#Q.P$(()&*:Q4 M,5>%Y,/BLE'[+L J@MAZ&0B,:CL!X+6/#HN'+%$69265KD?<-EP_,=QEB8:$ M+A0%.)M$<$X+U%6EH),-F1YL0N\MN9Y0E2'[BK9FRM3J2"-XXP*C5V9ES77; MSG0 +PG 8-BK&Q3G*.XA7$<2DL]46BVU= MO)6AR(HSZUHV!T4>*7=Y>]MP_3 '5PH\$9%!JEHOV)A%,&!8\OH:0T!M0EPI M>7O?]MR?'N[0J$FWB?%^78M]_9V&!4M(+&ND"PC1.W2I8"##>J72BL[9I>L: MQ*U1TE_S%GM6BM>H!V%"00'&LRZAT(D,FBII6P"I>_[7&L0$5A4'V@*_,G@C MY*JK#@I %E(]4O[6X3K3('RLZ&KTHAKO!8!3K/HG$+E$[RT;[Y35@TV]H3I4 MU[2*@T/O$D&Q6A9P$I)V,LED26(L*I^S3]=%[BUB>,YHSY!="(QAS*W'?&J; M[=X8D3&JI'/UP=C5$+FW7I5QC:6NKE3 %E.*]*"B2:7$6GTRTM2J=>Q2][81 M.Y.ZMH:<9:I"0B@"K$&1BI0B:D\Z2Q70U)62NO=MNWV+@9:';W&W[[)_DWB MBBW:>UU\9IM=I6*9AE"YMEV;0\^U6T4Z>CYOLQ,; %:K+%RP48!/06!$+YR. M+F:M,.C8O?YK#6)B73\D"5HF!=CJ0V7*B!!8E7#QO!(5':XW ]>Y77:OI=2V M"$.M5;6-)*)5;+/G%!T5LBST'VPJN+[ZT+&ZBEB5&DNBJE!%":K6X&6POH:0 M*^OZ]H(ECKO O6$$SUGL4'2L2K/";R;Y:%$+)!U$1!N\"U+ILCB+O8-X%4&, ME9%JLDF:-'A-F*)*07E7'05_GM;JK%8#5OL/@B@5$6*_-:Q]A;"IP^HX_#M6%]N4R$E5#9J$'C 6I 3&5,G2-EB0/3!^-1$\9[$S;DUM M86W>.U;\*1B1<@Q"%YY$=+84+%W@KC6(036OJR)KHH<0?*RN@//))YD2D.L" M][;A.I?0#BX'EU& #E% )13!0Q;5)8F83+&@5TO@+G*'7=L-O^H6^[.#0]P= MX+D=% ;?E6NU.;S'[9<7TP:Q:QPW2F&OYDU\R*1"]4J@3D6 HBB";/M]R!*G M8G0JRD7O$:Q,(^8%[B'<8Q*X>E/%#O>;@?M,8\E6A@"D1*[)"9 ^M6KU11@% M-6FM? T3C44OK,53!_M:@7VYW1@[!2R) N9\#,Y6$T/5@L!4 :D4@:4Z(75. M($$G9U67^)T$EM+>L'0\6Y/(D5]P./HO[A[1X^$X[QZ,CT;4F>U2S/9FWG51C;S<7)QW?HZ"ZP7"RS*:='QOF2\SZ4@UB15<4XHHW(K8$ B MDC3\UF1;9)&ZJ+LC\1<9>^'O2NA%'>[C?AZV((P&D/$@XV@T;-T #P>5T3+X MI\%E:2ZF+W+8R@W5_RSO^=?&Y[P8M\W^T5XY.#P^_ID[>K)".X=?D\-?/YSW MTJ3*/%T"B5)]%:Q^*Q%C5H+-MP >0#F4#S:5_-Y)M;#,MKNRW]1YKO/9J;J7%!IZQC :%3D2WI 470Q8I@+52JNH"CB4T:M=V(=X7GCOV+)S=R MLJAAPF*+WFBXP#7F'MCP(Y6#H[1+GSWQ=;ZAW^6=O\L%.<576I3^8SE)KRE)+C@OO?+10/IHKQ2-!ZQBSL*FUE(9<6U9K$H:T M-"'[DGP+,[CE2CR=BSH7KH&V"HN;TUGBB;6.45ODS2U6H5H1044>50 MJI0I!-W6M,H7K79)DN=ZEGX[&?'/C\:.# MO33S<_2*5MU:KH4-?W^2/ZCMWU MQ>ZBK/V.W1O [MSV"$7-QKX5)KHLP '+7C;Q!820>*X\4&L-M%K8761WP3N8 M+__-6,$K5C>8/N27 C3O;0;#X@=H;?A^N7Z5_\S6>/?N7I?P_YIWH4CMD8G; MBI( 6W%$*6(N2CC07E=B"5#UDDHE+0 _*[Y7U9FT,^FM119USEPL9\YE]WM" M)4$*2"&Q:DS 2C)6D5-128<0<\!%[HAUONQ\V?ERV5["SI<+Y.FO(J)1I(4Z%SI>=+SM?WI!GMO/E8OGRPUS#@JI38TF9 M)NUB,XD@M18Z%L\3%!P39],OKUT[:F7X&PM?CAGV7XS^;)HVT?[3$B M\O1]GGC^CR;N_LW_,_G8]$G3Z(?-TZ>>_/U;!\]4/P ]=?R^/1@/V]5_'-$N M?\T_].]WPW*X>T+L1;?$4BC0C?"*Q\LS_B[CO\,'[PPR?/M#?<%V?&\.SC?WT>IJ]G M)G9*%S(5"2JZ*FT GP$M)"(J259*Q;DIJ?$Y5!XVYZ'-K$<@1AL"@ XE1B-3 MDE*W38M)ZZ(O?P]_$JI*/AI$(+(I6F3M41E24DEKSWZ/LPG(^LP?=F!#QF13 M5>0M@Y)(POPCWZ 0T)_6#SBNH8O[Y=O; Y-/[1$VUBX#'A<I!P M/.3KC <'=?"8,NTE&DU)QJCO!RPHY !'-,B[_(W#VJX]W!\<[M!@9T@C'.6= M#^WD>K"[>_!N//B.#_)S[_+HC__UXUC5[RLCA'6EM3Q7QH!V6F9DD85 M,RA.Z(F'>1??CNG'DU_^78;CM[OXX&-R:$SI#H]!H&7OOGJ8;FAOGKLO,LJM>%4O-)ESS]FS=>_],HW*S< [M#- M>M!WZ6;]A2[[C;W02U14."<4>BJ\5DK__0_]0[L#=8&J%VL^!+H/@;G/0S") M#KA,"9&[E/+PF8)S]=I(%[%H+K$X+E*BIG_E8BI[W<$2-X]PO#.@_ST:\@)E MSAA?K7S7 BNP]6OBW^)9&UPD(7#>G])<> M<6W/?8>OO/X9;^K]O^'L_O'C]T^L7K__[>EO_;,[Z MG5\\>_5NZ\E?DN]J[\63_[[9?OSJ_8LGOWY\\3<_W\??]K;XFMM_;YGGSTH] MC6GX4[Y["35([9,6ID 4X*01,8)LG;04QH3D5%GCM)M.3&M*3-;HZE56&4H% ME0/J@HH2058INHA?)Z9.03="01]/*4A;0E=S$#9[IB!M001+_)LM)0:/E $> M;():J?2#SC^=?\[E'\HUD;& KH KDCDG,-\87NF64J*N&*TD*ZE35K(Q.1-; M,Z>@@@#O@@@E1.&M;A*%HL:N&'5B6HUGNP0Q1;JWO'NE!5RJO"!I@!Y.LM0G?E-)%$ FU"DD$& LTH$$XP@XVL$IY)S ML?4IVY =JNL(5=8'8R3,P24)UE.2*K-R'T&&3,GY[F)820#/7 RL$E'0R0A3 MHQ=0'L("W] M.6>S:V(-,&G+-GLM L UZYUB4RMJB4E%5&F-MRHZDD^03%Z;H%UV15G 9*+, MU;$5GVJNO#9J5R5N&;,SXQVT)U;O43A4K/MG'P0Z%02E"MDD8T/-K3K"HOJ+ M=[RN(%ZS+:2#MZSP(_B)D\U2-M4851($U27O2J)8S7G+K958@P@N!@$:@!5/ MTB(:8Z$6BKH7+;\72"[:V< FNXY& K$"W>I@LB0.N7@9B^F2]Y8Q.S/B8RED MI%*B2'"MQ'$4$6T5,9O6:$!CGA8[7B7)>]\VU?_:^'-C\.J ;VE_K[4Z&K\] MV!\?M$H%^(KV\U7-^?OA3R22T6B5,RL5+JN@4Y6H"UE-2D7H2L4*$M3PU)S7 MVZ]>ZJJ8A22*&IUN<=#,3E%KH;2O.1@"I7$U-@:64@!M0?F@=QK%V44;-UQ-3WFS]_I)R@2INR\KD": V5YX9!/9%PJB2.L%%*\%*PI)4 I0*4)0UCW8=/+Z;1JNY=Z[ M0D#=K?OB[P1449F,!G+U5H*O.L@@DZO61N-5=N?8S5WE7P%K^MW+:F/@V M.[^:&)YMBVNC9:W!"D_6":A%"=0N"XO6!L?S6:7I&%YK#+-YGJU$PZHS08X^ M1ED*50_.0Z+@NLJ\(N;ZNY=8DS7:,UISR()5IR(P1B-,2#(5MM]ED:NE,B]R M.US;N]+\-Y\I)SKX#O]UG6WPZ[4)NM/.1%8L8D'#8BHC9,K!>Q53"^(*A9BQ M.CO=*CO-%RB,K 5JI;)(MJ K5 DIXHP;.>GY PHP@>;WB^ZC]C*MPGK4+^8 M[\[4;$,@GW, 'TWP(2=/7H,!TOJ<&-L.]1N!^LSTC[EJ$TD*E#()GA\M@O5! M2 R^V%@#Z/)@T]I%MUCM4%\/J),JVLJHE L9E(ZI$I56* F+=;J6[C=820*8 M^0U*5N@42!$HDX#0I'ZT1@097&9US>F2E]26OG/ >G" HNQ"\%H5%O>%V0 E M4T V*3I5@^Q;=;>-]IG?P47GP1_?_C-WM09D:[FC#@>@250UIWPD[I:*ILD M!)& _\-8M'(FAQ!D#CZ=4\3G4[Z:S'A*6)VF+D%33^C24Y.\B7 M"?*9TR$D2*1-$J2B9.&NK8@Y!E&]-+%8-KE0K;@VOY32 "OMN,,/<\7\ M!M_E:X4^K+'5<76'PKSVL7^T5PX.CX^?9:?I=/QY.AN__+,][(QT&4::K]YG MI).J$@F*2@E(5HJ4O10\9XA&!S(!'VS&[VW0&]"K *\C9I?K*>APO3Y<9]X! MARJ40$D$W:KN&YM8@=!&1)]===$':^UJ)"3?1;C>%45_N39^1^SU$3NSZZOV MBB15D4HA5OG1",PY"<#BM";T5.MJ(/;6 P?6&[17M\Z[:GR#R)T9Z\E71JH# MX< :P3QK10A012R8@$QB(\>LAFI\_\( 'OZ#PUU,NR08'&+,"WP^'.#'*Q4V MNJ@3LE]C=:YQWTI3/CH8O3T8X6%K^I@.K]M@8OUMVU19IM:D7+(&2FLQFXE< M5D5ZHYV[9C+O*0O]6L]498 MF94 '4 DDX)P)E#6JN@BXVKHSW?1XKT3():@>;)54*E@ZQD=$R5' 5U.-4&Z M<%?(#M=EP?7##*ZR:+*6]3*K5:N\I40,M97!B=KEL#I$%X2A+?G)2ZZHE(45 S;O06R2. :CKTK M!0BL$>L("=6D,EJ82RX4J4':7'%).Y]*W6YI(82ZU_'I[ HBE:BK9(@D4]0)5;+ MJH2NENWYKDRL(#O].F^^5^M8'TQ28 U! $(2&)"$+4K5 KY"7-SV5R_&M8H@ M)NGZEA=EL!U2BLL2-XS53L=V90GZRFQZN=EN681BX[@)2%X MSGKW2=90C6V60&4$*V+1ZQS#&%N@7XW1+\Y?WD&\BB!VM<4$QEH3 1CT:,%' MR(Q<(J7D.2W5.UQO!JXS@9MR)*5=$"HY$)!M$#$4*XSQEA25ZGU9+8%[W[;< M>?'SV_UY^_T@\6UAFX2^[_YE"C(Y:"<)F6,\0"DAF,@2)X#,EGSMAOLJ$M/6 MO.%>R$63K12DV1P %[.(UAI1K+7*9)= 4M\%6&L0LWV>M4K%QIB@!!6R][$U M'8^*?#FO$GZ'Z\W =:9'5*@R&\Q"2:L$&(<",6N1HD\I%V6"Q >;L"$[5-<1 MJC%3,2K'XIV#ZE5K6I)C;2E\!2-=,R.D WA) )ZSVR'69#WQFF4C0 I*9(L M6;3:#XGGD7\LKFM%!_$J@MB$FI65Z$RP8*4*A<"'6(W+IL#%J[%UN"X+KC-Y MJVTT.KHB"K8R33M?=MS?WJX0Z,FW2;&^W4M]O5W M&DHHQM5H*B@S 73P;N\O6$ SUGLF:=/HP(A;;/84S0B:N>%!LA4E2:;%]>VK M2$=_S5OKB6(@XZ*H+E0!*BD15)(B)18G_!:1>B6W]09Q:PO%."Y@LV-YE%&7 M6(R.7D) >.*S^"?JC&74LI&'1:;((I>TK;F: ML]C93M.@LF=9BXQ@?B.BNU=SP'O=?74SSPZYQW"B%Y4^2 MWCVY4*$9"8EY+$02(9 4(=:L2\X1Z\)+WZY,$^8%[B'<8Q*X>C?%#O>;@?M, M8S'98G"6&.F57UC!;/OY)"R:2D3,!CX]V-3.;[@.]@[VFV[$V"E@210PYV,P MJ6I2-8OJ2A%@HA/HE6^5:EF5:PL<%]Y>II/ 6I' U1L[=KC?#-SGDNX4:(S& M,\B+;3U8V_9=+:)F%T'YBL;G.R;Q[T.[1T;$.QR5TW1^>I]W=<+ NUV=Q7#OQT=%H1/OYPZ/CV9I$COR"P]%_('@_' M>?=@?#2BSFR78K97\ZZ+F)VK;',*+0LV9DLB&M9K=(42J/*TYL7E$UP6-'=E M)^6^LL"BG!8=[TO&^YSO E3*%'D%.U\%:"=%TD BH7(5*F)JXDGIK'R)A0ITB=]98*E.BX[W M)>-]KM&?,K*&[$0K\B1 )M;P9>6W1DNJH$OV>'2^-E\E'YZ(@&15S.'@1T+;J44Y+$\#;$!YLQN^= M_,<.%>B10%$:U&H'%I%50*!K!2*W!J^Q^R1 M+=UFS,8H-^Q=X H[=(W67;][K)_ MPY*^84&.^)66PK^<^MUWAYB&NY,XVB\[WW_\:A3A(B*I^S56YQH]<'8:.%L_ M"YR]=L&!E1N'BZOA7WK$M=&T;R7:=_R?8\[]T/7O:^K?KW^=WTP"HY..DH3) MU0I6Q;V(2%;86(L.N@9H'816H3[*U=P,W]!/.TNM*4LM.1JY\]%"^6BN1GIQ MJMJJA,_5"#!2B10LO_4(TM=80JO7M+@ I%S_=*^X<-9^-AH=&D'=W@NU?7*HZW MWH4PENM=^NEHS#^V:]47UU;TQ']8J@>J9PZ*Q5K,Z*..FJ MXZL4@;$MK"JD:[32EQ5I@M51O:)^C8[?F\;OG /#Z<)D;*,H+GG!Y@&PP1"3 MH#:!1F:@Y!]LRH5%W'?LKB!V%V7M=^S> ';GC/U8K4X41%2>9:]&+T*T5J!! MDS5Y0\FM&G87V=/N#F9I?S-:[(HY]=.'_%*(WKT-?U_\ *T-WR_7K_*?V1KO MWMWK$O[O\RZ4FG+T8+- ZTF =$E@]"B\<=(8-KN\3$LJT+, _*SX7E5GTLZD MMQ99U#ESL9PY4Y*=R\FDXH0%#:*%#8GHDQ'!1W#9))XQOX0B1YTO.U]VOER: ME[#SY4+Y&P-9;AGV7X MS^;_F;Q,GR.-?M@\?::3@R=/=?SUHI'5C\:=,-APO]#^X8]"A0FCWC F=/%W>9LTN!>/?]K9 M?IT_OGC\VYNGS[)BE [Y&N^>/O[CS=;KK7?/]W[;V][[C:^W7;>>/?RX_?CG MEQJMBVQ>"Y=*$!"HU39,(%AK!*>;CW"\,Z#_/1K^P\37NM3BJ'6MS;M'A0K_ M,IA\ /=9-SC[23YXN#-)>.55.Z8RB>AK*,-#?I-P%_37_Y=AN.WN_CAQ^'^9 %/ M3OI"U>A_OQN6PYT?H]^(UC2=['A/\OCRTZ-J8Z*NG1'-TV,N;'C[]<-R0WWU MV'F757K#AZM=]KQC>D.%L)R;U1>Z[#?V?2]1D^&2 +Y,UA>/PBCG%ZQ::Q_! MY1Y^;>Q_9*E8BE'D(H).&-"&MI$AKSAKJ+$> M'H#7/\/SUS]_W'KVQKYXG.'%8S[W]7/8_OCPW?:S7]76Z^?FQ>O\_NF3W^U9 M#\#6LYWAUK.M]T^?[;[9_KCS9OLQ*WZO7YFMQP_YO+\^;+\N>]L??^9K[M;3 M'?D_Y;N7OB@3:I;"%,\Z8)%:H"(K/I^P6,>88(XB@ MVNZY-EY$9[,@0S(&J9*JX>ZPVWTHT/:4+?K1>?KEA<+>+YJ_?\?IIRKRR?BJ M+)A"*5#(F'0J,6=G2E>N;H-^AG/*E7* .2G-I%-**TAF1:S2"6>4LCJ00Y@$ M[^@52F>_A9Z#ZPU3K6K6P6*QU@ HAJEW6I5*5B4R-G8MX79@.M,25%;*U^H$ M([*UGDIL [66@D[&:@VFZGQJ,%4K!-/[X'":CN[GKY.LE"NJ9CU^Y08&:&VX MF^5TE28"&J;NC!YCB,:I E$5S39$5[%N@[L_S*E85>IJ% 5>*CX(J$B"#3L4 M19%.P3H?/*M8BV@>N&B4W*R/ZYHW?$4_6&?;SK8W'RW8V7:Q;#O3E"F5ZC4Z MD6Q 8A*H$Q5\)Q8K,Z6FG)CV^NG;*\*VWX:+7@F]N/.1D+E'@GU^.'+&""" MJU*4HK4 %UKQD/:;=E@\059>GHV$"H8RA( F*PDAQ@0Z(,F0LO9\&_ZJD5 _ M_^_1\/##8$SY:#3-KU_1(*A6LN#X+PUU]DN!&U^+DOKFX"TI2BIN>.FO%"5E M-Z)<0N"1V;#N8H%'EXR2 K?XFX6-$*!'2?4HJ9N/DBJNUJ+OE-/JSYV#T:'@ M>=F[4I34\1/?6_/HTL^_-M9/"22]=\5KQ7)1I9C!:>E#+/ M4T7BEW^VA^MA\>P]AQ>OMX?;'U_P?;3S?CUOZ5[.]]\MKMG;8XBEOGC_;??WBV9OW_+WR>5,=G[5G+I_&1U6P MP02V>&S)14"M2B03HC!!.;3:5[92V>*!Z^_A77;E+]M_=)G[N;![J-/;?:4W ME9P"Z]G><@[0.XR6HK6ZN) P^'11YTZGM^O3V\RA8W0I3E,4K+O3%0H*D+MQ+O3/2=1EI/F;*>&V-BC6%_[^V5_F8EN^%+IR@4"N8Z2!GK;P>'LP'K9+_SBB7?Z.?^@X M\.08B7,G'@^?G)V"B4?JZ/#KIWSM%A='*/)"06/*?3H<\Z\[HUFXPBL2:43X M1F#EF_T1=]_AA_&#'SX-*1KNBS-C>/;QOSX/T]]:BP79P_U4+'YNV9MG#T1LZG'9H&? S'!R-)B7A/@TX M8S*?A)(=[HR(!GO\13OC >VW\+-)@,N4-TZB7 ;O<#S P?]<0LXD:X(&@[)8 M#RJW':#L-:;LT3M?\>7CB:;/_Q-+4?G_VN=UN,7C^?W@W<>SP$O]N$^CCX,_CEH7>8&TTF>H.%R"R%(59.M38-O"$6U.'(3A?:L?:B87)0T5<<#KX//,]&8 M+JG2B/;S)6OX/F)IED;#ZY$27?)+%\J()TN>:?$3@?#=Z;M_?=\./CF@PVDC MQN\'3XC7[/Z'[UG[>#LZR#0>#PXI[^SS+;]BA>;H[=O=(8V:U&G:3!H>S(Y^ M/WC+W[>'F8XF=L;WK"G17OMM KIZ<% FOR1B2P0G&E0Y:LE$--X8#/Z>5B:)K/SKGN>0;7U\_E)'EO)>LNIG0V$EL*!(*I/(JDK0-4G2^JS7 M 30Y6:*.UA%826@4&%V!K3'OD[QR#MG#?W"XV]QC@M4Z,6;,WX6JVI\GE'W- MZ_+-<5M2^IC;,&"O6&1;@U]&^IA4RT@?TWI)-[O0]+$+[DOQ!-Z\IW0NUN(2 M:6 7SNU:QC/=P12WVQN&15A+/__:[#8O M*L_M5-OYY6#T)^LZ,U__8TJ'LW=WW<]_7.WCM^'6X]^&V\\R/'WR8F_KX^_V M^<[K MI\_>O-]Z_>;]]N.?U?;K%SLO6+5]KK<_S7VSTMJC\MDYKRZ&UN>@9*;/R;;N3 MFLE>HQ(Q&R=<;/'K1B=-;$QKYS?L7:&URUE.=T*_O$J.V]7R86[O&6^AV'>G MEV70RWP"6XY&&2TMZTJ5M28;0"2#03BK@JV:J:9I39?.7;L:34S7]G7,]'N! MKD75Z.[H6@ZZ9L([>,2L*@KO8A: +VB#)S!,HTVV@:Y&N'VU77#9? ML@!W[B5A;WB UL:J6E0![D[,RR#F3PIQA\2JCB?AG&R%N*42H2 (TFB!6)!* M7Z?.HFNGA"T<+W?#F]29LS/GS1?3[LRY'.:<5VDK"SCE1:S!"YZK)!*:(D(D M6=#'6IV<^J.NWZ9N59AS>66UC3MAMV$+8#G\4=QFC!3=^QBIUS^_3+E&';,4 M068G(-;F<*U!H-8V5] ZIG#5F"=FI7*+]>ZN^GKO5_W'5R^K M+RQUT0AM6_._%**(BE\*U&"24C*@7?*J'^P.,0UW6Y[?!1?^R0DM'["O_JNM M_E?W?O4_SB^K23X$HP58B:S4.%[]GI2H 8VFH"O5>C8N-D7^2,@AAAS!46+] MQP?/PL-[Z8J,5T7+H\FWO&KKNRWA(:LVTZC2&3R&X[L1&GOQ7@O?',PE!KFO##(NYV9M[[5P5P)1UZG7PI-;0P9O6DLBCAXON+/QT-.;;&(\?'>RE MX?Y$ ,_TC4?SZL9_3K2--7&5_6I>_/VSV7[RRYOMQ_G]]C,^]\FO\/SU*[7] M^(_73_G<[;^W7V_I7^$S5]GKLOO\69;/__Y=;G_\6;7B1\]?[PR?/OY+;C_9 M@J>/?U?/]=9'_MNG$:D@;049BK!5M]@*R"+8Y$5,9)4N5:'&MON[8$?9NNP@ M='Z[/_Q67,Q1VE0+(;0N)I*<]#I;GTJRH5S4_]_Y;>G\-ML*2#Q16>LH=-!9 M0"HD8D$O$I,;KU*3M"EWBM\6F]*W LKF[L'^JVG6TSGJYL*"Y^X*V6!0,B?O MLRT>*+M8DE)%0W#&.@C8E:D5(9OY0%7T&H.U452=H@!GI0@(24B($JI7VE&X ML5"ZBZA%2X]5O2MP Y)957 E.P5%EYBK M EVX"M&%&7[2L#M[GN")XEKBBQ6C\6Z[2C6SM=+YNOY@%;M M*J@@G3"FE7?T*$7200I/$0HZ*K+8QM>?EQ*[JT%9/9RU4^BJ4NBBPED[A2Z= M0FC28G+ M23#,T>AP9_"_1S@ZI%&K=LAS&R=EJUO1[E?[K:KZ (\#>LX-M6EEY@E'^^+@ MZ'!PB*-7+5AFTCB!KW!<*ASS_QX-CP/6^+OP--"M#%LUUG1T>##:& Q:J?LZ M'(T/9Q=\BQ\F%<;YK,N4IO=20F(+33N($(W%JHS78*4&&9+6D]+TDEEK4IK^ M>KU0?L'AZ+^M%/_6I'3HI)+YW\/#G;_V#Q+/U#]M\?RZ__;H-^8; MG9Q(K&D+90/)YI!$7[[,-R>16M/J]J#MC6\A^^'>T=[GZ_B5CV? M+WN9E1QC4BICUC);2%IAJ-%JBHI"L=JX1399Z"MYX2MY^_'/'[?>O90J>R(' M I/W E0. HTLPD3C%5N,O*SK@\VOM^4^7L['Z^NKK#SIX9'SZ*B1-Z]@9F(: M'TY*6Y=IZY#CGB&78]-@R&KGB])>@7=XTU]>O[ MK8;8BHO[*Y>,J.7RUT?-S[@[GJ:'\:BL[K M9W2P-^6]V4+B1782MO;)!>2J]^\XJQ"-&Z&53Q4B+:^D$!V]/6[)42[ M8Z+O![_NYXWC\1W1VQ&-)]5\)P-[=,BL.WA[<,A_&N+N9P)D,EU';YLLN@Q^ M6^^7))UDP1% ^H@,:&E33*P7%1W.*=&W!/P^'(W:>IH\SA_MMZ?UZ=%AZ_DR MGLB>_\L3=(^A_?M[%AM MB<*KX?Y$0^)K_(9L[(P^#$[XHJE1-*VMST?/AK+J5CA]JMY_(H3:U4_7^)2, MVI\>S@'G<5/2)G+MDS8-EUG^FA=_B2RO=-)4*GB@LYB\)#+Z &%,'EQ*M=%C39:=;]S]L_.]7P3[M4%6J!'#P/ M$VV_S<@K9NR?=C&_$7_FG8-=&HLM7NB-CM^V*XFW(U;O6SL(7I!3&M\[*+3+ MB[!I3],$DO%@S);JL XS3C,)C_8F)T_[^AS-J<9\1M.-!^,COB$<'W<:.'A- MN:E?I[ Z%06#@W]H]"D&CJ%V8I3PV>E$K)R%2VOK-N:':L!LS[!'AQM?P]A7 MI=:D2=?>5-N?J(R$4[%T,)HTR#B!/K;LF!/J.#,$QT]]?'1B5/'7GEZV4SUB3<=7QZ2$69[*ZU4ZB MQURW?;3'Y^<%]/)\/Q[^N#_4V.J*O.I/^,PNL//8KE:=G7$:?.9@^]2\] MX]O\:?<@O[EG%->2;[>?;;UT'KPO68F0HQ6 ,HM 8(1V,3FE62!Y'GYB0?"6 MCB=C\X3NCF=[\]G!J2OH"X+S/RR'=P>:Y58ZG.\A^U56_'YBX4[[@GX8G.A1 M+%K_:2**E2\^^0]BBAJ-9ZK0IQ\>\Q4RL<[R='JEDRM,.L!A2]8=\W6:K3NF M7=:A6)=C_6'4[F6B#7UZG:FY,G?K.[1;^.*_UM/[* ("!4#8B53X3,LWAKE?Z.%U,08&!^>J,ZS%/FSR>Y7[_RTE*3TN.&E MOTI2NG$;8-SB\[SEAO=7N^SYQZPQB[]9/NB_?GC%;O:>C.PW+WNQN[TG+;4.EA<]8?+A,2L>$&$AWO-"_61RD0/>G0P/KQ >8@+/?_]&L>_]MFT MWCT=R"11+>H05RGG^&/2UQ:J_7\EVY:ND3ZZ2/3 M1^:V1-_*C_!]:C+[Z&#T]F#47-!G',V7S0RX!UE#ZYGWXY.DD&6.Y"5HYZ/# MPG\ "R63J735!B!G/-_O]MZ_,?NUNLML_WZC3R;]/-B;TMM/?YM]^F3W_@JN96P MET\?OU%/__[YW8O'#]]M/_GKP];'K)\^^^/3O,D:>+]2VO(G9JZM2T]M0T M'V?XD48'!<<[BR*LYIGKA'5%PE*SBJ>(+;(?!8&7 G)"$72,0B='UNJ IK55 M^__^GZ"5_G_O 6V /F.WK;6FP4N95J )1LDMG6-DNE M[#V@"BB;OTAOZ!7BCDM[X>ODOSOIA=]BG+6J%KN#@\2W,@FQOTC-XPL-PL6K ML][> %RF-"M0],$F$QP"D>3EF] $U$J!JOFO3A12LC8) M:[ *X,D1*=HL= A83#4%+&LO"KZ:.WUA^CF' KY-/]/5?RG;ZLSW7:!L%"2PIW)8I4;1!80-F:%:9LKU!>N:-XW5'T]4*L<]'MBKO+.BI! M!K0E^5:C61N,%4IP_*^D6D/JCK558)_Y9JT>3,Q1*:&K:Y66=! I&1!!^J@Q M4+&@'FQJO[#R[S>FLG\C:*$C]B81VQUKRX#QQ[F>R[JJ3$6 4R!X(IT('K)( M1FI3?72N3LH&WVXT=T?QRJ&X.]96%-LSQYJS!;Q%ML2#1\8V3%JI2Q%2];DB M2^B\.$N\X_O^X;L[UI8/YYEC#4I!:8H33C.(06(1L2;&M+223*14W(H$XEW! ML=:AV!UKMPNTF6,-HY1%)FS->UDQSBJ(J%IYOUJ-DC4G&PV;MN'Z,2.+0ME] MBE?[:^//C<&K5BQ]?U([?/SV8']\,"E8_HKV\U5];.OOV=>E6O*II@0 R9EH MO91H70K\9Z^ZCVTEB&@X'[P6$KD8+1-1<@("OV"T1N3J4K&N6EWS@TW_I:8^ M*["/UK?%[PABNX]M&3">^=B*Y^D#-,)@J*RX&RG02B_0J919U\AHL*4E7]O' MUE%\8RC^[@[!N+O3K@'CF3M-5Q.KS5:H2@QC+XV(NEA14L"JK(G@\,LQJ/_J M"%X]!-\(@+L7;350/)?.&L%&9[-PH;;>JS:Q,/8@BLS11)T8W+J'IZTA%+L7 M[2: -O.B$<\+SX 1"N0D;YR-UP155&V\R\HD(UE<>K415@5E]RD\C9<]O]V? M=Z1=-_US_5WX9+!%6,:L(H*&'*P"'RTE!YAC]-V#M@HD-%^NT)CJ/94HM&YM M17TJ(EKE18JQ*HPQ294?;"X@^[-O?Z\78)<9WM+=:M? ]EQ.J%&4M$2A-+*" M@1A$C"Z(I)1UF')U+0)UA??#.[[7$]_=WW8-?,_\;:D9#A*3**'EA9J@!)J$ M0BO'QI\SEF3L^.[X[HZW%8;SS/%6T$M5BA2Z6A;760:!NG@12F$]'"-XL]IP M[E!1<4O;:ZSK;I MN$Y?GQ[NT*B)IXG[[7(^MS6FEV(R4)7:DS;@D@F M4A%.ICJ2B[=M;8"-/-T MOK):(%N]=D98B!/_OA;"I+YM]OL);WQU^W5%V=Y ZN'UOL8R[)<&'?OUO)1._-N52=YYI(1OOK8-J.:(NP8 MOSJDR.LXUU1Z6-D:0K%[MVX":# 7T0'@BF;M5;6J9ZS9BE"D%VQNFN@PDE'N M"F;GRD>5W89W2RZB3_0%W.87[N:\;JP32'KOBM%747!/W&^? MB$HJ^\;[!!&4<7E3MR3*+EP._,>1+0@+B2,)V_#TW\PE@00&C$#-$F0U(-0L MYZ@13M@A'G/- M8RXYPC8PPJ(@(LV]#-ORB*" >.GRN_@(YP/1B8]06.*\ $Q&;B3B6'ED:33( MN2"9C8Q&07,!M_DU'5TL0)]]@MR?O>XA&L;^2:/=_1H'PWP>=?#J3I?B VY] ME@6I[[S\Q+4ZCQ!LFZX MML*Q$(AVFD1>0E(U4':;(T5W%);:_JQT4LIHBX@U"O$4+3*>:<2MBY1)QQ3E M]!2$MR;RFSE'C,, [LAQU64 Z:0#2L$83!2.UJ:"\(+P$B"J-: G M(EM;3Z*1--<8C8AS99&.(J 8!#4J1JQKWGBK@'$1-G )],P):E?GD$$[#M'$ M*!3R@@G$@P#;-U**G$HJ48 A#[I6MN\:QW(6G@X^J]OUF?&.=#(Y$K0W-G!' MM75>:T]CHEI$XT3QO=6"?W:G?6\R4N>MIDC3'&I.0@#U$##1HTA&8LQT]'/A MGT>$)-;B?&=G M A1N*-Q0_'WUYH8I?Y]T0CA)/)*Y_B''^:RX=1$%SB7W3#&MY]Z"I'!#X8;B M*:P)%4S4!*&P M=_**P<2&WAG ZFK>GT94M\W0Z+M6-$G_M<()^NEN7>G,S$#BC)"$F>$V%Z7Q M5EFC#9,D<$,"91$7AVTMR+PY[;!US%B5,$5,1XNXT!2,+YJ]MI0%*P4Q*HTJ M>#RY+]WPJM3T0*-M;.1)^2-<8C+ M7 \ZIPC;8+R(WD@CXWSKS11*+93Z4BAU*8Q:(B]UH=6)NBJ#X50:B@2U!G&< M"'*<6V0E5DEP)K&=7Q"V3OQ:N+%P8XVXL82SEL)\4^$LK!.LKP32TRHA3DU$ MSA.!*/>*NNA2DFI4'8D]&]ZK@EZ_#O/.@M^A_77K\M9:9R> #K_U/]63H_MR M_5^WKNZQ>O[:>Z]O?2>8IIQ9'(3BQ%L#2KFBUGEEE53)?MZIMC[\BR88N+[K M=R=%CUYW[NT8?CM_#5^3)_[,=IIVF'?^^0Y86OOY+O;A^W_K]/R7]=S_ MG?B?]^>?/H931[G\M//;4>O87WS:^>/+WKXGK;>M-ESCV][.^R^P_[\=G/QQ MTCKY Z[7@KV\?=':>??92:XB9WQV?][HI<807K6701[87(-A MPW8##'X(/ F6=2/9=K_QU7;.8GY[[ZP/'.J&4\5,&G;8:-J^/QKADY%?&GFO M-=QYM5?'FZAQ,MY%C0"7;?RKW6W O79R\\G_?G5]O\./RSF"41ZVNY?@S:5> MQL]DM(K*[*IP=<4"(RS#U';LZ2"^NGSP[] >G';L^:MVMYJ@ZD.W1(W__:T= MAD>OC-G4@F4I-(Y5CR\_>I5L5@+J!@&-7I-R4S-QY\M@*=_YVGV7)7Q32/FH MR][_FF!T,8-5#[KL3_(!9JBC=$^&@ =NB_U::3=78=6*[G-L]0'UK)[M;+RY M(IO?@6RJ*?DG$\XBRD;5-W6D$K.Q <38B8,!$#,,H=>-C?-H^PLK"?F\S:27 M9 4E%E6,AE+/+)<^6$F\L"EP8C46=$Y=I,:Z(/SUL3T\:G?WNO$ ]N>U-)'G M81\=?P#;Z #&\D?GX"/H@!?OC[)N>'#QA1P<[YZW=CY